
<html lang="en"     class="pb-page"  data-request-id="acfce595-a650-48bc-8e61-cd05bc605a09"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;issue:issue:10.1021/jmcmar.2017.60.issue-18;website:website:acspubs;article:article:10.1021/acs.jmedchem.7b00604;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery and Characterization of (R)-6-Neopentyl-2-(pyridin-2-ylmethoxy)-6,7-dihydropyrimido[2,1-c][1,4]oxazin-4(9H)-one (PF-06462894), an Alkyne-Lacking Metabotropic Glutamate Receptor 5 Negative Allosteric Modulator Profiled in both Rat and Nonhuman Primates" /></meta><meta name="dc.Creator" content="Antonia F.  Stepan" /></meta><meta name="dc.Creator" content="Michelle M.  Claffey" /></meta><meta name="dc.Creator" content="Matthew R.  Reese" /></meta><meta name="dc.Creator" content="Gayatri  Balan" /></meta><meta name="dc.Creator" content="Gabriela  Barreiro" /></meta><meta name="dc.Creator" content="Jason  Barricklow" /></meta><meta name="dc.Creator" content="Michael J.  Bohanon" /></meta><meta name="dc.Creator" content="Brian P.  Boscoe" /></meta><meta name="dc.Creator" content="Gregg D.  Cappon" /></meta><meta name="dc.Creator" content="Lois K.  Chenard" /></meta><meta name="dc.Creator" content="Julie  Cianfrogna" /></meta><meta name="dc.Creator" content="Laigao  Chen" /></meta><meta name="dc.Creator" content="Karen J.  Coffman" /></meta><meta name="dc.Creator" content="Susan E.  Drozda" /></meta><meta name="dc.Creator" content="Joshua R.  Dunetz" /></meta><meta name="dc.Creator" content="Somraj  Ghosh" /></meta><meta name="dc.Creator" content="Xinjun  Hou" /></meta><meta name="dc.Creator" content="Christopher  Houle" /></meta><meta name="dc.Creator" content="Kapil  Karki" /></meta><meta name="dc.Creator" content="John T.  Lazzaro" /></meta><meta name="dc.Creator" content="Jessica Y.  Mancuso" /></meta><meta name="dc.Creator" content="John M.  Marcek" /></meta><meta name="dc.Creator" content="Emily L.  Miller" /></meta><meta name="dc.Creator" content="Mark A.  Moen" /></meta><meta name="dc.Creator" content="Steven  O’Neil" /></meta><meta name="dc.Creator" content="Isao  Sakurada" /></meta><meta name="dc.Creator" content="Marc  Skaddan" /></meta><meta name="dc.Creator" content="Vinod  Parikh" /></meta><meta name="dc.Creator" content="Deborah L.  Smith" /></meta><meta name="dc.Creator" content="Patrick  Trapa" /></meta><meta name="dc.Creator" content="Jamison B.  Tuttle" /></meta><meta name="dc.Creator" content="Patrick R.  Verhoest" /></meta><meta name="dc.Creator" content="Daniel P.  Walker" /></meta><meta name="dc.Creator" content="Annie  Won" /></meta><meta name="dc.Creator" content="Ann S.  Wright" /></meta><meta name="dc.Creator" content="Jessica  Whritenour" /></meta><meta name="dc.Creator" content="Kenneth  Zasadny" /></meta><meta name="dc.Creator" content="Margaret M.  Zaleska" /></meta><meta name="dc.Creator" content="Lei  Zhang" /></meta><meta name="dc.Creator" content="Christopher L.  Shaffer" /></meta><meta name="dc.Description" content="We previously observed a cutaneous type IV immune response in nonhuman primates (NHP) with the mGlu5 negative allosteric modulator (NAM) 7. To determine if this adverse event was chemotype- or mech..." /></meta><meta name="Description" content="We previously observed a cutaneous type IV immune response in nonhuman primates (NHP) with the mGlu5 negative allosteric modulator (NAM) 7. To determine if this adverse event was chemotype- or mech..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="September 13, 2017" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.7b00604" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2017 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b00604" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.7b00604" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b00604" /></link>
        
    
    

<title>Discovery and Characterization of (R)-6-Neopentyl-2-(pyridin-2-ylmethoxy)-6,7-dihydropyrimido[2,1-c][1,4]oxazin-4(9H)-one (PF-06462894), an Alkyne-Lacking Metabotropic Glutamate Receptor 5 Negative Allosteric Modulator Profiled in both Rat and Nonhuman Primates | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.7b00604" /></meta><meta property="og:title" content="Discovery and Characterization of (R)-6-Neopentyl-2-(pyridin-2-ylmethoxy)-6,7-dihydropyrimido[2,1-c][1,4]oxazin-4(9H)-one (PF-06462894), an Alkyne-Lacking Metabotropic Glutamate Receptor 5 Negative Allosteric Modulator Profiled in both Rat and Nonhuman Primates" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00604/20170922/images/large/jm-2017-006048_0012.jpeg" /></meta><meta property="og:description" content="We previously observed a cutaneous type IV immune response in nonhuman primates (NHP) with the mGlu5 negative allosteric modulator (NAM) 7. To determine if this adverse event was chemotype- or mechanism-based, we evaluated a distinct series of mGlu5 NAMs. Increasing the sp3 character of high-throughput screening hit 40 afforded a novel morpholinopyrimidone mGlu5 NAM series. Its prototype, (R)-6-neopentyl-2-(pyridin-2-ylmethoxy)-6,7-dihydropyrimido[2,1-c][1,4]oxazin-4(9H)-one (PF-06462894, 8), possessed favorable properties and a predicted low clinical dose (2 mg twice daily). Compound 8 did not show any evidence of immune activation in a mouse drug allergy model. Additionally, plasma samples from toxicology studies confirmed that 8 did not form any reactive metabolites. However, 8 caused the identical microscopic skin lesions in NHPs found with 7, albeit with lower severity. Holistically, this work supports the hypothesis that this unique toxicity may be mechanism-based although additional work is required to confirm this and determine clinical relevance." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.7b00604"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b00604">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.7b00604&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.7b00604&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.7b00604&amp;href=/doi/10.1021/acs.jmedchem.7b00604" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2017</span><span class="cit-fg-volume">, 60</span><span class="cit-fg-issue">, 18</span><span class="cit-fg-pageRange">, 7764-7780</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/60/18" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.7b00593" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.7b00816" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery and Characterization of (<i>R</i>)-6-Neopentyl-2-(pyridin-2-ylmethoxy)-6,7-dihydropyrimido[2,1-<i>c</i>][1,4]oxazin-4(9<i>H</i>)-one (PF-06462894), an Alkyne-Lacking Metabotropic Glutamate Receptor 5 Negative Allosteric Modulator Profiled in both Rat and Nonhuman Primates</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Antonia+F.++Stepan">Antonia F. Stepan</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0003-2203-129X" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michelle+M.++Claffey">Michelle M. Claffey</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Matthew+R.++Reese">Matthew R. Reese</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Gayatri++Balan">Gayatri Balan</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Gabriela++Barreiro">Gabriela Barreiro</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jason++Barricklow">Jason Barricklow</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michael+J.++Bohanon">Michael J. Bohanon</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Brian+P.++Boscoe">Brian P. Boscoe</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Gregg+D.++Cappon">Gregg D. Cappon</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∇</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lois+K.++Chenard">Lois K. Chenard</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Julie++Cianfrogna">Julie Cianfrogna</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Laigao++Chen">Laigao Chen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>○</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Karen+J.++Coffman">Karen J. Coffman</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Susan+E.++Drozda">Susan E. Drozda</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Joshua+R.++Dunetz">Joshua R. Dunetz</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Somraj++Ghosh">Somraj Ghosh</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Xinjun++Hou">Xinjun Hou</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Christopher++Houle">Christopher Houle</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∇</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kapil++Karki">Kapil Karki</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=John+T.++Lazzaro">John T. Lazzaro</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jessica+Y.++Mancuso">Jessica Y. Mancuso</a></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=John+M.++Marcek">John M. Marcek</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∇</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Emily+L.++Miller">Emily L. Miller</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mark+A.++Moen">Mark A. Moen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Steven++O%E2%80%99Neil">Steven O’Neil</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Isao++Sakurada">Isao Sakurada</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Marc++Skaddan">Marc Skaddan</a></span><span class="author-xref-symbol author-aff-symbol"><sup>○</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Vinod++Parikh">Vinod Parikh</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Deborah+L.++Smith">Deborah L. Smith</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Patrick++Trapa">Patrick Trapa</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jamison+B.++Tuttle">Jamison B. Tuttle</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Patrick+R.++Verhoest">Patrick R. Verhoest</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Daniel+P.++Walker">Daniel P. Walker</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Annie++Won">Annie Won</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ann+S.++Wright">Ann S. Wright</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jessica++Whritenour">Jessica Whritenour</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∇</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kenneth++Zasadny">Kenneth Zasadny</a></span><span class="author-xref-symbol author-aff-symbol"><sup>○</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Margaret+M.++Zaleska">Margaret M. Zaleska</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lei++Zhang">Lei Zhang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0001-8118-1402" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Christopher+L.++Shaffer">Christopher L. Shaffer</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text"><sup>†</sup>Neuroscience and Pain Medicinal Chemistry, <sup>‡</sup>Pharmacokinetics, Dynamics, and Metabolism, and <sup>§</sup>Neuroscience and Pain Research Unit, Pfizer Inc., Cambridge, Massachusetts 02139, United States</span></div><div class="aff-info" id="aff2"><span class="aff-text"><sup>∥</sup>Pharmaceutical Sciences, <sup>⊥</sup>Pharmacokinetics, Dynamics, and Metabolism, <sup>#</sup>Biostatistics, Early Clinical Development, <sup>∇</sup>Drug Safety Research and Development, and <sup>○</sup>BioImaging Center, Pfizer Inc., Groton, Connecticut 06340, United States</span></div><div class="corresp-info"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#91d0ffe5fefff8f0bfc2e5f4e1f0ffd1e1f7f8ebf4e3bff2fefc"><span class="__cf_email__" data-cfemail="eaab849e8584838bc4b99e8f9a8b84aa9a8c83908f98c4898587">[email protected]</span></a>. Phone: +1-860-686-3247.</div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b00604&amp;href=/doi/10.1021%2Facs.jmedchem.7b00604" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2017</span></span><span class="cit-volume">, 60</span><span class="cit-issue">, 18</span><span class="cit-pageRange">, 7764–7780</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">August 17, 2017</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>1 June 2017</li><li><span class="item_label"><b>Published</b> online</span>13 September 2017</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 28 September 2017</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.7b00604" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00604</a></div><div class="article_header-article-copyright"><strong>Copyright © 2017 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D7764%26pageCount%3D17%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DAntonia%2BF.%2BStepan%252C%2BMichelle%2BM.%2BClaffey%252C%2BMatthew%2BR.%2BReese%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D60%26issueNum%3D18%26contentID%3Dacs.jmedchem.7b00604%26title%3DDiscovery%2Band%2BCharacterization%2Bof%2B%2528R%2529-6-Neopentyl-2-%2528pyridin-2-ylmethoxy%2529-6%252C7-dihydropyrimido%255B2%252C1-c%255D%255B1%252C4%255Doxazin-4%25289H%2529-one%2B%2528PF-06462894%2529%252C%2Ban%2BAlkyne-Lacking%2BMetabotropic%2BGlutamate%2BReceptor%2B5%2BNegative%2BAllosteric%2BModulator%2BProfiled%2Bin%2Bboth%2BRat%2Band%2BNonhuman%2BPrimates%26numPages%3D17%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D7780%26publicationDate%3DSeptember%2B2017">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.7b00604"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1709</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">4</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.7b00604" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery and Characterization of (R)-6-Neopentyl-2-(pyridin-2-ylmethoxy)-6,7-dihydropyrimido[2,1-c][1,4]oxazin-4(9H)-one (PF-06462894), an Alkyne-Lacking Metabotropic Glutamate Receptor 5 Negative Allosteric Modulator Profiled in both Rat and Nonhuman Primates&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Antonia&quot;,&quot;last_name&quot;:&quot;F. Stepan&quot;},{&quot;first_name&quot;:&quot;Michelle&quot;,&quot;last_name&quot;:&quot;M. Claffey&quot;},{&quot;first_name&quot;:&quot;Matthew&quot;,&quot;last_name&quot;:&quot;R. Reese&quot;},{&quot;first_name&quot;:&quot;Gayatri&quot;,&quot;last_name&quot;:&quot;Balan&quot;},{&quot;first_name&quot;:&quot;Gabriela&quot;,&quot;last_name&quot;:&quot;Barreiro&quot;},{&quot;first_name&quot;:&quot;Jason&quot;,&quot;last_name&quot;:&quot;Barricklow&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;J. Bohanon&quot;},{&quot;first_name&quot;:&quot;Brian&quot;,&quot;last_name&quot;:&quot;P. Boscoe&quot;},{&quot;first_name&quot;:&quot;Gregg&quot;,&quot;last_name&quot;:&quot;D. Cappon&quot;},{&quot;first_name&quot;:&quot;Lois&quot;,&quot;last_name&quot;:&quot;K. Chenard&quot;},{&quot;first_name&quot;:&quot;Julie&quot;,&quot;last_name&quot;:&quot;Cianfrogna&quot;},{&quot;first_name&quot;:&quot;Laigao&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Karen&quot;,&quot;last_name&quot;:&quot;J. Coffman&quot;},{&quot;first_name&quot;:&quot;Susan&quot;,&quot;last_name&quot;:&quot;E. Drozda&quot;},{&quot;first_name&quot;:&quot;Joshua&quot;,&quot;last_name&quot;:&quot;R. Dunetz&quot;},{&quot;first_name&quot;:&quot;Somraj&quot;,&quot;last_name&quot;:&quot;Ghosh&quot;},{&quot;first_name&quot;:&quot;Xinjun&quot;,&quot;last_name&quot;:&quot;Hou&quot;},{&quot;first_name&quot;:&quot;Christopher&quot;,&quot;last_name&quot;:&quot;Houle&quot;},{&quot;first_name&quot;:&quot;Kapil&quot;,&quot;last_name&quot;:&quot;Karki&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;T. Lazzaro&quot;},{&quot;first_name&quot;:&quot;Jessica&quot;,&quot;last_name&quot;:&quot;Y. Mancuso&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;M. Marcek&quot;},{&quot;first_name&quot;:&quot;Emily&quot;,&quot;last_name&quot;:&quot;L. Miller&quot;},{&quot;first_name&quot;:&quot;Mark&quot;,&quot;last_name&quot;:&quot;A. Moen&quot;},{&quot;first_name&quot;:&quot;Steven&quot;,&quot;last_name&quot;:&quot;O’Neil&quot;},{&quot;first_name&quot;:&quot;Isao&quot;,&quot;last_name&quot;:&quot;Sakurada&quot;},{&quot;first_name&quot;:&quot;Marc&quot;,&quot;last_name&quot;:&quot;Skaddan&quot;},{&quot;first_name&quot;:&quot;Vinod&quot;,&quot;last_name&quot;:&quot;Parikh&quot;},{&quot;first_name&quot;:&quot;Deborah&quot;,&quot;last_name&quot;:&quot;L. Smith&quot;},{&quot;first_name&quot;:&quot;Patrick&quot;,&quot;last_name&quot;:&quot;Trapa&quot;},{&quot;first_name&quot;:&quot;Jamison&quot;,&quot;last_name&quot;:&quot;B. Tuttle&quot;},{&quot;first_name&quot;:&quot;Patrick&quot;,&quot;last_name&quot;:&quot;R. Verhoest&quot;},{&quot;first_name&quot;:&quot;Daniel&quot;,&quot;last_name&quot;:&quot;P. Walker&quot;},{&quot;first_name&quot;:&quot;Annie&quot;,&quot;last_name&quot;:&quot;Won&quot;},{&quot;first_name&quot;:&quot;Ann&quot;,&quot;last_name&quot;:&quot;S. Wright&quot;},{&quot;first_name&quot;:&quot;Jessica&quot;,&quot;last_name&quot;:&quot;Whritenour&quot;},{&quot;first_name&quot;:&quot;Kenneth&quot;,&quot;last_name&quot;:&quot;Zasadny&quot;},{&quot;first_name&quot;:&quot;Margaret&quot;,&quot;last_name&quot;:&quot;M. Zaleska&quot;},{&quot;first_name&quot;:&quot;Lei&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Christopher&quot;,&quot;last_name&quot;:&quot;L. Shaffer&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2017&quot;,&quot;month&quot;:&quot;09&quot;,&quot;day&quot;:&quot;13&quot;,&quot;issue&quot;:&quot;18&quot;,&quot;volume&quot;:&quot;60&quot;,&quot;pages&quot;:&quot;7764-7780&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.7b00604&quot;},&quot;abstract&quot;:&quot;We previously observed a cutaneous type IV immune response in nonhuman primates (NHP) with the mGlu5 negative allosteric modulator (NAM) 7. To determine if this adverse event was chemotype- or mechanism-based, we evaluated a distinct series of mGlu5 NAMs. Increasing the sp3 character of high-throughput screening hit 40 afforded a novel morpholinopyrimidone mGlu5 NAM series. Its prototype, (R)-6-neopentyl-2-(pyridin-2-ylmethoxy)-6,7-dihydropyrimido[2,1-c][1,4]oxazin-4(9H)-one (PF-06462894, 8), possessed favorable properties and a predicted low clinical dose (2 mg twice daily). Compound 8 did not show any evidence of immune activation in a mouse drug allergy model. Additionally, plasma samples from toxicology studies confirmed that 8 did not form any reactive metabolites. However, 8 caused the identical microscopic skin lesions in NHPs found with 7, albeit with lower severity. Holistically, this work supports the hypothesis that this unique toxicity may be mechanism-based although additional work is required to&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00604&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00604" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00604&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00604" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00604&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00604" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b00604&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00604&amp;href=/doi/10.1021/acs.jmedchem.7b00604" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.7b00604" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.7b00604" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00604&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.7b00604%26sid%3Dliteratum%253Aachs%26pmid%3D28817277%26genre%3Darticle%26aulast%3DStepan%26date%3D2017%26atitle%3DDiscovery%2Band%2BCharacterization%2Bof%2B%2528R%2529-6-Neopentyl-2-%2528pyridin-2-ylmethoxy%2529-6%252C7-dihydropyrimido%255B2%252C1-c%255D%255B1%252C4%255Doxazin-4%25289H%2529-one%2B%2528PF-06462894%2529%252C%2Ban%2BAlkyne-Lacking%2BMetabotropic%2BGlutamate%2BReceptor%2B5%2BNegative%2BAllosteric%2BModulator%2BProfiled%2Bin%2Bboth%2BRat%2Band%2BNonhuman%2BPrimates%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D60%26issue%3D18%26spage%3D7764%26epage%3D7780%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290758" title="Anatomy">Anatomy</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=291650" title="Alcohols">Alcohols</a>,</li><li><a href="/action/doSearch?ConceptID=291071" title="Nicotinamide">Nicotinamide</a>,</li><li><a href="/action/doSearch?ConceptID=292143" title="Metabolism">Metabolism</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/60/18" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/jmcmar.2017.60.issue-18/20170928/jmcmar.2017.60.issue-18.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00604/20170922/images/medium/jm-2017-006048_0012.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00604/20170922/images/large/jm-2017-006048_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00604&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">We previously observed a cutaneous type IV immune response in nonhuman primates (NHP) with the mGlu<sub>5</sub> negative allosteric modulator (NAM) <b>7</b>. To determine if this adverse event was chemotype- or mechanism-based, we evaluated a distinct series of mGlu<sub>5</sub> NAMs. Increasing the sp<sup>3</sup> character of high-throughput screening hit <b>40</b> afforded a novel morpholinopyrimidone mGlu<sub>5</sub> NAM series. Its prototype, (<i>R</i>)-6-neopentyl-2-(pyridin-2-ylmethoxy)-6,7-dihydropyrimido[2,1-<i>c</i>][1,4]oxazin-4(9<i>H</i>)-one (PF-06462894, <b>8</b>), possessed favorable properties and a predicted low clinical dose (2 mg twice daily). Compound <b>8</b> did not show any evidence of immune activation in a mouse drug allergy model. Additionally, plasma samples from toxicology studies confirmed that <b>8</b> did not form any reactive metabolites. However, <b>8</b> caused the identical microscopic skin lesions in NHPs found with <b>7</b>, albeit with lower severity. Holistically, this work supports the hypothesis that this unique toxicity may be mechanism-based although additional work is required to confirm this and determine clinical relevance.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81143" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81143" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Glutamate is the major excitatory neurotransmitter in the mammalian central nervous system (CNS) that exerts its signaling function through activation of both ionotropic (iGlus) and metabotropic glutamate receptors (mGlus). While iGlus are ligand-gated ion channels responsible for fast excitatory signaling, mGlus belong to class C of the G protein-coupled receptor superfamily that causes slower neurotransmission.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1, 2)</a> The eight identified mGlu subtypes are classified into groups I (mGlu<sub>1</sub>,<sub>5</sub>), II (mGlu<sub>2</sub>,<sub>3</sub>), and III (mGlu<sub>4,6–8</sub>) based on sequence homology, second messenger coupling, and pharmacology.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> The mGlu<sub>5</sub> receptor is localized postsynaptically and coupled to Gq/11 proteins that activate phospholipase C, which leads to hydrolysis of phosphoinositide and formation of the two intracellular secondary messengers, inositol triphosphate and diacylglycerol.<a onclick="showRef(event, 'ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref4 ref5">(4, 5)</a> Neurotherapeutic interest in mGlu<sub>5</sub> negative allosteric modulators (NAMs) is based on a plethora of preclinical data linking both mGlu<sub>5</sub> antagonism and mGlu<sub>5</sub> knockout mice to CNS disorders such as anxiety,<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> pain,<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> depression,<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> epilepsy,<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> neurodegeneration,<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Parkinson’s disease,<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> cocaine-dependence,<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> and fragile X syndrome (FXS).<a onclick="showRef(event, 'ref13 ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref13 ref14 ref15">(13-15)</a> Some of these indications have been tested clinically with the mGlu<sub>5</sub> NAMs <b>1</b> (AFQ056, mavoglurant; <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>), <b>2</b> (ADX48621, dipraglurant), and <b>3</b> (RG7090, basimglurant),<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> and <b>3</b> has been evaluated in a phase II clinical trial as an adjunct therapy for major depression. Although <b>3</b> did not meet its primary clinical end point, antidepressant effects across secondary end points based on patient-rated scores were noted.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Like the early mGlu<sub>5</sub>-selective antagonist <b>4</b> (MPEP),<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> clinical NAMs <b>1</b>–<b>3</b> contain an alkyne moiety, a potentially reactive motif that could lead to adverse safety findings, especially at daily doses >10 mg.<a onclick="showRef(event, 'ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref19 ref20">(19, 20)</a> To minimize the risk of such toxicities, medicinal chemists have recently identified alternative, alkyne-lacking mGlu<sub>5</sub> NAMs that have been reviewed previously<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> and are exemplified by phase I mGlu<sub>5</sub> NAM <b>5</b> (AZD9272)<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> and the amino-pyrimidine chemotype represented by compound <b>6</b> (VU0366058).<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00604/20170922/images/medium/jm-2017-006048_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00604/20170922/images/large/jm-2017-006048_0001.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of select mGlu<sub>5</sub> NAMs. (a) 2-Methyl-6-(phenylethynyl)pyridine (MPEP), one of the first subtype-selective mGlu<sub>5</sub> antagonists. (b) Clinical alkyne-containing mGlu<sub>5</sub> NAMs. (c) Recently disclosed alkyne-lacking mGlu<sub>5</sub> NAMs. (d) Alkyne-lacking mGlu<sub>5</sub> NAMs discovered by Pfizer.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00604/20170922/images/large/jm-2017-006048_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00604&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In our quest to identify alkyne-lacking mGlu<sub>5</sub> NAMs, we discovered 1-methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-ylmethoxy)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]-pyrazine (PF470, <b>7</b>),<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> a highly potent, selective, and orally bioavailable compound with robust efficacy in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-rendered Parkinsonian nonhuman primate (NHP) model of PD-LID (levodopa induced dyskinesia).<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> However, clinical progression of <b>7</b> was terminated due to findings consistent with an immune-mediated type IV hypersensitivity response in a 90-d NHP regulatory toxicology study.<a onclick="showRef(event, 'ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref25 ref26">(25, 26)</a> To understand if these adverse findings are most likely chemotype- or mechanism-based, we thoroughly profiled a novel series of mGlu<sub>5</sub> NAMs characterized by a central morpholinopyrimidone moiety, whose medicinal chemistry discovery and optimization effort is reported in this publication. The lead compound, (<i>R</i>)-6-neopentyl-2-(pyridin-2-ylmethoxy)-6,7-dihydropyrimido[2,1-<i>c</i>][1,4]oxazin-4(9<i>H</i>)-one (PF-06462894, <b>8</b>), had favorable biopharmaceutical properties, affording projected low daily oral doses and a long half-life in humans and was therefore profiled in both rat and NHP studies.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_13666" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_13666" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Chemistry</h3><div class="NLM_p">The synthesis of early leads <b>9</b>, <b>10</b>, and <b>11</b> employed a malonate condensation with an appropriate 2-aminopyridine to yield the pyrimidone core, which was alkylated to afford the final targets (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). Specifically, 2-aminopyridines <b>12</b> and <b>13</b> (<b>13</b> was readily synthesized in two steps from 3-hydroxypyridine, see <a href="/doi/suppl/10.1021/acs.jmedchem.7b00604/suppl_file/jm7b00604_si_001.pdf" class="ext-link">Supporting Information</a>) were condensed with bis(2,4,6-trichlorophenyl)malonate to afford hydroxypyrimidones <b>14</b> and <b>15</b>, respectively, which were etherified with either 3-chlorobenzyl bromide to yield analogues <b>9</b> and <b>10</b> or with 2-(bromomethyl)-6-methylpyridine to give compound <b>11</b>. Similarly, tetrahydropyridin-2-amine <b>16</b> and dihydro-oxazin-3-amine <b>17</b> were condensed with dimethyl malonate to afford the partially saturated cores <b>18</b> and <b>19</b>, which were subsequently alkylated with <i>m</i>-chlorobenzyl tosylate to give analogues <b>20</b> and <b>21</b>.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00604/20170922/images/medium/jm-2017-006048_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00604/20170922/images/large/jm-2017-006048_0004.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of the Early Lead mGlu<sub>5</sub> NAMs <b>9</b>, <b>10</b>, <b>11</b>, <b>20</b>, and <b>21</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00604/20170922/images/large/jm-2017-006048_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00604&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) bis(2,4,6-trichlorophenyl)malonate, 94% yield (in THF, 66 °C, for <b>14</b>) and 93% yield (in dioxane, 101 °C, for <b>15</b>); (ii) 3-chlorobenzyl bromide, TBAI or TBAB, acetone, reflux, 57% yield (for <b>9</b>) and 51% yield (for <b>10</b>); (iii) 2-(bromomethyl)-6-methylpyridine, Cs<sub>2</sub>CO<sub>3</sub>, NMP, 45 °C, 42% yield; (iv) CH<sub>2</sub>(CO<sub>2</sub>Me)<sub>2</sub>, NaOMe, methanol, 75 °C, 90% yield (for <b>18</b>) and 21% yield (for <b>19</b>); (v) <i>m</i>-chlorobenzyl tosylate, K<sub>2</sub>CO<sub>3</sub>, 58% yield (in DMF, 68 °C, for <b>20</b>) and 21% yield (in NMP, 50 °C, for <b>21</b>).</p></p></figure><div class="NLM_p">Two synthetic strategies were used to access the substituted morpholinopyrimidones shown in <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>. In the first strategy, amino alcohols <b>22a</b>/<b>d</b> were acylated with chloroacetyl chloride to give compounds <b>23a/d</b>, and a subsequent intramolecular alkylation then afforded morpholinones <b>24a/d</b> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>, method A). Their stepwise conversion first to imidates <b>25a/d</b> using Meerwein’s reagent and displacement with ammonium chloride gave amidines <b>26a/d</b>, which could be isolated as the hydrochloride salt or used without isolation. Condensation with dimethyl malonate afforded morpholinopyrimidone cores <b>27a/d.</b> Despite the relatively short length of this synthetic sequence, isolation and purification made high operational throughput challenging, thus we sought an approach that would allow more rapid access to the desired SAR.</div><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00604/20170922/images/medium/jm-2017-006048_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00604/20170922/images/large/jm-2017-006048_0005.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Pyrimidinones <b>8</b> and <b>30</b>–<b>39</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00604/20170922/images/large/jm-2017-006048_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00604&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) ClCH<sub>2</sub>COCl, TEA, THF, 0–20 °C; (ii) KO<i>t</i>Bu, THF, 0–20 °C; (iii) EtO<sub>3</sub>BF<sub>4</sub>, dichloromethane, 20 °C; (iv) NH<sub>4</sub>Cl, methanol, reflux; (v) CH<sub>2</sub>(CO<sub>2</sub>Me)<sub>2,</sub> NaOMe, methanol, reflux; (vi) chloroacetonitrile, NaOMe, MeOH, 20 °C; (vii) NaOMe, MeOH, 35 °C; (viii) (a) R<sub>2</sub>CH<sub>2</sub>OH, polymer-supported triphenylphosphine, DIAD, THF or (b) R<sub>2</sub>CH<sub>2</sub>Br, K<sub>2</sub>CO<sub>3</sub>, TBAB, acetone, 45 °C.</p></p></figure><div class="NLM_p">To improve throughput, an alternate means of accessing the requisite amidine was explored using a modification of a known procedure<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>, method B). Specifically, addition of catalytic amounts of methoxide to chloroacetonitrile afforded the corresponding imidate, which upon addition of amino alcohols <b>21b/c</b> gave acyclic amidines <b>28b/c</b>. Further addition of sodium methoxide effected alkylation to cyclic amidines <b>29b/c</b>, which were not isolated but condensed in the same reaction vessel with dimethyl malonate to provide the desired morpholinopyrimidones <b>27b/c</b>. The products isolated after only an aqueous workup were sufficiently pure to use directly, and a final etherification of hydroxypyrimidones <b>27a</b>–<b>d</b> was accomplished by either Mitsunobu conditions or alkylation in the presence of tetrabutylammonium bromide to give the key analogues <b>8</b> and <b>30</b>–<b>39</b>.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> The yields of this three-step, one-pot approach to cores <b>27b/c</b> were modest at best (typically <20%). However, the efficient throughput and limited physical manipulations enabled rapid access to a variety of novel hydroxypyrimidone cores despite the introduction of diversity in the first step. As such, this route represented a speed-to-compound approach and was used to quickly assess SAR in the series in both a singleton and parallel format. Preferred compounds were resynthesized through an optimized stepwise route favored for its higher yields and readily isolated intermediates, as illustrated by the large-scale synthesis of <b>8</b> and <b>38</b> (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>).</div><figure id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00604/20170922/images/medium/jm-2017-006048_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00604/20170922/images/large/jm-2017-006048_0006.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Large-Scale Synthesis of Key Analogue <b>8</b> and <b>38</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00604/20170922/images/large/jm-2017-006048_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00604&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) ClCH<sub>2</sub>COCl, K<sub>2</sub>CO<sub>3</sub>, THF/H<sub>2</sub>O, 0–20 °C; (ii) KO<i>t</i>Bu, <i>i</i>PrOH, 0–20 °C, 75% yield (over two steps, for <b>24c</b>) and 95% yield (over two steps, for <b>24e</b>); (iii) EtO<sub>3</sub>BF<sub>4</sub>, dichloromethane, 20 °C; (iv) NH<sub>4</sub>Cl, methanol, reflux; (v) CH<sub>2</sub>(CO<sub>2</sub>Me)<sub>2,</sub> NaOMe, methanol, reflux, 45% yield (over three steps, for <b>27c</b>) and 63% yield (over three steps, for <b>27d</b>); (vi) 2-Py-CH<sub>2</sub>OH, triphenylphosphine, DIAD, THF (62%); (vii) 3-cyanobenzyl alcohol, polymer-supported triphenylphosphine, DIAD, THF (78%).</p></p></figure><div class="NLM_p last">As shown in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>, key compounds <b>8</b> and <b>38</b> were prepared on scale starting from the amino alcohols <b>22c/d</b>. Acylation with chloroacetyl chloride to give <b>23c/d</b> was followed by an intramolecular alkylation to yield morpholinones <b>24c/d</b>. Stepwise conversion first to imidates <b>25c</b>/<b>d</b> using Meerwein’s reagent, then displacement with ammonium chloride, afforded the amidines <b>26c</b>/<b>d</b>, which were subsequently condensed with dimethyl malonate to afford the morpholinopyrimidone cores <b>27c</b>/<b>d.</b> Alkylation as described above yielded the final analogues <b>8</b> and <b>38</b>.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> In Vitro Pharmacology</h3><div class="NLM_p">Our effort to find alkyne-lacking mGlu<sub>5</sub> NAMs distinct from <b>7</b> (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>) began with a high-throughput screen (HTS) of our proprietary compound collection. As outlined previously,<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> this effort yielded 15 diverse chemotypes, one of which was pyridopyrimidone <b>40</b> (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>), a molecule structurally distinct from <b>7</b> and other reported mGlu<sub>5</sub> NAMs. Molecule <b>40</b> demonstrated a favorable, submicromolar mGlu<sub>5</sub> binding affinity (mGlu<sub>5</sub><i>K</i><sub>i</sub> = 194 nM) and functional inhibitory activity (mGlu<sub>5</sub> IC<sub>50</sub> = 168 nM). Additionally, <b>40</b> had moderate human liver microsome (HLM) stability (CL<sub>int,app</sub> = 33 mL/min/kg), high passive transcellular permeability (RRCK <i>P</i><sub>app,A→B</sub> = 26 × 10<sup>–6</sup> cm/s),<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> and no human P-glycoprotein liability (MDR1/MDCK BA/AB = 1.2).<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> The favorable balance of potency and metabolic stability of <b>40</b>, relative to lipophilicity (clogP = 1.6), is also reflected by lipophilic efficiency (LipE)<a onclick="showRef(event, 'ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref31 ref32">(31, 32)</a> and lipophilic metabolism efficiency (LipMetE)<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> values that are in a good range for an HTS starting point (<b>40</b>: LipE = 5.1, LipMetE = 0.06). As described previously,<a onclick="showRef(event, 'ref31 ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref31 ref32 ref33">(31-33)</a> these medicinal chemistry parameters can be used evaluate the design progression during lead optimization and are calculated as follows: LipE = −log(mGlu<sub>5</sub><i>K</i><sub>i</sub> in Molar) – clogP; LipMetE = clogD<sub>7.4</sub> – log(CL<sub>int,u</sub>); CL<sub>int,u</sub> is defined as the microsomal unbound clearance.</div><div class="NLM_p">Because of its desirable properties and structural novelty, analogue <b>40</b> was an ideal lead for further optimization. Initial SAR studies maintained the pyridopyrimidone core and revealed compounds (representative analogues are shown in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>) with an improved affinity relative to <b>40</b>. For example, replacing the thio-ether linker in <b>40</b> with an ether led to <b>9</b>, an analogue with a >20-fold improved human mGlu<sub>5</sub> binding affinity (mGlu<sub>5</sub><i>K</i><sub>i</sub> = 7 nM; the chloro-phenyl right-hand piece improves affinity by about 5-fold relative to the pyridyl side chain, vide infra). In addition, left-hand core substitution was tolerated with regard to affinity as exemplified by <b>10</b>, which has LipE and LipMetE values comparable to lead <b>40</b>, thus indicating efficient utilization of its added lipophilicity for affinity and microsomal stability (<b>10</b>: LipE = 4.6, LipMetE = 2.2, clogP = 3.8). Notably, despite the higher binding affinity of chloro-phenyl-containing <b>10</b> (mGlu<sub>5</sub><i>K</i><sub>i</sub> = 4.0 nM) relative to its methyl-pyridyl congener <b>11</b> (mGlu<sub>5</sub><i>K</i><sub>i</sub> = 31 nM), <b>11</b> resides in a more favorable CNS property space as exemplified by its lower clogP<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> (<b>10</b>, clogP = 3.8; <b>11</b>, clogP = 2.1) and higher TPSA (<b>10</b>, TPSA = 66 Å<sup>2</sup>; <b>11</b>, TPSA = 79 Å<sup>2</sup>). This is likely also reflected by the higher HLM stability (<b>10</b>, CL<sub>int,app</sub> = 26 mL/min/kg; <b>11</b>, CL<sub>int,app</sub> < 12 mL/min/kg) and passive permeability (<b>10</b>, RRCK = 7 × 10<sup>–6</sup> cm/s; <b>11</b>, RRCK = 24 × 10<sup>–6</sup> cm/s) of <b>11</b> relative to <b>10</b>. However, the in vivo receptor occupancy (IVRO) of <b>11</b> in rat [unbound plasma compound concentration (<i>C</i><sub>p,u</sub>)-derived IC<sub>50</sub> = 278 nM, vide infra] was significantly right-shifted, which prompted us to further optimize the properties of this series with a focus on increasing its intrinsic sp<sup>3</sup> character.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Early mGlu<sub>5</sub> NAM Leads</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00604/20170922/images/medium/jm-2017-006048_0007.gif" alt="" id="fx1" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last"><i>K</i><sub>i</sub> in HEK293FT cells expressing human mGlu<sub>5</sub> using [<sup>3</sup>H]MPEPy ([<sup>3</sup>H]3-methoxy-5-pyridin-2-ylethynylpyridine).</p></div><div class="footnote" id="t1fn2"><sup>Table b</sup><p class="last">IC<sub>50</sub> in HEK293 cells expressing rat mGlu<sub>5</sub> using a fluorimetric imaging plate reader (FLIPR) functional assay.</p></div><div class="footnote" id="t1fn3"><sup>Table c</sup><p class="last">Number of repetitions indicated in parentheses.</p></div><div class="footnote" id="t1fn4"><sup>Table d</sup><p class="last">IC<sub>50</sub> in HEK293 cells expressing human mGlu<sub>1</sub> using a FLIPR functional assay.</p></div><div class="footnote" id="t1fn5"><sup>Table e</sup><p class="last">Human liver microsomes-derived apparent intrinsic clearance.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a></p></div><div class="footnote" id="t1fn6"><sup>Table f</sup><p class="last">RRCK cells, isolated from Madin–Darby canine kidney (MDCK) cells and having low transporter activity, were used to estimate absorptive apparent permeability (<i>P</i><sub>app,A→B</sub>) of a compound (1 μM).<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a></p></div><div class="footnote" id="t1fn7"><sup>Table g</sup><p class="last">The ratio of secretory apparent permeability (<i>P</i><sub>app,B→A</sub>)-to-(<i>P</i><sub>app,A→B</sub>) of a compound (1 μM) across contiguous monolayers from human MDR1-transfected MDCK cells.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a></p></div><div class="footnote" id="t1fn8"><sup>Table h</sup><p class="last">Values for clogP were calculated using the BIOBYTE (<a href="http://www.biobyte.com" class="extLink">www.biobyte.com</a>) program clogP, version 4.3.</p></div><div class="footnote" id="t1fn9"><sup>Table i</sup><p class="last">TPSA is calculated using the Topological Polar Surface Area algorithm.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a></p></div></div><div></div></div><div class="NLM_p">It is well-documented that achiral compounds with high sp<sup>2</sup> character have a lower chance of clinical success than chiral compounds incorporating higher levels of saturation, partly as increased saturation correlates with increased aqueous solubility and a lower probability to interact with off-targets.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> As shown with <b>20</b>, we were able to readily increase the sp<sup>3</sup> character by replacing the central pyridopyrimidone moiety with its corresponding tetrahydro-version. Relative to <b>9</b>, compound <b>20</b> maintained binding at mGlu<sub>5</sub> (<b>9</b>, mGlu<sub>5</sub><i>K</i><sub>i</sub> = 7.0 nM; <b>20</b>, mGlu<sub>5</sub><i>K</i><sub>i</sub> = 10 nM), indicating that aromaticity adjacent to the pyrimidone moiety is not required for binding affinity. A total of four additional structures with increased aliphaticity were explored, and the morpholinopyrimidones, exemplified by <b>21</b>, were identified as the most favorable core with respect to affinity and properties (the SAR of additional cores is shown in the <a href="/doi/suppl/10.1021/acs.jmedchem.7b00604/suppl_file/jm7b00604_si_001.pdf" class="ext-link">Supporting Information</a>). As seen in <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>, <b>21</b> (mGlu<sub>5</sub><i>K</i><sub>i</sub> = 27 nM) largely maintained its affinity relative to <b>20</b> (mGlu<sub>5</sub><i>K</i><sub>i</sub> = 10 nM), while its higher polarity (<b>21</b>, cLogP = 1.3, TPSA = 53 Å<sup>2</sup>; <b>20</b>, cLogP = 3.0, TPSA = 44 Å<sup>2</sup>) somewhat increased HLM stability and passive permeability (<i>P</i><sub>app,A→B</sub>: <b>21</b>, CL<sub>int,app</sub> = 26 mL/min/kg <i>P</i><sub>app,A→B</sub> = 31 × 10<sup>–6</sup> cm/s; <b>20</b>, CL<sub>int,app</sub> < 40 mL/min/kg <i>P</i><sub>app,A→B</sub> = 26 × 10<sup>–6</sup> cm/s). Analogous to <b>10</b> and <b>11</b>, substituents on the left-hand portion of the core were tolerated and led to a significant improvement in affinity, with the (<i>R</i>)-isomers having a higher affinity than the (<i>S</i>)-isomers (see, for example: <b>31</b>, mGlu<sub>5</sub><i>K</i><sub>i</sub> = 1 nM; <b>30</b>, mGlu<sub>5</sub><i>K</i><sub>i</sub> = 3 nM).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. mGlu<sub>5</sub> NAMs with Increased Bond Saturation/3-Dimensionality Relative to the Initial HTS Leads</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00604/20170922/images/medium/jm-2017-006048_0008.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last"><i>K</i><sub>i</sub> in HEK293FT cells expressing human mGlu<sub>5</sub> using [<sup>3</sup>H]MPEPy ([<sup>3</sup>H]3-methoxy-5-pyridin-2-ylethynylpyridine).</p></div><div class="footnote" id="t2fn2"><sup>Table b</sup><p class="last">IC<sub>50</sub> in HEK293 cells expressing rat mGlu<sub>5</sub> using a fluorimetric imaging plate reader (FLIPR) functional assay.</p></div><div class="footnote" id="t2fn3"><sup>Table c</sup><p class="last">Number of repetitions indicated in parentheses.</p></div><div class="footnote" id="t2fn4"><sup>Table d</sup><p class="last">IC<sub>50</sub> in HEK293 cells expressing human mGlu<sub>1</sub> using a FLIPR functional assay.</p></div><div class="footnote" id="t2fn5"><sup>Table e</sup><p class="last">Human liver microsomes-derived apparent intrinsic clearance.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a></p></div><div class="footnote" id="t2fn6"><sup>Table f</sup><p class="last">RRCK cells, isolated from Madin–Darby canine kidney (MDCK) cells and having low transporter activity, were used to estimate absorptive apparent permeability (<i>P</i><sub>app,A→B</sub>) of a compound (1 μM).<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a></p></div><div class="footnote" id="t2fn7"><sup>Table g</sup><p class="last">The ratio of secretory apparent permeability (<i>P</i><sub>app,B→A</sub>)-to-(<i>P</i><sub>app,A→B</sub>) of a compound (1 μM) across contiguous monolayers from human MDR1-transfected MDCK cells.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a></p></div><div class="footnote" id="t2fn8"><sup>Table h</sup><p class="last">Values for clogP were calculated using the BIOBYTE (<a href="http://www.biobyte.com" class="extLink">www.biobyte.com</a>) program clogP, version 4.3.</p></div><div class="footnote" id="t2fn9"><sup>Table i</sup><p class="last">TPSA is calculated using the Topological Polar Surface Area algorithm.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a></p></div></div><div></div></div><div class="NLM_p">To improve the moderate lability in HLM (CL<sub>int,app</sub> = 39 mL/min/kg) and passive permeabilty (<i>P</i><sub>app,A→B</sub> = 4 × 10<sup>–6</sup> cm/s) of <b>31</b>, further SAR exploration focused on variations of the ether side chain and the benzyl substituent on the morpholino moiety. As shown in <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>, a range of 5- and 6-membered heteroaromatic rings yielded compounds with good mGlu<sub>5</sub> affinity (e.g., <b>32</b>–<b>35</b>, mGlu<sub>5</sub><i>K</i><sub>i</sub> = 3.8–16 nM), with the 2-pyridyl ether <b>32</b> offering the best combination of affinity (mGlu<sub>5</sub><i>K</i><sub>i</sub> = 10 nM) and low HLM turnover (CL<sub>int,app</sub> = 8.7 mL/min/kg). As indicated by analogue <b>36</b> (mGlu<sub>5</sub><i>K</i><sub>i</sub> = 98 nM), aromaticity was required for affinity in the right-hand portion of the series of molecules. However, the sp<sup>3</sup> character of analogues such as <b>32</b> could be further increased by replacing the phenyl group in the left-hand portion with aliphatic moieties (<b>8</b>, <b>37</b>–<b>39</b>), indicating that the activity of the benzyl substituent in <b>32</b> was due to lipophilic rather than π-system interactions. As such, <b>8</b> and <b>38</b> offered the most favorable combination of high affinity (mGlu<sub>5</sub><i>K</i><sub>i</sub> ≤ 6.1 nM), HLM stability (CL<sub>int,app</sub> < 8 mL/min/kg), and high passive permeability (<i>P</i><sub>app,A→B</sub> ≥ 28 × 10<sup>–6</sup> cm/s), which is reflected by a favorable balance of LipE and LipMetE values (LipE ≥ 6.7 and LipMetE ≥ 0.5 for both <b>8</b> and <b>38</b>).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. In Vitro Pharmacology, in Vitro ADME, and Physicochemical Properties of the Key mGlu<sub>5</sub> NAMs</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00604/20170922/images/medium/jm-2017-006048_0009.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00604/20170922/images/medium/jm-2017-006048_0010.gif" alt="" id="GRAPHIC-d38e1948-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>Table a</sup><p class="last"><i>K</i><sub>i</sub> in HEK293FT cells expressing human mGlu<sub>5</sub> using [<sup>3</sup>H]MPEPy ([<sup>3</sup>H]3-methoxy-5-pyridin-2-ylethynylpyridine).</p></div><div class="footnote" id="t3fn2"><sup>Table b</sup><p class="last">IC<sub>50</sub> in HEK293 cells expressing rat mGlu<sub>5</sub> using a fluorimetric imaging plate reader (FLIPR) functional assay.</p></div><div class="footnote" id="t3fn3"><sup>Table c</sup><p class="last">Number of repetitions indicated in parentheses.</p></div><div class="footnote" id="t3fn4"><sup>Table d</sup><p class="last">Human liver microsomes-derived apparent intrinsic clearance.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a></p></div><div class="footnote" id="t3fn5"><sup>Table e</sup><p class="last">RRCK cells, isolated from Madin–Darby canine kidney (MDCK) cells and having low transporter activity, were used to estimate absorptive apparent permeability (<i>P</i><sub>app,A→B</sub>) of a compound (1 μM).<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a></p></div><div class="footnote" id="t3fn6"><sup>Table f</sup><p class="last">The ratio of secretory apparent permeability (<i>P</i><sub>app,B→A</sub>)-to-(<i>P</i><sub>app,A→B</sub>) of a compound (1 μM) across contiguous monolayers from human MDR1-transfected MDCK cells.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a></p></div><div class="footnote" id="t3fn7"><sup>Table g</sup><p class="last">Values for clogP were calculated using the BIOBYTE (<a href="http://www.biobyte.com" class="extLink">www.biobyte.com</a>) program clogP, version 4.3.</p></div><div class="footnote" id="t3fn8"><sup>Table h</sup><p class="last">TPSA is calculated using the Topological Polar Surface Area algorithm.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a></p></div></div><div></div></div><div class="NLM_p">A binding model of <b>8</b> to mGlu<sub>5</sub> transmembrane domain (mGlu<sub>5</sub> TMD) was built by both traditional docking<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> and induced-fit docking<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> based on the X-ray crystal structure of mGlu<sub>5</sub> TMD with <b>1</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4OO9">4OO9</a>).<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> The induced-fit docking method produces a reasonable model to explain the observed structure–activity relationship (see <a href="/doi/suppl/10.1021/acs.jmedchem.7b00604/suppl_file/jm7b00604_si_001.pdf" class="ext-link">Supporting Information</a>). In this model, <b>8</b> occupies the binding site in a similar fashion to <b>1</b> (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>). The morpholinopyrimidone ring of <b>8</b> overlays with the bicycle of <b>1</b>, and the <i>t</i>-butyl group is positioned toward the extracellular region in the pocket formed by Val-740<sup>5.40</sup>, Ile-651<sup>3.36</sup>, and Leu-744<sup>5.44</sup>, favoring the (<i>R</i>)-isomer (<b>30</b> vs <b>31</b>, <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). Meanwhile, the pyridine ring aligns with the 3-methylphenyl ring of <b>1</b>, situated between Pro-655<sup>3.40</sup> and Ala-810<sup>7.40</sup>. The induced-fit docking study demonstrates different interaction motifs of <b>8</b> in the binding site that are not observed with <b>1</b>. The morpholinopyrimidone carbonyl accepts a hydrogen bond from Asn-474<sup>5.47</sup>. Because of the absence of a hydroxyl group as in <b>1</b>, Ser-805<sup>7.35</sup> does not interact with <b>8</b> directly, but with the backbone carbonyl of Thr-801<sup>7.31</sup> (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>B). At the same time, the pyridine ring of <b>8</b> accepts a hydrogen bond from Tyr-659<sup>3.44</sup> hydroxyl. Because this tyrosine hydroxyl could also interact with the buried crystal water in the <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4OO9">4OO9</a> structure,<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> one could envision that in the absence of a pyridine nitrogen (as in <b>31</b>, <b>34</b>, <b>38</b>, and <b>39</b>), the tyrosine hydroxyl could switch its interaction to the crystal water, consistent with the observation that the pyridine nitrogen is not critical for activity. A nonaromatic substituent at the R2 position, such as in <b>36</b>, is less favorable in the flat pocket formed by Pro-655<sup>3.40</sup> and Ala-810<sup>7.40</sup>. Similarly, <i>meta</i>-substitution of the aryl ring, such as in <b>33</b> and <b>39</b>, improves activity because it reaches further into the binding pocket, similar to the methyl group on the phenyl ring in <b>1</b> (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>B).</div><figure id="fig2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00604/20170922/images/medium/jm-2017-006048_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00604/20170922/images/large/jm-2017-006048_0002.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Binding model of <b>8</b>. (A) Compound <b>8</b> binds in the region similar to <b>1</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4OO9">4OO9</a>), mostly formed by TM3, TM5, and TM7. (B) At an atomic level, <b>8</b> binds to mGlu<sub>5</sub> with unique interactions to Asn-747<sup>5.47</sup> and Tyr-659<sup>3.44</sup>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00604/20170922/images/large/jm-2017-006048_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00604&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> in Vivo Studies with <b>8</b> and <b>38</b></h3><div class="NLM_p">Having discovered <b>8</b> and <b>38</b> as mGlu<sub>5</sub> NAMs in the desired property space based on their in vitro pharmacological and absorption, distribution, metabolism, and excretion (ADME) profiles, both compounds underwent pharmacokinetic (PK) studies in rats and NHP (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). From a neuropharmacokinetic perspective in rats, <b>8</b> and <b>38</b> had net equilibrium at the blood–brain barrier with parallel elimination rates in both central and peripheral compartments. In both rats and NHP, <b>8</b> had high total blood clearance (<i>CL</i><sub>b</sub>), low steady-state volume of distribution (<i>V</i><sub>ss</sub>), short half-life (<i>t</i><sub>1/2</sub>), and low oral bioavailability (<i>F</i>). Alternatively in these species, <b>38</b> had moderate CL<sub>b</sub> and <i>V</i><sub>ss</sub>, short-to-moderate <i>t</i><sub>1/2</sub>, and moderate <i>F</i>. Because of both compounds’ lack of metabolism in interpecies intestinal microsomes (data not shown) and inherent high permeability, the observed low-to-moderate <i>F</i> of <b>8</b> and <b>38</b> seemed predominately due to hepatic first-pass extraction.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Pharmacokinetic Parameters of Compounds <b>8</b> and <b>38</b> in Rats and NHPs</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00604/20170922/images/medium/jm-2017-006048_0011.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>Table a</sup><p class="last">Unbound fraction of compound in brain homogenate.</p></div><div class="footnote" id="t4fn2"><sup>Table b</sup><p class="last">Unbound fraction of compound in plasma.</p></div><div class="footnote" id="t4fn3"><sup>Table c</sup><p class="last">For rat, an AUC<sub>0–4</sub>-derived ratio of unbound brain compound concentration-to-unbound plasma compound concentration determined from a rat neuropharmacokinetics study (0.32 or 1 mg/kg, SC; <i>N</i> = 2/time point). For NHP, a single time point-derived ratio from the 14-d NHP ETS (600 mg/kg, PO; <i>N</i> = 1; 7.65 h postdose on day 1); <i>C</i><sub>b,u</sub> was calculated using an average of frontal cortex and cerebellum concentrations of <b>8</b> and rat <i>f</i><sub>u,b</sub>.</p></div><div class="footnote" id="t4fn4"><sup>Table d</sup><p class="last">Observed blood clearance (CL<sub>b</sub>) following a single IV bolus (0.3 or 1 mg/kg studies, <i>N</i> = 2/species).</p></div><div class="footnote" id="t4fn5"><sup>Table e</sup><p class="last">Steady-state volume of distribution.</p></div><div class="footnote" id="t4fn6"><sup>Table f</sup><p class="last">Half-life.</p></div><div class="footnote" id="t4fn7"><sup>Table g</sup><p class="last">Bioavailability was calculated from the mean observed AUC<sub>0–∞</sub> following doses (<i>N</i> = 2/dose) of 1 mg/kg, IV, and 25 or 30 mg/kg, PO, in rats or NHP, respectively.</p></div><div class="footnote" id="t4fn8"><sup>Table h</sup><p class="last">An IVRO- or PET-determined value for rat or NHP, respectively.</p></div></div><div></div></div><div class="NLM_p">With favorable pharmacokinetics for in vivo profiling, the exposure-mGlu<sub>5</sub> receptor occupancy (RO) relationship for both <b>8</b> and <b>38</b> were defined in rats by an in vivo binding assay using [<sup>3</sup>H]3-methoxy-5-pyridin-2-ylethynylpyridine ([<sup>3</sup>H]MPEPy) and application of a direct-response model.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> The <i>C</i><sub>p,u</sub>-derived IC<sub>50</sub> [95% confidence interval (CI)] for <b>8</b> and <b>38</b> were 4.21 (3.54, 4.98) nM and 6.67 (5.13, 8.58) nM, respectively (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>), thus 40–60-fold left-shifted relative to that of the original lead <b>11</b> (<i>C</i><sub>p,u</sub>-derived IC<sub>50</sub> = 278 nM, see <a href="/doi/suppl/10.1021/acs.jmedchem.7b00604/suppl_file/jm7b00604_si_001.pdf" class="ext-link">Supporting Information</a> for IVRO curve, vide supra). On the basis of its favorable PK and rat in vivo RO profile, <b>38</b> advanced to a 14-d rat exploratory toxicology study (ETS). Adverse findings (based on degenerative effects in the liver of rats and monkeys, see <a href="/doi/suppl/10.1021/acs.jmedchem.7b00604/suppl_file/jm7b00604_si_001.pdf" class="ext-link">Supporting Information</a> for details) different from those described in this paper (vide infra) led <b>38</b> to have an insufficient therapeutic index (TI). Unlike compound <b>8</b> (vide infra), <b>38</b> was therefore not further developed. Subsequently, using previously described dosing methodology with positron emission tomography (PET) and [<sup>18</sup>F]FPEB,<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> the NHP <i>C</i><sub>p,u</sub>-derived IC<sub>50</sub> (95% CI) of <b>8</b> was determined to be 2.68 (1.34, 4.41) nM. For <b>8</b>, the mGlu<sub>5</sub> RO versus <i>C</i><sub>p,u</sub> in rats and NHP, as well as representative NHP PET displacement images, are shown in <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>. The excellent consistency between human in vitro <i>K</i><sub>i</sub> and <i>C</i><sub>p,u</sub>-based IC<sub>50</sub> in both rats and NHP provided high confidence in the quantitative clinical translatability of the binding interactions of <b>8</b> with mGlu<sub>5</sub>. Essentially equivalent IC<sub>50</sub> values in rats and NHP also suggested similar interneurocompartmental relationships in both species, which is to be expected<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> for a non-P-glycoprotein/non-BCRP substrate, demonstrating equilibrium at the blood–brain barrier in rats. This was ultimately confirmed by empirically determining <i>C</i><sub>b,u</sub>:<i>C</i><sub>p,u</sub> in both species (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). However, instead of next using these exposure-RO data to determine the RO at which it might attenuate the levodopa induced dyskinesia in MPTP-rendered parkinsonian NHP (i.e., “efficacy”),<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> compound <b>8</b> was immediately progressed to rat and NHP toxicology studies. This strategic decision was directly based on our prior experience<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> in NHP with the structurally distinct mGlu<sub>5</sub> NAM <b>7</b> that had significant effectiveness in this model<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> of PD-LID at an RO of 77 < <i>x</i> ≤ 90%. Integration of the collective in vitro and preclinical in vivo properties with expected efficacy at 80% mGlu<sub>5</sub> RO (human <i>C</i><sub>p</sub> of 31 ng/mL) projected <b>8</b> to display clinically low CL<sub>p</sub> (1.4 mL/min/kg), moderate <i>V</i><sub>ss</sub> (1.0 L/kg) and <i>t</i><sub>1/2</sub> (8 h), and high <i>F</i> (91%) to afford a 2 mg BID (bis in die) dosing regimen to maintain 80% RO as an average central concentration at steady-state.</div><figure id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00604/20170922/images/medium/jm-2017-006048_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00604/20170922/images/large/jm-2017-006048_0003.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A,B) mGlu<sub>5</sub> RO vs unbound plasma concentration (<i>C</i><sub>p,u</sub>) of compound <b>8</b> in rats and NHPs, respectively. (C) Coronal views of [<sup>18</sup>F]FPEB-dependent PET images from a NHP receiving vehicle (baseline) and <b>8</b> (displacement) at 65% RO (0.00682 mg/kg bolus + 0.00772 mg/kg/h infusion over 2 h) and 90% RO (0.0274 mg/kg bolus + 0.0310 mg/kg/h infusion over 2 h), respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00604/20170922/images/large/jm-2017-006048_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00604&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> in Vitro and in Vivo Safety Profile of <b>8</b></h3><div class="NLM_p">Broader selectivity screening with <b>8</b> (10 μM) demonstrated no significant activities (i.e., IC<sub>50</sub> or EC<sub>50</sub> > 10 μM) in kinase panels, a proprietary phospodiesterase panel and a broad spectrum BioPrint panel, in which the μ opioid receptor had the greatest interaction (EC<sub>20</sub> of 10 μM, see <a href="/doi/suppl/10.1021/acs.jmedchem.7b00604/suppl_file/jm7b00604_si_001.pdf" class="ext-link">Supporting Information</a> for the complete list of off-targets profiled). Compound <b>8</b> further differentiated from <b>7</b> in the mouse allergy model (MAM),<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> an in vivo model developed internally to predict the allergenic potential of systemically administered low molecular weight drugs.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> In this model, draining lymph node cellularity is determined by flow cytometry following a once daily subcutaneous injection of test compound for three consecutive days. A stimulation index (SI; mean total lymph node cell number in the drug-treated group/mean total lymph node cell number in the vehicle control group) of >2.5 is considered a positive response in the model. There appears to be a good correlation between drugs associated with hypersensitivity reactions in the clinic and a positive response in the MAM.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> Because several pieces of data suggested that the skin lesions observed in the NHP regulatory toxicology study with <b>7</b> were immune-mediated, the MAM was used as a tool to assess the allergenic potential of <b>8</b> compared to <b>7</b>. Whereas <b>7</b> resulted in a positive response (SI > 5.4), compound <b>8</b> was negative (SI values ≤ 1.7, <i>n</i> = 3 experiments), indicating low potential for hypersensitivity reactions.</div><div class="NLM_p">Because of the favorable in vitro and in vivo profile of <b>8</b> and its differentiation from <b>7</b> in the MAM, the safety of <b>8</b> was subsequently assessed in 14-d exploratory toxicology studies (ETS) in rats and NHPs (i.e., cynomolgus macaques). As reported previously<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> and summarized in <a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>, in rats at 50, 150, or 500 mg/kg/d (PO; <i>N</i> = 3/gender/dose), no adverse clinical or histopathological findings were observed up to a steady-state AUC<sub>0–24</sub>-based exposure that was 448 times the 80% RO (500 mg/kg/d). In NHPs (50, 150, and 600 mg/kg/d, PO, <i>N</i> = 1/gender/dose), 600 mg/kg/d was poorly tolerated in the female, resulting in early euthanasia on day 1, although this occurred without clinical or microscopic evidence of skin toxicity. In the remaining animals at 50 and 150 mg/kg/d, the compound was clinically tolerated for the duration of the study (14 days) reaching steady-state AUC<sub>0–24</sub>-based exposures up to 86 times the 80% RO. However, at this exposure (150 mg/kg/d), histopathological analysis detected microscopic lesions in skin (chest, scrotum) and oral mucosa that were identical to those observed in the 90-day toxicology study with <b>7</b>. Although these skin lesions were of lower severity relative to those observed with <b>7</b>, the similar histopathological characteristics<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> indicated that both were due to the same underlying pathogenesis. As described by Palanisamy,<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> collectively, the microscopic features of these skin lesions, including the cellular makeup and distribution of the inflammatory infiltrate and the time of onset for lesion development were consistent with a delayed type IV hypersensitivity reaction.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Rat (14-d) and NHP (14-d) ETS Summary for <b>8</b>.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="left" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="rowsep1 colsep0" colspan="3" align="center">rat (3/gender/dose group)</th><th class="rowsep1 colsep0" colspan="3" align="center">NHP (1/gender/dose group)<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">dose (mg/kg/d)</th><th class="colsep0 rowsep0" align="center">total AUC<sub>0–24</sub> (ng·h/mL) day 13</th><th class="colsep0 rowsep0" align="center">histopathological findings<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">dose (mg/kg/d)</th><th class="colsep0 rowsep0" align="center">total AUC<sub>0–24</sub> (ng·h/mL) day 13</th><th class="colsep0 rowsep0" align="center">histopathological findings<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">50</td><td class="colsep0 rowsep0" align="center">23200 (33)<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="center">NTR<a class="ref internalNav" href="#t5fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">50</td><td class="colsep0 rowsep0" align="center">3680 (7)<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="center">NTR</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">150</td><td class="colsep0 rowsep0" align="center">117000 (168)<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="center">NTR</td><td class="colsep0 rowsep0" align="left">150</td><td class="colsep0 rowsep0" align="center">45400 (86)<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="center">interface lymphocytic inflammation, minimal (M)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">500</td><td class="colsep0 rowsep0" align="center">313000 (448)<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="center">NTR</td><td class="colsep0 rowsep0" align="left">600</td><td class="colsep0 rowsep0" align="center">41500 (78)<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a>,<a class="ref internalNav" href="#t5fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="center">NTR</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">The female in the 600 mg/kg/d group was euthanized on day 1 due to adverse clinical observations.</p></div><div class="footnote" id="t5fn2"><sup>b</sup><p class="last">Test article-related effects from skin sections collected from the chest, genital areas, and from oral mucosa.</p></div><div class="footnote" id="t5fn3"><sup>c</sup><p class="last">Therapeutic index based on 80% mGlu<sub>5</sub> RO.</p></div><div class="footnote" id="t5fn4"><sup>d</sup><p class="last">NTR, no treatment-related findings.</p></div><div class="footnote" id="t5fn5"><sup>e</sup><p class="last"><i>N</i> = 1; emesis, observed within 1 h of dosing, may have affected exposure.</p></div></div></div><div class="NLM_p">Interestingly, <b>8</b> did not form any detectable glutathione adducts in liver microsomes (±NADPH),<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> suggesting neither itself nor its CYP-generated metabolic intermediates/metabolites form macromolecular adducts in vivo (see <a href="/doi/suppl/10.1021/acs.jmedchem.7b00604/suppl_file/jm7b00604_si_001.pdf" class="ext-link">Supporting Information</a>). Furthermore, due to the possibility of toxicity being metabolite-dependent, both rat (500 mg/kg/d) and NHP (150 mg/kg/d) plasma samples [day 1 and day 12 (rat) or day 13 (NHP)] from the respective 14-d ETS underwent qualitative metabolite profiling using UV-supplemented LC-MS/MS; a quantitative analysis could not be performed due to the use of nonradiolabeled <b>8</b> and the lack of an authentic standard for each detected metabolite. In both species, <b>8</b> had complex metabolite profiles but showed structurally common metabolites with no differences in plasma metabolite profiles acutely (day 1) and at steady-state (day 12 or day 13) within or across genders. In NHP, 23 different metabolites were observed with the most abundant (based on both UV and MS signals) metabolites arising from monohydroxylation (6 metabolites), <i>N</i>-oxygenation (1), <i>O</i>-dealkylation (1), morpholine-opening (1), and glucuronidation of primary metabolites (10). The respective interspecies biotransformation data for <b>8</b> and <b>7</b><a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> are highly consistent and show no evidence that is compelling enough to suggest a common metabolite or metabolite substructure is responsible for the NHP-specific toxicity induced by both compounds.</div><div class="NLM_p last">We have previously proposed that the cutaneous type IV immune response in NHPs observed with mGlu<sub>5</sub> NAM <b>7</b> may be due to a mechanism-based event. As reported herein, <b>8</b> leads to the identical microscopic skin lesions in NHPs found with <b>7</b>, although the skin lesions with <b>8</b> are of reduced severity relative to those with compound <b>7</b>. In our opinion, this supports the hypothesis that this skin toxicity is mechanism-, not compound-, mediated, because we believe compounds <b>7</b> and <b>8</b> are from structurally distinct series. This is supported by the finding that compounds <b>7</b> and <b>8</b> have distinct fingerprints in a phenotypic screen using standardized panels of human primary cell/coculture systems.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> In addition, both compounds have seemingly innocuous secondary pharmacological profiles without any intrinsic (or metabolism-dependent) chemical reactivity. It is worth noting, however, that additional work is required for the unequivocal confirmation of this hypothesis because the current data cannot fully rule out that an unidentified commonality between molecules <b>7</b> and <b>8</b> caused the adverse skin reactions. For example, while the ancillary pharmacology of both compounds has been screened extensively, exhaustive screening is not feasible and it is possible that both <b>7</b> and <b>8</b> have an effect at an unknown off-target that triggered the skin lesions. We have also not resynthesized the metabolites of <b>7</b> and <b>8</b> to fully characterize their primary and secondary pharmacology, and it cannot completely be ruled out that a metabolite common to compounds <b>7</b> and <b>8</b> caused the type IV immune response in NHPs. Additional work is also necessary to understand why similar adverse events were not observed preclinically with other mGlu<sub>5</sub> NAMs, especially with compounds that advanced into clinical development (i.e., compounds <b>1</b>, <b>2</b>, and <b>3</b>).</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_03822" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_03822" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In summary, we have developed a series of alkyne-lacking mGlu<sub>5</sub> NAMs with favorable physicochemical properties and ADME characteristics. Our design strategy was guided by increasing the three-dimensionality of our early leads <b>9</b>, <b>10</b> and <b>11</b> by introducing bond saturation within the central core structure. In vitro and in vivo profiling in both rats and NHPs predicted lead <b>8</b> to require low clinically therapeutic doses (2 mg BID) to achieve an average of 80% mGlu<sub>5</sub> RO at steady state. Despite these positive attributes, further development of <b>8</b> was stopped due to microscopic skin lesions in NHP, which were classified as a type IV immune response analogous to the observations with our prior candidate <b>7</b>.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Compound <b>8</b> does not have any known significant off-target activities, and the characterization of plasma samples from both rat and NHP toxicology studies suggest it does not form any reactive metabolites. In addition, <b>8</b> did not lead to immune activation in a mouse drug allergy model. In totality, the results support the hypothesis that in NHP these adverse findings may have been caused by functionally blocking mGlu<sub>5</sub>. Additional work is required to rule out any other causes for this common skin reaction with compounds <b>7</b> and <b>8</b>. It is currently also unknown why a similar adverse event has not been reported with any of the clinical mGlu<sub>5</sub> NAMs <b>1</b>, <b>2</b>, and <b>3</b>. Finally, it will be important to understand the translatability of this NHP finding to humans in order to adequately assess the clinical safety of the mGlu<sub>5</sub> NAM mechanism. However, because of the risk of a similar skin toxicity in humans and its clinically nonmonitorable nature, the described work led to the discontinuation of both <b>8</b> and the Pfizer mGlu<sub>5</sub> NAM program.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34030" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34030" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Biology</h3><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18"> Recombinant Human mGlu<sub>5</sub> Radioligand Binding Assay</h4><div class="NLM_p last">Binding studies were performed in HEK-293FT cells transiently transfected with the human mGlu<sub>5</sub> as reported previously.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a></div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> mGlu<sub>5</sub> and mGlu<sub>1</sub>-Mediated Inhibition of Calcium Flux in HEK-293 Cells Expressing Rat mGlu<sub>5</sub> or Human mGlu<sub>1</sub> Using FLIPR</h4><div class="NLM_p last">The FLIPR assay was performed HEK-293 cells stably expressing rat mGlu<sub>5</sub> or human mGlu<sub>1</sub> as reported previously.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a></div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> Rat in Vivo Receptor Occupancy (IVRO) Studies</h4><div class="NLM_p last">Animals used were Sprague–Dawley male rats aged 7–8 weeks purchased from Charles River Laboratories (Wilmington, MA). All procedures performed on animals in this study were in accordance with established guidelines and regulations and were reviewed and approved by the Pfizer Institutional Animal Care and Use Committee. Pfizer animal care facilities that supported this work are fully accredited by AAALAC International. Jugular vein cannulated male Sprague–Dawley rats (150–200 g; Charles River Laboratories) were administered compounds <b>8</b>, <b>11</b>, or <b>38</b> (sc) at 2 mL/kg body weight 1 h prior to euthanasia. [<sup>3</sup>H]MPEPy (30 Ci/kg) was administered intravenously at 1 mL/kg body weight 1 min prior to euthanasia. After the treatment period, rats were humanely euthanized by rapid decapitation. The forebrain (whole brain minus cerebellum was rapidly dissected, weighed, and homogenized in 10 volumes of ice-cold assay buffer (10 mM K<sub>2</sub>HPO<sub>4</sub>, 100 mM KCl, pH 7.4) for 3–5 s using a Brinkmann polytron homogenizer at its highest setting. Three replicates (400 μL) of the homogenate were filtered using a vacuum manifold filtration system fitted with 25 mm Whatman GF/B filters soaked in assay buffer. The filters were immediately washed (2 × 5 mL assay buffer) and transferred to scintillation vials where they soaked overnight in Ultima Gold (PerkinElmer) scintillation cocktail before counting in a Tri-Carb liquid scintillation counter (PerkinElmer). Total binding was determined by measuring radioactivity in vehicle treated animals, while nonspecific binding was determined using animals treated with a saturating dose of MPEP (50 mg/kg, sc).</div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> Nonhuman Primate (NHP) Positron Emission Tomography (PET) Studies</h4><div class="NLM_p last">This study employed 2 male cynomolgus monkeys (11–12 years old). Each subject underwent three positron emission tomography (PET) scans with the radiotracer [<sup>18</sup>F]FPEB: at baseline and after pretreatment with 2 doses of <b>8</b> (0.00682 or 0.0274 mg/kg iv bolus plus 0.00772 or 0.03103 mg/kg/h infusion, respectively), targeting mGlu<sub>5</sub> RO of 50 and 80%, respectively. The PET scanning procedures and data analysis methods have been reported in detail previously.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> All procedures performed on animals in this study were in accordance with established guidelines and regulations and were reviewed and approved by the Pfizer Institutional Animal Care and Use Committee. Pfizer animal care facilities that supported this work are fully accredited by AAALAC International.</div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Chemistry</h3><div class="NLM_p">Unless specified otherwise, starting materials were available from commercial sources. Dry solvents and reagents were of commercial quality and were used as purchased. Prior to use, polymer supported triphenylphosphine was washed sequentially with methanol (3×), dichloromethane (3×), and diethyl ether (3×) and then dried in vacuo. <sup>1</sup>H NMR spectra were recorded on Varian INOVA spectrometers (400, 500, or 600 MHz; Varian Inc., Palo Alto, CA) at room temperature. Chemical shifts are expressed in parts per million δ relative to residual solvent as an internal reference. Peak multiplicity is reported as observed and is expressed as follows: singlet (s), doublet (d), triplet (t), quartet (q), multiplet (m), and broad singlet (br s). The purity of title compounds used in pharmacology testing was verified by HPLC-MS using the following method: 12 min gradient on a HP1100C pump of an acetonitrile in water gradient (5 → 95%) containing 0.1% formic acid with a flow rate of 1 mL/min and UV detection at λ 220 and 254 nm on a Gemini C18 150 mm × 4.6 mm, 5 μm column (Phenomenex, Torrance, CA). Title compounds used in pharmacology testing were >95% pure. Melting points were determined on a Stanford Research Systems Optimelt MPA100 automated melting point system at 3 °C/min. Electrospray ionization mass spectra were obtained on a Waters ZQ and ZMD instrument (Milford, MA) mass spectrometer operated in positive or negative ionization mode using nitrogen as a carrier gas. All synthetic reactions were carried out under nitrogen atmosphere or in sealed vials.</div><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> General Procedure A (Alkylation of Hydroxypyrimidones under Basic Conditions)</h4><div class="NLM_p last">The hydroxypyrimidone (1 equiv), potassium carbonate (2 equiv), and tetrabutylammonium bromide (0.1 equiv) were suspended in acetone at 20 °C and heated to 45 °C. The halide was added, and the temperature was increased to 60–75 °C. The reaction mixture was heated for 1–24 h. Upon reaction completion, as indicated by TLC and/or LC-MS, the reaction was cooled to 20 °C, filtered, and concentrated in vacuo. Purification by column chromatography afforded the final products.</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> General Procedure B (Alkylation of Hydroxypyrimidones under Mitsunobu Conditions)</h4><div class="NLM_p last">The hydroxypyrimidone (1.0 equiv), alcohol (1.0 equiv), and triphenylphosphine (1.3 equiv) or polymer-supported triphenylphosphine (2.0 equiv) were suspended in tetrahydrofuran (∼0.12 M). Diisopropylazodicarboxylate (1.5 equiv) was added dropwise, and the resulting yellow solution was stirred at 20 °C. Reactions were monitored by LC-MS, typically reaching completion in less than 2 h, but were generally allowed to stir overnight. After reaction completion, the solvent was removed in vacuo and the crude material was purified by column chromatography to afford the final products. If polymer-supported triphenylphosphine was used, the reactions were filtered prior to concentration and purification.</div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> General Procedure C (One-Pot Hydroxypyrimidone Synthesis Shown in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>, Method B)</h4><div class="NLM_p last">To a solution of chloroacetonitrile (1.1 equiv) in methanol (∼3.6 M solution) was added sodium methoxide (25% in methanol, 0.05 equiv). The reaction mixture was stirred at 20 °C for 1 h. The amino alcohol (1.0 equiv), dissolved in methanol (∼3.3 M solution), was added at 20 °C using an addition funnel over a period of 2–3 min, and the resulting mixture was stirred for 24 h. Sodium methoxide (25% in methanol, 1.5 equiv) was then added, and the resulting mixture was heated at 35 °C for 2.5 h. Dimethyl malonate (1.0 equiv) was then added via syringe followed by sodium methoxide (25% in methanol, 1 equiv), and the resulting mixture was refluxed for 5 h. The mixture was cooled to 20 °C, concentrated in vacuo, and the residue was dissolved in water (2.25 mL per mmol of amino alcohol) and washed with ethyl acetate (3–4 × with 2.5 mL per mmol of amino alcohol). The ethyl acetate layers were discarded, and the aqueous solution was cooled to 10 °C and acidified to pH ∼ 4–5 with an aqueous hydrochloric solution (1 M) under stirring. The resulting mixture was stirred for 45 min, and the crude product was then either collected as a solid after filtration or after extraction with ethyl acetate and concentration in vacuo.</div></div><div id="sec4_2_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> (<i>R</i>)-6-Neopentyl-2-(pyridin-2-ylmethoxy)-6,7-dihydropyrimido[2,1-<i>c</i>][1,4]oxazin-4(9<i>H</i>)-one (<b>8</b>)</h4><div class="NLM_p last">Compound <b>8</b> was prepared according to general procedure B, using hydroxypyrimidone <b>27d</b> (1.35 g, 5.67 mmol), 2-pyridyl carbinol, and triphenylphosphine in tetrahydrofuran (0.2 M). Diisopropylazodicarboxylate was added dropwise to control the exotherm. After stirring for 1 h, the reaction mixture was diluted with ethyl acetate (50 mL) and extracted with an aqueous solution of 1 M hydrochloric acid (2 × 25 mL). The combined aqueous layers were washed with 40 mL of ethyl acetate, made basic with the addition of a 2 M aqueous solution of sodium hydroxide and extracted with dichloromethane (2 × 60 mL). The combined organics were dried over MgSO<sub>4</sub>, filtered, and concentrated in vacuo to a reddish solid which was purified by silica-gel column chromatography (40 → 100% ethyl acetate in heptanes) to afford 1.20 g of compound <b>8</b> (64% yield) as a white solid (melting point 121.8–122.8 °C). <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 8.59 (d, <i>J</i> = 4.3 Hz, 1 H), 7.72 (t, <i>J</i> = 7.7 Hz, 1 H), 7.44 (d, <i>J</i> = 7.7 Hz, 1 H), 7.24 (s, 1 H), 5.72 (s, 1 H), 5.33 (s, 2 H), 4.71 (d, <i>J</i> = 17.9 Hz, 1 H) 4.58–4.60 (m, 1 H), 4.54 (d, <i>J</i> = 17.9 Hz, 1 H), 4.24 (d, <i>J</i> = 12.1 Hz, 1 H), 3.70–3.79 (m, 1 H), 1.96 (dd, <i>J</i> = 13.9, 10.3 Hz, 1 H), 1.36–1.48 (m, 1 H), 1.06 (s, 9 H). MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>18</sub>H<sub>24</sub>NO<sub>3</sub>) is <i>m</i>/<i>z</i> = 330.2, found <i>m</i>/<i>z</i> = 330.3.</div></div><div id="sec4_2_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> 2-[(3-Chlorobenzyl)oxy]-4<i>H</i>-pyrido[1,2-<i>a</i>]pyrimidin-4-one (<b>9</b>)</h4><div class="NLM_p last">Compound <b>9</b> was made from <b>14</b> (500 mg, 3.10 mmol) and 3-chlorobenzyl bromide according to general procedure A, replacing tetrabutylammonium bromide with tetrabutylammonium iodide (0.2 equiv). The crude product was purified by silica-gel column chromatography (25 → 100%, ethyl acetate in heptanes) to afford 507 mg of <b>9</b> (57% yield) as a white solid (melting point 16.9–117.9 °C). <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 9.09 (d, <i>J</i> = 6.8 Hz, 1 H), 7.78 (dd, <i>J</i> = 8.8, 6.8 Hz, 1 H), 7.55 (d, <i>J</i> = 8.8 Hz, 1 H), 7.46–7.48 (m, 1 H), 7.29–7.36 (m, 3 H), 7.14 (t, <i>J</i> = 6.8 Hz, 1 H), 5.89 (s, 1 H), 5.43 (s, 2 H). MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>15</sub>H<sub>12</sub>ClN<sub>2</sub>O<sub>2</sub>) is <i>m</i>/<i>z</i> = 287.1, found <i>m</i>/<i>z</i> = 287.1.</div></div><div id="sec4_2_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> 2-[(3-Chlorobenzyl)oxy]-7-(pyridin-3-yloxy)-4<i>H</i>-pyrido[1,2-<i>a</i>]pyrimidin-4-one (<b>10</b>)</h4><div class="NLM_p last">Compound <b>10</b> was made from <b>15</b> (50.0 mg, 0.20 mmol) and 3-chlorobenzyl bromide according to general procedure A. The crude product was purified by silica-gel column chromatography (20 → 80%, ethyl acetate in heptanes) to afford 38.0 mg of compound <b>10</b> (51% yield) as a clear glass. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 8.77 (d, <i>J</i> = 2.3 Hz, 1 H), 8.46–8.53 (m, 2 H), 7.67 (dd, <i>J</i> = 9.8, 2.7 Hz, 1 H), 7.58 (d, <i>J</i> = 9.0 Hz, 1 H), 7.46 (d, <i>J</i> = 1.6 Hz, 1 H), 7.28–7.43 (m, 5 H), 5.88 (s, 1 H), 5.42 (s, 2 H). MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>20</sub>H<sub>15</sub>ClN<sub>3</sub>O<sub>3</sub>) is <i>m</i>/<i>z</i> = 380.1, found <i>m</i>/<i>z</i> = 380.4.</div></div><div id="sec4_2_3_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> 2-[(6-Methylpyridin-2-yl)methoxy]-7-(pyridin-3-yloxy)-4<i>H</i>-pyrido[1,2-<i>a</i>]pyrimidin-4-one (<b>11</b>)</h4><div class="NLM_p last">To a solution of compound <b>15</b> (500 mg, 1.96 mmol) and cesium carbonate (766 mg, 2.35 mmol) in NMP at 45 °C was added 2-(bromomethyl)-6-methylpyridine (400 mg, 2.16 mmol), and the resulting mixture was stirred at that temperature for 1 h. Water (10 mL) was then added, the layers were separated and the organic phase was extracted with a solution of 10% methanol in dichloromethane. The organic layer was washed with water, followed by brine, dried over MgSO<sub>4</sub>, filtered, and concentrated in vacuo. The residue was purified by silica-gel column chromatography (dichloromethane/methanol/NH<sub>4</sub>Cl: 95/4/1) to afford a tan solid (400 mg) that was triturated with diethyl ether to afford 300 mg of compound <b>11</b> (42% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.56 (dd, <i>J</i> = 8.5, 2.8 Hz, 2 H), 8.46 (dd, <i>J</i> = 4.6, 1.3 Hz, 1H), 8.00 (dd, <i>J</i> = 9.5, 2.8 Hz, 1 H), 7.62–7.75 (m, 3 H), 7.49 (dd, <i>J</i> = 8.4, 4.7 Hz, 1 H), 7.28 (d, <i>J</i> = 7.6 Hz, 1 H), 7.20 (d, <i>J</i> = 7.4 Hz, 1 H), 5.81 (s, 1 H), 5.45 (s, 2 H), 2.48 (s, 3 H). MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>20</sub>H<sub>17</sub>N<sub>4</sub>O<sub>3</sub>) is <i>m</i>/<i>z</i> = 361.1, found <i>m</i>/<i>z</i> = 361.2.</div></div><div id="sec4_2_3_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> 2-Hydroxy-4<i>H</i>-pyrido[1,2-<i>a</i>]pyrimidin-4-one (<b>14</b>)</h4><div class="NLM_p last">To a suspension of bis(2,4,6-trichlorophenyl)malonate (7.50 g, 16.2 mmol) in tetrahydrofuran (50 mL), 2-aminopyridine (<b>12</b>, 1.52 g, 16.2 mmol) in tetrahydrofuran (46 mL) was added. The mixture was refluxed for 5 h, then cooled to 0 °C, filtered, and washed with diethyl ether. The solid was dried in vacuo to afford 2.46 g of <b>14</b> (93% yield, melting point 312.4 °C, decomposition). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.03 (br s, 1 H), 8.92 (d, <i>J</i> = 6.8 Hz, 1 H), 8.08 (dd, <i>J</i> = 8.6, 6.9 Hz, 1 H), 7.40 (d, <i>J</i> = 8.6 Hz, 1 H), 7.32 (dd, <i>J</i> = 6.9, 6.8 Hz, 1 H), 4.96 (s, 1 H). MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>8</sub>H<sub>7</sub>N<sub>2</sub>O<sub>2</sub>) is <i>m</i>/<i>z</i> = 163.0, found <i>m</i>/<i>z</i> = 163.3.</div></div><div id="sec4_2_3_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> 2-Hydroxy-7-(pyridin-3-yloxy)-4<i>H</i>-pyrido[1,2-<i>a</i>]pyrimidin-4-one (<b>15</b>)</h4><div class="NLM_p last">Compound <b>13</b> (10.3 g, 55.0 mmol) and bis(2,4,6-trichlorophenyl)malonate (25.5 g, 55.0 mmol) were combined in dioxane (275 mL) and heated to 101 °C for 3 h. The mixture was cooled to 20 °C and concentrated in vacuo, and the resulting solids were then triturated with diethyl ether, filtered, and dried in vacuo to afford 12.9 g of compound <b>15</b> (92% yield) as a yellow solid (melting point 233.2 °C, decomposition). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.96 (br s, 1 H), 8.55 (dd, <i>J</i> = 14.1, 2.7 Hz, 2 H), 8.44 (dd, <i>J</i> = 4.7, 1.2 Hz, 1 H), 8.05 (dd, <i>J</i> = 9.4, 2.7 Hz, 1 H), 7.58–7.70 (m, 1 H), 7.44–7.54 (m, 2 H), 5.13 (s, 1 H). MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>13</sub>H<sub>10</sub>N<sub>3</sub>O<sub>3</sub>) is <i>m</i>/<i>z</i> = 256.1, found <i>m</i>/<i>z</i> = 256.2.</div></div><div id="sec4_2_3_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> 2-Hydroxy-6,7,8,9-tetrahydro-4<i>H</i>-pyrido[1,2-<i>a</i>]pyrimidin-4-one (<b>18</b>)</h4><div class="NLM_p last">In an oven-dried flask, sodium (1.0 g, 44.6 mmol) was dissolved in methanol (37 mL) and 2-iminopiperidine hydrochloride (<b>16</b>, 2.0 g, 14.9 mmol) was added at 20 °C under stirring. Dimethyl malonate (1.96 g, 1.70 mL, 14.9 mmol) was added, and the reaction mixture was heated at 75 °C for 16 h, then acidified with hydrochloric acid (4 M in dioxane, 6 mL) and concentrated in vacuo. Methanol was added to the crude product, and the mixture was warmed to 35 °C, filtered, and concentrated in vacuo. The mixture was triturated with diethyl ether (2 × 50 mL) and dried in vacuo to give 2.24 g of compound <b>18</b> (90% yield) as a white solid (melting point, 230.7 °C, decomposition). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.41 (br s, 1 H), 5.02 (s, 1 H), 3.69 (t, <i>J</i> = 6.1 Hz, 2 H), 2.75 (t, <i>J</i> = 6.5 Hz, 2 H), 1.70–1.88 (m, 4 H). MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>8</sub>H<sub>11</sub>N<sub>2</sub>O<sub>2</sub>) is <i>m</i>/<i>z</i> = 167.1, found <i>m</i>/<i>z</i> = 167.1.</div></div><div id="sec4_2_3_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> 2-Hydroxy-6,7-dihydropyrimido[2,1-<i>c</i>][1,4]oxazin-4(9<i>H</i>)-one (<b>19</b>)</h4><div class="NLM_p last">To 6-dihydro-2<i>H</i>-1,4-oxazin-3-amine (<b>17</b>, 250 mg, 1.83 mmol) was added sodium methoxide (0.5 M in methanol, 11.0 mL, 5.49 mmol) at 20 °C. Dimethyl malonate (241 mg, 1.83 mmol) was added, the resulting mixture was heated at 60 °C for 48 h, cooled to 20 °C, and then concentrated in vacuo. The residue was diluted with water and washed with ethyl acetate (the organic wash was discarded). The aqueous layer was then acidified with 3 M hydrochloric acid (2 mL, 6 mmol) and concentrated in vacuo to a pale-yellow sticky solid. This solid was suspended in hot ethanol (20 mL), filtered to remove insoluble material, and concentrated in vacuo. The solid was suspended in hot ethanol (20 mL), filtered to remove insoluble material, and concentrated in vacuo. This process was repeated (using 10 mL of methanol) to afford a pale-yellow solid which was adsorbed onto diatomaceous earth and purified using silica gel chromatography (0 → 15% methanol in dichloromethane) to afford 65 mg of compound <b>19</b> (21% yield) as a white solid (melting point 230.1 °C, decomposition). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 5.27 (s, 1 H), 4.55 (s, 2 H), 4.01 (t, <i>J</i> = 5.3 Hz, 2 H), 3.70 (t, <i>J</i> = 5.3 Hz, 2 H). MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>7</sub>H<sub>9</sub>N<sub>2</sub>O<sub>3</sub>) is <i>m</i>/<i>z</i> = 169.1, found <i>m</i>/<i>z</i> = 169.2.</div></div><div id="sec4_2_3_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 2-[(3-Chlorobenzyl)oxy]-6,7,8,9-tetrahydro-4<i>H</i>-pyrido[1,2-<i>a</i>]pyrimidin-4-one (<b>20</b>)</h4><div class="NLM_p last">To a mixture of <b>18</b> (45.0 mg, 0.27 mmol) and potassium carbonate (150 mg, 1.08 mmol) in DMF (1.4 mL), 3-chlorobenzyl tosylate (104 mg, 0.35 mmol) was added at 20 °C. The mixture was heated at 68 °C for 16 h, water was then added, and the mixture was extracted (3×) with ethyl acetate. The organic layers were combined, washed with water and brine, dried over MgSO<sub>4</sub>, filtered, and concentrated in vacuo. The crude product was purified by silica gel chromatography (20 → 100% ethyl acetate in heptanes) to afford 46.0 mg of compound <b>20</b> (58% yield) as a white solid (melting point 77.3–79.6 °C). <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 7.39 (s, 1 H), 7.24–7.29 (m, 3 H), 5.63 (s, 1 H), 5.16 (s, 2 H), 3.89 (t, <i>J</i> = 6.2 Hz, 2 H), 2.85 (t, <i>J</i> = 6.6 Hz, 2 H), 1.82–1.99 (m, 4 H). MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>15</sub>H<sub>16</sub>ClN<sub>2</sub>O<sub>2</sub>) is <i>m</i>/<i>z</i> 291.1, found <i>m</i>/<i>z</i> = 291.1.</div></div><div id="sec4_2_3_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> 2-[(3-Chlorobenzyl)oxy]-6,7-dihydropyrimido[2,1-<i>c</i>][1,4]oxazin-4(9<i>H</i>)-one (<b>21</b>)</h4><div class="NLM_p last">Compound <b>19</b> (848 mg, 5.05 mmol) was dissolved in NMP (10 mL), potassium carbonate (1.54 g, 11.1 mmol) followed by 3-chlorobenzyl tosylate (1.5 g, 5.05 mmol) was added at 20 °C, and the reaction heated at 50 °C for 5 h. The reaction mixture was cooled to 20 °C, poured into water (100 mL), and extracted with ethyl acetate (3×). The combined organics were dried over MgSO<sub>4</sub>, filtered, and concentrated in vacuo. The crude product was purified by silica-gel column chromatography (0 → 100%, ethyl acetate in heptane) to afford 308 mg of compound <b>21</b> (21% yield) as a white solid (melting point 134.5–135.8 °C). <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 7.37 (s, 1 H), 7.18–7.31 (m, 3 H), 5.67 (s, 1 H), 5.17 (s, 2 H), 4.61 (s, 2 H), 4.02–4.07 (m, 2 H), 3.87–3.96 (m, 2 H). MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>14</sub>H<sub>14</sub>ClN<sub>2</sub>O<sub>3</sub>) is <i>m</i>/<i>z</i> = 293.1, found <i>m</i>/<i>z</i> = 293.2.</div></div><div id="sec4_2_3_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> (<i>S</i>)-6-Benzyl-2-hydroxy-6,7-dihydropyrimido[2,1-<i>c</i>][1,4]oxazin-4(9<i>H</i>)-one (<b>27a</b>)</h4><div class="NLM_p last"><i>Step 1</i>: To a solution of (<i>S</i>)-2-amino-3-phenyl-propan-1-ol (15.0 g, 99.3 mmol) in tetrahydrofuran (300 mL) was added triethylamine (11.1 g, 109 mmol), followed by chloroacetyl chloride (11.2 g, 99.2 mmol) dropwise at 0 °C. The reaction mixture was warmed to 20 °C and stirred for 2 h, diluted with water, and extracted with ethyl acetate. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo to afford compound <b>23a</b> (16 g, 70.2 mmol). <i>Step 2</i>: Compound <b>23a</b> was dissolved in tetrahydrofuran (300 mL) and cooled to 0 °C. Potassium <i>t</i>-butoxide (16.2 g, 144 mmol) was added, and the reaction mixture was warmed to 20 °C for 2 h. An aqueous solution of 1 M hydrochloric acid was added, and the resulting mixture was extracted with ethyl acetate. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. Purification by silica-gel column chromatography (80% ethyl acetate in petroleum ether) afforded compound <b>24a</b> (6.0 g, 31.4 mmol) as a white solid. <i>Step 3</i>: Compound <b>24a</b> (6.0 g, 31.4 mmol) was dissolved in dichloromethane (100 mL), trimethyloxonium tetrafluoroborate (5.1 g, 34.5 mmol) was added, and the mixture was stirred at 20 °C for 48 h. The mixture was diluted with dichloromethane and washed with a saturated aqueous solution of sodium bicarbonate, the organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo to afford compound <b>25a</b> (6.0 g, 27.4 mmol). <i>Step 4</i>: Compound <b>25a</b> was dissolved in ethanol (100 mL), ammonium chloride (1.61 g, 30.1 mmol) was added, and the reaction mixture was heated at reflux for 2 h. The reaction mixture was then cooled to 20 °C and concentrated in vacuo, and the resulting residue was triturated with diethyl ether to afford compound <b>26a</b> (4.53 g, 23.8 mmol) as an off-white solid. <i>Step 5</i>: Compound <b>26a</b> was dissolved in methanol (100 mL). Sodium methoxide (2.7 g, 50.0 mmol) and dimethyl malonate (2.2 g, 16.65 mmol) were added at 20 °C, and the resulting mixture was heated at75 °C for 16 h, concentrated in vacuo, diluted with water, and washed with ethyl acetate (the organic wash was discarded). The aqueous layer was acidified with 1 M aqueous hydrochloric acid and extracted with ethyl acetate. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo to afford 2.25 g of compound <b>27a</b> (9% over 5 steps) as an off-white solid (melting point 198.9–204.6 °C). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.69 (br s, 1 H), 7.17–7.45 (m, 5 H), 5.34 (s, 1 H), 4.64 (d, <i>J</i> = 17.6 Hz, 1 H), 4.55 (d, <i>J</i> = 17.6 Hz, 1 H), 4.40 (d, <i>J</i> = 10.5 Hz, 1 H), 3.69–3.85 (m, 2 H), 2.99 (dd, <i>J</i> = 2.7, 12.9 Hz, 1 H), 2.79–2.91 (m, 1 H). MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>14</sub>H<sub>15</sub>N<sub>2</sub>O<sub>3</sub>) is <i>m</i>/<i>z</i> = 259.1, found <i>m</i>/<i>z</i> = 259.0.</div></div><div id="sec4_2_3_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> (<i>R</i>)-6-Benzyl-2-hydroxy-6,7-dihydropyrimido[2,1-<i>c</i>][1,4]oxazin-4(9<i>H</i>)-one (<b>27b</b>)</h4><div class="NLM_p last">Compound <b>27b</b> was prepared according to general procedure C, using (<i>R</i>)-2-amino-3-phenylpropan-1-ol (5.0 g, 33 mmol). After workup, the product was isolated by extraction with ethyl acetate (3×). Purification by silica-gel chromatography (0 → 5% methanol in dichloromethane) afforded 1.0 g of compound <b>27b</b> (12% yield) as a white solid (melting point 202.3–207.9 °C). <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 7.22–7.39 (m, 5 H), 5.52 (s, 1 H), 4.71 (d, <i>J</i> = 17.3 Hz, 1 H), 4.59 (d, <i>J</i> = 17.4 Hz, 1 H), 4.51 (dt, <i>J</i> = 10.7, 3.0 Hz, 1 H), 3.96 (d, <i>J</i> = 12.5 Hz, 1 H), 3.72 (ddd, <i>J</i> = 12.5, 12.7, 1.8 Hz, 1 H), 3.15 (ddd, <i>J</i> = 12.9, 3.1, 1.4 Hz, 2 H), 2.98 (dd, <i>J</i> = 10.7, 12.9 Hz, 1 H). MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>14</sub>H<sub>15</sub>N<sub>2</sub>O<sub>3</sub>) is <i>m</i>/<i>z</i> = 259.1, found <i>m</i>/<i>z</i> = 259.2.</div></div><div id="sec4_2_3_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> (<i>R</i>)-2-Hydroxy-6-isobutyl-6,7-dihydropyrimido[2,1-<i>c</i>][1,4]oxazin-4(9<i>H</i>)-one (<b>27c</b>)</h4><div class="NLM_p last">Compound <b>27c</b> was prepared according to general procedure C, using <span class="smallcaps smallerCapital">d</span>-leucinol (4.60 g, 39.3 mmol). After acidification, filtration afforded 1.80 g of compound <b>27c</b> (20% yield) as a tan solid (melting point 200.7–202.8 °C). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.39 (br s, 1 H), 5.25 (s, 1 H), 4.62 (d, <i>J</i> = 17.1 Hz, 1 H), 4.52 (d, <i>J</i> = 17.0 Hz, 1 H), 4.32 (dt, <i>J</i> = 10.2, 2.54 Hz, 1 H), 4.07 (d, <i>J</i> = 12.3 Hz, 1 H), 3.74–3.84 (m, 1 H), 1.60–1.79 (m, 2 H), 1.25–1.37 (m, 1 H), 0.94 (d, <i>J</i> = 6.60 Hz, 3 H), 0.89 (d, <i>J</i> = 6.65 Hz, 3 H). MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>11</sub>H<sub>17</sub>N<sub>2</sub>O<sub>3</sub>) is <i>m</i>/<i>z</i> = 225.1, found <i>m</i>/<i>z</i> = 225.1.</div></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> Large-Scale Preparation of Compound <b>27c</b> According to <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a></h4><div id="sec4_2_4_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i40" class="anchor-spacer"></div><h5 class="article-section__title" id="_i40"> (<i>R</i>)-5-Isobutylmorpholin-3-one (<b>24c</b>)</h5><div class="NLM_p last"><i>Step 1</i>: A solution of <span class="smallcaps smallerCapital">d</span>-leucinol (25.0 g, 210 mmol) and potassium carbonate (29.2 g, 211 mmol) in a mixture of tetrahydrofuran/water (1:1, 600 mL total) was cooled to 0 °C in an ice bath. Chloroacetyl chloride (26.9 mL, 338 mmol) was added dropwise over a period of 1 h at a rate that maintained the internal temperature <10 °C. The reaction was then allowed to warm to 20 °C and stirred at that temperature for 1 h. Ethyl acetate (200 mL) and water (200 mL) were added, the phases were separated, and the aqueous phase was extracted with ethyl acetate (150 mL). The combined organics were washed with brine (100 mL), dried over MgSO<sub>4</sub>, and concentrated in vacuo to afford 36.1 g of compound <b>23c</b> as pale-orange oil. The crude product was used in the next step without any further purification. <i>Step 2</i>: A solution of compound <b>23c</b> (36.0 g, 190 mmol) in anhydrous 2-propanol (600 mL) was cooled to 0 °C, and a solution of potassium <i>t</i>-butoxide (42.4 g, 378 mmol) in anhydrous 2-propanol (400 mL) was added dropwise over a period of 1 h. The reaction mixture was warmed to 20 °C and stirred at that temperature for 1 h. The mixture was acidified to a pH ∼ 4 with an aqueous solution of hydrochloric acid, then filtered to remove white solids and concentrated in vacuo. The residue was separated between water and dichloromethane (150 mL), and the aqueous phase was extracted twice with dichloromethane. The combined organics were washed with brine, dried over MgSO<sub>4</sub>, filtered, and concentrated in vacuo to afford 24.8 g of compound <b>24c</b> (75% over two steps) as a pale-yellow solid. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 5.96 (br s, 1 H), 4.22 (d, <i>J</i> = 16.7 Hz, 1 H), 4.12 (d, <i>J</i> = 16.7 Hz, 1 H), 3.91 (dd, <i>J</i> = 11.6, 3.9 Hz, 1 H), 3.58–3.71 (m, 1 H), 3.43 (dd, <i>J</i> = 11.6, 7.3 Hz, 1 H), 1.62–1.74 (m, 1 H), 1.29–1.48 (m, 2 H), 0.97 (d, <i>J</i> = 6.6 Hz, 3 H), 0.95 (d, <i>J</i> = 6.6 Hz, 3 H). Compound did not ionize well, therefore LCMS data are not reported.</div></div><div id="sec4_2_4_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i41" class="anchor-spacer"></div><h5 class="article-section__title" id="_i41"> (<i>R</i>)-2-Hydroxy-6-isobutyl-6,7-dihydropyrimido[2,1-<i>c</i>][1,4]oxazin-4(9<i>H</i>)-one (<b>27c</b>)</h5><div class="NLM_p last"><i>Step 1</i>: To a solution of compound <b>24c</b> (24.8 g, 157 mmol) in dichloromethane (600 mL) was added triethyloxonium tetrafluoroborate (37.4 g, 197 mmol) at 20 °C. The resulting mixture was stirred for 2.5 h, the reaction mixture was then quenched into a saturated solution of sodium bicarbonate (600 mL). The phases were separated, and the aqueous phase was extracted with dichloromethane. The combined organic layers were washed with brine, dried over MgSO<sub>4</sub>, filtered, and concentrated in vacuo to afford crude <b>25c</b> as orange oil. <i>Step 2</i>: To crude <b>25c</b> in methanol (165 mL) was added ammonium chloride (8.7 g, 159 mmol) at 20 °C, and the resulting mixture was heated at 55 °C for 2.5 h. Dimethyl malonate (21.2 g, 161 mmol) and a solution of sodium methoxide in methanol (25% by weight, 72.8 mL, 320 mmol) were then added, and the mixture was heated at 65 °C for 3 h. The reaction mixture was concentrated in vacuo, and the residue was partitioned between ethyl acetate (200 mL) and water (300 mL). The aqueous phase was washed with ethyl acetate, and the organic phases were discarded. The aqueous phase was acidified with a 1 M aqueous solution of hydrochloric acid to a pH < 5, the resulting white solid was isolated via filtration, rinsed with water and heptanes, and dried in vacuo to afford 16.1 g of compound <b>27c</b> (45% yield over two steps) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.39 (br s, 1 H), 5.25 (s, 1 H), 4.62 (d, <i>J</i> = 17.1 Hz, 1 H), 4.52 (d, <i>J</i> = 17.0 Hz, 1 H), 4.32 (dt, <i>J</i> = 10.2, 2.54 Hz, 1 H), 4.07 (d, <i>J</i> = 12.3 Hz, 1 H), 3.74–3.84 (m, 1 H), 1.60–1.79 (m, 2 H), 1.25–1.37 (m, 1 H), 0.94 (d, <i>J</i> = 6.60 Hz, 3 H), 0.89 (d, <i>J</i> = 6.65 Hz, 3 H). MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>11</sub>H<sub>17</sub>N<sub>2</sub>O<sub>3</sub>) is <i>m</i>/<i>z</i> = 225.1, found <i>m</i>/<i>z</i> = 225.1.</div></div></div><div id="sec4_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> Large-Scale Preparation of Compound <b>27d</b> According to <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a></h4><div id="sec4_2_5_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i43" class="anchor-spacer"></div><h5 class="article-section__title" id="_i43"> (<i>R</i>)-5-Neopentylmorpholin-3-one (<b>24d</b>)</h5><div class="NLM_p last"><i>Step 1</i>: Chloroacetyl chloride (40.2 mL, 505 mmol) was added dropwise to a solution of amino alcohol <b>22d</b> (41.4 g, 316 mmol) and potassium carbonate (43.6 g, 316 mmol) in a mixture of tetrahydrofuran/water (1/1, 600 mL total) that was cooled in an ice bath. The internal temperature was maintained <12 °C during the addition, and after the addition was completed, the reaction was allowed to warm to 20 °C and stirred for 1 h. The organic phase was then separated, and the aqueous phase was extracted with ethyl acetate (3 × 100 mL). The combined organic layers were dried over MgSO<sub>4</sub> and concentrated in vacuo to afford crude compound <b>23d</b> as a brown oil. <i>Step 2</i>: Compound <b>23d</b> (71.0 g, 342 mmol) was dissolved in anhydrous 2-propanol (500 mL) and cooled in an ice bath. A solution of potassium <i>t</i>-butoxide (102 g, 642 mmol) in 2-propanol (500 mL) was added dropwise over a period of 1.5 h, maintaining the internal temperature <10 °C during the addition. After the addition was completed, the mixture was acidified to a pH ∼ 4 with an aqueous solution of hydrochloric acid (3 M, 140 mL). The reaction mixture was concentrated in vacuo to give a sticky white solid, which was partitioned between water (150 mL) and dichloromethane (150 mL). The layers were separated and the aqueous layer was extracted with dichloromethane (2 × 100 mL), and the combined organic layers were dried over MgSO<sub>4</sub> and concentrated in vacuo to afford 51.4 g of compound <b>24d</b> (95% yield over two steps) as a solid. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 6.69 (br s, 1 H), 4.21 (d, <i>J</i> = 16.8 Hz, 1 H), 4.10 (d, <i>J</i> = 16.8 Hz, 1 H), 3.90 (dd, <i>J</i> = 11.6, 4.0 Hz, 1 H), 3.60–3.75 (m, 1 H), 3.38 (dd, <i>J</i> = 11.6, 8.2 Hz, 2 H), 1.40 (m, 1 H), 0.97 (s, 9 H). Compound did not ionize well, therefore LC-MS data are not reported.</div></div><div id="sec4_2_5_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i44" class="anchor-spacer"></div><h5 class="article-section__title" id="_i44"> (<i>R</i>)-2-Hydroxy-6-neopentyl-6,7-dihydropyrimido[2,1-<i>c</i>][1,4]oxazin-4(9<i>H</i>)-one (<b>27d</b>)</h5><div class="NLM_p last"><i>Step 1</i>: To a solution of compound <b>24d</b> (128 g, 747 mmol) in dichloromethane (600 mL) was added triethyloxonium tetrafluoroborate (178 g, 934 mmol) in three portions over a period of 10 min, and the resulting reaction mixture was stirred for 2 h. An additional portion of triethyloxonium tetrafluoroborate (80.0 g, 421 mmol) was added, and the mixture was stirred for an additional 1 h. A saturated aqueous solution of sodium bicarbonate (1200 mL) was then added at a rate that allowed controlling the gas evolution, and the mixture was stirred for 1 h before it was extracted with dichloromethane (2 × 1500 mL). The combined organic layers were washed with brine (200 mL) and passed through a silica pad that was then further eluted with dichloromethane. The solvent was then removed in vacuo to afford 95.1 g of compound <b>25d</b>, which was used without further purification. <i>Step 2</i>: Ammonium chloride (27.9 g, 511 mmol) was added to a solution of compound <b>25d</b> (95.1 g, 477 mmol) in methanol (516 mL), and the resulting mixture was heated for 4.5 h at 55 °C. Dimethyl malonate (67.5 g, 58.4 mL, 511 mmol) was added followed by a solution of sodium methoxide in methanol (25% w/w, 260 mL), at which point the reaction became a turbid tan suspension. The reaction mixture was heated at 60 °C for 16 h, then cooled to 20 °C and concentrated in vacuo. Ethyl acetate and water were then added, the layers were separated, and the aqueous layer was extracted with ethyl acetate. The combined organic layers were acidified with 1 M aqueous hydrochloric acid to pH < 5, and a white solid was collected by filtration and dried in vacuo to afford 64.5 g of compound <b>27d</b>. Extraction of the aqueous layer with dichloromethane (5 × 100 mL) afforded another 7.6 g to yield a total of 72.1 g of compound <b>27d</b> (41% over two steps, melting point 204.1–206.8 °C). <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 5.42 (s, 1 H), 4.70 (d, <i>J</i> = 17.2 Hz, 1 H), 4.56 (d, <i>J</i> = 17.2 Hz, 1 H), 4.54 (m, 1 H), 4.21 (d, <i>J</i> = 12.5 Hz, 1 H), 3.84 (dt, <i>J</i> = 12.5, 2.0 Hz, 1 H), 1.97 (dd, <i>J</i> = 13.9, 10.2 Hz, 1 H), 1.35 (dt, <i>J</i> = 13.9, 2.0 Hz, 1 H), 1.05 (s, 9 H). MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>12</sub>H<sub>19</sub>N<sub>2</sub>O<sub>3</sub>) is <i>m</i>/<i>z</i> = 239.1, found <i>m</i>/<i>z</i> = 239.3.</div></div><div id="sec4_2_5_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i45" class="anchor-spacer"></div><h5 class="article-section__title" id="_i45"> (<i>S</i>)-6-Benzyl-2-[(3-chlorobenzyl)oxy]-6,7-dihydropyrimido[2,1-<i>c</i>][1,4]oxazin-4(9<i>H</i>)-one (<b>30</b>)</h5><div class="NLM_p last">Compound <b>30</b> was prepared from compound <b>27a</b> (50.0 mg, 0.19 mmol) according to general procedure B, using 3-chlorobenzyl alcohol and polymer-supported triphenylphosphine. The residue was dissolved in dimethyl sulfoxide (1 mL) and purified by reversed-phase HPLC column [Waters Sunfire, C18 19 mm × 100 mm, 5 μm; mobile phase A, 0.05% formic acid in water (v/v); mobile phase B, 0.05% formic acid in acetonitrile (v/v); gradient, 60.0% H<sub>2</sub>O/40.0% acetonitrile linear to 30% H<sub>2</sub>O/70% acetonitrile in 8.5 min, 30% H<sub>2</sub>O/70% acetonitrile linear to 0% H<sub>2</sub>O/100% acetonitrile in 0.5 min, hold at 0% H<sub>2</sub>O/100% acetonitrile from 9.0 to 10.0 min; flow, 25 mL/min] to afford 25.5 mg of compound <b>30</b> (35% yield). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.49 (s, 1 H), 7.24–7.46 (m, 8 H), 5.71 (s, 1 H), 5.25 (s, 2 H), 4.69 (d, <i>J</i> = 17.8 Hz, 1 H), 4.59 (d, <i>J</i> = 17.8 Hz, 1 H), 4.44 (s, 1 H), 3.73–3.83 (m, 2 H), 3.00 (dd, <i>J</i> = 2.52, 13.0 Hz, 1 H), 2.88 (dd, <i>J</i> = 10.6, 13.0 Hz, 1 H). MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>21</sub>H<sub>20</sub>ClN<sub>2</sub>O<sub>3</sub>) is <i>m</i>/<i>z</i> = 383.1, found <i>m</i>/<i>z</i> = 383.1.</div></div><div id="sec4_2_5_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i46" class="anchor-spacer"></div><h5 class="article-section__title" id="_i46"> (<i>R</i>)-6-Benzyl-2-((3-chlorobenzyl)oxy)-6,7-dihydropyrimido[2,1-<i>c</i>][1,4]oxazin-4(9<i>H</i>)-one (<b>31</b>)</h5><div class="NLM_p last">Compound <b>31</b> was prepared from compound <b>27b</b> (59.0 mg, 0.23 mmol) according to general procedure A, using 3-chlorobenzyl bromide. The residue was purified using silica-gel chromatography (15 → 40% ethyl acetate in heptanes) to afford 38.0 mg of compound <b>31</b> (44% yield). <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 7.17–7.44 (m, 9 H), 5.72 (s, 1 H), 5.19 (s, 2 H), 4.74 (d, <i>J</i> = 17.4 Hz, 1 H), 4.54 (d, <i>J</i> = 17.4 Hz, 1 H) 4.52–4.59 (m, 1 H), 4.01 (d, <i>J</i> = 12.4 Hz, 1 H), 3.57 (dt, <i>J</i> = 12.4, 2.2 Hz, 1 H), 3.16–3.23 (m, 1 H), 2.90 (dd, <i>J</i> = 12.7, 11.0 Hz, 1 H). MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>21</sub>H<sub>20</sub>ClN<sub>2</sub>O<sub>3</sub>) is <i>m</i>/<i>z</i> = 383.1, found <i>m</i>/<i>z</i> = 383.1.</div></div><div id="sec4_2_5_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i47" class="anchor-spacer"></div><h5 class="article-section__title" id="_i47"> (<i>R</i>)-6-Benzyl-2-(pyridin-2-ylmethoxy)-6,7-dihydropyrimido[2,1-<i>c</i>][1,4]oxazin-4(9<i>H</i>)-one (<b>32</b>)</h5><div class="NLM_p last">Compound <b>27</b> was prepared according to general procedure A, using <b>27b</b> (615 mg, 2.38 mmol) and 2-pyridylmethyl bromide hydrobromide (1.30 g, 5.10 mmol) and 5 equiv of potassium carbonate. The residue was purified using silica-gel chromatography (60 → 100% ethyl acetate in heptanes) to afford 433 mg of compound <b>32</b> (52% yield) as a white solid (melting point 127.3–129.0 °C). <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 8.61 (d, <i>J</i> = 4.7 Hz, 1 H), 7.73 (td, <i>J</i> = 7.7, 1.7 Hz, 1 H), 7.46 (d, <i>J</i> = 7.7 Hz, 1 H), 7.21–7.43 (m, 6 H), 5.81 (s, 1 H), 5.37 (s, 2 H), 4.76 (d, <i>J</i> = 17.8 Hz, 1 H), 4.53–4.62 (m, 1 H), 4.55 (d, <i>J</i> = 17.8 Hz, 1 H), 4.04 (d, <i>J</i> = 12.4 Hz, 1 H), 3.59 (dt, <i>J</i> = 12.4, 2.0 Hz, 1 H), 3.23 (br d, <i>J</i> = 12.7 Hz, 1 H), 2.92 (dd, <i>J</i> = 12.7, 11.0 Hz, 1 H). MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>20</sub>H<sub>20</sub>N<sub>3</sub>O<sub>3</sub>) is <i>m</i>/<i>z</i> = 350.1, found <i>m</i>/<i>z</i> = 350.1.</div></div><div id="sec4_2_5_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i48" class="anchor-spacer"></div><h5 class="article-section__title" id="_i48"> (<i>R</i>)-6-Benzyl-2-((6-methylpyridin-2-yl)methoxy)-6,7-dihydropyrimido[2,1-<i>c</i>][1,4]oxazin-4(9<i>H</i>)-one (<b>33</b>)</h5><div class="NLM_p last">Compound <b>33</b> was prepared according to general procedure A, using compound <b>27b</b> (59.0 mg, 0.23 mmol) and 2-(bromomethyl)-6-methylpyridine (42.5 mg, 0.23 mmol). The residue was purified using silica-gel chromatography (20 → 70% ethyl acetate in heptanes) to afford 58.0 mg of compound <b>33</b> (70% yield). <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 7.62 (t, <i>J</i> = 7.6 Hz, 1 H), 7.31–7.43 (m, 4 H), 7.24–7.30 (m, 2 H), 7.11 (d, <i>J</i> = 7.8 Hz, 1 H), 5.79 (s, 1 H), 5.33 (s, 2 H), 4.75 (d, <i>J</i> = 17.5 Hz, 1 H), 4.55 (d, <i>J</i> = 17.5 Hz, 1 H), 4.52–4.58 (m, 1 H), 4.03 (d, <i>J</i> = 12.5 Hz, 1 H), 3.56–3.62 (m, 1 H), 3.19–3.26 (m, 1 H), 2.92 (dd, <i>J</i> = 12.7, 11.0 Hz, 1 H), 2.58 (s, 3 H). MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>21</sub>H<sub>22</sub>N<sub>3</sub>O<sub>3</sub>) is <i>m</i>/<i>z</i> = 364.2, found <i>m</i>/<i>z</i> = 364.1.</div></div><div id="sec4_2_5_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i49" class="anchor-spacer"></div><h5 class="article-section__title" id="_i49"> (<i>R</i>)-3-{[(6-Benzyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-<i>c</i>][1,4]oxazin-2-yl)oxy]methyl}benzonitrile (<b>34</b>)</h5><div class="NLM_p last">Compound <b>34</b> was prepared according to general procedure B, using compound <b>27b</b> (25 mg, 0.10 mmol), 3-cyanobenzyl alcohol (13.0 mg, 0.10 mmol), and polymer-supported triphenylphosphine. The residue was dissolved in dimethyl sulfoxide (1 mL) and purified by reversed-phase HPLC Column (Waters XBridge C18 19 mm × 100 mm, 5 μm; mobile phase A, 0.03% NH<sub>4</sub>OH in water (v/v); mobile phase B, 0.03% NH<sub>4</sub>OH in acetonitrile (v/v); gradient, 70.0% H<sub>2</sub>O/30.0% acetonitrile linear to 50.0% H<sub>2</sub>O/50.0% acetonitrile in 10.5 min, 50.0% H<sub>2</sub>O/50.0% acetonitrile linear to 0% H<sub>2</sub>O/100% acetonitrile in 0.5 min, hold at 0% H<sub>2</sub>O/100% acetonitrile from 11.0 to 12.0 min; flow, 25 mL/min) to afford 3.62 mg of compound <b>34</b> (10% yield). <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 7.72 (s, 1 H), 7.65 (dt, <i>J</i> = 7.8, 1.6 Hz, 2 H), 7.48–7.55 (m, 1 H), 7.25–7.42 (m, 5 H), 5.75 (s, 1 H), 5.28 (s, 2 H), 4.77 (d, <i>J</i> = 17.6 Hz, 1 H), 4.56 (d, <i>J</i> = 17.6 Hz, 1 H), 4.51–4.63 (m, 1 H), 4.05 (d, <i>J</i> = 12.5 Hz, 1 H), 3.57–3.64 (m, 1 H), 3.22 (d, <i>J</i> = 12.5 Hz, 1 H), 2.93 (dd, <i>J</i> = 12.9, 10.9 Hz, 1 H). MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>22</sub>H<sub>20</sub>N<sub>3</sub>O<sub>3</sub>) is <i>m</i>/<i>z</i> = 374.1, found <i>m</i>/<i>z</i> = 374.1.</div></div><div id="sec4_2_5_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i50" class="anchor-spacer"></div><h5 class="article-section__title" id="_i50"> (<i>R</i>)-6-Benzyl-2-((4-methylthiazol-2-yl)methoxy)-6,7-dihydropyrimido[2,1-<i>c</i>][1,4]oxazin-4(9<i>H</i>)-one (<b>35</b>)</h5><div class="NLM_p last">Compound <b>35</b> was prepared according to general procedure B, using compound <b>27b</b> (49.0 mg, 0.19 mmol), 2-hydroxymethyl-4-methyl-thiazole (25.0 mg, 0.19 mmol), and polymer-supported triphenylphosphine. The crude residue was dissolved in dimethyl sulfoxide (1 mL) and purified by reversed-phase HPLC Column [Waters XBridge C18 19 mm × 100 mm, 5 μm; mobile phase A, 0.03% NH<sub>4</sub>OH in water (v/v); mobile phase B, 0.03% NH<sub>4</sub>OH in acetonitrile (v/v); gradient, 80.0% H<sub>2</sub>O/20.0% acetonitrile linear to 40% H<sub>2</sub>O/60% acetonitrile in 8.5 min, 40% H<sub>2</sub>O/60% acetonitrile linear to 0% H<sub>2</sub>O/100% acetonitrile in 0.5 min, hold at 0% H<sub>2</sub>O/100% acetonitrile to 10 min; flow, 25 mL/min] to afford 12.4 mg of compound <b>35</b> (18% yield). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.20–7.42 (m, 6 H), 5.76 (s, 1 H), 5.49 (s, 2 H), 4.72 (d, <i>J</i> = 17.1 Hz, 1 H), 4.61 (d, <i>J</i> = 17.1 Hz, 1 H), 4.39–4.48 (m, 1 H), 3.73–3.83 (m, 2 H), 3.00 (dd, <i>J</i> = 13.1, 4.0 Hz, 1 H), 2.88 (dd, <i>J</i> = 13.1, 10.8 Hz, 1 H), 2.37 (s, 3 H). MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>19</sub>H<sub>20</sub>N<sub>3</sub>O<sub>3</sub>S) is <i>m</i>/<i>z</i> = 370.1, found <i>m</i>/<i>z</i> = 370.1.</div></div><div id="sec4_2_5_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i51" class="anchor-spacer"></div><h5 class="article-section__title" id="_i51"> (<i>R</i>)-6-Benzyl-2-(2-cyclopropylethoxy)-6,7-dihydropyrimido[2,1-<i>c</i>][1,4]oxazin-4(9<i>H</i>)-one (<b>36</b>)</h5><div class="NLM_p last">Compound <b>36</b> was prepared according to general procedure B, using compound <b>27b</b> (25.8 mg, 0.10 mmol), 2-cyclopropylethanol (12.8 mg, 0.15 mmol), and polymer-supported triphenylphosphine. The residue was dissolved in dimethyl sulfoxide (1 mL) and purified by reversed-phase HPLC column [Waters Sunfire C18 mm 19 mm × 100 mm, 5 μm; mobile phase A, 0.05% TFA in water (v/v); mobile phase B, 0.05% TFA in acetonitrile (v/v); gradient, hold at 95.0% H<sub>2</sub>O/5.0% acetonitrile for 1 min, 95.0% H<sub>2</sub>O/5.0% acetonitrile linear to 0% H<sub>2</sub>O/100% acetonitrile in 7.5 min, hold at 0% H<sub>2</sub>O/100% acetonitrile from 7.5 to 8.5 min; flow, 25 mL/min] to afford 7.45 mg of compound <b>36</b> (23% yield). MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>19</sub>H<sub>23</sub>N<sub>2</sub>O<sub>3</sub>) is <i>m</i>/<i>z</i> = 327.2, found <i>m</i>/<i>z</i> = 327.1.</div></div><div id="sec4_2_5_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i52" class="anchor-spacer"></div><h5 class="article-section__title" id="_i52"> (<i>R</i>)-6-Isobutyl-2-(pyridin-2-ylmethoxy)-6,7-dihydropyrimido[2,1-<i>c</i>][1,4]oxazin-4(9<i>H</i>)-one (<b>37</b>)</h5><div class="NLM_p last">Compound <b>37</b> was prepared according to general procedure B, using compound <b>27c</b> (500 mg, 2.20 mmol), 2-pyridyl carbinol (246 mg, 2.20 mmol), and polymer-supported triphenylphosphine. The residue was purified by silica gel chromatography (40 → 85% ethyl acetate in heptanes), and the resulting solid was triturated with a mixture of heptanes/diethyl ether (3/1) and filtered to afford 218 mg of compound <b>37</b> (31% yield) as a white solid (melting point 102.1–103.3 °C). <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 8.61 (ddd, <i>J</i> = 5.0, 1.7, 0.9 Hz, 1 H), 7.81 (t, <i>J</i> = 7.7 Hz, 1 H), 7.46–7.54 (m, 1 H), 7.28–7.38 (m, 1 H), 5.74 (s, 1 H), 5.41 (s, 2 H), 4.71 (d, <i>J</i> = 17.8 Hz, 1 H), 4.51 (d, <i>J</i> = 17.8 Hz, 1 H), 4.46–4.58 (m, 1 H), 4.19 (d, <i>J</i> = 12.3 Hz, 1 H), 3.69–3.77 (m, 1 H), 1.69–1.84 (m, 2 H), 1.48–1.58 (m, 1 H), 1.05 (d, <i>J</i> = 6.7 Hz, 3 H), 0.98 (d, <i>J</i> = 6.5 Hz, 3 H). MS (ESI) mass calculated for [M + H]+ (C<sub>17</sub>H<sub>22</sub>N<sub>3</sub>O<sub>3</sub>) is <i>m</i>/<i>z</i> = 316.2, found <i>m</i>/<i>z</i> = 316.2.</div></div><div id="sec4_2_5_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i53" class="anchor-spacer"></div><h5 class="article-section__title" id="_i53"> (<i>R</i>)-3-{[(6-Isobutyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-<i>c</i>][1,4]oxazin-2-yl)oxy]methyl}benzonitrile (<b>38</b>)</h5><div class="NLM_p last">Compound <b>38</b> was prepared according to general procedure B, using compound <b>27c</b> (13.9 g, 62.0 mmol), 3-cyanobenzyl alcohol, polymer-supported triphenylphosphine, and tetrahydrofuran (0.2 M). Note: On this scale, diisopropylazodicarboxylate was added over 10 min to control the exotherm. The residue was triturated with a mixture of diethyl ether/heptanes (4:1, 125 mL total), filtered, and triturated again with diethyl ether (50 mL). This mixture was stirred overnight, then filtered to collect the resulting white solid (12.3 g). The concentrated filtrates from the trituration steps were purified by silica gel chromatography (10 → 40% ethyl acetate in heptanes) to recover additional product (4.3 g) to afford a total of 16.6 g of compound <b>38</b> (78% yield, melting point 106.2–108.0 °C). <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 7.69 (s, 1 H), 7.59–7.64 (m, 2 H), 7.46–7.52 (m, 1 H), 5.66 (s, 1 H), 5.24 (s, 2 H), 4.71 (d, <i>J</i> = 17.6 Hz, 1 H), 4.53 (d, <i>J</i> = 17.6 Hz, 1 H), 4.46–4.54 (m, 1 H), 4.19 (d, <i>J</i> = 12.3 Hz, 1 H), 3.73 (dt, <i>J</i> = 12.3, 2.1 Hz, 1 H), 1.69–1.84 (m, 2 H), 1.46–1.58 (m, 1 H), 1.04 (d, <i>J</i> = 6.5 Hz, 3 H), 0.97 (d, <i>J</i> = 6.5 Hz, 3 H). MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>19</sub>H<sub>22</sub>N<sub>3</sub>O<sub>3</sub>) is <i>m</i>/<i>z</i> = 340.2, found <i>m</i>/<i>z</i> = 340.3.</div></div><div id="sec4_2_5_12" class="NLM_sec NLM_sec_level_4"><div id="ac_i54" class="anchor-spacer"></div><h5 class="article-section__title" id="_i54"> (<i>R</i>)-3-{[(6-Neopentyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-<i>c</i>][1,4]oxazin-2-yl)oxy]methyl}benzonitrile (<b>39</b>)</h5><div class="NLM_p last">Compound <b>39</b> was prepared according to general procedure A, using compound <b>27d</b> (35.0 mg, 0.15 mmol) and 3-cyanobenzyl bromide (35.0 mg, 0.18 mmol). The residue was dissolved in dimethyl sulfoxide (1 mL) and purified by reversed-phase HPLC [Waters XBridge C18 19 mm × 100 mm, 5 μm; mobile phase A, 0.03% NH<sub>4</sub>OH in water (v/v); mobile phase B, 0.03% NH<sub>4</sub>OH in acetonitrile (v/v); gradient, 95.0% H<sub>2</sub>O/5.0% acetonitrile linear to 0% H<sub>2</sub>O/100% acetonitrile in 8.5 min, hold at 0% H<sub>2</sub>O/100% acetonitrile to 10 min; flow, 25 mL/min] to afford 17.7 mg of compound <b>39</b> (34% yield). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.88 (s, 1 H), 7.82 (d, <i>J</i> = 7.8 Hz, 1 H), 7.76 (d, <i>J</i> = 8.2 Hz, 1 H), 7.62 (dd, <i>J</i> = 8.2, 7.8 Hz, 1 H), 5.63 (s, 1 H), 5.27 (s, 2 H), 4.68 (d, <i>J</i> = 17.6 Hz, 1 H), 4.58 (d, <i>J</i> = 17.6 Hz, 1 H), 4.42–4.48 (m, 1 H), 4.07 (d, <i>J</i> = 12.3 Hz, 1 H), 3.80–3.89 (m, 1 H), 1.83 (dd, <i>J</i> = 13.6, 10.1 Hz, 1 H), 1.23 (d, <i>J</i> = 13.6 Hz, 1 H), 0.99 (s, 9 H). MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>20</sub>H<sub>23</sub>N<sub>3</sub>O<sub>3</sub>) is <i>m</i>/<i>z</i> = 354.2, found <i>m</i>/<i>z</i> = 354.3.</div></div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i55"><a href="/doi/suppl/10.1021/acs.jmedchem.7b00604">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54012" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54012" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.7b00604" class="ext-link">10.1021/acs.jmedchem.7b00604</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Data on core modifications (supplementary to <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>), characterization of the HTS hit <b>40</b>, characterization and synthesis of compounds <b>12</b> and <b>21e</b>, plasma metabolite profile of compound <b>8</b> from the rat and nonhuman primate toxicology studies, rat in vivo receptor occupancy of compound <b>11</b>, detailed off-target profile of compound <b>8</b>, and computational methods (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00604/suppl_file/jm7b00604_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00604/suppl_file/jm7b00604_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00604/suppl_file/jm7b00604_si_001.pdf">jm7b00604_si_001.pdf (1.9 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00604/suppl_file/jm7b00604_si_002.csv">jm7b00604_si_002.csv (1.01 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.7b00604" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86742" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86742" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Antonia F. Stepan</span> - <span class="hlFld-Affiliation affiliation">†Neuroscience and Pain Medicinal
Chemistry, ‡Pharmacokinetics, Dynamics, and
Metabolism, and §Neuroscience and Pain Research Unit, Pfizer
Inc., Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Pharmaceutical Sciences, ⊥Pharmacokinetics,
Dynamics, and Metabolism, #Biostatistics, Early Clinical
Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc., Groton, Connecticut 06340, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-2203-129X" title="Orcid link">http://orcid.org/0000-0003-2203-129X</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#c382adb7acadaaa2ed90b7a6b3a2ad83b3a5aab9a6b1eda0acae"><span class="__cf_email__" data-cfemail="2c6d42584342454d027f58495c4d426c5c4a4556495e024f4341">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michelle M. Claffey</span> - <span class="hlFld-Affiliation affiliation">†Neuroscience and Pain Medicinal
Chemistry, ‡Pharmacokinetics, Dynamics, and
Metabolism, and §Neuroscience and Pain Research Unit, Pfizer
Inc., Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Pharmaceutical Sciences, ⊥Pharmacokinetics,
Dynamics, and Metabolism, #Biostatistics, Early Clinical
Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc., Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Matthew R. Reese</span> - <span class="hlFld-Affiliation affiliation">†Neuroscience and Pain Medicinal
Chemistry, ‡Pharmacokinetics, Dynamics, and
Metabolism, and §Neuroscience and Pain Research Unit, Pfizer
Inc., Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Pharmaceutical Sciences, ⊥Pharmacokinetics,
Dynamics, and Metabolism, #Biostatistics, Early Clinical
Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc., Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gayatri Balan</span> - <span class="hlFld-Affiliation affiliation">†Neuroscience and Pain Medicinal
Chemistry, ‡Pharmacokinetics, Dynamics, and
Metabolism, and §Neuroscience and Pain Research Unit, Pfizer
Inc., Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Pharmaceutical Sciences, ⊥Pharmacokinetics,
Dynamics, and Metabolism, #Biostatistics, Early Clinical
Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc., Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gabriela Barreiro</span> - <span class="hlFld-Affiliation affiliation">†Neuroscience and Pain Medicinal
Chemistry, ‡Pharmacokinetics, Dynamics, and
Metabolism, and §Neuroscience and Pain Research Unit, Pfizer
Inc., Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Pharmaceutical Sciences, ⊥Pharmacokinetics,
Dynamics, and Metabolism, #Biostatistics, Early Clinical
Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc., Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jason Barricklow</span> - <span class="hlFld-Affiliation affiliation">†Neuroscience and Pain Medicinal
Chemistry, ‡Pharmacokinetics, Dynamics, and
Metabolism, and §Neuroscience and Pain Research Unit, Pfizer
Inc., Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Pharmaceutical Sciences, ⊥Pharmacokinetics,
Dynamics, and Metabolism, #Biostatistics, Early Clinical
Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc., Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael J. Bohanon</span> - <span class="hlFld-Affiliation affiliation">†Neuroscience and Pain Medicinal
Chemistry, ‡Pharmacokinetics, Dynamics, and
Metabolism, and §Neuroscience and Pain Research Unit, Pfizer
Inc., Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Pharmaceutical Sciences, ⊥Pharmacokinetics,
Dynamics, and Metabolism, #Biostatistics, Early Clinical
Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc., Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brian P. Boscoe</span> - <span class="hlFld-Affiliation affiliation">†Neuroscience and Pain Medicinal
Chemistry, ‡Pharmacokinetics, Dynamics, and
Metabolism, and §Neuroscience and Pain Research Unit, Pfizer
Inc., Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Pharmaceutical Sciences, ⊥Pharmacokinetics,
Dynamics, and Metabolism, #Biostatistics, Early Clinical
Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc., Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gregg D. Cappon</span> - <span class="hlFld-Affiliation affiliation">†Neuroscience and Pain Medicinal
Chemistry, ‡Pharmacokinetics, Dynamics, and
Metabolism, and §Neuroscience and Pain Research Unit, Pfizer
Inc., Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Pharmaceutical Sciences, ⊥Pharmacokinetics,
Dynamics, and Metabolism, #Biostatistics, Early Clinical
Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc., Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lois K. Chenard</span> - <span class="hlFld-Affiliation affiliation">†Neuroscience and Pain Medicinal
Chemistry, ‡Pharmacokinetics, Dynamics, and
Metabolism, and §Neuroscience and Pain Research Unit, Pfizer
Inc., Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Pharmaceutical Sciences, ⊥Pharmacokinetics,
Dynamics, and Metabolism, #Biostatistics, Early Clinical
Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc., Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Julie Cianfrogna</span> - <span class="hlFld-Affiliation affiliation">†Neuroscience and Pain Medicinal
Chemistry, ‡Pharmacokinetics, Dynamics, and
Metabolism, and §Neuroscience and Pain Research Unit, Pfizer
Inc., Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Pharmaceutical Sciences, ⊥Pharmacokinetics,
Dynamics, and Metabolism, #Biostatistics, Early Clinical
Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc., Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Laigao Chen</span> - <span class="hlFld-Affiliation affiliation">†Neuroscience and Pain Medicinal
Chemistry, ‡Pharmacokinetics, Dynamics, and
Metabolism, and §Neuroscience and Pain Research Unit, Pfizer
Inc., Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Pharmaceutical Sciences, ⊥Pharmacokinetics,
Dynamics, and Metabolism, #Biostatistics, Early Clinical
Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc., Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Karen J. Coffman</span> - <span class="hlFld-Affiliation affiliation">†Neuroscience and Pain Medicinal
Chemistry, ‡Pharmacokinetics, Dynamics, and
Metabolism, and §Neuroscience and Pain Research Unit, Pfizer
Inc., Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Pharmaceutical Sciences, ⊥Pharmacokinetics,
Dynamics, and Metabolism, #Biostatistics, Early Clinical
Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc., Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Susan E. Drozda</span> - <span class="hlFld-Affiliation affiliation">†Neuroscience and Pain Medicinal
Chemistry, ‡Pharmacokinetics, Dynamics, and
Metabolism, and §Neuroscience and Pain Research Unit, Pfizer
Inc., Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Pharmaceutical Sciences, ⊥Pharmacokinetics,
Dynamics, and Metabolism, #Biostatistics, Early Clinical
Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc., Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Joshua R. Dunetz</span> - <span class="hlFld-Affiliation affiliation">†Neuroscience and Pain Medicinal
Chemistry, ‡Pharmacokinetics, Dynamics, and
Metabolism, and §Neuroscience and Pain Research Unit, Pfizer
Inc., Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Pharmaceutical Sciences, ⊥Pharmacokinetics,
Dynamics, and Metabolism, #Biostatistics, Early Clinical
Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc., Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Somraj Ghosh</span> - <span class="hlFld-Affiliation affiliation">†Neuroscience and Pain Medicinal
Chemistry, ‡Pharmacokinetics, Dynamics, and
Metabolism, and §Neuroscience and Pain Research Unit, Pfizer
Inc., Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Pharmaceutical Sciences, ⊥Pharmacokinetics,
Dynamics, and Metabolism, #Biostatistics, Early Clinical
Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc., Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xinjun Hou</span> - <span class="hlFld-Affiliation affiliation">†Neuroscience and Pain Medicinal
Chemistry, ‡Pharmacokinetics, Dynamics, and
Metabolism, and §Neuroscience and Pain Research Unit, Pfizer
Inc., Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Pharmaceutical Sciences, ⊥Pharmacokinetics,
Dynamics, and Metabolism, #Biostatistics, Early Clinical
Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc., Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christopher Houle</span> - <span class="hlFld-Affiliation affiliation">†Neuroscience and Pain Medicinal
Chemistry, ‡Pharmacokinetics, Dynamics, and
Metabolism, and §Neuroscience and Pain Research Unit, Pfizer
Inc., Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Pharmaceutical Sciences, ⊥Pharmacokinetics,
Dynamics, and Metabolism, #Biostatistics, Early Clinical
Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc., Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kapil Karki</span> - <span class="hlFld-Affiliation affiliation">†Neuroscience and Pain Medicinal
Chemistry, ‡Pharmacokinetics, Dynamics, and
Metabolism, and §Neuroscience and Pain Research Unit, Pfizer
Inc., Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Pharmaceutical Sciences, ⊥Pharmacokinetics,
Dynamics, and Metabolism, #Biostatistics, Early Clinical
Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc., Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John T. Lazzaro</span> - <span class="hlFld-Affiliation affiliation">†Neuroscience and Pain Medicinal
Chemistry, ‡Pharmacokinetics, Dynamics, and
Metabolism, and §Neuroscience and Pain Research Unit, Pfizer
Inc., Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Pharmaceutical Sciences, ⊥Pharmacokinetics,
Dynamics, and Metabolism, #Biostatistics, Early Clinical
Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc., Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jessica Y. Mancuso</span> - <span class="hlFld-Affiliation affiliation">†Neuroscience and Pain Medicinal
Chemistry, ‡Pharmacokinetics, Dynamics, and
Metabolism, and §Neuroscience and Pain Research Unit, Pfizer
Inc., Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Pharmaceutical Sciences, ⊥Pharmacokinetics,
Dynamics, and Metabolism, #Biostatistics, Early Clinical
Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc., Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John M. Marcek</span> - <span class="hlFld-Affiliation affiliation">†Neuroscience and Pain Medicinal
Chemistry, ‡Pharmacokinetics, Dynamics, and
Metabolism, and §Neuroscience and Pain Research Unit, Pfizer
Inc., Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Pharmaceutical Sciences, ⊥Pharmacokinetics,
Dynamics, and Metabolism, #Biostatistics, Early Clinical
Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc., Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Emily L. Miller</span> - <span class="hlFld-Affiliation affiliation">†Neuroscience and Pain Medicinal
Chemistry, ‡Pharmacokinetics, Dynamics, and
Metabolism, and §Neuroscience and Pain Research Unit, Pfizer
Inc., Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Pharmaceutical Sciences, ⊥Pharmacokinetics,
Dynamics, and Metabolism, #Biostatistics, Early Clinical
Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc., Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mark A. Moen</span> - <span class="hlFld-Affiliation affiliation">†Neuroscience and Pain Medicinal
Chemistry, ‡Pharmacokinetics, Dynamics, and
Metabolism, and §Neuroscience and Pain Research Unit, Pfizer
Inc., Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Pharmaceutical Sciences, ⊥Pharmacokinetics,
Dynamics, and Metabolism, #Biostatistics, Early Clinical
Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc., Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Steven O’Neil</span> - <span class="hlFld-Affiliation affiliation">†Neuroscience and Pain Medicinal
Chemistry, ‡Pharmacokinetics, Dynamics, and
Metabolism, and §Neuroscience and Pain Research Unit, Pfizer
Inc., Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Pharmaceutical Sciences, ⊥Pharmacokinetics,
Dynamics, and Metabolism, #Biostatistics, Early Clinical
Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc., Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Isao Sakurada</span> - <span class="hlFld-Affiliation affiliation">†Neuroscience and Pain Medicinal
Chemistry, ‡Pharmacokinetics, Dynamics, and
Metabolism, and §Neuroscience and Pain Research Unit, Pfizer
Inc., Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Pharmaceutical Sciences, ⊥Pharmacokinetics,
Dynamics, and Metabolism, #Biostatistics, Early Clinical
Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc., Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marc Skaddan</span> - <span class="hlFld-Affiliation affiliation">†Neuroscience and Pain Medicinal
Chemistry, ‡Pharmacokinetics, Dynamics, and
Metabolism, and §Neuroscience and Pain Research Unit, Pfizer
Inc., Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Pharmaceutical Sciences, ⊥Pharmacokinetics,
Dynamics, and Metabolism, #Biostatistics, Early Clinical
Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc., Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Vinod Parikh</span> - <span class="hlFld-Affiliation affiliation">†Neuroscience and Pain Medicinal
Chemistry, ‡Pharmacokinetics, Dynamics, and
Metabolism, and §Neuroscience and Pain Research Unit, Pfizer
Inc., Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Pharmaceutical Sciences, ⊥Pharmacokinetics,
Dynamics, and Metabolism, #Biostatistics, Early Clinical
Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc., Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Deborah L. Smith</span> - <span class="hlFld-Affiliation affiliation">†Neuroscience and Pain Medicinal
Chemistry, ‡Pharmacokinetics, Dynamics, and
Metabolism, and §Neuroscience and Pain Research Unit, Pfizer
Inc., Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Pharmaceutical Sciences, ⊥Pharmacokinetics,
Dynamics, and Metabolism, #Biostatistics, Early Clinical
Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc., Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Patrick Trapa</span> - <span class="hlFld-Affiliation affiliation">†Neuroscience and Pain Medicinal
Chemistry, ‡Pharmacokinetics, Dynamics, and
Metabolism, and §Neuroscience and Pain Research Unit, Pfizer
Inc., Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Pharmaceutical Sciences, ⊥Pharmacokinetics,
Dynamics, and Metabolism, #Biostatistics, Early Clinical
Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc., Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jamison B. Tuttle</span> - <span class="hlFld-Affiliation affiliation">†Neuroscience and Pain Medicinal
Chemistry, ‡Pharmacokinetics, Dynamics, and
Metabolism, and §Neuroscience and Pain Research Unit, Pfizer
Inc., Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Pharmaceutical Sciences, ⊥Pharmacokinetics,
Dynamics, and Metabolism, #Biostatistics, Early Clinical
Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc., Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Patrick R. Verhoest</span> - <span class="hlFld-Affiliation affiliation">†Neuroscience and Pain Medicinal
Chemistry, ‡Pharmacokinetics, Dynamics, and
Metabolism, and §Neuroscience and Pain Research Unit, Pfizer
Inc., Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Pharmaceutical Sciences, ⊥Pharmacokinetics,
Dynamics, and Metabolism, #Biostatistics, Early Clinical
Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc., Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Daniel P. Walker</span> - <span class="hlFld-Affiliation affiliation">†Neuroscience and Pain Medicinal
Chemistry, ‡Pharmacokinetics, Dynamics, and
Metabolism, and §Neuroscience and Pain Research Unit, Pfizer
Inc., Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Pharmaceutical Sciences, ⊥Pharmacokinetics,
Dynamics, and Metabolism, #Biostatistics, Early Clinical
Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc., Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Annie Won</span> - <span class="hlFld-Affiliation affiliation">†Neuroscience and Pain Medicinal
Chemistry, ‡Pharmacokinetics, Dynamics, and
Metabolism, and §Neuroscience and Pain Research Unit, Pfizer
Inc., Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Pharmaceutical Sciences, ⊥Pharmacokinetics,
Dynamics, and Metabolism, #Biostatistics, Early Clinical
Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc., Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ann S. Wright</span> - <span class="hlFld-Affiliation affiliation">†Neuroscience and Pain Medicinal
Chemistry, ‡Pharmacokinetics, Dynamics, and
Metabolism, and §Neuroscience and Pain Research Unit, Pfizer
Inc., Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Pharmaceutical Sciences, ⊥Pharmacokinetics,
Dynamics, and Metabolism, #Biostatistics, Early Clinical
Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc., Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jessica Whritenour</span> - <span class="hlFld-Affiliation affiliation">†Neuroscience and Pain Medicinal
Chemistry, ‡Pharmacokinetics, Dynamics, and
Metabolism, and §Neuroscience and Pain Research Unit, Pfizer
Inc., Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Pharmaceutical Sciences, ⊥Pharmacokinetics,
Dynamics, and Metabolism, #Biostatistics, Early Clinical
Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc., Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kenneth Zasadny</span> - <span class="hlFld-Affiliation affiliation">†Neuroscience and Pain Medicinal
Chemistry, ‡Pharmacokinetics, Dynamics, and
Metabolism, and §Neuroscience and Pain Research Unit, Pfizer
Inc., Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Pharmaceutical Sciences, ⊥Pharmacokinetics,
Dynamics, and Metabolism, #Biostatistics, Early Clinical
Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc., Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Margaret M. Zaleska</span> - <span class="hlFld-Affiliation affiliation">†Neuroscience and Pain Medicinal
Chemistry, ‡Pharmacokinetics, Dynamics, and
Metabolism, and §Neuroscience and Pain Research Unit, Pfizer
Inc., Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Pharmaceutical Sciences, ⊥Pharmacokinetics,
Dynamics, and Metabolism, #Biostatistics, Early Clinical
Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc., Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lei Zhang</span> - <span class="hlFld-Affiliation affiliation">†Neuroscience and Pain Medicinal
Chemistry, ‡Pharmacokinetics, Dynamics, and
Metabolism, and §Neuroscience and Pain Research Unit, Pfizer
Inc., Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Pharmaceutical Sciences, ⊥Pharmacokinetics,
Dynamics, and Metabolism, #Biostatistics, Early Clinical
Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc., Groton, Connecticut 06340, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8118-1402" title="Orcid link">http://orcid.org/0000-0001-8118-1402</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christopher L. Shaffer</span> - <span class="hlFld-Affiliation affiliation">†Neuroscience and Pain Medicinal
Chemistry, ‡Pharmacokinetics, Dynamics, and
Metabolism, and §Neuroscience and Pain Research Unit, Pfizer
Inc., Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Pharmaceutical Sciences, ⊥Pharmacokinetics,
Dynamics, and Metabolism, #Biostatistics, Early Clinical
Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc., Groton, Connecticut 06340, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d38e5405-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i56">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_80365" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_80365" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank James Bradow, Robert P. Depianta, and Drs. Qi Yan and Laurence Philippe-Venec from the purification group. We also thank Brendon Kapinos, Walter E. Mitchell, Jillian B. Van Hausen, James J. Frederico, III, John P. Umland, Mark W. Snyder, and Dr. Marina Y. Shalaeva from the ADME high-throughput screening group at Pfizer, Groton. We also thank Drs. Karamjeet Pandher, Kathleen Biddle, and Ingrid Pardo for pathology support and Drs. R. Scott Obach and Michael A. Brodney for valuable discussions regarding the metabolic profiling of key compounds. Compound <b>7</b> (PF-06297470, catalogue no. PZ019) and compound <b>8</b> (PF-06462894, catalogue no. PZ0231) are commercially available via MilliporeSigma.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i57" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i57"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i58" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i58"> Abbreviations Used</h2><tr><td class="NLM_term">ADME</td><td class="NLM_def"><p class="first last">administration, distribution, metabolism and excretion</p></td></tr><tr><td class="NLM_term">BID</td><td class="NLM_def"><p class="first last">bis in die</p></td></tr><tr><td class="NLM_term">CI</td><td class="NLM_def"><p class="first last">confidence interval</p></td></tr><tr><td class="NLM_term">CNS</td><td class="NLM_def"><p class="first last">central nervous system</p></td></tr><tr><td class="NLM_term">CL<sub>b</sub></td><td class="NLM_def"><p class="first last">total blood clearance</p></td></tr><tr><td class="NLM_term"><i>C</i><sub>p,u</sub></td><td class="NLM_def"><p class="first last">unbound plasma compound concentration</p></td></tr><tr><td class="NLM_term">CL<sub>int,app</sub></td><td class="NLM_def"><p class="first last">bound intrinsic clearance</p></td></tr><tr><td class="NLM_term">CL<sub>int,u</sub></td><td class="NLM_def"><p class="first last">unbound clearance</p></td></tr><tr><td class="NLM_term">DIAD</td><td class="NLM_def"><p class="first last">diisopropylazodicarboxylate</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last">dimethylformamide</p></td></tr><tr><td class="NLM_term">equiv</td><td class="NLM_def"><p class="first last">equivalent</p></td></tr><tr><td class="NLM_term">ETS</td><td class="NLM_def"><p class="first last">exploratory toxicology studies</p></td></tr><tr><td class="NLM_term"><i>F</i></td><td class="NLM_def"><p class="first last">oral bioavailability</p></td></tr><tr><td class="NLM_term">FXS</td><td class="NLM_def"><p class="first last">fragile X syndrome</p></td></tr><tr><td class="NLM_term">iGlu</td><td class="NLM_def"><p class="first last">ionotropic glutamate receptor</p></td></tr><tr><td class="NLM_term">IVRO</td><td class="NLM_def"><p class="first last">in vivo receptor occupancy</p></td></tr><tr><td class="NLM_term">HPLC</td><td class="NLM_def"><p class="first last">high-performance liquid chromatography</p></td></tr><tr><td class="NLM_term">HTS</td><td class="NLM_def"><p class="first last">high-throughput screen</p></td></tr><tr><td class="NLM_term">LC-MS</td><td class="NLM_def"><p class="first last">liquid chromatography–mass spectrometry</p></td></tr><tr><td class="NLM_term">LID</td><td class="NLM_def"><p class="first last">levodopa induced dyskinesia</p></td></tr><tr><td class="NLM_term">MAM</td><td class="NLM_def"><p class="first last">mouse allergy model</p></td></tr><tr><td class="NLM_term">mGlu</td><td class="NLM_def"><p class="first last">metabotropic glutamate receptor</p></td></tr><tr><td class="NLM_term">MPEP</td><td class="NLM_def"><p class="first last">2-methyl-6-(phenylethynyl)pyridine</p></td></tr><tr><td class="NLM_term">[<sup>3</sup>H]MPEPy</td><td class="NLM_def"><p class="first last">[<sup>3</sup>H]3-methoxy-5-pyridin-2-ylethynylpyridine</p></td></tr><tr><td class="NLM_term">MPTP</td><td class="NLM_def"><p class="first last">1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine</p></td></tr><tr><td class="NLM_term">NAM</td><td class="NLM_def"><p class="first last">negative allosteric modulator</p></td></tr><tr><td class="NLM_term">ND</td><td class="NLM_def"><p class="first last">not determined</p></td></tr><tr><td class="NLM_term">NHP</td><td class="NLM_def"><p class="first last">nonhuman primate</p></td></tr><tr><td class="NLM_term">NMP</td><td class="NLM_def"><p class="first last"><i>N</i>-methyl-2-pyrrolidone</p></td></tr><tr><td class="NLM_term">NTR</td><td class="NLM_def"><p class="first last">nontreatment related finding</p></td></tr><tr><td class="NLM_term">PET</td><td class="NLM_def"><p class="first last">positron emission tomography</p></td></tr><tr><td class="NLM_term">PD-LID</td><td class="NLM_def"><p class="first last">levadopa-induced dyskinesia in Parkinson’s disease</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term"><i>t</i><sub>1/2</sub></td><td class="NLM_def"><p class="first last">half-life</p></td></tr><tr><td class="NLM_term">TEA</td><td class="NLM_def"><p class="first last">triethylamine</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">TI</td><td class="NLM_def"><p class="first last">therapeutic index</p></td></tr><tr><td class="NLM_term">TLC</td><td class="NLM_def"><p class="first last">thin-layer chromatography</p></td></tr><tr><td class="NLM_term">TMD</td><td class="NLM_def"><p class="first last">transmembrane domain</p></td></tr><tr><td class="NLM_term">UHPLC</td><td class="NLM_def"><p class="first last">ultrahigh performance liquid chromatography</p></td></tr><tr><td class="NLM_term"><i>V</i><sub>ss</sub></td><td class="NLM_def"><p class="first last">steady-state volume of distribution</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i59">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08174" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08174" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 44 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Crawford, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wainwright, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heavens, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollock, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seabrook, G. R.</span><span> </span><span class="NLM_article-title">Mobilization of intracellular Ca2+ by mGluR5 metabotropic glutamate receptor activation in neonatal rat cultured dorsal root ganglia neurones</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">621</span><span class="NLM_x">–</span> <span class="NLM_lpage">630</span><span class="refDoi"> DOI: 10.1016/S0028-3908(99)00167-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=10.1016%2FS0028-3908%2899%2900167-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2000&pages=621-630&author=J.+H.+Crawfordauthor=A.+Wainwrightauthor=R.+Heavensauthor=J.+Pollockauthor=D.+J.+Martinauthor=R.+H.+Scottauthor=G.+R.+Seabrook&title=Mobilization+of+intracellular+Ca2%2B+by+mGluR5+metabotropic+glutamate+receptor+activation+in+neonatal+rat+cultured+dorsal+root+ganglia+neurones&doi=10.1016%2FS0028-3908%2899%2900167-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2FS0028-3908%2899%2900167-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0028-3908%252899%252900167-7%26sid%3Dliteratum%253Aachs%26aulast%3DCrawford%26aufirst%3DJ.%2BH.%26aulast%3DWainwright%26aufirst%3DA.%26aulast%3DHeavens%26aufirst%3DR.%26aulast%3DPollock%26aufirst%3DJ.%26aulast%3DMartin%26aufirst%3DD.%2BJ.%26aulast%3DScott%26aufirst%3DR.%2BH.%26aulast%3DSeabrook%26aufirst%3DG.%2BR.%26atitle%3DMobilization%2520of%2520intracellular%2520Ca2%252B%2520by%2520mGluR5%2520metabotropic%2520glutamate%2520receptor%2520activation%2520in%2520neonatal%2520rat%2520cultured%2520dorsal%2520root%2520ganglia%2520neurones%26jtitle%3DNeuropharmacology%26date%3D2000%26volume%3D39%26spage%3D621%26epage%3D630%26doi%3D10.1016%2FS0028-3908%2899%2900167-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Recasens, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guiramand, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aimar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abdulkarim, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbanel, G.</span><span> </span><span class="NLM_article-title">Metabotropic glutamate receptors as drug targets</span> <span class="citation_source-journal">Curr. Drug Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">651</span><span class="NLM_x">–</span> <span class="NLM_lpage">681</span><span class="refDoi"> DOI: 10.2174/138945007780618544</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=10.2174%2F138945007780618544" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=17504108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlsVWmu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2007&pages=651-681&author=M.+Recasensauthor=J.+Guiramandauthor=R.+Aimarauthor=A.+Abdulkarimauthor=G.+Barbanel&title=Metabotropic+glutamate+receptors+as+drug+targets&doi=10.2174%2F138945007780618544"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Metabotropic glutamate receptors as drug targets</span></div><div class="casAuthors">Recasens, Max; Guiramand, Janique; Aimar, Rose; Abdulkarim, Ahmad; Barbanel, Gerard</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Targets</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">651-681</span>CODEN:
                <span class="NLM_cas:coden">CDTUAU</span>;
        ISSN:<span class="NLM_cas:issn">1389-4501</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  L-glutamate (Glu), the main excitatory amino acid neurotransmitter in the mammalian central nervous system, is involved in many physiol. functions, including learning and memory, but also in toxic phenomena occurring in numerous degenerative or neurol. diseases.  These functions mainly result from its interaction with Glu receptors (GluRs).  The broad spectrum of roles played by glutamate derived from the large no. of membrane receptors, which are currently classified in two main categories, ionotropic (iGluRs) and metabotropic (mGluRs) receptors.  The iGluRs are ion channels, permeant to Na+ (Ca2+) while the mGluRs belongs to the superfamily of G-protein coupled receptors (GPCRs).  Despite continuous efforts over more than two decades, the use of iGluR agonists or antagonists to improve or inhibit excitatory transmission in pathol. states still remains a major challenge, though the discovery and development of recent mols. may prove it worthwhile.  This probably results form the vital role of fast excitatory transmission in many fundamental physiol. functions.  Since the discovery of mGluRs, hope has emerged.  Indeed, mGluRs are mainly involved in the regulation of fast excitatory transmission.  Consequently, it was logically thought that modulating mGluRs with agonists or antagonists might lead to more subtle regulation of fast excitatory transmission than by directly blocking iGluRs.  As a result of intensive investigation, new drugs permitting to discriminate between these receptors have emerged.  Moreover, a new class of mols. acting as neg. or pos. allosteric modulators or mGluRs is now available and appears to be promising.  In the following, we will review the classification of mGluRs and the functions in which mGluRs are involved.  We will focus on their potential as therapeutic targets for improving numerous physiol. functions and for different neurodegenerative and neuropsychiatric disorders, which are related to malfunction of Glu signaling in human beings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2Y9ty-Qq5tLVg90H21EOLACvtfcHk0liVnzJPKn-wvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlsVWmu7w%253D&md5=9c51d9468835f67e5e54d4b6a10f5dce</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.2174%2F138945007780618544&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138945007780618544%26sid%3Dliteratum%253Aachs%26aulast%3DRecasens%26aufirst%3DM.%26aulast%3DGuiramand%26aufirst%3DJ.%26aulast%3DAimar%26aufirst%3DR.%26aulast%3DAbdulkarim%26aufirst%3DA.%26aulast%3DBarbanel%26aufirst%3DG.%26atitle%3DMetabotropic%2520glutamate%2520receptors%2520as%2520drug%2520targets%26jtitle%3DCurr.%2520Drug%2520Targets%26date%3D2007%26volume%3D8%26spage%3D651%26epage%3D681%26doi%3D10.2174%2F138945007780618544" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Swanson, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bures, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linden, A.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monn, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoepp, D. D.</span><span> </span><span class="NLM_article-title">Metabotropic glutamate receptors as novel targets for anxiety and stress disorders</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">131</span><span class="NLM_x">–</span> <span class="NLM_lpage">144</span><span class="refDoi"> DOI: 10.1038/nrd1630</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=10.1038%2Fnrd1630" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2005&pages=131-144&author=C.+J.+Swansonauthor=M.+Buresauthor=M.+P.+Johnsonauthor=A.-M.+Lindenauthor=J.+A.+Monnauthor=D.+D.+Schoepp&title=Metabotropic+glutamate+receptors+as+novel+targets+for+anxiety+and+stress+disorders&doi=10.1038%2Fnrd1630"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrd1630&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1630%26sid%3Dliteratum%253Aachs%26aulast%3DSwanson%26aufirst%3DC.%2BJ.%26aulast%3DBures%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DM.%2BP.%26aulast%3DLinden%26aufirst%3DA.-M.%26aulast%3DMonn%26aufirst%3DJ.%2BA.%26aulast%3DSchoepp%26aufirst%3DD.%2BD.%26atitle%3DMetabotropic%2520glutamate%2520receptors%2520as%2520novel%2520targets%2520for%2520anxiety%2520and%2520stress%2520disorders%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2005%26volume%3D4%26spage%3D131%26epage%3D144%26doi%3D10.1038%2Fnrd1630" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Pin, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duvoisin, R.</span><span> </span><span class="NLM_article-title">Review: neurotransmitter receptors I. The metabotropic glutamate receptors: structure and functions</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">26</span><span class="refDoi"> DOI: 10.1016/0028-3908(94)00129-G</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=10.1016%2F0028-3908%2894%2900129-G" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=1995&pages=1-26&author=J.+P.+Pinauthor=R.+Duvoisin&title=Review%3A+neurotransmitter+receptors+I.+The+metabotropic+glutamate+receptors%3A+structure+and+functions&doi=10.1016%2F0028-3908%2894%2900129-G"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2F0028-3908%2894%2900129-G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0028-3908%252894%252900129-G%26sid%3Dliteratum%253Aachs%26aulast%3DPin%26aufirst%3DJ.%2BP.%26aulast%3DDuvoisin%26aufirst%3DR.%26atitle%3DReview%253A%2520neurotransmitter%2520receptors%2520I.%2520The%2520metabotropic%2520glutamate%2520receptors%253A%2520structure%2520and%2520functions%26jtitle%3DNeuropharmacology%26date%3D1995%26volume%3D34%26spage%3D1%26epage%3D26%26doi%3D10.1016%2F0028-3908%2894%2900129-G" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Conn, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pin, J.-P.</span><span> </span><span class="NLM_article-title">Pharmacology and functions of metabotropic glutamate receptors</span> <span class="citation_source-journal">Annu. Rev. Pharmacol. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">205</span><span class="NLM_x">–</span> <span class="NLM_lpage">237</span><span class="refDoi"> DOI: 10.1146/annurev.pharmtox.37.1.205</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=10.1146%2Fannurev.pharmtox.37.1.205" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=9131252" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=1%3ACAS%3A528%3ADyaK2sXisl2ktr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1997&pages=205-237&author=P.+J.+Connauthor=J.-P.+Pin&title=Pharmacology+and+functions+of+metabotropic+glutamate+receptors&doi=10.1146%2Fannurev.pharmtox.37.1.205"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacology and functions of metabotropic glutamate receptors</span></div><div class="casAuthors">Conn, P. Jeffrey; Pin, Jean-Philippe</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">205-237</span>CODEN:
                <span class="NLM_cas:coden">ARPTDI</span>;
        ISSN:<span class="NLM_cas:issn">0362-1642</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews</span>)
        </div><div class="casAbstract">A review, with 198 refs.  In the mid to late 1980s, studies were published that provided the first evidence for the existence of glutamate receptors that are not ligand-gated cation channels but are coupled to effector systems through GTP-binding proteins.  Since those initial reports, tremendous progress has been made in characterizing these metabotropic glutamate receptors (mGluRs), including cloning and characterization of cDNA that encodes a family of eight mGluR subtypes, several of which have multiple splice variants.  Also, tremendous progress has been made in developing new highly selective mGluR agonists and antagonists and toward detg. the physiol. roles of the mGluRs in mammalian brain.  These findings have exciting implications for drug development and suggest that the mGluRs provide a novel target for development of therapeutic agents that could have a significant impact on neuropharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGph1fuaHYNvC7Vg90H21EOLACvtfcHk0liVnzJPKn-wvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXisl2ktr0%253D&md5=d9df228141c4747f80bbd9d2f0843a24</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1146%2Fannurev.pharmtox.37.1.205&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.pharmtox.37.1.205%26sid%3Dliteratum%253Aachs%26aulast%3DConn%26aufirst%3DP.%2BJ.%26aulast%3DPin%26aufirst%3DJ.-P.%26atitle%3DPharmacology%2520and%2520functions%2520of%2520metabotropic%2520glutamate%2520receptors%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D1997%26volume%3D37%26spage%3D205%26epage%3D237%26doi%3D10.1146%2Fannurev.pharmtox.37.1.205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Spooren, W. P. J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vassout, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neijt, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuhn, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gasparini, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roux, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porsolt, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gentsch, C.</span><span> </span><span class="NLM_article-title">Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">295</span><span class="NLM_x">, </span> <span class="NLM_fpage">1267</span><span class="NLM_x">–</span> <span class="NLM_lpage">1275</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=11082464" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=1%3ACAS%3A528%3ADC%252BD3cXosVKitr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=295&publication_year=2000&pages=1267-1275&author=W.+P.+J.+M.+Spoorenauthor=A.+Vassoutauthor=H.+C.+Neijtauthor=R.+Kuhnauthor=F.+Gaspariniauthor=S.+Rouxauthor=R.+D.+Porsoltauthor=C.+Gentsch&title=Anxiolytic-like+effects+of+the+prototypical+metabotropic+glutamate+receptor+5+antagonist+2-methyl-6-%28phenylethynyl%29pyridine+in+rodents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents</span></div><div class="casAuthors">Spooren, Will P. J. M.; Vassout, Annick; Neijt, Hans C.; Kuhn, Rainer; Gasparini, Fabrizio; Roux, Silvain; Porsolt, Roger D.; Gentsch, Conrad</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">295</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1267-1275</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Recently, selective and systemically active antagonists for the metabotropic glutamate 5 receptor (mGlu5) were discovered, and the most potent deriv. was found to be MPEP (2-methyl-6-(phenylethynyl)pyridine).  Given the high expression of mGlu5 receptors in limbic forebrain regions, it was decided to evaluate the anxiolytic potential of MPEP.  After an acute oral administration, MPEP attenuated the anxiety-dependent variable in a variety of well established anxiety test paradigms.  In rats, MPEP (10, 30, and 100 mg/kg) increased punished responses in the Geller-Seifter test, but none of these effects reached statistical significance.  MPEP significantly increased the ratio (open/total arm entries; 0.1, 1, and 10 mg/kg), the no. of open arm entries (0.1, 1, and 10 mg/kg), as well as time spent on open arm (0.1 and 1 mg/kg) in the elevated plus maze test.  Furthermore, MPEP (0.3 and 1 mg/kg) significantly increased the time spent in social contact in the social exploration test.  In mice, MPEP attenuated stress-induced hyperthermia (15 and 30 mg/kg) and decreased the no. of buried marbles in the marble burying test (7.5 and 30 mg/kg).  Finally, MPEP (0.01, 0.1, 1, 10, and 100 mg/kg) was tested on spontaneous locomotor activity in mice, and only a dose of 100 mg/kg significantly reduced vertical activity; no effect was seen on horizontal activity.  MPEP (7.5, 15, and 30 mg/kg) was ineffective on d-amphetamine-induced (2.5 mg/kg) locomotor activity in mice and prepulse inhibition in rats (1, 3, or 10 mg/kg).  Thus, these findings indicate that MPEP exhibits anxiolytic-like effects and low risks for sedation and psychotomimetic side-effects in rodents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqR0smnEgHr_rVg90H21EOLACvtfcHk0liVnzJPKn-wvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXosVKitr8%253D&md5=b08c1a7ba794c4be8ca048c9925be7da</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSpooren%26aufirst%3DW.%2BP.%2BJ.%2BM.%26aulast%3DVassout%26aufirst%3DA.%26aulast%3DNeijt%26aufirst%3DH.%2BC.%26aulast%3DKuhn%26aufirst%3DR.%26aulast%3DGasparini%26aufirst%3DF.%26aulast%3DRoux%26aufirst%3DS.%26aulast%3DPorsolt%26aufirst%3DR.%2BD.%26aulast%3DGentsch%26aufirst%3DC.%26atitle%3DAnxiolytic-like%2520effects%2520of%2520the%2520prototypical%2520metabotropic%2520glutamate%2520receptor%25205%2520antagonist%25202-methyl-6-%2528phenylethynyl%2529pyridine%2520in%2520rodents%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2000%26volume%3D295%26spage%3D1267%26epage%3D1275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Walker, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reeve, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bowes, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winter, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wotherspoon, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmid, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gasparini, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuhn, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urban, L.</span><span> </span><span class="NLM_article-title">mGlu5 receptors and nociceptive function. II. mGlu5 receptors functionally expressed on peripheral sensory neurones mediate inflammatory hyperalgesia</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">10</span><span class="NLM_x">–</span> <span class="NLM_lpage">19</span><span class="refDoi"> DOI: 10.1016/S0028-3908(00)00114-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=10.1016%2FS0028-3908%2800%2900114-3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2001&pages=10-19&author=K.+Walkerauthor=A.+Reeveauthor=M.+Bowesauthor=J.+Winterauthor=G.+Wotherspoonauthor=A.+Davisauthor=P.+Schmidauthor=F.+Gaspariniauthor=R.+Kuhnauthor=L.+Urban&title=mGlu5+receptors+and+nociceptive+function.+II.+mGlu5+receptors+functionally+expressed+on+peripheral+sensory+neurones+mediate+inflammatory+hyperalgesia&doi=10.1016%2FS0028-3908%2800%2900114-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2FS0028-3908%2800%2900114-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0028-3908%252800%252900114-3%26sid%3Dliteratum%253Aachs%26aulast%3DWalker%26aufirst%3DK.%26aulast%3DReeve%26aufirst%3DA.%26aulast%3DBowes%26aufirst%3DM.%26aulast%3DWinter%26aufirst%3DJ.%26aulast%3DWotherspoon%26aufirst%3DG.%26aulast%3DDavis%26aufirst%3DA.%26aulast%3DSchmid%26aufirst%3DP.%26aulast%3DGasparini%26aufirst%3DF.%26aulast%3DKuhn%26aufirst%3DR.%26aulast%3DUrban%26aufirst%3DL.%26atitle%3DmGlu5%2520receptors%2520and%2520nociceptive%2520function.%2520II.%2520mGlu5%2520receptors%2520functionally%2520expressed%2520on%2520peripheral%2520sensory%2520neurones%2520mediate%2520inflammatory%2520hyperalgesia%26jtitle%3DNeuropharmacology%26date%3D2001%26volume%3D40%26spage%3D10%26epage%3D19%26doi%3D10.1016%2FS0028-3908%2800%2900114-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Tatarczynska, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klodzinska, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chojnacka-Wojcik, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palucha, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gasparini, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuhn, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pilc, A.</span><span> </span><span class="NLM_article-title">Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist</span> <span class="citation_source-journal">br J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">132</span><span class="NLM_x">, </span> <span class="NLM_fpage">1423</span><span class="NLM_x">–</span> <span class="NLM_lpage">1430</span><span class="refDoi"> DOI: 10.1038/sj.bjp.0703923</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=10.1038%2Fsj.bjp.0703923" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=11264235" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=1%3ACAS%3A528%3ADC%252BD3MXivVahs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2001&pages=1423-1430&author=E.+Tatarczynskaauthor=A.+Klodzinskaauthor=E.+Chojnacka-Wojcikauthor=A.+Paluchaauthor=F.+Gaspariniauthor=R.+Kuhnauthor=A.+Pilc&title=Potential+anxiolytic-+and+antidepressant-like+effects+of+MPEP%2C+a+potent%2C+selective+and+systemically+active+mGlu5+receptor+antagonist&doi=10.1038%2Fsj.bjp.0703923"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist</span></div><div class="casAuthors">Tatarczynska, Ewa; Klodzinska, Aleksandra; Chojnacka-Wojcik, Ewa; Palucha, Agnieszka; Gasparini, Fabrizio; Kuhn, Rainer; Pilc, Andrzej</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1423-1430</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Several lines of evidence suggest a crucial involvement of glutamate in the mechanism of action of anxiolytic and/or antidepressant drugs.  The involvement of group I metabotropic glutamate (mGlu) receptors in anxiety and depression has also been proposed.  Given the recent discovery of selective and brain-penetrating mGlu5 receptor antagonists, the effect of 2-methyl-6-(phenylethynyl)pyridine (MPEP), i.e., the most potent compd. described, was evaluated in established models of anxiety and depression.  Expts. were performed on male Wistar rats or male Albino Swiss or C57BL/6J mice.  The anxiolytic-like effects of MPEP were tested in the conflict drinking test and the elevated plus-maze test in rats as well as in the 4-plate test in mice.  The antidepressant-like effect was estd. by the tail suspension test in mice and the behavioral despair test in rats.  MPEP (1-30 mg/kg) induced anxiolytic-like effects in the conflict drinking test and the elevated plus-maze test in rats as well as in the 4-plate test in mice.  MPEP had no effect on locomotor activity or motor coordination.  MPEP (1-20 mg/kg) shortened the immobility time in the tail suspension test in mice; however, it was inactive in the behavioral despair test in rats.  These data suggest that selective mGlu5 receptor antagonists may be useful in the therapy of anxiety and/or depression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcmuBTvCR_HrVg90H21EOLACvtfcHk0ljR5u-H8D9ETg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXivVahs70%253D&md5=8840ee76df4717c51c3bc7e529fa1762</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0703923&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0703923%26sid%3Dliteratum%253Aachs%26aulast%3DTatarczynska%26aufirst%3DE.%26aulast%3DKlodzinska%26aufirst%3DA.%26aulast%3DChojnacka-Wojcik%26aufirst%3DE.%26aulast%3DPalucha%26aufirst%3DA.%26aulast%3DGasparini%26aufirst%3DF.%26aulast%3DKuhn%26aufirst%3DR.%26aulast%3DPilc%26aufirst%3DA.%26atitle%3DPotential%2520anxiolytic-%2520and%2520antidepressant-like%2520effects%2520of%2520MPEP%252C%2520a%2520potent%252C%2520selective%2520and%2520systemically%2520active%2520mGlu5%2520receptor%2520antagonist%26jtitle%3Dbr%2520J.%2520Pharmacol.%26date%3D2001%26volume%3D132%26spage%3D1423%26epage%3D1430%26doi%3D10.1038%2Fsj.bjp.0703923" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Chapman, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nanan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meldrum, B. S.</span><span> </span><span class="NLM_article-title">Anticonvulsant activity of two metabotropic glutamate Group I antagonists selective for the mGlu5 receptor: 2-methyl-6-(phenylethynyl)-pyridine (MPEP), and (E)-6-methyl-2-styryl-pyridine (SIB 1893)</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">1567</span><span class="NLM_x">–</span> <span class="NLM_lpage">1574</span><span class="refDoi"> DOI: 10.1016/S0028-3908(99)00242-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=10.1016%2FS0028-3908%2899%2900242-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2000&pages=1567-1574&author=A.+G.+Chapmanauthor=K.+Nananauthor=M.+Williamsauthor=B.+S.+Meldrum&title=Anticonvulsant+activity+of+two+metabotropic+glutamate+Group+I+antagonists+selective+for+the+mGlu5+receptor%3A+2-methyl-6-%28phenylethynyl%29-pyridine+%28MPEP%29%2C+and+%28E%29-6-methyl-2-styryl-pyridine+%28SIB+1893%29&doi=10.1016%2FS0028-3908%2899%2900242-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2FS0028-3908%2899%2900242-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0028-3908%252899%252900242-7%26sid%3Dliteratum%253Aachs%26aulast%3DChapman%26aufirst%3DA.%2BG.%26aulast%3DNanan%26aufirst%3DK.%26aulast%3DWilliams%26aufirst%3DM.%26aulast%3DMeldrum%26aufirst%3DB.%2BS.%26atitle%3DAnticonvulsant%2520activity%2520of%2520two%2520metabotropic%2520glutamate%2520Group%2520I%2520antagonists%2520selective%2520for%2520the%2520mGlu5%2520receptor%253A%25202-methyl-6-%2528phenylethynyl%2529-pyridine%2520%2528MPEP%2529%252C%2520and%2520%2528E%2529-6-methyl-2-styryl-pyridine%2520%2528SIB%25201893%2529%26jtitle%3DNeuropharmacology%26date%3D2000%26volume%3D39%26spage%3D1567%26epage%3D1574%26doi%3D10.1016%2FS0028-3908%2899%2900242-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Bruno, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ksiazek, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Battaglia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lukic, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonhardt, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sauer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gasparini, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuhn, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicoletti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flor, P. J.</span><span> </span><span class="NLM_article-title">Selective blockade of metabotropic glutamate receptor subtype 5 is neuroprotective</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">2223</span><span class="NLM_x">–</span> <span class="NLM_lpage">2230</span><span class="refDoi"> DOI: 10.1016/S0028-3908(00)00079-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=10.1016%2FS0028-3908%2800%2900079-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2000&pages=2223-2230&author=V.+Brunoauthor=I.+Ksiazekauthor=G.+Battagliaauthor=S.+Lukicauthor=T.+Leonhardtauthor=D.+Sauerauthor=F.+Gaspariniauthor=R.+Kuhnauthor=F.+Nicolettiauthor=P.+J.+Flor&title=Selective+blockade+of+metabotropic+glutamate+receptor+subtype+5+is+neuroprotective&doi=10.1016%2FS0028-3908%2800%2900079-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2FS0028-3908%2800%2900079-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0028-3908%252800%252900079-4%26sid%3Dliteratum%253Aachs%26aulast%3DBruno%26aufirst%3DV.%26aulast%3DKsiazek%26aufirst%3DI.%26aulast%3DBattaglia%26aufirst%3DG.%26aulast%3DLukic%26aufirst%3DS.%26aulast%3DLeonhardt%26aufirst%3DT.%26aulast%3DSauer%26aufirst%3DD.%26aulast%3DGasparini%26aufirst%3DF.%26aulast%3DKuhn%26aufirst%3DR.%26aulast%3DNicoletti%26aufirst%3DF.%26aulast%3DFlor%26aufirst%3DP.%2BJ.%26atitle%3DSelective%2520blockade%2520of%2520metabotropic%2520glutamate%2520receptor%2520subtype%25205%2520is%2520neuroprotective%26jtitle%3DNeuropharmacology%26date%3D2000%26volume%3D39%26spage%3D2223%26epage%3D2230%26doi%3D10.1016%2FS0028-3908%2800%2900079-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Ossowska, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konieczny, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolfarth, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wieronska, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pilc, A.</span><span> </span><span class="NLM_article-title">Blockade of the metabotropic glutamate receptor subtype 5 (mGluR5) produces antiparkinsonian-like effects in rats</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">413</span><span class="NLM_x">–</span> <span class="NLM_lpage">420</span><span class="refDoi"> DOI: 10.1016/S0028-3908(01)00083-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=10.1016%2FS0028-3908%2801%2900083-1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2001&pages=413-420&author=K.+Ossowskaauthor=J.+Koniecznyauthor=S.+Wolfarthauthor=J.+Wieronskaauthor=A.+Pilc&title=Blockade+of+the+metabotropic+glutamate+receptor+subtype+5+%28mGluR5%29+produces+antiparkinsonian-like+effects+in+rats&doi=10.1016%2FS0028-3908%2801%2900083-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2FS0028-3908%2801%2900083-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0028-3908%252801%252900083-1%26sid%3Dliteratum%253Aachs%26aulast%3DOssowska%26aufirst%3DK.%26aulast%3DKonieczny%26aufirst%3DJ.%26aulast%3DWolfarth%26aufirst%3DS.%26aulast%3DWieronska%26aufirst%3DJ.%26aulast%3DPilc%26aufirst%3DA.%26atitle%3DBlockade%2520of%2520the%2520metabotropic%2520glutamate%2520receptor%2520subtype%25205%2520%2528mGluR5%2529%2520produces%2520antiparkinsonian-like%2520effects%2520in%2520rats%26jtitle%3DNeuropharmacology%26date%3D2001%26volume%3D41%26spage%3D413%26epage%3D420%26doi%3D10.1016%2FS0028-3908%2801%2900083-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Chiamulera, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Epping-Jordan, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zocchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcon, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cottiny, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tacconi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corsi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orzi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conquet, F.</span><span> </span><span class="NLM_article-title">Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice</span> <span class="citation_source-journal">Nat. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">873</span><span class="NLM_x">–</span> <span class="NLM_lpage">874</span><span class="refDoi"> DOI: 10.1038/nn0901-873</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=10.1038%2Fnn0901-873" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=11528416" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=1%3ACAS%3A528%3ADC%252BD3MXmtlaqurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2001&pages=873-874&author=C.+Chiamuleraauthor=M.+P.+Epping-Jordanauthor=A.+Zocchiauthor=C.+Marconauthor=C.+Cottinyauthor=S.+Tacconiauthor=M.+Corsiauthor=F.+Orziauthor=F.+Conquet&title=Reinforcing+and+locomotor+stimulant+effects+of+cocaine+are+absent+in+mGluR5+null+mutant+mice&doi=10.1038%2Fnn0901-873"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice</span></div><div class="casAuthors">Chiamulera, Christian; Epping-Jordan, Mark P.; Zocchi, Alessandro; Marcon, Clara; Cottiny, Cecilia; Tacconi, Stefano; Corsi, Mauro; Orzi, Francesco; Conquet, Francois</div><div class="citationInfo"><span class="NLM_cas:title">Nature Neuroscience</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">873-874</span>CODEN:
                <span class="NLM_cas:coden">NANEFN</span>;
        ISSN:<span class="NLM_cas:issn">1097-6256</span>.
    
            (<span class="NLM_cas:orgname">Nature America Inc.</span>)
        </div><div class="casAbstract">The study aims to show that mice lacking the mGluR5 gene do not self-administer (SA) cocaine.  It also aims to show that there was no increased locomotor activity in the mice following cocaine treatment, despite showing cocaine-induced increases in nucleus accumbens (NAcc) dopamine concns. similar to wild-type (WT) mice.  Baseline locomotor activity to cocaine did not differ between mutant and WT mice, which indicates that mGluR5 is essential for cocaine-induced hyperactivity.  When i.v. cocaine was substituted for food, WT mice acquired stable cocaine SA across a typical concn. range.  However, mutant mice did not self-administer cocaine at any concn., suggesting that the reinforcing properties of cocaine are absent in mice lacking mGluR5.  Although the exact mechanism of the mGluR5 contribution to cocaine dependence are not known, these results suggest that mGluR5 is essential in cocaine SA and locomotor effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcydOKjmWE77Vg90H21EOLACvtfcHk0ljD9Q2wBOzRMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXmtlaqurc%253D&md5=707263d630dd1c17e6d200f885a48a60</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fnn0901-873&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnn0901-873%26sid%3Dliteratum%253Aachs%26aulast%3DChiamulera%26aufirst%3DC.%26aulast%3DEpping-Jordan%26aufirst%3DM.%2BP.%26aulast%3DZocchi%26aufirst%3DA.%26aulast%3DMarcon%26aufirst%3DC.%26aulast%3DCottiny%26aufirst%3DC.%26aulast%3DTacconi%26aufirst%3DS.%26aulast%3DCorsi%26aufirst%3DM.%26aulast%3DOrzi%26aufirst%3DF.%26aulast%3DConquet%26aufirst%3DF.%26atitle%3DReinforcing%2520and%2520locomotor%2520stimulant%2520effects%2520of%2520cocaine%2520are%2520absent%2520in%2520mGluR5%2520null%2520mutant%2520mice%26jtitle%3DNat.%2520Neurosci.%26date%3D2001%26volume%3D4%26spage%3D873%26epage%3D874%26doi%3D10.1038%2Fnn0901-873" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">O’Neil, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fell, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Svensson, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witkin, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, S. N.</span><span> </span><span class="NLM_article-title">Recent developments in metabotropic glutamate receptors as novel drug targets</span> <span class="citation_source-journal">Drugs Future</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">307</span><span class="NLM_x">–</span> <span class="NLM_lpage">324</span><span class="refDoi"> DOI: 10.1358/dof.2010.035.04.1487693</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=10.1358%2Fdof.2010.035.04.1487693" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2010&pages=307-324&author=M.+J.+O%E2%80%99Neilauthor=M.+J.+Fellauthor=K.+A.+Svenssonauthor=J.+M.+Witkinauthor=S.+N.+Mitchell&title=Recent+developments+in+metabotropic+glutamate+receptors+as+novel+drug+targets&doi=10.1358%2Fdof.2010.035.04.1487693"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1358%2Fdof.2010.035.04.1487693&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdof.2010.035.04.1487693%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Neil%26aufirst%3DM.%2BJ.%26aulast%3DFell%26aufirst%3DM.%2BJ.%26aulast%3DSvensson%26aufirst%3DK.%2BA.%26aulast%3DWitkin%26aufirst%3DJ.%2BM.%26aulast%3DMitchell%26aufirst%3DS.%2BN.%26atitle%3DRecent%2520developments%2520in%2520metabotropic%2520glutamate%2520receptors%2520as%2520novel%2520drug%2520targets%26jtitle%3DDrugs%2520Future%26date%3D2010%26volume%3D35%26spage%3D307%26epage%3D324%26doi%3D10.1358%2Fdof.2010.035.04.1487693" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Nicoletti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bockaert, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collingridge, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conn, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferraguti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoepp, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wroblewski, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pin, J. P.</span><span> </span><span class="NLM_article-title">Metabotropic glutamate receptors: From the workbench to the bedside</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">1017</span><span class="NLM_x">–</span> <span class="NLM_lpage">1041</span><span class="refDoi"> DOI: 10.1016/j.neuropharm.2010.10.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=10.1016%2Fj.neuropharm.2010.10.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=21036182" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkvVKisbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2011&pages=1017-1041&author=F.+Nicolettiauthor=J.+Bockaertauthor=G.+L.+Collingridgeauthor=P.+J.+Connauthor=F.+Ferragutiauthor=D.+D.+Schoeppauthor=J.+T.+Wroblewskiauthor=J.+P.+Pin&title=Metabotropic+glutamate+receptors%3A+From+the+workbench+to+the+bedside&doi=10.1016%2Fj.neuropharm.2010.10.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Metabotropic glutamate receptors: From the workbench to the bedside</span></div><div class="casAuthors">Nicoletti, F.; Bockaert, J.; Collingridge, G. L.; Conn, P. J.; Ferraguti, F.; Schoepp, D. D.; Wroblewski, J. T.; Pin, J. P.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">7-8</span>),
    <span class="NLM_cas:pages">1017-1041</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Metabotropic glutamate (mGlu) receptors were discovered in the mid 1980s and originally described as glutamate receptors coupled to polyphosphoinositide hydrolysis.  Almost 6500 articles have been published since then, and subtype-selective mGlu receptor ligands are now under clin. development for the treatment of a variety of disorders such as Fragile-X syndrome, schizophrenia, Parkinson's disease and L-DOPA-induced dyskinesias, generalized anxiety disorder, chronic pain, and gastroesophageal reflux disorder.  Prof. Erminio Costa was linked to the early times of the mGlu receptor history, when a few research groups challenged the general belief that glutamate could only activate ionotropic receptors and all metabolic responses to glutamate were secondary to calcium entry.  This review moves from those nostalgic times to the most recent advances in the physiol. and pharmacol. of mGlu receptors, and highlights the role of individual mGlu receptor subtypes in the pathophysiol. of human disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYXazI2Fc24bVg90H21EOLACvtfcHk0ljD9Q2wBOzRMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkvVKisbo%253D&md5=9262bcfab0471270ff1b39ee022f0a8f</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2010.10.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2010.10.022%26sid%3Dliteratum%253Aachs%26aulast%3DNicoletti%26aufirst%3DF.%26aulast%3DBockaert%26aufirst%3DJ.%26aulast%3DCollingridge%26aufirst%3DG.%2BL.%26aulast%3DConn%26aufirst%3DP.%2BJ.%26aulast%3DFerraguti%26aufirst%3DF.%26aulast%3DSchoepp%26aufirst%3DD.%2BD.%26aulast%3DWroblewski%26aufirst%3DJ.%2BT.%26aulast%3DPin%26aufirst%3DJ.%2BP.%26atitle%3DMetabotropic%2520glutamate%2520receptors%253A%2520From%2520the%2520workbench%2520to%2520the%2520bedside%26jtitle%3DNeuropharmacology%26date%3D2011%26volume%3D60%26spage%3D1017%26epage%3D1041%26doi%3D10.1016%2Fj.neuropharm.2010.10.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Rocher, J.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonnet, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolea, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lutjens, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Poul, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Epping-Jordan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bessis, A.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludwig, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mutel, V.</span><span> </span><span class="NLM_article-title">mGluR5 negative allosteric modulators overview: a medicinal chemistry approach towards a series of novel therapeutic agents</span> <span class="citation_source-journal">Curr. Top. Med. Chem. (Sharjah, United Arab Emirates)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">680</span><span class="NLM_x">–</span> <span class="NLM_lpage">695</span><span class="refDoi"> DOI: 10.2174/1568026611109060680</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=10.2174%2F1568026611109060680" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=21261592" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkslSmsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=680-695&author=J.-P.+Rocherauthor=B.+Bonnetauthor=C.+Boleaauthor=R.+Lutjensauthor=E.+Le+Poulauthor=S.+Poliauthor=M.+Epping-Jordanauthor=A.-S.+Bessisauthor=B.+Ludwigauthor=V.+Mutel&title=mGluR5+negative+allosteric+modulators+overview%3A+a+medicinal+chemistry+approach+towards+a+series+of+novel+therapeutic+agents&doi=10.2174%2F1568026611109060680"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">mGluR5 negative allosteric modulators overview: a medicinal chemistry approach towards a series of novel therapeutic agents</span></div><div class="casAuthors">Rocher, Jean-Philippe; Bonnet, Beatrice; Bolea, Christelle; Lutjens, Robert; Le Poul, Emmanuel; Poli, Sonia; Epping-Jordan, Mark; Bessis, Anne-Sophie; Ludwig, Bernard; Mutel, Vincent</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">680-695</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Allosteric modulators of metabotropic glutamate receptors (mGluRs) subtypes 1-8 have been shown to offer a valid way to develop small mol. non aminoacid-like therapeutics that can be administered orally and that readily cross the blood-brain barrier.  Allosteric modulators of glutamatergic receptors and in particular mGluR5 have emerged as a novel and highly desirable class of compds. for the treatment of central nervous system (CNS) disorders and peripheral disorders.  This article provides medicinal chem. highlights around the chem. classes of potent and highly selective mGluR5 neg. allosteric modulators (NAMs) and their therapeutic potential.  In addn., it describes the medicinal chem. approach from the discovery to the clin. candidate selection of a new series of heteroaryl-butynylpyridines targeting mGluR5.  The multiparametric optimization of the initial starting point which ended in the selection of potential clin. candidates combining the best pharmacophoric features is presented.  The pharmacol. properties are reported and support the interest of these agents for new therapeutic approaches.  Furthermore, a summary of the diverse mGluR5 Positron Emission Tomog. (PET) radioligands is reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeXrv5HnHG77Vg90H21EOLACvtfcHk0liffkQsGUeoPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkslSmsrw%253D&md5=aab29725fa93c1895f32f7dbe93a16f1</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.2174%2F1568026611109060680&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026611109060680%26sid%3Dliteratum%253Aachs%26aulast%3DRocher%26aufirst%3DJ.-P.%26aulast%3DBonnet%26aufirst%3DB.%26aulast%3DBolea%26aufirst%3DC.%26aulast%3DLutjens%26aufirst%3DR.%26aulast%3DLe%2BPoul%26aufirst%3DE.%26aulast%3DPoli%26aufirst%3DS.%26aulast%3DEpping-Jordan%26aufirst%3DM.%26aulast%3DBessis%26aufirst%3DA.-S.%26aulast%3DLudwig%26aufirst%3DB.%26aulast%3DMutel%26aufirst%3DV.%26atitle%3DmGluR5%2520negative%2520allosteric%2520modulators%2520overview%253A%2520a%2520medicinal%2520chemistry%2520approach%2520towards%2520a%2520series%2520of%2520novel%2520therapeutic%2520agents%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%2520%2528Sharjah%252C%2520United%2520Arab%2520Emirates%2529%26date%3D2011%26volume%3D11%26spage%3D680%26epage%3D695%26doi%3D10.2174%2F1568026611109060680" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Fuxe, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borroto-Escuela, D. O.</span><span> </span><span class="NLM_article-title">Basimglurant for treatment of major depressive disorder: a novel negative allosteric modulator of metabotropic glutamate receptor 5</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">1247</span><span class="NLM_x">–</span> <span class="NLM_lpage">1260</span><span class="refDoi"> DOI: 10.1517/13543784.2015.1074175</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=10.1517%2F13543784.2015.1074175" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2015&pages=1247-1260&author=K.+Fuxeauthor=D.+O.+Borroto-Escuela&title=Basimglurant+for+treatment+of+major+depressive+disorder%3A+a+novel+negative+allosteric+modulator+of+metabotropic+glutamate+receptor+5&doi=10.1517%2F13543784.2015.1074175"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1517%2F13543784.2015.1074175&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2015.1074175%26sid%3Dliteratum%253Aachs%26aulast%3DFuxe%26aufirst%3DK.%26aulast%3DBorroto-Escuela%26aufirst%3DD.%2BO.%26atitle%3DBasimglurant%2520for%2520treatment%2520of%2520major%2520depressive%2520disorder%253A%2520a%2520novel%2520negative%2520allosteric%2520modulator%2520of%2520metabotropic%2520glutamate%2520receptor%25205%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2015%26volume%3D24%26spage%3D1247%26epage%3D1260%26doi%3D10.1517%2F13543784.2015.1074175" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Quiroz, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamburri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deptula, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banken, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beyer, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabbia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parkar, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fontoura, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santarelli, L.</span><span> </span><span class="NLM_article-title">Efficacy and Safety of Basimglurant as Adjunctive Therapy for Major Depression: A Randomized Clinical Trial</span> <span class="citation_source-journal">JAMA Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">675</span><span class="NLM_x">–</span> <span class="NLM_lpage">684</span><span class="refDoi"> DOI: 10.1001/jamapsychiatry.2016.0838</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=10.1001%2Fjamapsychiatry.2016.0838" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2016&pages=675-684&author=J.+A.+Quirozauthor=P.+Tamburriauthor=D.+Deptulaauthor=L.+Bankenauthor=U.+Beyerauthor=M.+Rabbiaauthor=N.+Parkarauthor=P.+Fontouraauthor=L.+Santarelli&title=Efficacy+and+Safety+of+Basimglurant+as+Adjunctive+Therapy+for+Major+Depression%3A+A+Randomized+Clinical+Trial&doi=10.1001%2Fjamapsychiatry.2016.0838"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1001%2Fjamapsychiatry.2016.0838&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjamapsychiatry.2016.0838%26sid%3Dliteratum%253Aachs%26aulast%3DQuiroz%26aufirst%3DJ.%2BA.%26aulast%3DTamburri%26aufirst%3DP.%26aulast%3DDeptula%26aufirst%3DD.%26aulast%3DBanken%26aufirst%3DL.%26aulast%3DBeyer%26aufirst%3DU.%26aulast%3DRabbia%26aufirst%3DM.%26aulast%3DParkar%26aufirst%3DN.%26aulast%3DFontoura%26aufirst%3DP.%26aulast%3DSantarelli%26aufirst%3DL.%26atitle%3DEfficacy%2520and%2520Safety%2520of%2520Basimglurant%2520as%2520Adjunctive%2520Therapy%2520for%2520Major%2520Depression%253A%2520A%2520Randomized%2520Clinical%2520Trial%26jtitle%3DJAMA%2520Psychiatry%26date%3D2016%26volume%3D73%26spage%3D675%26epage%3D684%26doi%3D10.1001%2Fjamapsychiatry.2016.0838" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Micheli, F.</span><span> </span><span class="NLM_article-title">Methylphenyl ethynyl pyridine (MPEP)(Novartis)</span> <span class="citation_source-journal">Curr. Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">355</span><span class="NLM_x">–</span> <span class="NLM_lpage">359</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2000&pages=355-359&author=F.+Micheli&title=Methylphenyl+ethynyl+pyridine+%28MPEP%29%28Novartis%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMicheli%26aufirst%3DF.%26atitle%3DMethylphenyl%2520ethynyl%2520pyridine%2520%2528MPEP%2529%2528Novartis%2529%26jtitle%3DCurr.%2520Opin.%2520Invest.%2520Drugs%26date%3D2000%26volume%3D1%26spage%3D355%26epage%3D359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Kalgutkar, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardner, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obach, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaffer, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Callegari, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henne, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mutlib, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalvie, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Donnell, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harriman, S. P.</span><span> </span><span class="NLM_article-title">A comprehensive listing of bioactivation pathways of organic functional groups</span> <span class="citation_source-journal">Curr. Drug Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">161</span><span class="NLM_x">–</span> <span class="NLM_lpage">225</span><span class="refDoi"> DOI: 10.2174/1389200054021799</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=10.2174%2F1389200054021799" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=15975040" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=1%3ACAS%3A528%3ADC%252BD2MXkvF2is7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2005&pages=161-225&author=A.+S.+Kalgutkarauthor=I.+Gardnerauthor=R.+S.+Obachauthor=C.+L.+Shafferauthor=E.+Callegariauthor=K.+R.+Henneauthor=A.+E.+Mutlibauthor=D.+K.+Dalvieauthor=J.+S.+Leeauthor=Y.+Nakaiauthor=J.+P.+O%E2%80%99Donnellauthor=J.+Boerauthor=S.+P.+Harriman&title=A+comprehensive+listing+of+bioactivation+pathways+of+organic+functional+groups&doi=10.2174%2F1389200054021799"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">A comprehensive listing of bioactivation pathways of organic functional groups</span></div><div class="casAuthors">Kalgutkar, Amit S.; Gardner, Iain; Obach, R. Scott; Shaffer, Christopher L.; Callegari, Ernesto; Henne, Kirk R.; Mutlib, Abdul E.; Dalvie, Deepak K.; Lee, Jae S.; Nakai, Yasuhiro; O'Donnell, John P.; Boer, Jason; Harriman, Shawn P.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">161-225</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The occurrence of idiosyncratic adverse drug reactions during late clin. trials or after a drug has been released can lead to a severe restriction in its use and even in its withdrawal.  Metabolic activation of relatively inert functional groups to reactive electrophilic intermediates is considered to be an obligatory event in the etiol. of many drug-induced adverse reactions.  Therefore, a thorough examn. of the biochem. reactivity of functional groups/structural motifs in all new drug candidates is essential from a safety standpoint.  A major theme attempted in this review is the comprehensive cataloging of all of the known bioactivation pathways of functional groups or structural motifs commonly utilized in drug design efforts.  Potential strategies in the detection of reactive intermediates in biochem. systems are also discussed.  The intention of this review is not to "black list" functional groups or to immediately discard compds. based on their potential to form reactive metabolites, but rather to serve as a resource describing the structural diversity of these functionalities as well as exptl. approaches that could be taken to evaluate whether a "structural alert" in a new drug candidate undergoes bioactivation to reactive metabolites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOVj7cmxfwXrVg90H21EOLACvtfcHk0liffkQsGUeoPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXkvF2is7k%253D&md5=b16dfc2de97c40a11218ecc3043bed66</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.2174%2F1389200054021799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389200054021799%26sid%3Dliteratum%253Aachs%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DGardner%26aufirst%3DI.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DShaffer%26aufirst%3DC.%2BL.%26aulast%3DCallegari%26aufirst%3DE.%26aulast%3DHenne%26aufirst%3DK.%2BR.%26aulast%3DMutlib%26aufirst%3DA.%2BE.%26aulast%3DDalvie%26aufirst%3DD.%2BK.%26aulast%3DLee%26aufirst%3DJ.%2BS.%26aulast%3DNakai%26aufirst%3DY.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DJ.%2BP.%26aulast%3DBoer%26aufirst%3DJ.%26aulast%3DHarriman%26aufirst%3DS.%2BP.%26atitle%3DA%2520comprehensive%2520listing%2520of%2520bioactivation%2520pathways%2520of%2520organic%2520functional%2520groups%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2005%26volume%3D6%26spage%3D161%26epage%3D225%26doi%3D10.2174%2F1389200054021799" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Stepan, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baillie, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalgutkar, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aleo, M. D.</span><span> </span><span class="NLM_article-title">Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: A perspective based on the critical examination of trends in the top 200 drugs marketed in the United States</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">1345</span><span class="NLM_x">–</span> <span class="NLM_lpage">1410</span><span class="refDoi"> DOI: 10.1021/tx200168d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx200168d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=1%3ACAS%3A528%3ADC%252BC3MXos1Whtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2011&pages=1345-1410&author=A.+F.+Stepanauthor=D.+P.+Walkerauthor=J.+Baumanauthor=D.+A.+Priceauthor=T.+A.+Baillieauthor=A.+S.+Kalgutkarauthor=M.+D.+Aleo&title=Structural+alert%2Freactive+metabolite+concept+as+applied+in+medicinal+chemistry+to+mitigate+the+risk+of+idiosyncratic+drug+toxicity%3A+A+perspective+based+on+the+critical+examination+of+trends+in+the+top+200+drugs+marketed+in+the+United+States&doi=10.1021%2Ftx200168d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Alert/Reactive Metabolite Concept as Applied in Medicinal Chemistry to Mitigate the Risk of Idiosyncratic Drug Toxicity: A Perspective Based on the Critical Examination of Trends in the Top 200 Drugs Marketed in the United States</span></div><div class="casAuthors">Stepan, Antonia F.; Walker, Daniel P.; Bauman, Jonathan; Price, David A.; Baillie, Thomas A.; Kalgutkar, Amit S.; Aleo, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1345-1410</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Because of a preconceived notion that eliminating reactive metabolite (RM) formation with new drug candidates could mitigate the risk of idiosyncratic drug toxicity, the potential for RM formation is routinely examd. as part of lead optimization efforts in drug discovery.  Likewise, avoidance of "structural alerts" is almost a norm in drug design.  However, there is a growing concern that the perceived safety hazards assocd. with structural alerts and/or RM screening tools as standalone predictors of toxicity risks may be over exaggerated.  In addn., the multifactorial nature of idiosyncratic toxicity is now well recognized based upon observations that mechanisms other than RM formation (e.g., mitochondrial toxicity and inhibition of bile salt export pump (BSEP)) also can account for certain target organ toxicities.  Hence, fundamental questions arise such as: When is a mol. that contains a structural alert (RM pos. or neg.) a cause for concern.  Could the mol. in its parent form exert toxicity.  Can a low dose drug candidate truly mitigate metab.-dependent and -independent idiosyncratic toxicity risks.  In an effort to address these questions, we have retrospectively examd. 68 drugs (recalled or assocd. with a black box warning due to idiosyncratic toxicity) and the top 200 drugs (prescription and sales) in the United States in 2009 for trends in physiochem. characteristics, daily doses, presence of structural alerts, evidence for RM formation as well as toxicity mechanism(s) potentially mediated by parent drugs.  Collectively, our anal. revealed that a significant proportion (∼78-86%) of drugs assocd. with toxicity contained structural alerts and evidence indicating that RM formation as a causative factor for toxicity has been presented in 62-69% of these mols.  In several cases, mitochondrial toxicity and BSEP inhibition mediated by parent drugs were also noted as potential causative factors.  Most drugs were administered at daily doses exceeding several hundred milligrams.  There was no obvious link between idiosyncratic toxicity and physicochem. properties such as mol. wt., lipophilicity, etc.  Approx. half of the top 200 drugs for 2009 (prescription and sales) also contained one or more alerts in their chem. architecture, and many were found to be RM-pos.  Several instances of BSEP and mitochondrial liabilities were also noted with agents in the top 200 category.  However, with relatively few exceptions, the vast majority of these drugs are rarely assocd. with idiosyncratic toxicity, despite years of patient use.  The major differentiating factor appeared to be the daily dose; most of the drugs in the top 200 list are administered at low daily doses.  In addn., competing detoxication pathways and/or alternate nonmetabolic clearance routes provided suitable justifications for the safety records of RM-pos. drugs in the top 200 category.  Thus, while RM elimination may be a useful and pragmatic starting point in mitigating idiosyncratic toxicity risks, our anal. suggests a need for a more integrated screening paradigm for chem. hazard identification in drug discovery.  Thus, in addn. to a detailed assessment of RM formation potential (in relationship to the overall elimination mechanisms of the compd.(s)) for lead compds., effects on cellular health (e.g., cytotoxicity assays), BSEP inhibition, and mitochondrial toxicity are the recommended suite of assays to characterize compd. liabilities.  However, the prospective use of such data in compd. selection will require further validation of the cellular assays using marketed agents.  Until we gain a better understanding of the pathophysiol. mechanisms assocd. with idiosyncratic toxicities, improving pharmacokinetics and intrinsic potency as means of decreasing the dose size and the assocd. "body burden" of the parent drug and its metabolites will remain an overarching goal in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3IhczIcvVDLVg90H21EOLACvtfcHk0lgps0OhW-EwXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXos1Whtbo%253D&md5=632b73f755738e49eb233bc8dca1fbcc</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Ftx200168d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx200168d%26sid%3Dliteratum%253Aachs%26aulast%3DStepan%26aufirst%3DA.%2BF.%26aulast%3DWalker%26aufirst%3DD.%2BP.%26aulast%3DBauman%26aufirst%3DJ.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DAleo%26aufirst%3DM.%2BD.%26atitle%3DStructural%2520alert%252Freactive%2520metabolite%2520concept%2520as%2520applied%2520in%2520medicinal%2520chemistry%2520to%2520mitigate%2520the%2520risk%2520of%2520idiosyncratic%2520drug%2520toxicity%253A%2520A%2520perspective%2520based%2520on%2520the%2520critical%2520examination%2520of%2520trends%2520in%2520the%2520top%2520200%2520drugs%2520marketed%2520in%2520the%2520United%2520States%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2011%26volume%3D24%26spage%3D1345%26epage%3D1410%26doi%3D10.1021%2Ftx200168d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Emmitte, K. A.</span><span> </span><span class="NLM_article-title">mGlu5 negative allosteric modulators: a patent review (2013 - 2016)</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">691</span><span class="NLM_x">–</span> <span class="NLM_lpage">706</span><span class="refDoi"> DOI: 10.1080/13543776.2017.1280466</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=10.1080%2F13543776.2017.1280466" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=28067079" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlemsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=691-706&author=K.+A.+Emmitte&title=mGlu5+negative+allosteric+modulators%3A+a+patent+review+%282013+-+2016%29&doi=10.1080%2F13543776.2017.1280466"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">mGlu5 negative allosteric modulators: a patent review (2013 - 2016)</span></div><div class="casAuthors">Emmitte, Kyle A.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">691-706</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Introduction: The pursuit of small mol. mGlu5 NAMs as treatments for a variety of psychiatric and neurodegenerative disorders has developed into a mature field.  In addn. to extensive preclin. studies, multiple compds. have advanced into clin. trials with the most advanced studies occurring in patients with FXS, PD-LID, and MDD.  Areas Covered: This review begins with an update of the clin. activity with mGlu5 NAMs, and then moves into a summary of patent applications filed since 2013.  The summaries are organized into three sep. sections: (1) inventions centered on improvements to existing clin. compds.; (2) new small mols. that maintain the prototypical disubstituted alkyne chemotype found in many mGlu5 NAM compds.; and (3) new small mols. that are not from a disubstituted alkyne chemotype.  Expert Opinion: It is a crit. moment for mGlu5 NAM research as recent reports from clin. trials have included some significant disappointments that have blunted prior optimism.  Still, research in this area remains active, and recent years have added several more attractive small mols. to this field.  There is now an arsenal of diverse chemotypes available to continue to probe this target in the hopes that a drug may yet emerge.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWQ94UvPC2ALVg90H21EOLACvtfcHk0lgps0OhW-EwXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlemsb0%253D&md5=f2c86384dc509c8677e4c94ec2bfabb9</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1080%2F13543776.2017.1280466&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2017.1280466%26sid%3Dliteratum%253Aachs%26aulast%3DEmmitte%26aufirst%3DK.%2BA.%26atitle%3DmGlu5%2520negative%2520allosteric%2520modulators%253A%2520a%2520patent%2520review%2520%25282013%2520-%25202016%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2017%26volume%3D27%26spage%3D691%26epage%3D706%26doi%3D10.1080%2F13543776.2017.1280466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Raboisson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breitholtz-Emanuelsson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahlloef, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heaton, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isaac, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jarvie, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kers, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minidis, A. B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nordmark, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheehan, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slassi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stroem, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terelius, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wensbo, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLeod, D. A.</span><span> </span><span class="NLM_article-title">Discovery and characterization of AZD9272 and AZD6538-Two novel mGluR5 negative allosteric modulators selected for clinical development</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">6974</span><span class="NLM_x">–</span> <span class="NLM_lpage">6979</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2012.08.100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=10.1016%2Fj.bmcl.2012.08.100" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=6974-6979&author=P.+Raboissonauthor=A.+Breitholtz-Emanuelssonauthor=H.+Dahlloefauthor=L.+Edwardsauthor=W.+L.+Heatonauthor=M.+Isaacauthor=K.+Jarvieauthor=A.+Kersauthor=A.+B.+E.+Minidisauthor=A.+Nordmarkauthor=S.+M.+Sheehanauthor=A.+Slassiauthor=P.+Stroemauthor=Y.+Tereliusauthor=D.+Wensboauthor=J.+M.+Wilsonauthor=T.+Xinauthor=D.+A.+McLeod&title=Discovery+and+characterization+of+AZD9272+and+AZD6538-Two+novel+mGluR5+negative+allosteric+modulators+selected+for+clinical+development&doi=10.1016%2Fj.bmcl.2012.08.100"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.08.100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.08.100%26sid%3Dliteratum%253Aachs%26aulast%3DRaboisson%26aufirst%3DP.%26aulast%3DBreitholtz-Emanuelsson%26aufirst%3DA.%26aulast%3DDahlloef%26aufirst%3DH.%26aulast%3DEdwards%26aufirst%3DL.%26aulast%3DHeaton%26aufirst%3DW.%2BL.%26aulast%3DIsaac%26aufirst%3DM.%26aulast%3DJarvie%26aufirst%3DK.%26aulast%3DKers%26aufirst%3DA.%26aulast%3DMinidis%26aufirst%3DA.%2BB.%2BE.%26aulast%3DNordmark%26aufirst%3DA.%26aulast%3DSheehan%26aufirst%3DS.%2BM.%26aulast%3DSlassi%26aufirst%3DA.%26aulast%3DStroem%26aufirst%3DP.%26aulast%3DTerelius%26aufirst%3DY.%26aulast%3DWensbo%26aufirst%3DD.%26aulast%3DWilson%26aufirst%3DJ.%2BM.%26aulast%3DXin%26aufirst%3DT.%26aulast%3DMcLeod%26aufirst%3DD.%2BA.%26atitle%3DDiscovery%2520and%2520characterization%2520of%2520AZD9272%2520and%2520AZD6538-Two%2520novel%2520mGluR5%2520negative%2520allosteric%2520modulators%2520selected%2520for%2520clinical%2520development%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D6974%26epage%3D6979%26doi%3D10.1016%2Fj.bmcl.2012.08.100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Mueller, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dawson, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meiler, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chauder, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bates, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felts, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamb, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menon, U. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jadhav, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kane, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gregory, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niswender, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conn, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsen, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winder, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emmitte, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindsley, C. W.</span><span> </span><span class="NLM_article-title">Discovery of 2-(2-benzoxazoyl amino)-4-aryl-5-cyanopyrimidine as negative allosteric modulators (NAMs) of metabotropic glutamate receptor 5 (mGlu5): From an artificial neural network virtual screen to an in vivo tool compound</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">406</span><span class="NLM_x">–</span> <span class="NLM_lpage">414</span><span class="refDoi"> DOI: 10.1002/cmdc.201100510</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=10.1002%2Fcmdc.201100510" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=406-414&author=R.+Muellerauthor=E.+S.+Dawsonauthor=J.+Meilerauthor=A.+L.+Rodriguezauthor=B.+A.+Chauderauthor=B.+S.+Batesauthor=A.+S.+Feltsauthor=J.+P.+Lambauthor=U.+N.+Menonauthor=S.+B.+Jadhavauthor=A.+S.+Kaneauthor=C.+K.+Jonesauthor=K.+J.+Gregoryauthor=C.+M.+Niswenderauthor=P.+J.+Connauthor=C.+M.+Olsenauthor=D.+G.+Winderauthor=K.+A.+Emmitteauthor=C.+W.+Lindsley&title=Discovery+of+2-%282-benzoxazoyl+amino%29-4-aryl-5-cyanopyrimidine+as+negative+allosteric+modulators+%28NAMs%29+of+metabotropic+glutamate+receptor+5+%28mGlu5%29%3A+From+an+artificial+neural+network+virtual+screen+to+an+in+vivo+tool+compound&doi=10.1002%2Fcmdc.201100510"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201100510&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201100510%26sid%3Dliteratum%253Aachs%26aulast%3DMueller%26aufirst%3DR.%26aulast%3DDawson%26aufirst%3DE.%2BS.%26aulast%3DMeiler%26aufirst%3DJ.%26aulast%3DRodriguez%26aufirst%3DA.%2BL.%26aulast%3DChauder%26aufirst%3DB.%2BA.%26aulast%3DBates%26aufirst%3DB.%2BS.%26aulast%3DFelts%26aufirst%3DA.%2BS.%26aulast%3DLamb%26aufirst%3DJ.%2BP.%26aulast%3DMenon%26aufirst%3DU.%2BN.%26aulast%3DJadhav%26aufirst%3DS.%2BB.%26aulast%3DKane%26aufirst%3DA.%2BS.%26aulast%3DJones%26aufirst%3DC.%2BK.%26aulast%3DGregory%26aufirst%3DK.%2BJ.%26aulast%3DNiswender%26aufirst%3DC.%2BM.%26aulast%3DConn%26aufirst%3DP.%2BJ.%26aulast%3DOlsen%26aufirst%3DC.%2BM.%26aulast%3DWinder%26aufirst%3DD.%2BG.%26aulast%3DEmmitte%26aufirst%3DK.%2BA.%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26atitle%3DDiscovery%2520of%25202-%25282-benzoxazoyl%2520amino%2529-4-aryl-5-cyanopyrimidine%2520as%2520negative%2520allosteric%2520modulators%2520%2528NAMs%2529%2520of%2520metabotropic%2520glutamate%2520receptor%25205%2520%2528mGlu5%2529%253A%2520From%2520an%2520artificial%2520neural%2520network%2520virtual%2520screen%2520to%2520an%2520in%2520vivo%2520tool%2520compound%26jtitle%3DChemMedChem%26date%3D2012%26volume%3D7%26spage%3D406%26epage%3D414%26doi%3D10.1002%2Fcmdc.201100510" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><div class="note"><p class="first last">The full PF number of PF470 is PF-06297470.</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=The+full+PF+number+of+PF470+is+PF-06297470."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balan, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barreiro, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boscoe, B. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chenard, L. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cianfrogna, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Claffey, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coffman, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drozda, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunetz, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fonseca, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galatsis, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grimwood, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lazzaro, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mancuso, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reese, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogers, B. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakurada, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skaddan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stepan, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trapa, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuttle, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verhoest, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaleska, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zasadny, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaffer, C. L.</span><span> </span><span class="NLM_article-title">Discovery and preclinical characterization of 1-methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-ylmethoxy)-1H-pyrazolo-[3,4-b]-pyrazine (PF470): A highly potent, selective, and efficacious metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">861</span><span class="NLM_x">–</span> <span class="NLM_lpage">877</span><span class="refDoi"> DOI: 10.1021/jm401622k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401622k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=861-877&author=L.+Zhangauthor=G.+Balanauthor=G.+Barreiroauthor=B.+P.+Boscoeauthor=L.+K.+Chenardauthor=J.+Cianfrognaauthor=M.+M.+Claffeyauthor=L.+Chenauthor=K.+J.+Coffmanauthor=S.+E.+Drozdaauthor=J.+R.+Dunetzauthor=K.+R.+Fonsecaauthor=P.+Galatsisauthor=S.+Grimwoodauthor=J.+T.+Lazzaroauthor=J.+Y.+Mancusoauthor=E.+L.+Millerauthor=M.+R.+Reeseauthor=B.+N.+Rogersauthor=I.+Sakuradaauthor=M.+Skaddanauthor=D.+L.+Smithauthor=A.+F.+Stepanauthor=P.+Trapaauthor=J.+B.+Tuttleauthor=P.+R.+Verhoestauthor=D.+P.+Walkerauthor=A.+S.+Wrightauthor=M.+M.+Zaleskaauthor=K.+Zasadnyauthor=C.+L.+Shaffer&title=Discovery+and+preclinical+characterization+of+1-methyl-3-%284-methylpyridin-3-yl%29-6-%28pyridin-2-ylmethoxy%29-1H-pyrazolo-%5B3%2C4-b%5D-pyrazine+%28PF470%29%3A+A+highly+potent%2C+selective%2C+and+efficacious+metabotropic+glutamate+receptor+5+%28mGluR5%29+negative+allosteric+modulator&doi=10.1021%2Fjm401622k"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm401622k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401622k%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DBalan%26aufirst%3DG.%26aulast%3DBarreiro%26aufirst%3DG.%26aulast%3DBoscoe%26aufirst%3DB.%2BP.%26aulast%3DChenard%26aufirst%3DL.%2BK.%26aulast%3DCianfrogna%26aufirst%3DJ.%26aulast%3DClaffey%26aufirst%3DM.%2BM.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DCoffman%26aufirst%3DK.%2BJ.%26aulast%3DDrozda%26aufirst%3DS.%2BE.%26aulast%3DDunetz%26aufirst%3DJ.%2BR.%26aulast%3DFonseca%26aufirst%3DK.%2BR.%26aulast%3DGalatsis%26aufirst%3DP.%26aulast%3DGrimwood%26aufirst%3DS.%26aulast%3DLazzaro%26aufirst%3DJ.%2BT.%26aulast%3DMancuso%26aufirst%3DJ.%2BY.%26aulast%3DMiller%26aufirst%3DE.%2BL.%26aulast%3DReese%26aufirst%3DM.%2BR.%26aulast%3DRogers%26aufirst%3DB.%2BN.%26aulast%3DSakurada%26aufirst%3DI.%26aulast%3DSkaddan%26aufirst%3DM.%26aulast%3DSmith%26aufirst%3DD.%2BL.%26aulast%3DStepan%26aufirst%3DA.%2BF.%26aulast%3DTrapa%26aufirst%3DP.%26aulast%3DTuttle%26aufirst%3DJ.%2BB.%26aulast%3DVerhoest%26aufirst%3DP.%2BR.%26aulast%3DWalker%26aufirst%3DD.%2BP.%26aulast%3DWright%26aufirst%3DA.%2BS.%26aulast%3DZaleska%26aufirst%3DM.%2BM.%26aulast%3DZasadny%26aufirst%3DK.%26aulast%3DShaffer%26aufirst%3DC.%2BL.%26atitle%3DDiscovery%2520and%2520preclinical%2520characterization%2520of%25201-methyl-3-%25284-methylpyridin-3-yl%2529-6-%2528pyridin-2-ylmethoxy%2529-1H-pyrazolo-%255B3%252C4-b%255D-pyrazine%2520%2528PF470%2529%253A%2520A%2520highly%2520potent%252C%2520selective%252C%2520and%2520efficacious%2520metabotropic%2520glutamate%2520receptor%25205%2520%2528mGluR5%2529%2520negative%2520allosteric%2520modulator%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D861%26epage%3D877%26doi%3D10.1021%2Fjm401622k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Palanisamy, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcek, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cappon, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whritenour, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaffer, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brady, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houle, C.</span><span> </span><span class="NLM_article-title">Drug-induced skin lesions in cynomolgus macaques treated with metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulators</span> <span class="citation_source-journal">Toxicol. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">995</span><span class="NLM_x">–</span> <span class="NLM_lpage">1003</span><span class="refDoi"> DOI: 10.1177/0192623315588114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=10.1177%2F0192623315588114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=26059827" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=1%3ACAS%3A528%3ADC%252BC28Xlt1Wqsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2015&pages=995-1003&author=G.+S.+Palanisamyauthor=J.+M.+Marcekauthor=G.+D.+Capponauthor=J.+Whritenourauthor=C.+L.+Shafferauthor=J.+T.+Bradyauthor=C.+Houle&title=Drug-induced+skin+lesions+in+cynomolgus+macaques+treated+with+metabotropic+glutamate+receptor+5+%28mGluR5%29+negative+allosteric+modulators&doi=10.1177%2F0192623315588114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-induced skin lesions in cynomolgus macaques treated with metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulators</span></div><div class="casAuthors">Palanisamy, Gopinath S.; Marcek, John M.; Cappon, Gregg D.; Whritenour, Jessica; Shaffer, Christopher L.; Brady, Joseph T.; Houle, Christopher</div><div class="citationInfo"><span class="NLM_cas:title">Toxicologic Pathology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">995-1003</span>CODEN:
                <span class="NLM_cas:coden">TOPADD</span>;
        ISSN:<span class="NLM_cas:issn">0192-6233</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Three orally administered metabotropic glutamate receptor 5 (mGluR5) neg. allosteric modulators caused skin lesions consistent with delayed type-IV hypersensitivity in cynomolgus macaques in 2- and 12-wk toxicity studies.  Several monkeys developed macroscopic skin lesions in multiple locations after 8 to 9 days of dosing; the most prominent effects involved the genital region of males and generalized erythema occurred in both sexes.  Microscopic lesions occurred in both clin. affected and unaffected areas and were characterized by lymphocytic interface inflammation, subepidermal bullae, and individual keratinocyte vacuolation/necrosis.  In the 12-wk study, clin. effects in 2 animals resolved with continued dosing, whereas in others the inflammatory process progressed with 1 female exhibiting systemic lymphocytic inflammation in multiple tissues.  The inflammatory infiltrate consisted of CD3 and CD4 pos. T lymphocytes with minimal CD68 pos. macrophages and only rare CD8 pos. T lymphocytes.  A subset of animals given a dosing holiday was subsequently rechallenged with similar lesions developing but with a more rapid clin. onset.  These skin lesions were consistent with type-IV delayed hypersensitivity with some features comparable to bullous drug eruptions in humans.  A relationship between these findings and the intended mode of action for these compds. could not be ruled out, given the occurrence across different chemotypes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpS0b8GvuCkpLVg90H21EOLACvtfcHk0lhovEWtIAA7cw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xlt1Wqsbo%253D&md5=99ad96bc755c182aca73a1d14dc1d614</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1177%2F0192623315588114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0192623315588114%26sid%3Dliteratum%253Aachs%26aulast%3DPalanisamy%26aufirst%3DG.%2BS.%26aulast%3DMarcek%26aufirst%3DJ.%2BM.%26aulast%3DCappon%26aufirst%3DG.%2BD.%26aulast%3DWhritenour%26aufirst%3DJ.%26aulast%3DShaffer%26aufirst%3DC.%2BL.%26aulast%3DBrady%26aufirst%3DJ.%2BT.%26aulast%3DHoule%26aufirst%3DC.%26atitle%3DDrug-induced%2520skin%2520lesions%2520in%2520cynomolgus%2520macaques%2520treated%2520with%2520metabotropic%2520glutamate%2520receptor%25205%2520%2528mGluR5%2529%2520negative%2520allosteric%2520modulators%26jtitle%3DToxicol.%2520Pathol.%26date%3D2015%26volume%3D43%26spage%3D995%26epage%3D1003%26doi%3D10.1177%2F0192623315588114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Kremer, K. A. M.; Krishnan, L.; Venkatesan, A. M.; Jennings, M.; Zeldis, J.; Abe, T.; Mansour, T.; Strong, H.</span>Processes for Preparing Bicyclic Oxazine Carboxaldehyde and β-Lactamase Inhibitors. WO2009/006243A2, Jan 8,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=K.+A.+M.+Kremer&author=L.+Krishnan&author=A.+M.+Venkatesan&author=M.+Jennings&author=J.+Zeldis&author=T.+Abe&author=T.+Mansour&author=H.+Strong&title=Processes+for+Preparing+Bicyclic+Oxazine+Carboxaldehyde+and+%CE%B2-Lactamase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKremer%26aufirst%3DK.%2BA.%2BM.%26jtitle%3DProcesses%2520for%2520Preparing%2520Bicyclic%2520Oxazine%2520Carboxaldehyde%2520and%2520%25CE%25B2-Lactamase%2520Inhibitors%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Abass, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayas, A. S.</span><span> </span><span class="NLM_article-title">Substituted pyridopyrimidinones, 1: Convenient PTC alkylation and halogenation of 2-hydroxy-4H-pyrido[1,2-a]pyrimidin-4-one</span> <span class="citation_source-journal">Heteroat. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">19</span><span class="NLM_x">–</span> <span class="NLM_lpage">27</span><span class="refDoi"> DOI: 10.1002/hc.20245</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=10.1002%2Fhc.20245" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpsVyntw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2007&pages=19-27&author=M.+Abassauthor=A.+S.+Mayas&title=Substituted+pyridopyrimidinones%2C+1%3A+Convenient+PTC+alkylation+and+halogenation+of+2-hydroxy-4H-pyrido%5B1%2C2-a%5Dpyrimidin-4-one&doi=10.1002%2Fhc.20245"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Substituted pyridopyrimidinones, 1: Convenient PTC alkylation and halogenation of 2-hydroxy-4H-pyrido[1,2-a]pyrimidin-4-one</span></div><div class="casAuthors">Abass, Mohamed; Mayas, Aisha S.</div><div class="citationInfo"><span class="NLM_cas:title">Heteroatom Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">19-27</span>CODEN:
                <span class="NLM_cas:coden">HETCE8</span>;
        ISSN:<span class="NLM_cas:issn">1042-7163</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Alkylation of 2-hydroxy-4H-pyrido[1,2-a]pyrimidin-4-one (I) was investigated under solid-liq. phase transfer catalysis conditions (PTC) using tetrabutylammonium bromide and potassium carbonate.  The reaction with alkyl halides gave various 2-alkoxy products in fair yields.  Reaction of I with epichlorohydrin and chloroacetonitrile, under the same PTC conditions, afforded novel 1,3-disubstituted glycerol and oxazolopyridopyrimidone betaine derivs., resp.  Some 3-halo-, 3,3-dihalo, and 2,3-dihalopyrido[1,2-a]pyrimidines were also prepd. using different halogenating agents at different reaction conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBh9_2obzgT7Vg90H21EOLACvtfcHk0lhovEWtIAA7cw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpsVyntw%253D%253D&md5=a7c7b0c7b8f6f04ed41fcb35cb94a3f0</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1002%2Fhc.20245&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhc.20245%26sid%3Dliteratum%253Aachs%26aulast%3DAbass%26aufirst%3DM.%26aulast%3DMayas%26aufirst%3DA.%2BS.%26atitle%3DSubstituted%2520pyridopyrimidinones%252C%25201%253A%2520Convenient%2520PTC%2520alkylation%2520and%2520halogenation%2520of%25202-hydroxy-4H-pyrido%255B1%252C2-a%255Dpyrimidin-4-one%26jtitle%3DHeteroat.%2520Chem.%26date%3D2007%26volume%3D18%26spage%3D19%26epage%3D27%26doi%3D10.1002%2Fhc.20245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Callegari, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malhotra, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bungay, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webster, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fenner, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kempshall, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaPerle, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michel, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kay, G. G.</span><span> </span><span class="NLM_article-title">A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder</span> <span class="citation_source-journal">br J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">235</span><span class="NLM_x">–</span> <span class="NLM_lpage">246</span><span class="refDoi"> DOI: 10.1111/j.1365-2125.2011.03961.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=10.1111%2Fj.1365-2125.2011.03961.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=21392072" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtV2qtrrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2011&pages=235-246&author=E.+Callegariauthor=B.+Malhotraauthor=P.+J.+Bungayauthor=R.+Websterauthor=K.+S.+Fennerauthor=S.+Kempshallauthor=J.+L.+LaPerleauthor=M.+C.+Michelauthor=G.+G.+Kay&title=A+comprehensive+non-clinical+evaluation+of+the+CNS+penetration+potential+of+antimuscarinic+agents+for+the+treatment+of+overactive+bladder&doi=10.1111%2Fj.1365-2125.2011.03961.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder</span></div><div class="casAuthors">Callegari, Ernesto; Malhotra, Bimal; Bungay, Peter J.; Webster, Rob; Fenner, Katherine S.; Kempshall, Sarah; LaPerle, Jennifer L.; Michel, Martin C.; Kay, Gary G.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">235-246</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">AIMS: To assess and compare the mechanisms of central nervous system (CNS) penetration of antimuscarinic overactive bladder (OAB) agents.  METHODS: Phys. properties were computed or compiled from the literature.  Rats were administered 5-hydroxymethyl tolterodine (HMT), darifenacin, oxybutynin, solifenacin, tolterodine or trospium s.c.  At 1 h postdose, plasma, brain and cerebrospinal fluid (CSF) concns. were detd. using LC-MS/MS assays.  Brain and plasma protein binding were detd. in vitro.  Permeability in the presence and absence of the efflux transporter P-glycoprotein (P-gp) was assessed in RRCK and MDCK-MDR1 transwell assays.  RESULTS: Oxybutynin displayed extensive CNS penetration, with brain: plasma ratios (B:P), unbound brain:unbound plasma ratios (Kp,free) and CSF:free plasma ratios each >1.  Tolterodine (B:P = 2.95, Kp,free = 0.23 and CSF:free plasma = 0.16) and solifenacin (B:P = 3.04, Kp,free = 0.28 and CSF:free plasma = 1.41) showed significant CNS penetration but with some restriction from CNS as indicated by Kp,free values significantly <1.5-HMT, darifenacin and trospium displayed much lower B:P (0.03-0.16), Kp,free (0.01-0.04) and CSF:free plasma (0.004-0.06), consistent with poor CNS penetration.  Permeability in RRCK cells was low for trospium (0.63 × 10-6 cm s-1), moderate for 5-HMT (11.7 × 10-6 cm s-1) and high for darifenacin, solifenacin, tolterodine and oxybutynin (21.5-38.2 × 10-6 cm s-1).  In MDCK-MDR1 cells 5-HMT, darifenacin and trospium, were P-gp substrates, whereas oxybutynin, solifenacin and tolterodine were not P-gp substrates.  CONCLUSIONS: Brain penetration was low for antimuscarinics that are P-gp substrates (5-HMT, darifenacin and trospium), and significant for those that are not P-gp substrates (oxybutynin, solifenacin and tolterodine).  CNS adverse events reported in randomized controlled clin. trials show general alignment with the preclin. data described in this study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB9FelRyq-h7Vg90H21EOLACvtfcHk0lhvw5XEEDOzsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtV2qtrrM&md5=dbd56eb7943853a1f58f9d56d92316bb</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2125.2011.03961.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2125.2011.03961.x%26sid%3Dliteratum%253Aachs%26aulast%3DCallegari%26aufirst%3DE.%26aulast%3DMalhotra%26aufirst%3DB.%26aulast%3DBungay%26aufirst%3DP.%2BJ.%26aulast%3DWebster%26aufirst%3DR.%26aulast%3DFenner%26aufirst%3DK.%2BS.%26aulast%3DKempshall%26aufirst%3DS.%26aulast%3DLaPerle%26aufirst%3DJ.%2BL.%26aulast%3DMichel%26aufirst%3DM.%2BC.%26aulast%3DKay%26aufirst%3DG.%2BG.%26atitle%3DA%2520comprehensive%2520non-clinical%2520evaluation%2520of%2520the%2520CNS%2520penetration%2520potential%2520of%2520antimuscarinic%2520agents%2520for%2520the%2520treatment%2520of%2520overactive%2520bladder%26jtitle%3Dbr%2520J.%2520Clin.%2520Pharmacol.%26date%3D2011%26volume%3D72%26spage%3D235%26epage%3D246%26doi%3D10.1111%2Fj.1365-2125.2011.03961.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Feng, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mills, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davidson, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mireles, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janiszewski, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Troutman, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Morais, S. M.</span><span> </span><span class="NLM_article-title">In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">268</span><span class="NLM_x">–</span> <span class="NLM_lpage">275</span><span class="refDoi"> DOI: 10.1124/dmd.107.017434</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=10.1124%2Fdmd.107.017434" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=17962372" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1yktbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2008&pages=268-275&author=B.+Fengauthor=J.+B.+Millsauthor=R.+E.+Davidsonauthor=R.+J.+Mirelesauthor=J.+S.+Janiszewskiauthor=M.+D.+Troutmanauthor=S.+M.+de+Morais&title=In+vitro+P-glycoprotein+assays+to+predict+the+in+vivo+interactions+of+P-glycoprotein+with+drugs+in+the+central+nervous+system&doi=10.1124%2Fdmd.107.017434"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system</span></div><div class="casAuthors">Feng, Bo; Mills, Jessica B.; Davidson, Ralph E.; Mireles, Rouchelle J.; Janiszewski, John S.; Troutman, Matthew D.; de Morais, Sonia M.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">268-275</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Thirty-one structurally diverse marketed central nervous system (CNS)-active drugs, one active metabolite, and seven non-CNS-active compds. were tested in three P-glycoprotein (P-gp) in vitro assays: transwell assays using MDCK, human MDR1-MDCK, and mouse Mdr1a-MDCK cells, ATPase, and calcein AM inhibition.  Addnl., the permeability for these compds. was measured in two in vitro models: parallel artificial membrane permeation assay and apical-to-basolateral apparent permeability in MDCK.  The exposure of the same set of compds. in brain and plasma was measured in P-gp knockout (KO) and wild-type (WT) mice after s.c. administration.  One drug and its metabolite, risperidone and 9-hydroxyrisperidone, of the 32 CNS compds., and 6 of the 7 non-CNS drugs were detd. to have pos. efflux using ratio of ratios in MDR1-MDCK vs. MDCK transwell assays.  Data from transwell studies correlated well with the brain-to-plasma area under the curve ratios between P-gp KO and WT mice for the 32 CNS compds.  In addn., 3300 Pfizer compds. were tested in MDR1-MDCK and Mdr1a-MDCK transwell assays, with a good correlation (R2 = 0.92) between the efflux ratios in human MDR1-MDCK and mouse Mdr1a-MDCK cells.  Permeability data showed that the majority of the 32 CNS compds. have moderate to high passive permeability.  This work has demonstrated that in vitro transporter assays help in understanding the role of P-gp-mediated efflux activity in detg. the disposition of CNS drugs in vivo, and the transwell assay is a valuable in vitro assay to evaluate human P-gp interaction with compds. for assessing brain penetration of new chem. entities to treat CNS disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsQyRSOySyGLVg90H21EOLACvtfcHk0lhvw5XEEDOzsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1yktbc%253D&md5=bbf8b6969bd6d6b3d741b6ef9e7853f3</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1124%2Fdmd.107.017434&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.107.017434%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DB.%26aulast%3DMills%26aufirst%3DJ.%2BB.%26aulast%3DDavidson%26aufirst%3DR.%2BE.%26aulast%3DMireles%26aufirst%3DR.%2BJ.%26aulast%3DJaniszewski%26aufirst%3DJ.%2BS.%26aulast%3DTroutman%26aufirst%3DM.%2BD.%26aulast%3Dde%2BMorais%26aufirst%3DS.%2BM.%26atitle%3DIn%2520vitro%2520P-glycoprotein%2520assays%2520to%2520predict%2520the%2520in%2520vivo%2520interactions%2520of%2520P-glycoprotein%2520with%2520drugs%2520in%2520the%2520central%2520nervous%2520system%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2008%26volume%3D36%26spage%3D268%26epage%3D275%26doi%3D10.1124%2Fdmd.107.017434" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Leeson, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springthorpe, B.</span><span> </span><span class="NLM_article-title">The influence of drug-like concepts on decision-making in medicinal chemistry</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">881</span><span class="NLM_x">–</span> <span class="NLM_lpage">890</span><span class="refDoi"> DOI: 10.1038/nrd2445</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=10.1038%2Fnrd2445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=17971784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=881-890&author=P.+D.+Leesonauthor=B.+Springthorpe&title=The+influence+of+drug-like+concepts+on+decision-making+in+medicinal+chemistry&doi=10.1038%2Fnrd2445"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">The influence of drug-like concepts on decision-making in medicinal chemistry</span></div><div class="casAuthors">Leeson, Paul D.; Springthorpe, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">881-890</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Despite the wide acceptance of drug-like principles such as the 'rule of five', this anal. of mols. currently being synthesized in leading pharmaceutical companies reveals that their phys. properties differ significantly from those of recently discovered oral drugs.  The marked increase in lipophilicity in particular could increase the likelihood of attrition in drug development.  The application of guidelines linked to the concept of drug-likeness, such as the 'rule of five', has gained wide acceptance as an approach to reduce attrition in drug discovery and development.  However, despite this acceptance, anal. of recent trends reveals that the phys. properties of mols. that are currently being synthesized in leading drug discovery companies differ significantly from those of recently discovered oral drugs and compds. in clin. development.  The consequences of the marked increase in lipophilicity - the most important drug-like phys. property - include a greater likelihood of lack of selectivity and attrition in drug development.  Tackling the threat of compd.-related toxicol. attrition needs to move to the mainstream of medicinal chem. decision-making.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTUeonLD6iebVg90H21EOLACvtfcHk0lhvw5XEEDOzsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL&md5=5665a9e2dc266a1ee096e20625757ef7</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1038%2Fnrd2445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2445%26sid%3Dliteratum%253Aachs%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DSpringthorpe%26aufirst%3DB.%26atitle%3DThe%2520influence%2520of%2520drug-like%2520concepts%2520on%2520decision-making%2520in%2520medicinal%2520chemistry%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D881%26epage%3D890%26doi%3D10.1038%2Fnrd2445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Ryckmans, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horne, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Correia, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owen, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tutt, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, T.</span><span> </span><span class="NLM_article-title">Rapid assessment of a novel series of selective CB2 agonists using parallel synthesis protocols: A Lipophilic Efficiency (LipE) analysis</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">4406</span><span class="NLM_x">–</span> <span class="NLM_lpage">4409</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2009.05.062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=10.1016%2Fj.bmcl.2009.05.062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=19500981" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosVGlsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=4406-4409&author=T.+Ryckmansauthor=M.+P.+Edwardsauthor=V.+A.+Horneauthor=A.+M.+Correiaauthor=D.+R.+Owenauthor=L.+R.+Thompsonauthor=I.+Tranauthor=M.+F.+Tuttauthor=T.+Young&title=Rapid+assessment+of+a+novel+series+of+selective+CB2+agonists+using+parallel+synthesis+protocols%3A+A+Lipophilic+Efficiency+%28LipE%29+analysis&doi=10.1016%2Fj.bmcl.2009.05.062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Rapid assessment of a novel series of selective CB2 agonists using parallel synthesis protocols: A Lipophilic Efficiency (LipE) analysis</span></div><div class="casAuthors">Ryckmans, Thomas; Edwards, Martin P.; Horne, Val A.; Correia, Ana Monica; Owen, Dafydd R.; Thompson, Lisa R.; Tran, Isabelle; Tutt, Michelle F.; Young, Tim</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4406-4409</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of libraries were designed using the 1-(cyclopropylmethyl)-2-alkyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-5-ium templates 2a-b, and Sulfonamide derivs. 11a-n proved to be potent agonists of the CB2 receptor.  Anal. of the Lipophilic Efficiency (LipE) of potent compds. provided new insight for the design of potent, metabolically stable CB2 agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1cihq9YHuO7Vg90H21EOLACvtfcHk0ljlWZDsGCFYlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosVGlsrg%253D&md5=b62d97e5f52a594cfdd510f32d2e566f</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.05.062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.05.062%26sid%3Dliteratum%253Aachs%26aulast%3DRyckmans%26aufirst%3DT.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26aulast%3DHorne%26aufirst%3DV.%2BA.%26aulast%3DCorreia%26aufirst%3DA.%2BM.%26aulast%3DOwen%26aufirst%3DD.%2BR.%26aulast%3DThompson%26aufirst%3DL.%2BR.%26aulast%3DTran%26aufirst%3DI.%26aulast%3DTutt%26aufirst%3DM.%2BF.%26aulast%3DYoung%26aufirst%3DT.%26atitle%3DRapid%2520assessment%2520of%2520a%2520novel%2520series%2520of%2520selective%2520CB2%2520agonists%2520using%2520parallel%2520synthesis%2520protocols%253A%2520A%2520Lipophilic%2520Efficiency%2520%2528LipE%2529%2520analysis%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D4406%26epage%3D4409%26doi%3D10.1016%2Fj.bmcl.2009.05.062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Stepan, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kauffman, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keefer, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verhoest, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, M.</span><span> </span><span class="NLM_article-title">Evaluating the differences in cycloalkyl ether metabolism using the design parameter ″Lipophilic Metabolism Efficiency″ (LipMetE) and a matched molecular pairs analysis</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">6985</span><span class="NLM_x">–</span> <span class="NLM_lpage">6990</span><span class="refDoi"> DOI: 10.1021/jm4008642</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4008642" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=6985-6990&author=A.+F.+Stepanauthor=G.+W.+Kauffmanauthor=C.+E.+Keeferauthor=P.+R.+Verhoestauthor=M.+Edwards&title=Evaluating+the+differences+in+cycloalkyl+ether+metabolism+using+the+design+parameter+%E2%80%B3Lipophilic+Metabolism+Efficiency%E2%80%B3+%28LipMetE%29+and+a+matched+molecular+pairs+analysis&doi=10.1021%2Fjm4008642"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fjm4008642&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4008642%26sid%3Dliteratum%253Aachs%26aulast%3DStepan%26aufirst%3DA.%2BF.%26aulast%3DKauffman%26aufirst%3DG.%2BW.%26aulast%3DKeefer%26aufirst%3DC.%2BE.%26aulast%3DVerhoest%26aufirst%3DP.%2BR.%26aulast%3DEdwards%26aufirst%3DM.%26atitle%3DEvaluating%2520the%2520differences%2520in%2520cycloalkyl%2520ether%2520metabolism%2520using%2520the%2520design%2520parameter%2520%25E2%2580%25B3Lipophilic%2520Metabolism%2520Efficiency%25E2%2580%25B3%2520%2528LipMetE%2529%2520and%2520a%2520matched%2520molecular%2520pairs%2520analysis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D6985%26epage%3D6990%26doi%3D10.1021%2Fjm4008642" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Gehlhaar, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verkhivker, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rejto, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherman, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fogel, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fogel, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freer, S. T.</span><span> </span><span class="NLM_article-title">Molecular recognition of the inhibitor AG-1343 by HIV-1 protease: Conformationally flexible docking by evolutionary programming</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">317</span><span class="NLM_x">–</span> <span class="NLM_lpage">324</span><span class="refDoi"> DOI: 10.1016/1074-5521(95)90050-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=10.1016%2F1074-5521%2895%2990050-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=9383433" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=1%3ACAS%3A528%3ADyaK2MXmvVClsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1995&pages=317-324&author=D.+K.+Gehlhaarauthor=G.+M.+Verkhivkerauthor=P.+A.+Rejtoauthor=C.+J.+Shermanauthor=D.+B.+Fogelauthor=L.+J.+Fogelauthor=S.+T.+Freer&title=Molecular+recognition+of+the+inhibitor+AG-1343+by+HIV-1+protease%3A+Conformationally+flexible+docking+by+evolutionary+programming&doi=10.1016%2F1074-5521%2895%2990050-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular recognition of the inhibitor AG-1343 by HIV-1 protease: Conformationally flexible docking by evolutionary programming</span></div><div class="casAuthors">Gehlhaar, Daniel K.; Verkhivker, Gennady M.; Rejto, Paul A.; Sherman, Christopher J.; Fogel, David B.; Fogel, Lawrence J.; Freer, Stephan T.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">317-24</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Current Biology</span>)
        </div><div class="casAbstract">An important prerequisite for computational structure-based drug design is prediction of the structures of ligand-protein complexes that have not yet been exptl. detd. by x-ray crystallog. or NMR.  For this task, docking of rigid ligands is inadequate because it assumes knowledge of the conformation of the bound ligand.  Docking of flexible ligands would be desirable, but requires one to search an enormous conformational space.  We set out to develop a strategy for flexible docking by combining a simple model of ligand-protein interactions for mol. recognition with an evolutionary programming search technique.  We have developed an intermol. energy function that incorporates steric and hydrogen-bonding terms.  The parameters in this function were obtained by docking in three different protein systems.  The effectiveness of this method was demonstrated by conformationally flexible docking of the inhibitor AG-1343, a potential new drug against AIDS, into HIV-1 protease.  For this mol., which has nine rotatable bonds, the crystal structure was reproduced within 1.5 Å rootmean-square deviation 34 times in 100 simulations, each requiring eight minutes on a Silicon Graphics R4400 workstation.  The energy function correctly evaluates the crystal structure as the global energy min.  We believe that a soln. of the docking problem may be achieved by matching a simple model of mol. recognition with an efficient search procedure.  The necessary ingredients of a mol. recognition model include only steric and hydrogen-bond interaction terms.  Although these terms are not necessarily sufficient to predict binding affinity, they describe ligand-protein interactions faithfully enough to enable a docking program to predict the structure of the bound ligand.  This docking strategy thus provides an important tool for the interdisciplinary field of rational drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAErS8tcVx2bVg90H21EOLACvtfcHk0ljlWZDsGCFYlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXmvVClsbg%253D&md5=527cfc114545ea76b64b48d0aee21856</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2F1074-5521%2895%2990050-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F1074-5521%252895%252990050-0%26sid%3Dliteratum%253Aachs%26aulast%3DGehlhaar%26aufirst%3DD.%2BK.%26aulast%3DVerkhivker%26aufirst%3DG.%2BM.%26aulast%3DRejto%26aufirst%3DP.%2BA.%26aulast%3DSherman%26aufirst%3DC.%2BJ.%26aulast%3DFogel%26aufirst%3DD.%2BB.%26aulast%3DFogel%26aufirst%3DL.%2BJ.%26aulast%3DFreer%26aufirst%3DS.%2BT.%26atitle%3DMolecular%2520recognition%2520of%2520the%2520inhibitor%2520AG-1343%2520by%2520HIV-1%2520protease%253A%2520Conformationally%2520flexible%2520docking%2520by%2520evolutionary%2520programming%26jtitle%3DChem.%2520Biol.%26date%3D1995%26volume%3D2%26spage%3D317%26epage%3D324%26doi%3D10.1016%2F1074-5521%2895%2990050-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Lovering, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bikker, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humblet, C.</span><span> </span><span class="NLM_article-title">Escape from flatland: Increasing saturation as an approach to improving clinical success</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">6752</span><span class="NLM_x">–</span> <span class="NLM_lpage">6756</span><span class="refDoi"> DOI: 10.1021/jm901241e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901241e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=6752-6756&author=F.+Loveringauthor=J.+Bikkerauthor=C.+Humblet&title=Escape+from+flatland%3A+Increasing+saturation+as+an+approach+to+improving+clinical+success&doi=10.1021%2Fjm901241e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success</span></div><div class="casAuthors">Lovering, Frank; Bikker, Jack; Humblet, Christine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6752-6756</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The medicinal chem. community has become increasingly aware of the value of tracking calcd. phys. properties such as mol. wt., topol. polar surface area, rotatable bonds, and hydrogen bond donors and acceptors.  The authors hypothesized that the shift to high-throughput synthetic practices over the past decade may be another factor that may predispose mols. to fail by steering discovery efforts toward achiral, arom. compds.  The authors have proposed two simple and interpretable measures of the complexity of mols. prepd. as potential drug candidates.  The first is carbon bond satn. as defined by fraction Sp3 (Fsp3) where Fsp3 = (no. of Sp3 hybridized carbons/total carbon count).  The second is simply whether a chiral carbon exists in the mol.  The authors demonstrate that both complexity (as measured by Fsp3) and the presence of chiral centers correlate with success as compds. transition from discovery, through clin. testing, to drugs.  To explain these observations, the authors further demonstrate that satn. correlates with soly., an exptl. phys. property important to success in the drug discovery setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC1f3Ed7nUBbVg90H21EOLACvtfcHk0ljlWZDsGCFYlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN&md5=4ca92c30c17c53d77ad376719bad951e</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm901241e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901241e%26sid%3Dliteratum%253Aachs%26aulast%3DLovering%26aufirst%3DF.%26aulast%3DBikker%26aufirst%3DJ.%26aulast%3DHumblet%26aufirst%3DC.%26atitle%3DEscape%2520from%2520flatland%253A%2520Increasing%2520saturation%2520as%2520an%2520approach%2520to%2520improving%2520clinical%2520success%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D6752%26epage%3D6756%26doi%3D10.1021%2Fjm901241e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Sherman, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beard, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farid, R.</span><span> </span><span class="NLM_article-title">Use of an induced fit receptor structure in virtual screening</span> <span class="citation_source-journal">Chem. Biol. Drug Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">83</span><span class="NLM_x">–</span> <span class="NLM_lpage">84</span><span class="refDoi"> DOI: 10.1111/j.1747-0285.2005.00327.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=10.1111%2Fj.1747-0285.2005.00327.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=16492153" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=1%3ACAS%3A528%3ADC%252BD28XhsVSjtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2006&pages=83-84&author=W.+Shermanauthor=H.+S.+Beardauthor=R.+Farid&title=Use+of+an+induced+fit+receptor+structure+in+virtual+screening&doi=10.1111%2Fj.1747-0285.2005.00327.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Use of an induced fit receptor structure in virtual screening</span></div><div class="casAuthors">Sherman, Woody; Beard, Hege S.; Farid, Ramy</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">83-84</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">A review.  The automated induced fit docking protocol was used to generate the DFG-out conformation from a p38 MAP kinase activation loop starting from a DFG-in structure (1a9u) and the ligand from 1kv1 (BMU).  In a virtual screening study of 25K decoy ligands and 46 known actives, using an ensemble consisting of the induced fit docking structure (DFG-out) and the 1a9u crystal structure (DFG-in), 14 actives were identified in the top 1% of the database, including BMU and BIRB 796.  3 Actives were identified when 1a9u was used alone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7PRgtFzy8u7Vg90H21EOLACvtfcHk0ljC1UmNwBy--A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhsVSjtL0%253D&md5=efe9900aacaaea6af805c1cbdb350c73</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1111%2Fj.1747-0285.2005.00327.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1747-0285.2005.00327.x%26sid%3Dliteratum%253Aachs%26aulast%3DSherman%26aufirst%3DW.%26aulast%3DBeard%26aufirst%3DH.%2BS.%26aulast%3DFarid%26aufirst%3DR.%26atitle%3DUse%2520of%2520an%2520induced%2520fit%2520receptor%2520structure%2520in%2520virtual%2520screening%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2006%26volume%3D67%26spage%3D83%26epage%3D84%26doi%3D10.1111%2Fj.1747-0285.2005.00327.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Dore, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okrasa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serrano-Vega, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennett, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooke, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Errey, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jazayeri, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tehan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weir, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiggin, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, F. H.</span><span> </span><span class="NLM_article-title">Structure of class C GPCR metabotropic glutamate receptor 5 transmembrane domain</span> <span class="citation_source-journal">Nature (London, U. K.)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">511</span><span class="NLM_x">, </span> <span class="NLM_fpage">557</span><span class="NLM_x">–</span> <span class="NLM_lpage">562</span><span class="refDoi"> DOI: 10.1038/nature13396</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=10.1038%2Fnature13396" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1ChurnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=511&publication_year=2014&pages=557-562&author=A.+S.+Doreauthor=K.+Okrasaauthor=J.+C.+Patelauthor=M.+Serrano-Vegaauthor=K.+Bennettauthor=R.+M.+Cookeauthor=J.+C.+Erreyauthor=A.+Jazayeriauthor=S.+Khanauthor=B.+Tehanauthor=M.+Weirauthor=G.+R.+Wigginauthor=F.+H.+Marshall&title=Structure+of+class+C+GPCR+metabotropic+glutamate+receptor+5+transmembrane+domain&doi=10.1038%2Fnature13396"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of class C GPCR metabotropic glutamate receptor 5 transmembrane domain</span></div><div class="casAuthors">Dore, Andrew S.; Okrasa, Krzysztof; Patel, Jayesh C.; Serrano-Vega, Maria; Bennett, Kirstie; Cooke, Robert M.; Errey, James C.; Jazayeri, Ali; Khan, Samir; Tehan, Ben; Weir, Malcolm; Wiggin, Giselle R.; Marshall, Fiona H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">511</span>
        (<span class="NLM_cas:issue">7511</span>),
    <span class="NLM_cas:pages">557-562</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Metabotropic glutamate receptors are class C G-protein-coupled receptors which respond to the neurotransmitter glutamate.  Structural studies have been restricted to the amino-terminal extracellular domain, providing little understanding of the membrane-spanning signal transduction domain.  Metabotropic glutamate receptor 5 (mGlu5 receptor) is of considerable interest as a drug target in the treatment of fragile X syndrome, autism, depression, anxiety, addiction and movement disorders.  Here we report the crystal structure of the transmembrane domain of the human receptor in complex with the neg. allosteric modulator, mavoglurant.  The structure provides detailed insight into the architecture of the transmembrane domain of class C receptors including the precise location of the allosteric binding site within the transmembrane domain and key micro-switches which regulate receptor signaling.  This structure also provides a model for all class C G-protein-coupled receptors and may aid in the design of new small-mol. drugs for the treatment of brain disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4LiHVA8klWLVg90H21EOLACvtfcHk0ljC1UmNwBy--A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1ChurnK&md5=43a1f0b72a923044fa718729f97c075d</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1038%2Fnature13396&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature13396%26sid%3Dliteratum%253Aachs%26aulast%3DDore%26aufirst%3DA.%2BS.%26aulast%3DOkrasa%26aufirst%3DK.%26aulast%3DPatel%26aufirst%3DJ.%2BC.%26aulast%3DSerrano-Vega%26aufirst%3DM.%26aulast%3DBennett%26aufirst%3DK.%26aulast%3DCooke%26aufirst%3DR.%2BM.%26aulast%3DErrey%26aufirst%3DJ.%2BC.%26aulast%3DJazayeri%26aufirst%3DA.%26aulast%3DKhan%26aufirst%3DS.%26aulast%3DTehan%26aufirst%3DB.%26aulast%3DWeir%26aufirst%3DM.%26aulast%3DWiggin%26aufirst%3DG.%2BR.%26aulast%3DMarshall%26aufirst%3DF.%2BH.%26atitle%3DStructure%2520of%2520class%2520C%2520GPCR%2520metabotropic%2520glutamate%2520receptor%25205%2520transmembrane%2520domain%26jtitle%3DNature%2520%2528London%252C%2520U.%2520K.%2529%26date%3D2014%26volume%3D511%26spage%3D557%26epage%3D562%26doi%3D10.1038%2Fnature13396" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Rylander, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iderberg, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dekundy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baishen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Danysz, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bezard, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cenci, M. A.</span><span> </span><span class="NLM_article-title">A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys</span> <span class="citation_source-journal">Neurobiol. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">352</span><span class="NLM_x">–</span> <span class="NLM_lpage">361</span><span class="refDoi"> DOI: 10.1016/j.nbd.2010.05.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=10.1016%2Fj.nbd.2010.05.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=20452425" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpt12nu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2010&pages=352-361&author=D.+Rylanderauthor=H.+Iderbergauthor=Q.+Liauthor=A.+Dekundyauthor=J.+Zhangauthor=H.+Liauthor=R.+Baishenauthor=W.+Danyszauthor=E.+Bezardauthor=M.+A.+Cenci&title=A+mGluR5+antagonist+under+clinical+development+improves+L-DOPA-induced+dyskinesia+in+parkinsonian+rats+and+monkeys&doi=10.1016%2Fj.nbd.2010.05.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys</span></div><div class="casAuthors">Rylander, Daniella; Iderberg, Hanna; Li, Qin; Dekundy, Andrzej; Zhang, Jinlan; Li, Hao; Baishen, Ren; Danysz, Wojciech; Bezard, Erwan; Cenci, M. Angela</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Disease</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">352-361</span>CODEN:
                <span class="NLM_cas:coden">NUDIEM</span>;
        ISSN:<span class="NLM_cas:issn">0969-9961</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">L-DOPA remains the gold-std. treatment for Parkinson's disease but causes motor fluctuations and dyskinesia.  Metabotropic glutamate receptor type 5 (mGluR5) has been proposed as a target for antidyskinetic therapies.  Here, we evaluate the effects of fenobam, a noncompetitive mGluR5 antagonist already tested in humans, using rodent and nonhuman primate models of Parkinson's disease.  In both animal models, acute administration of fenobam attenuated the L-DOPA-induced abnormal involuntary movements (50-70% redn. at the doses of 30 mg/kg in rats and 10 mg/kg in monkeys).  The effect consisted in a redn. of peak-dose dyskinesia, whereas the end-dose phase was not affected.  Chronic administration of fenobam to previously drug-naive animals (de novo treatment) attenuated the development of peak-dose dyskinesia without compromising the anti-parkinsonian effect of L-DOPA.  In addn., fenobam prolonged the motor stimulant effect of L-DOPA.  We conclude that fenobam acts similarly in rat and primate models of L-DOPA-induced dyskinesia and represents a good candidate for antidyskinetic treatment in Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDjlZraTHwS7Vg90H21EOLACvtfcHk0ljC1UmNwBy--A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpt12nu7w%253D&md5=19679fc03f2cba113ff8377f57893e71</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.nbd.2010.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nbd.2010.05.001%26sid%3Dliteratum%253Aachs%26aulast%3DRylander%26aufirst%3DD.%26aulast%3DIderberg%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DDekundy%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DBaishen%26aufirst%3DR.%26aulast%3DDanysz%26aufirst%3DW.%26aulast%3DBezard%26aufirst%3DE.%26aulast%3DCenci%26aufirst%3DM.%2BA.%26atitle%3DA%2520mGluR5%2520antagonist%2520under%2520clinical%2520development%2520improves%2520L-DOPA-induced%2520dyskinesia%2520in%2520parkinsonian%2520rats%2520and%2520monkeys%26jtitle%3DNeurobiol.%2520Dis.%26date%3D2010%26volume%3D39%26spage%3D352%26epage%3D361%26doi%3D10.1016%2Fj.nbd.2010.05.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Whritenour, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawabata, T. T.</span><span> </span><span class="NLM_article-title">Development and partial validation of a mouse model for predicting drug hypersensitivity reactions</span> <span class="citation_source-journal">J. Immunotoxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">141</span><span class="NLM_x">–</span> <span class="NLM_lpage">147</span><span class="refDoi"> DOI: 10.3109/1547691X.2013.812164</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=10.3109%2F1547691X.2013.812164" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=23879792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkvVyrs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2014&pages=141-147&author=J.+Whritenourauthor=S.+Coleauthor=X.+Zhuauthor=D.+Liauthor=T.+T.+Kawabata&title=Development+and+partial+validation+of+a+mouse+model+for+predicting+drug+hypersensitivity+reactions&doi=10.3109%2F1547691X.2013.812164"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Development and partial validation of a mouse model for predicting drug hypersensitivity reactions</span></div><div class="casAuthors">Whritenour, Jessica; Cole, Susan; Zhu, Xu; Li, Dingzhou; Kawabata, Thomas T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunotoxicology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">141-147</span>CODEN:
                <span class="NLM_cas:coden">JIOMAP</span>;
        ISSN:<span class="NLM_cas:issn">1547-691X</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Animal models that can be used to predict the allergenic potential of drug candidates have not been adequately optimized, validated, or characterized.  While initial validation data from an inter-lab. study of the mouse lymph node proliferation assay (LNPA) appeared promising, no addnl. investigations in this model have been reported.  The objectives of this study were to use pos. and neg. control drugs to further optimize and validate the LNPA utilizing a non-radioactive endpoint and det. the sensitivity, specificity, and predictivity of the model.  Drugs assocd. with hypersensitivity reactions in the literature were chosen to test in the model in addn. to drugs with few or no reports of hypersensitivity.  Mice received a s.c. injection of drug or vehicle into the scruff of the neck once daily for a period of 3 days.  On Day 6, draining lymph nodes were harvested, single cell suspensions prepd., and total cell nos. detd. for each animal by flow cytometry.  A stimulation index was calcd. by dividing the mean total cell no. for the drug-treated group by the mean total cell no. for the vehicle-treated animals.  Based on statistical anal. of the data, animals with a total cell no. ≥2.5× the mean of the vehicle group were classified as 'responders'.  Based on data generated to date with 12 pos. control and six neg. control drugs, the model had a sensitivity of 75%, a specificity of 74%, and a relatively good predictive value (measured by the Receiver Operating Characteristic AUC of 0.80).  The data here suggest that this model may be a useful tool for identifying drug candidates with the potential to produce allergic responses in the clinic.  Future studies will investigate the mechanism(s) for the lymph node responses in order to develop addnl. endpoints that may increase the sensitivity and specificity of the model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOLH2cKRcAyLVg90H21EOLACvtfcHk0lgrLidxrGZ6ZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkvVyrs7w%253D&md5=9f615491c1220b8f30095ed450822051</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.3109%2F1547691X.2013.812164&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F1547691X.2013.812164%26sid%3Dliteratum%253Aachs%26aulast%3DWhritenour%26aufirst%3DJ.%26aulast%3DCole%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DKawabata%26aufirst%3DT.%2BT.%26atitle%3DDevelopment%2520and%2520partial%2520validation%2520of%2520a%2520mouse%2520model%2520for%2520predicting%2520drug%2520hypersensitivity%2520reactions%26jtitle%3DJ.%2520Immunotoxicol.%26date%3D2014%26volume%3D11%26spage%3D141%26epage%3D147%26doi%3D10.3109%2F1547691X.2013.812164" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Soglia, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harriman, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barberia, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyd, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Contillo, L. G.</span><span> </span><span class="NLM_article-title">The development of a higher throughput reactive intermediate screening assay incorporating micro-bore liquid chromatography-micro-electrospray ionization-tandem mass spectrometry and glutathione ethyl ester as an in vitro conjugating agent</span> <span class="citation_source-journal">J. Pharm. Biomed. Anal.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">105</span><span class="NLM_x">–</span> <span class="NLM_lpage">116</span><span class="refDoi"> DOI: 10.1016/j.jpba.2004.04.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=10.1016%2Fj.jpba.2004.04.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=15351054" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=1%3ACAS%3A528%3ADC%252BD2cXntlems7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2004&pages=105-116&author=J.+R.+Sogliaauthor=S.+P.+Harrimanauthor=S.+Zhaoauthor=J.+Barberiaauthor=M.+J.+Coleauthor=J.+G.+Boydauthor=L.+G.+Contillo&title=The+development+of+a+higher+throughput+reactive+intermediate+screening+assay+incorporating+micro-bore+liquid+chromatography-micro-electrospray+ionization-tandem+mass+spectrometry+and+glutathione+ethyl+ester+as+an+in+vitro+conjugating+agent&doi=10.1016%2Fj.jpba.2004.04.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">The development of a higher throughput reactive intermediate screening assay incorporating micro-bore liquid chromatography-micro-electrospray ionization-tandem mass spectrometry and glutathione ethyl ester as an in vitro conjugating agent</span></div><div class="casAuthors">Soglia, John R.; Harriman, Shawn P.; Zhao, Sabrina; Barberia, John; Cole, Mark J.; Boyd, James G.; Contillo, Leonard G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical and Biomedical Analysis</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">105-116</span>CODEN:
                <span class="NLM_cas:coden">JPBADA</span>;
        ISSN:<span class="NLM_cas:issn">0731-7085</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">An in vitro reactive intermediate screening assay, incorporating the use of the close analog of glutathione, glutathione Et ester (GSH-EE) as a conjugating agent, was developed to identify compds. that form reactive intermediates in an in vitro metabolite generating system.  The biol. assay consisted of substrate [s] = 10 μM, human liver microsomes, an NADPH generating system, and glutathione Et ester.  Conjugates were extd. from the biol. matrix using a combination of protein pptn. and a semi-automated 96-well plate solid phase extn. (SPE) procedure.  A micro-bore liq. chromatog.-micro-electrospray ionization-tandem mass spectrometry (μLC-μESI-MS/MS) method detected glutathione Et ester conjugates using selected reaction monitoring (SRM) to simultaneously monitor for multiple MH+ to [MH - 129]+ transitions, where the 129 mass unit (Da) represents the neutral loss of the pyroglutamate moiety from GSH-EE.  The multiple MH+ to [MH - 129]+ transitions (SRM mass table) were generated for potential reactive intermediates of each compd.  Glutathione (GSH) and GSH-EE conjugate stds. were used to evaluate MS detection sensitivity.  Based on direct comparison of std. curve data, an approx. 10-fold increase in sensitivity was obsd. for conjugates contg. GSH-EE moiety vs. GSH.  In vitro expts. were conducted using literature substrates acetaminophen, rosiglitazone, clozapine, diclofenac and either GSH-EE or GSH as a reactive intermediate conjugating agent.  An increase in detection sensitivity was obsd. for each GSH-EE conjugate and in the case of acetaminophen-GSH-EE the peak area increase was approx. 80-fold.  Twelve drug compds., each having known biotransformation mechanisms, were used to further test the detection capabilities of the assay and establish a concordance to literature data.  When GSH was used in the assay, conjugates were detected for 4 out of the 12 test compds. (33%).  When GSH-EE was used in the assay, conjugates were detected for 10 out of the 12 test compds. (83%).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3NwMX6-E_3LVg90H21EOLACvtfcHk0lgrLidxrGZ6ZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXntlems7w%253D&md5=23e4c3df8558019ad3770d748a1f9815</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.jpba.2004.04.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jpba.2004.04.019%26sid%3Dliteratum%253Aachs%26aulast%3DSoglia%26aufirst%3DJ.%2BR.%26aulast%3DHarriman%26aufirst%3DS.%2BP.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DBarberia%26aufirst%3DJ.%26aulast%3DCole%26aufirst%3DM.%2BJ.%26aulast%3DBoyd%26aufirst%3DJ.%2BG.%26aulast%3DContillo%26aufirst%3DL.%2BG.%26atitle%3DThe%2520development%2520of%2520a%2520higher%2520throughput%2520reactive%2520intermediate%2520screening%2520assay%2520incorporating%2520micro-bore%2520liquid%2520chromatography-micro-electrospray%2520ionization-tandem%2520mass%2520spectrometry%2520and%2520glutathione%2520ethyl%2520ester%2520as%2520an%2520in%2520vitro%2520conjugating%2520agent%26jtitle%3DJ.%2520Pharm.%2520Biomed.%2520Anal.%26date%3D2004%26volume%3D36%26spage%3D105%26epage%3D116%26doi%3D10.1016%2Fj.jpba.2004.04.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Shaffer, C. L.</span><span> </span><span class="NLM_article-title">The discovery and preclinical characterization of the novel mGluR5 negative allosteric modulator PF470: Implications for mechanism-based toxicity</span> <span class="citation_source-journal">Curr. Neuropharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl 1</span><span class="NLM_x">) </span> <span class="NLM_fpage">55</span><span class="NLM_x">–</span> <span class="NLM_lpage">56</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2014&pages=55-56&issue=Suppl+1&author=C.+L.+Shaffer&title=The+discovery+and+preclinical+characterization+of+the+novel+mGluR5+negative+allosteric+modulator+PF470%3A+Implications+for+mechanism-based+toxicity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShaffer%26aufirst%3DC.%2BL.%26atitle%3DThe%2520discovery%2520and%2520preclinical%2520characterization%2520of%2520the%2520novel%2520mGluR5%2520negative%2520allosteric%2520modulator%2520PF470%253A%2520Implications%2520for%2520mechanism-based%2520toxicity%26jtitle%3DCurr.%2520Neuropharmacol.%26date%3D2014%26volume%3D12%26issue%3DSuppl%25201%26spage%3D55%26epage%3D56" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Shah, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stepan, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Mahony, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velichko, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Folias, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houle, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaffer, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcek, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whritenour, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stanton, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berg, E. L.</span><span> </span><span class="NLM_article-title">Mechanisms of skin toxicity associated with metabotropic glutamate receptor 5 negative allosteric modulators</span> <span class="citation_source-journal">Cell Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">858</span><span class="NLM_x">–</span> <span class="NLM_lpage">869</span><span class="refDoi"> DOI: 10.1016/j.chembiol.2017.06.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=10.1016%2Fj.chembiol.2017.06.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=28669525" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFSmsbjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2017&pages=858-869&author=F.+Shahauthor=A.+F.+Stepanauthor=A.+O%E2%80%99Mahonyauthor=S.+Velichkoauthor=A.+E.+Foliasauthor=C.+Houleauthor=C.+L.+Shafferauthor=J.+Marcekauthor=J.+Whritenourauthor=R.+Stantonauthor=E.+L.+Berg&title=Mechanisms+of+skin+toxicity+associated+with+metabotropic+glutamate+receptor+5+negative+allosteric+modulators&doi=10.1016%2Fj.chembiol.2017.06.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of Skin Toxicity Associated with Metabotropic Glutamate Receptor 5 Negative Allosteric Modulators</span></div><div class="casAuthors">Shah, Falgun; Stepan, Antonia F.; O'Mahony, Alison; Velichko, Sharlene; Folias, Alexandra E.; Houle, Christopher; Shaffer, Christopher L.; Marcek, John; Whritenour, Jessica; Stanton, Robert; Berg, Ellen L.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">858-869.e5</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Cutaneous reactions represent one of the most common adverse drug effects obsd. in clin. trials leading to substantial compd. attrition.  Three neg. allosteric modulators (NAMs) of metabotropic glutamate receptors (mGluRs), which represent an important target for neurol. diseases, developed by Pfizer, were recently failed in preclin. development due to delayed type IV skin hypersensitivity obsd. in non-human primates (NHPs).  Here we employed large-scale phenotypic profiling in standardized panels of human primary cell/co-culture systems to characterize the skin toxicity mechanism(s) of mGluR5 NAMs from two different series.  Investigation of a database of chems. tested in these systems and transcriptional profiling suggested that the mechanism of toxicity may involve modulation of nuclear receptor targets RAR/RXR, and/or VDR with AhR antagonism.  The studies reported here demonstrate how phenotypic profiling of preclin. drug candidates using human primary cells can provide insights into the mechanisms of toxicity and inform early drug discovery and development campaigns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvdz6FO63JvrVg90H21EOLACvtfcHk0lgrLidxrGZ6ZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFSmsbjP&md5=b50f053ff58a295fa7476d95d325a9c4</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2017.06.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2017.06.003%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DF.%26aulast%3DStepan%26aufirst%3DA.%2BF.%26aulast%3DO%25E2%2580%2599Mahony%26aufirst%3DA.%26aulast%3DVelichko%26aufirst%3DS.%26aulast%3DFolias%26aufirst%3DA.%2BE.%26aulast%3DHoule%26aufirst%3DC.%26aulast%3DShaffer%26aufirst%3DC.%2BL.%26aulast%3DMarcek%26aufirst%3DJ.%26aulast%3DWhritenour%26aufirst%3DJ.%26aulast%3DStanton%26aufirst%3DR.%26aulast%3DBerg%26aufirst%3DE.%2BL.%26atitle%3DMechanisms%2520of%2520skin%2520toxicity%2520associated%2520with%2520metabotropic%2520glutamate%2520receptor%25205%2520negative%2520allosteric%2520modulators%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2017%26volume%3D24%26spage%3D858%26epage%3D869%26doi%3D10.1016%2Fj.chembiol.2017.06.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Hosea, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collard, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maurer, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, R. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kakar, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webster, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaumont, K.</span><span> </span><span class="NLM_article-title">Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches</span> <span class="citation_source-journal">J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">513</span><span class="NLM_x">–</span> <span class="NLM_lpage">533</span><span class="refDoi"> DOI: 10.1177/0091270009333209</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=10.1177%2F0091270009333209" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=19299532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlsFWmu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2009&pages=513-533&author=N.+A.+Hoseaauthor=W.+T.+Collardauthor=S.+Coleauthor=T.+S.+Maurerauthor=R.+X.+Fangauthor=H.+Jonesauthor=S.+M.+Kakarauthor=Y.+Nakaiauthor=B.+J.+Smithauthor=R.+Websterauthor=K.+Beaumont&title=Prediction+of+human+pharmacokinetics+from+preclinical+information%3A+comparative+accuracy+of+quantitative+prediction+approaches&doi=10.1177%2F0091270009333209"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches</span></div><div class="casAuthors">Hosea, Natilie A.; Collard, Wendy T.; Cole, Susan; Maurer, Tristan S.; Fang, Rick X.; Jones, Hannah; Kakar, Shefali M.; Nakai, Yasuhiro; Smith, Bill J.; Webster, Rob; Beaumont, Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">513-533</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">A review.  Quant. prediction of human pharmacokinetics is crit. in assessing the viability of drug candidates and in detg. first-in-human dosing.  Numerous prediction methodologies, incorporating both in vitro and preclin. in vivo data, have been developed in recent years, each with advantages and disadvantages.  However, the lack of a comprehensive data set, both preclin. and clin., has limited efforts to evaluate the optimal strategy (or strategies) that results in quant. predictions of human pharmacokinetics.  To address this issue, the authors conducted a retrospective anal. using 50 proprietary compds. for which in vitro, preclin. pharmacokinetic data and oral single-dose human pharmacokinetic data were available.  Five predictive strategies, involving either allometry or use of unbound intrinsic clearance from microsomes or hepatocytes, were then compared for their ability to predict human oral clearance, half-life through predictions of systemic clearance, vol. of distribution, and bioavailability.  Use of a single-species scaling approach with rat, dog, or monkey was as accurate as or more accurate than using multiple-species allometry.  For those compds. cleared almost exclusively by P 450-mediated pathways, scaling from human liver microsomes was as predictive as single-species scaling of clearance based on data from rat, dog, or monkey.  These data suggest that use of predictive methods involving either single-species in vivo data or in vitro human liver microsomes can quant. predict human in vivo pharmacokinetics and suggest the possibility of streamlining the predictive methodol. through use of a single species or use only of human in vitro microsomal prepns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrg67HcwS4O4LVg90H21EOLACvtfcHk0lixuJo_FbEZ4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlsFWmu74%253D&md5=a0941d53fe43392f8fb1562ee546705e</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1177%2F0091270009333209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0091270009333209%26sid%3Dliteratum%253Aachs%26aulast%3DHosea%26aufirst%3DN.%2BA.%26aulast%3DCollard%26aufirst%3DW.%2BT.%26aulast%3DCole%26aufirst%3DS.%26aulast%3DMaurer%26aufirst%3DT.%2BS.%26aulast%3DFang%26aufirst%3DR.%2BX.%26aulast%3DJones%26aufirst%3DH.%26aulast%3DKakar%26aufirst%3DS.%2BM.%26aulast%3DNakai%26aufirst%3DY.%26aulast%3DSmith%26aufirst%3DB.%2BJ.%26aulast%3DWebster%26aufirst%3DR.%26aulast%3DBeaumont%26aufirst%3DK.%26atitle%3DPrediction%2520of%2520human%2520pharmacokinetics%2520from%2520preclinical%2520information%253A%2520comparative%2520accuracy%2520of%2520quantitative%2520prediction%2520approaches%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2009%26volume%3D49%26spage%3D513%26epage%3D533%26doi%3D10.1177%2F0091270009333209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Ertl, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rohde, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selzer, P.</span><span> </span><span class="NLM_article-title">Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">3714</span><span class="NLM_x">–</span> <span class="NLM_lpage">3717</span><span class="refDoi"> DOI: 10.1021/jm000942e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm000942e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmsFeitb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=3714-3717&author=P.+Ertlauthor=B.+Rohdeauthor=P.+Selzer&title=Fast+calculation+of+molecular+polar+surface+area+as+a+sum+of+fragment-based+contributions+and+its+application+to+the+prediction+of+drug+transport+properties&doi=10.1021%2Fjm000942e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Fast Calculation of Molecular Polar Surface Area as a Sum of Fragment-Based Contributions and Its Application to the Prediction of Drug Transport Properties</span></div><div class="casAuthors">Ertl, Peter; Rohde, Bernhard; Selzer, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">3714-3717</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Mol. polar surface area (PSA), i.e., surface belonging to polar atoms, is a descriptor that was shown to correlate well with passive mol. transport through membranes and, therefore, allows prediction of transport properties of drugs.  The calcn. of PSA, however, is rather time-consuming because of the necessity to generate a reasonable 3D mol. geometry and the calcn. of the surface itself.  A new approach for the calcn. of the PSA is presented here, based on the summation of tabulated surface contributions of polar fragments.  The method, termed topol. PSA (TPSA), provides results which are practically identical with the 3D PSA (the correlation coeff. between 3D PSA and fragment-based TPSA for 34 810 mols. from the World Drug Index is 0.99), while the computation speed is 2-3 orders of magnitude faster.  The new methodol. may, therefore, be used for fast bioavailability screening of virtual libraries having millions of mols.  This article describes the new methodol. and shows the results of validation studies based on sets of published absorption data, including intestinal absorption, Caco-2 monolayer penetration, and blood-brain barrier penetration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhP6Qncx_h6LVg90H21EOLACvtfcHk0lixuJo_FbEZ4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmsFeitb4%253D&md5=23ae4e7708bd8ddeb4a24ad160a29bd6</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Fjm000942e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm000942e%26sid%3Dliteratum%253Aachs%26aulast%3DErtl%26aufirst%3DP.%26aulast%3DRohde%26aufirst%3DB.%26aulast%3DSelzer%26aufirst%3DP.%26atitle%3DFast%2520calculation%2520of%2520molecular%2520polar%2520surface%2520area%2520as%2520a%2520sum%2520of%2520fragment-based%2520contributions%2520and%2520its%2520application%2520to%2520the%2520prediction%2520of%2520drug%2520transport%2520properties%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D3714%26epage%3D3717%26doi%3D10.1021%2Fjm000942e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 4 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Shaoyong Lu, <span class="NLM_string-name hlFld-ContribAuthor">Jian Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Small Molecule Allosteric Modulators of G-Protein-Coupled Receptors: Drug–Target Interactions. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (1)
                                     , 24-45. <a href="https://doi.org/10.1021/acs.jmedchem.7b01844" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01844</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01844&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b01844%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSmall%252BMolecule%252BAllosteric%252BModulators%252Bof%252BG-Protein-Coupled%252BReceptors%25253A%252BDrug%2525E2%252580%252593Target%252BInteractions%26aulast%3DLu%26aufirst%3DShaoyong%26date%3D2019%26date%3D2018%26date%3D2017%26date%3D14122017%26date%3D26022018%26date%3D19022018%26volume%3D62%26issue%3D1%26spage%3D24%26epage%3D45" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Robert J. Young, <span class="NLM_string-name hlFld-ContribAuthor">Paul D. Leeson</span>. </span><span class="cited-content_cbyCitation_article-title">Mapping the Efficiency and Physicochemical Trajectories of Successful Optimizations. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (15)
                                     , 6421-6467. <a href="https://doi.org/10.1021/acs.jmedchem.8b00180" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00180</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00180%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DMapping%252Bthe%252BEfficiency%252Band%252BPhysicochemical%252BTrajectories%252Bof%252BSuccessful%252BOptimizations%26aulast%3DYoung%26aufirst%3DRobert%2BJ.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D03022018%26date%3D25042018%26date%3D05042018%26volume%3D61%26issue%3D15%26spage%3D6421%26epage%3D6467" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mikhailo V.  Slivka</span>, <span class="hlFld-ContribAuthor ">Maksym M.  Fizer</span>, <span class="hlFld-ContribAuthor ">Nataliya I.  Korol</span>. </span><span class="cited-content_cbyCitation_article-title">Bicyclic 6-6 Systems With One Bridgehead Nitrogen Atom: Two Extra Heteroatoms 1:1. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,<a href="https://doi.org/10.1016/B978-0-12-818655-8.00009-3" title="DOI URL">https://doi.org/10.1016/B978-0-12-818655-8.00009-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-818655-8.00009-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-818655-8.00009-3%26sid%3Dliteratum%253Aachs%26atitle%3DBicyclic%252B6-6%252BSystems%252BWith%252BOne%252BBridgehead%252BNitrogen%252BAtom%25253A%252BTwo%252BExtra%252BHeteroatoms%252B1%25253A1%26aulast%3DSlivka%26aufirst%3DMikhailo%2BV.%26date%3D2020%26pub%3DElsevier%26atitle%3DReference%252BModule%252Bin%252BChemistry%25252C%252BMolecular%252BSciences%252Band%252BChemical%252BEngineering%26date%3D2020%26volume%3D15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Khodayar  Gholivand</span>, <span class="hlFld-ContribAuthor ">Fahimeh  Mohammadpanah</span>, <span class="hlFld-ContribAuthor ">Mahsa  Pooyan</span>, <span class="hlFld-ContribAuthor ">Ali Asghar Ebrahimi  Valmoozi</span>, <span class="hlFld-ContribAuthor ">Mahboobeh  Sharifi</span>, <span class="hlFld-ContribAuthor ">Ahmad  Mani-Varnosfaderani</span>, <span class="hlFld-ContribAuthor ">Zahra  Hosseini</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, crystal structure, insecticidal activities, molecular docking and QSAR studies of some new phospho guanidines and phospho pyrazines as cholinesterase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Pesticide Biochemistry and Physiology</span><span> <strong>2019,</strong> <em>157 </em>, 122-137. <a href="https://doi.org/10.1016/j.pestbp.2019.03.010" title="DOI URL">https://doi.org/10.1016/j.pestbp.2019.03.010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.pestbp.2019.03.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.pestbp.2019.03.010%26sid%3Dliteratum%253Aachs%26jtitle%3DPesticide%2520Biochemistry%2520and%2520Physiology%26atitle%3DSynthesis%25252C%252Bcrystal%252Bstructure%25252C%252Binsecticidal%252Bactivities%25252C%252Bmolecular%252Bdocking%252Band%252BQSAR%252Bstudies%252Bof%252Bsome%252Bnew%252Bphospho%252Bguanidines%252Band%252Bphospho%252Bpyrazines%252Bas%252Bcholinesterase%252Binhibitors%26aulast%3DGholivand%26aufirst%3DKhodayar%26date%3D2019%26volume%3D157%26spage%3D122%26epage%3D137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00604/20170922/images/medium/jm-2017-006048_0012.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00604/20170922/images/large/jm-2017-006048_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00604&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00604/20170922/images/medium/jm-2017-006048_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00604/20170922/images/large/jm-2017-006048_0001.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of select mGlu<sub>5</sub> NAMs. (a) 2-Methyl-6-(phenylethynyl)pyridine (MPEP), one of the first subtype-selective mGlu<sub>5</sub> antagonists. (b) Clinical alkyne-containing mGlu<sub>5</sub> NAMs. (c) Recently disclosed alkyne-lacking mGlu<sub>5</sub> NAMs. (d) Alkyne-lacking mGlu<sub>5</sub> NAMs discovered by Pfizer.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00604/20170922/images/large/jm-2017-006048_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00604&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00604/20170922/images/medium/jm-2017-006048_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00604/20170922/images/large/jm-2017-006048_0004.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of the Early Lead mGlu<sub>5</sub> NAMs <b>9</b>, <b>10</b>, <b>11</b>, <b>20</b>, and <b>21</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00604/20170922/images/large/jm-2017-006048_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00604&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) bis(2,4,6-trichlorophenyl)malonate, 94% yield (in THF, 66 °C, for <b>14</b>) and 93% yield (in dioxane, 101 °C, for <b>15</b>); (ii) 3-chlorobenzyl bromide, TBAI or TBAB, acetone, reflux, 57% yield (for <b>9</b>) and 51% yield (for <b>10</b>); (iii) 2-(bromomethyl)-6-methylpyridine, Cs<sub>2</sub>CO<sub>3</sub>, NMP, 45 °C, 42% yield; (iv) CH<sub>2</sub>(CO<sub>2</sub>Me)<sub>2</sub>, NaOMe, methanol, 75 °C, 90% yield (for <b>18</b>) and 21% yield (for <b>19</b>); (v) <i>m</i>-chlorobenzyl tosylate, K<sub>2</sub>CO<sub>3</sub>, 58% yield (in DMF, 68 °C, for <b>20</b>) and 21% yield (in NMP, 50 °C, for <b>21</b>).</p></p></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00604/20170922/images/medium/jm-2017-006048_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00604/20170922/images/large/jm-2017-006048_0005.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Pyrimidinones <b>8</b> and <b>30</b>–<b>39</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00604/20170922/images/large/jm-2017-006048_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00604&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) ClCH<sub>2</sub>COCl, TEA, THF, 0–20 °C; (ii) KO<i>t</i>Bu, THF, 0–20 °C; (iii) EtO<sub>3</sub>BF<sub>4</sub>, dichloromethane, 20 °C; (iv) NH<sub>4</sub>Cl, methanol, reflux; (v) CH<sub>2</sub>(CO<sub>2</sub>Me)<sub>2,</sub> NaOMe, methanol, reflux; (vi) chloroacetonitrile, NaOMe, MeOH, 20 °C; (vii) NaOMe, MeOH, 35 °C; (viii) (a) R<sub>2</sub>CH<sub>2</sub>OH, polymer-supported triphenylphosphine, DIAD, THF or (b) R<sub>2</sub>CH<sub>2</sub>Br, K<sub>2</sub>CO<sub>3</sub>, TBAB, acetone, 45 °C.</p></p></figure><figure data-id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00604/20170922/images/medium/jm-2017-006048_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00604/20170922/images/large/jm-2017-006048_0006.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Large-Scale Synthesis of Key Analogue <b>8</b> and <b>38</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00604/20170922/images/large/jm-2017-006048_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00604&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) ClCH<sub>2</sub>COCl, K<sub>2</sub>CO<sub>3</sub>, THF/H<sub>2</sub>O, 0–20 °C; (ii) KO<i>t</i>Bu, <i>i</i>PrOH, 0–20 °C, 75% yield (over two steps, for <b>24c</b>) and 95% yield (over two steps, for <b>24e</b>); (iii) EtO<sub>3</sub>BF<sub>4</sub>, dichloromethane, 20 °C; (iv) NH<sub>4</sub>Cl, methanol, reflux; (v) CH<sub>2</sub>(CO<sub>2</sub>Me)<sub>2,</sub> NaOMe, methanol, reflux, 45% yield (over three steps, for <b>27c</b>) and 63% yield (over three steps, for <b>27d</b>); (vi) 2-Py-CH<sub>2</sub>OH, triphenylphosphine, DIAD, THF (62%); (vii) 3-cyanobenzyl alcohol, polymer-supported triphenylphosphine, DIAD, THF (78%).</p></p></figure><figure data-id="fig2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00604/20170922/images/medium/jm-2017-006048_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00604/20170922/images/large/jm-2017-006048_0002.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Binding model of <b>8</b>. (A) Compound <b>8</b> binds in the region similar to <b>1</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4OO9">4OO9</a>), mostly formed by TM3, TM5, and TM7. (B) At an atomic level, <b>8</b> binds to mGlu<sub>5</sub> with unique interactions to Asn-747<sup>5.47</sup> and Tyr-659<sup>3.44</sup>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00604/20170922/images/large/jm-2017-006048_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00604&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00604/20170922/images/medium/jm-2017-006048_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00604/20170922/images/large/jm-2017-006048_0003.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A,B) mGlu<sub>5</sub> RO vs unbound plasma concentration (<i>C</i><sub>p,u</sub>) of compound <b>8</b> in rats and NHPs, respectively. (C) Coronal views of [<sup>18</sup>F]FPEB-dependent PET images from a NHP receiving vehicle (baseline) and <b>8</b> (displacement) at 65% RO (0.00682 mg/kg bolus + 0.00772 mg/kg/h infusion over 2 h) and 90% RO (0.0274 mg/kg bolus + 0.0310 mg/kg/h infusion over 2 h), respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00604/20170922/images/large/jm-2017-006048_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00604&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i59">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51754" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51754" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 44 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Crawford, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wainwright, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heavens, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollock, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seabrook, G. R.</span><span> </span><span class="NLM_article-title">Mobilization of intracellular Ca2+ by mGluR5 metabotropic glutamate receptor activation in neonatal rat cultured dorsal root ganglia neurones</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">621</span><span class="NLM_x">–</span> <span class="NLM_lpage">630</span><span class="refDoi"> DOI: 10.1016/S0028-3908(99)00167-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=10.1016%2FS0028-3908%2899%2900167-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2000&pages=621-630&author=J.+H.+Crawfordauthor=A.+Wainwrightauthor=R.+Heavensauthor=J.+Pollockauthor=D.+J.+Martinauthor=R.+H.+Scottauthor=G.+R.+Seabrook&title=Mobilization+of+intracellular+Ca2%2B+by+mGluR5+metabotropic+glutamate+receptor+activation+in+neonatal+rat+cultured+dorsal+root+ganglia+neurones&doi=10.1016%2FS0028-3908%2899%2900167-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2FS0028-3908%2899%2900167-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0028-3908%252899%252900167-7%26sid%3Dliteratum%253Aachs%26aulast%3DCrawford%26aufirst%3DJ.%2BH.%26aulast%3DWainwright%26aufirst%3DA.%26aulast%3DHeavens%26aufirst%3DR.%26aulast%3DPollock%26aufirst%3DJ.%26aulast%3DMartin%26aufirst%3DD.%2BJ.%26aulast%3DScott%26aufirst%3DR.%2BH.%26aulast%3DSeabrook%26aufirst%3DG.%2BR.%26atitle%3DMobilization%2520of%2520intracellular%2520Ca2%252B%2520by%2520mGluR5%2520metabotropic%2520glutamate%2520receptor%2520activation%2520in%2520neonatal%2520rat%2520cultured%2520dorsal%2520root%2520ganglia%2520neurones%26jtitle%3DNeuropharmacology%26date%3D2000%26volume%3D39%26spage%3D621%26epage%3D630%26doi%3D10.1016%2FS0028-3908%2899%2900167-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Recasens, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guiramand, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aimar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abdulkarim, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbanel, G.</span><span> </span><span class="NLM_article-title">Metabotropic glutamate receptors as drug targets</span> <span class="citation_source-journal">Curr. Drug Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">651</span><span class="NLM_x">–</span> <span class="NLM_lpage">681</span><span class="refDoi"> DOI: 10.2174/138945007780618544</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=10.2174%2F138945007780618544" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=17504108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlsVWmu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2007&pages=651-681&author=M.+Recasensauthor=J.+Guiramandauthor=R.+Aimarauthor=A.+Abdulkarimauthor=G.+Barbanel&title=Metabotropic+glutamate+receptors+as+drug+targets&doi=10.2174%2F138945007780618544"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Metabotropic glutamate receptors as drug targets</span></div><div class="casAuthors">Recasens, Max; Guiramand, Janique; Aimar, Rose; Abdulkarim, Ahmad; Barbanel, Gerard</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Targets</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">651-681</span>CODEN:
                <span class="NLM_cas:coden">CDTUAU</span>;
        ISSN:<span class="NLM_cas:issn">1389-4501</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  L-glutamate (Glu), the main excitatory amino acid neurotransmitter in the mammalian central nervous system, is involved in many physiol. functions, including learning and memory, but also in toxic phenomena occurring in numerous degenerative or neurol. diseases.  These functions mainly result from its interaction with Glu receptors (GluRs).  The broad spectrum of roles played by glutamate derived from the large no. of membrane receptors, which are currently classified in two main categories, ionotropic (iGluRs) and metabotropic (mGluRs) receptors.  The iGluRs are ion channels, permeant to Na+ (Ca2+) while the mGluRs belongs to the superfamily of G-protein coupled receptors (GPCRs).  Despite continuous efforts over more than two decades, the use of iGluR agonists or antagonists to improve or inhibit excitatory transmission in pathol. states still remains a major challenge, though the discovery and development of recent mols. may prove it worthwhile.  This probably results form the vital role of fast excitatory transmission in many fundamental physiol. functions.  Since the discovery of mGluRs, hope has emerged.  Indeed, mGluRs are mainly involved in the regulation of fast excitatory transmission.  Consequently, it was logically thought that modulating mGluRs with agonists or antagonists might lead to more subtle regulation of fast excitatory transmission than by directly blocking iGluRs.  As a result of intensive investigation, new drugs permitting to discriminate between these receptors have emerged.  Moreover, a new class of mols. acting as neg. or pos. allosteric modulators or mGluRs is now available and appears to be promising.  In the following, we will review the classification of mGluRs and the functions in which mGluRs are involved.  We will focus on their potential as therapeutic targets for improving numerous physiol. functions and for different neurodegenerative and neuropsychiatric disorders, which are related to malfunction of Glu signaling in human beings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2Y9ty-Qq5tLVg90H21EOLACvtfcHk0liCcpO-6G8vtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlsVWmu7w%253D&md5=9c51d9468835f67e5e54d4b6a10f5dce</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.2174%2F138945007780618544&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138945007780618544%26sid%3Dliteratum%253Aachs%26aulast%3DRecasens%26aufirst%3DM.%26aulast%3DGuiramand%26aufirst%3DJ.%26aulast%3DAimar%26aufirst%3DR.%26aulast%3DAbdulkarim%26aufirst%3DA.%26aulast%3DBarbanel%26aufirst%3DG.%26atitle%3DMetabotropic%2520glutamate%2520receptors%2520as%2520drug%2520targets%26jtitle%3DCurr.%2520Drug%2520Targets%26date%3D2007%26volume%3D8%26spage%3D651%26epage%3D681%26doi%3D10.2174%2F138945007780618544" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Swanson, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bures, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linden, A.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monn, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoepp, D. D.</span><span> </span><span class="NLM_article-title">Metabotropic glutamate receptors as novel targets for anxiety and stress disorders</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">131</span><span class="NLM_x">–</span> <span class="NLM_lpage">144</span><span class="refDoi"> DOI: 10.1038/nrd1630</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=10.1038%2Fnrd1630" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2005&pages=131-144&author=C.+J.+Swansonauthor=M.+Buresauthor=M.+P.+Johnsonauthor=A.-M.+Lindenauthor=J.+A.+Monnauthor=D.+D.+Schoepp&title=Metabotropic+glutamate+receptors+as+novel+targets+for+anxiety+and+stress+disorders&doi=10.1038%2Fnrd1630"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrd1630&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1630%26sid%3Dliteratum%253Aachs%26aulast%3DSwanson%26aufirst%3DC.%2BJ.%26aulast%3DBures%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DM.%2BP.%26aulast%3DLinden%26aufirst%3DA.-M.%26aulast%3DMonn%26aufirst%3DJ.%2BA.%26aulast%3DSchoepp%26aufirst%3DD.%2BD.%26atitle%3DMetabotropic%2520glutamate%2520receptors%2520as%2520novel%2520targets%2520for%2520anxiety%2520and%2520stress%2520disorders%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2005%26volume%3D4%26spage%3D131%26epage%3D144%26doi%3D10.1038%2Fnrd1630" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Pin, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duvoisin, R.</span><span> </span><span class="NLM_article-title">Review: neurotransmitter receptors I. The metabotropic glutamate receptors: structure and functions</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">26</span><span class="refDoi"> DOI: 10.1016/0028-3908(94)00129-G</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=10.1016%2F0028-3908%2894%2900129-G" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=1995&pages=1-26&author=J.+P.+Pinauthor=R.+Duvoisin&title=Review%3A+neurotransmitter+receptors+I.+The+metabotropic+glutamate+receptors%3A+structure+and+functions&doi=10.1016%2F0028-3908%2894%2900129-G"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2F0028-3908%2894%2900129-G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0028-3908%252894%252900129-G%26sid%3Dliteratum%253Aachs%26aulast%3DPin%26aufirst%3DJ.%2BP.%26aulast%3DDuvoisin%26aufirst%3DR.%26atitle%3DReview%253A%2520neurotransmitter%2520receptors%2520I.%2520The%2520metabotropic%2520glutamate%2520receptors%253A%2520structure%2520and%2520functions%26jtitle%3DNeuropharmacology%26date%3D1995%26volume%3D34%26spage%3D1%26epage%3D26%26doi%3D10.1016%2F0028-3908%2894%2900129-G" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Conn, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pin, J.-P.</span><span> </span><span class="NLM_article-title">Pharmacology and functions of metabotropic glutamate receptors</span> <span class="citation_source-journal">Annu. Rev. Pharmacol. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">205</span><span class="NLM_x">–</span> <span class="NLM_lpage">237</span><span class="refDoi"> DOI: 10.1146/annurev.pharmtox.37.1.205</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=10.1146%2Fannurev.pharmtox.37.1.205" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=9131252" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=1%3ACAS%3A528%3ADyaK2sXisl2ktr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1997&pages=205-237&author=P.+J.+Connauthor=J.-P.+Pin&title=Pharmacology+and+functions+of+metabotropic+glutamate+receptors&doi=10.1146%2Fannurev.pharmtox.37.1.205"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacology and functions of metabotropic glutamate receptors</span></div><div class="casAuthors">Conn, P. Jeffrey; Pin, Jean-Philippe</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">205-237</span>CODEN:
                <span class="NLM_cas:coden">ARPTDI</span>;
        ISSN:<span class="NLM_cas:issn">0362-1642</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews</span>)
        </div><div class="casAbstract">A review, with 198 refs.  In the mid to late 1980s, studies were published that provided the first evidence for the existence of glutamate receptors that are not ligand-gated cation channels but are coupled to effector systems through GTP-binding proteins.  Since those initial reports, tremendous progress has been made in characterizing these metabotropic glutamate receptors (mGluRs), including cloning and characterization of cDNA that encodes a family of eight mGluR subtypes, several of which have multiple splice variants.  Also, tremendous progress has been made in developing new highly selective mGluR agonists and antagonists and toward detg. the physiol. roles of the mGluRs in mammalian brain.  These findings have exciting implications for drug development and suggest that the mGluRs provide a novel target for development of therapeutic agents that could have a significant impact on neuropharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGph1fuaHYNvC7Vg90H21EOLACvtfcHk0lg7PBf4UlMqqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXisl2ktr0%253D&md5=d9df228141c4747f80bbd9d2f0843a24</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1146%2Fannurev.pharmtox.37.1.205&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.pharmtox.37.1.205%26sid%3Dliteratum%253Aachs%26aulast%3DConn%26aufirst%3DP.%2BJ.%26aulast%3DPin%26aufirst%3DJ.-P.%26atitle%3DPharmacology%2520and%2520functions%2520of%2520metabotropic%2520glutamate%2520receptors%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D1997%26volume%3D37%26spage%3D205%26epage%3D237%26doi%3D10.1146%2Fannurev.pharmtox.37.1.205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Spooren, W. P. J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vassout, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neijt, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuhn, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gasparini, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roux, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porsolt, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gentsch, C.</span><span> </span><span class="NLM_article-title">Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">295</span><span class="NLM_x">, </span> <span class="NLM_fpage">1267</span><span class="NLM_x">–</span> <span class="NLM_lpage">1275</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=11082464" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=1%3ACAS%3A528%3ADC%252BD3cXosVKitr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=295&publication_year=2000&pages=1267-1275&author=W.+P.+J.+M.+Spoorenauthor=A.+Vassoutauthor=H.+C.+Neijtauthor=R.+Kuhnauthor=F.+Gaspariniauthor=S.+Rouxauthor=R.+D.+Porsoltauthor=C.+Gentsch&title=Anxiolytic-like+effects+of+the+prototypical+metabotropic+glutamate+receptor+5+antagonist+2-methyl-6-%28phenylethynyl%29pyridine+in+rodents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents</span></div><div class="casAuthors">Spooren, Will P. J. M.; Vassout, Annick; Neijt, Hans C.; Kuhn, Rainer; Gasparini, Fabrizio; Roux, Silvain; Porsolt, Roger D.; Gentsch, Conrad</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">295</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1267-1275</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Recently, selective and systemically active antagonists for the metabotropic glutamate 5 receptor (mGlu5) were discovered, and the most potent deriv. was found to be MPEP (2-methyl-6-(phenylethynyl)pyridine).  Given the high expression of mGlu5 receptors in limbic forebrain regions, it was decided to evaluate the anxiolytic potential of MPEP.  After an acute oral administration, MPEP attenuated the anxiety-dependent variable in a variety of well established anxiety test paradigms.  In rats, MPEP (10, 30, and 100 mg/kg) increased punished responses in the Geller-Seifter test, but none of these effects reached statistical significance.  MPEP significantly increased the ratio (open/total arm entries; 0.1, 1, and 10 mg/kg), the no. of open arm entries (0.1, 1, and 10 mg/kg), as well as time spent on open arm (0.1 and 1 mg/kg) in the elevated plus maze test.  Furthermore, MPEP (0.3 and 1 mg/kg) significantly increased the time spent in social contact in the social exploration test.  In mice, MPEP attenuated stress-induced hyperthermia (15 and 30 mg/kg) and decreased the no. of buried marbles in the marble burying test (7.5 and 30 mg/kg).  Finally, MPEP (0.01, 0.1, 1, 10, and 100 mg/kg) was tested on spontaneous locomotor activity in mice, and only a dose of 100 mg/kg significantly reduced vertical activity; no effect was seen on horizontal activity.  MPEP (7.5, 15, and 30 mg/kg) was ineffective on d-amphetamine-induced (2.5 mg/kg) locomotor activity in mice and prepulse inhibition in rats (1, 3, or 10 mg/kg).  Thus, these findings indicate that MPEP exhibits anxiolytic-like effects and low risks for sedation and psychotomimetic side-effects in rodents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqR0smnEgHr_rVg90H21EOLACvtfcHk0li0n5Lqz_VfyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXosVKitr8%253D&md5=b08c1a7ba794c4be8ca048c9925be7da</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSpooren%26aufirst%3DW.%2BP.%2BJ.%2BM.%26aulast%3DVassout%26aufirst%3DA.%26aulast%3DNeijt%26aufirst%3DH.%2BC.%26aulast%3DKuhn%26aufirst%3DR.%26aulast%3DGasparini%26aufirst%3DF.%26aulast%3DRoux%26aufirst%3DS.%26aulast%3DPorsolt%26aufirst%3DR.%2BD.%26aulast%3DGentsch%26aufirst%3DC.%26atitle%3DAnxiolytic-like%2520effects%2520of%2520the%2520prototypical%2520metabotropic%2520glutamate%2520receptor%25205%2520antagonist%25202-methyl-6-%2528phenylethynyl%2529pyridine%2520in%2520rodents%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2000%26volume%3D295%26spage%3D1267%26epage%3D1275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Walker, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reeve, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bowes, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winter, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wotherspoon, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmid, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gasparini, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuhn, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urban, L.</span><span> </span><span class="NLM_article-title">mGlu5 receptors and nociceptive function. II. mGlu5 receptors functionally expressed on peripheral sensory neurones mediate inflammatory hyperalgesia</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">10</span><span class="NLM_x">–</span> <span class="NLM_lpage">19</span><span class="refDoi"> DOI: 10.1016/S0028-3908(00)00114-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=10.1016%2FS0028-3908%2800%2900114-3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2001&pages=10-19&author=K.+Walkerauthor=A.+Reeveauthor=M.+Bowesauthor=J.+Winterauthor=G.+Wotherspoonauthor=A.+Davisauthor=P.+Schmidauthor=F.+Gaspariniauthor=R.+Kuhnauthor=L.+Urban&title=mGlu5+receptors+and+nociceptive+function.+II.+mGlu5+receptors+functionally+expressed+on+peripheral+sensory+neurones+mediate+inflammatory+hyperalgesia&doi=10.1016%2FS0028-3908%2800%2900114-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2FS0028-3908%2800%2900114-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0028-3908%252800%252900114-3%26sid%3Dliteratum%253Aachs%26aulast%3DWalker%26aufirst%3DK.%26aulast%3DReeve%26aufirst%3DA.%26aulast%3DBowes%26aufirst%3DM.%26aulast%3DWinter%26aufirst%3DJ.%26aulast%3DWotherspoon%26aufirst%3DG.%26aulast%3DDavis%26aufirst%3DA.%26aulast%3DSchmid%26aufirst%3DP.%26aulast%3DGasparini%26aufirst%3DF.%26aulast%3DKuhn%26aufirst%3DR.%26aulast%3DUrban%26aufirst%3DL.%26atitle%3DmGlu5%2520receptors%2520and%2520nociceptive%2520function.%2520II.%2520mGlu5%2520receptors%2520functionally%2520expressed%2520on%2520peripheral%2520sensory%2520neurones%2520mediate%2520inflammatory%2520hyperalgesia%26jtitle%3DNeuropharmacology%26date%3D2001%26volume%3D40%26spage%3D10%26epage%3D19%26doi%3D10.1016%2FS0028-3908%2800%2900114-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Tatarczynska, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klodzinska, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chojnacka-Wojcik, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palucha, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gasparini, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuhn, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pilc, A.</span><span> </span><span class="NLM_article-title">Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist</span> <span class="citation_source-journal">br J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">132</span><span class="NLM_x">, </span> <span class="NLM_fpage">1423</span><span class="NLM_x">–</span> <span class="NLM_lpage">1430</span><span class="refDoi"> DOI: 10.1038/sj.bjp.0703923</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=10.1038%2Fsj.bjp.0703923" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=11264235" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=1%3ACAS%3A528%3ADC%252BD3MXivVahs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2001&pages=1423-1430&author=E.+Tatarczynskaauthor=A.+Klodzinskaauthor=E.+Chojnacka-Wojcikauthor=A.+Paluchaauthor=F.+Gaspariniauthor=R.+Kuhnauthor=A.+Pilc&title=Potential+anxiolytic-+and+antidepressant-like+effects+of+MPEP%2C+a+potent%2C+selective+and+systemically+active+mGlu5+receptor+antagonist&doi=10.1038%2Fsj.bjp.0703923"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist</span></div><div class="casAuthors">Tatarczynska, Ewa; Klodzinska, Aleksandra; Chojnacka-Wojcik, Ewa; Palucha, Agnieszka; Gasparini, Fabrizio; Kuhn, Rainer; Pilc, Andrzej</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1423-1430</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Several lines of evidence suggest a crucial involvement of glutamate in the mechanism of action of anxiolytic and/or antidepressant drugs.  The involvement of group I metabotropic glutamate (mGlu) receptors in anxiety and depression has also been proposed.  Given the recent discovery of selective and brain-penetrating mGlu5 receptor antagonists, the effect of 2-methyl-6-(phenylethynyl)pyridine (MPEP), i.e., the most potent compd. described, was evaluated in established models of anxiety and depression.  Expts. were performed on male Wistar rats or male Albino Swiss or C57BL/6J mice.  The anxiolytic-like effects of MPEP were tested in the conflict drinking test and the elevated plus-maze test in rats as well as in the 4-plate test in mice.  The antidepressant-like effect was estd. by the tail suspension test in mice and the behavioral despair test in rats.  MPEP (1-30 mg/kg) induced anxiolytic-like effects in the conflict drinking test and the elevated plus-maze test in rats as well as in the 4-plate test in mice.  MPEP had no effect on locomotor activity or motor coordination.  MPEP (1-20 mg/kg) shortened the immobility time in the tail suspension test in mice; however, it was inactive in the behavioral despair test in rats.  These data suggest that selective mGlu5 receptor antagonists may be useful in the therapy of anxiety and/or depression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcmuBTvCR_HrVg90H21EOLACvtfcHk0ljaFMbvKbw7Zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXivVahs70%253D&md5=8840ee76df4717c51c3bc7e529fa1762</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0703923&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0703923%26sid%3Dliteratum%253Aachs%26aulast%3DTatarczynska%26aufirst%3DE.%26aulast%3DKlodzinska%26aufirst%3DA.%26aulast%3DChojnacka-Wojcik%26aufirst%3DE.%26aulast%3DPalucha%26aufirst%3DA.%26aulast%3DGasparini%26aufirst%3DF.%26aulast%3DKuhn%26aufirst%3DR.%26aulast%3DPilc%26aufirst%3DA.%26atitle%3DPotential%2520anxiolytic-%2520and%2520antidepressant-like%2520effects%2520of%2520MPEP%252C%2520a%2520potent%252C%2520selective%2520and%2520systemically%2520active%2520mGlu5%2520receptor%2520antagonist%26jtitle%3Dbr%2520J.%2520Pharmacol.%26date%3D2001%26volume%3D132%26spage%3D1423%26epage%3D1430%26doi%3D10.1038%2Fsj.bjp.0703923" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Chapman, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nanan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meldrum, B. S.</span><span> </span><span class="NLM_article-title">Anticonvulsant activity of two metabotropic glutamate Group I antagonists selective for the mGlu5 receptor: 2-methyl-6-(phenylethynyl)-pyridine (MPEP), and (E)-6-methyl-2-styryl-pyridine (SIB 1893)</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">1567</span><span class="NLM_x">–</span> <span class="NLM_lpage">1574</span><span class="refDoi"> DOI: 10.1016/S0028-3908(99)00242-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=10.1016%2FS0028-3908%2899%2900242-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2000&pages=1567-1574&author=A.+G.+Chapmanauthor=K.+Nananauthor=M.+Williamsauthor=B.+S.+Meldrum&title=Anticonvulsant+activity+of+two+metabotropic+glutamate+Group+I+antagonists+selective+for+the+mGlu5+receptor%3A+2-methyl-6-%28phenylethynyl%29-pyridine+%28MPEP%29%2C+and+%28E%29-6-methyl-2-styryl-pyridine+%28SIB+1893%29&doi=10.1016%2FS0028-3908%2899%2900242-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2FS0028-3908%2899%2900242-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0028-3908%252899%252900242-7%26sid%3Dliteratum%253Aachs%26aulast%3DChapman%26aufirst%3DA.%2BG.%26aulast%3DNanan%26aufirst%3DK.%26aulast%3DWilliams%26aufirst%3DM.%26aulast%3DMeldrum%26aufirst%3DB.%2BS.%26atitle%3DAnticonvulsant%2520activity%2520of%2520two%2520metabotropic%2520glutamate%2520Group%2520I%2520antagonists%2520selective%2520for%2520the%2520mGlu5%2520receptor%253A%25202-methyl-6-%2528phenylethynyl%2529-pyridine%2520%2528MPEP%2529%252C%2520and%2520%2528E%2529-6-methyl-2-styryl-pyridine%2520%2528SIB%25201893%2529%26jtitle%3DNeuropharmacology%26date%3D2000%26volume%3D39%26spage%3D1567%26epage%3D1574%26doi%3D10.1016%2FS0028-3908%2899%2900242-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Bruno, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ksiazek, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Battaglia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lukic, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonhardt, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sauer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gasparini, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuhn, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicoletti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flor, P. J.</span><span> </span><span class="NLM_article-title">Selective blockade of metabotropic glutamate receptor subtype 5 is neuroprotective</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">2223</span><span class="NLM_x">–</span> <span class="NLM_lpage">2230</span><span class="refDoi"> DOI: 10.1016/S0028-3908(00)00079-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=10.1016%2FS0028-3908%2800%2900079-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2000&pages=2223-2230&author=V.+Brunoauthor=I.+Ksiazekauthor=G.+Battagliaauthor=S.+Lukicauthor=T.+Leonhardtauthor=D.+Sauerauthor=F.+Gaspariniauthor=R.+Kuhnauthor=F.+Nicolettiauthor=P.+J.+Flor&title=Selective+blockade+of+metabotropic+glutamate+receptor+subtype+5+is+neuroprotective&doi=10.1016%2FS0028-3908%2800%2900079-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2FS0028-3908%2800%2900079-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0028-3908%252800%252900079-4%26sid%3Dliteratum%253Aachs%26aulast%3DBruno%26aufirst%3DV.%26aulast%3DKsiazek%26aufirst%3DI.%26aulast%3DBattaglia%26aufirst%3DG.%26aulast%3DLukic%26aufirst%3DS.%26aulast%3DLeonhardt%26aufirst%3DT.%26aulast%3DSauer%26aufirst%3DD.%26aulast%3DGasparini%26aufirst%3DF.%26aulast%3DKuhn%26aufirst%3DR.%26aulast%3DNicoletti%26aufirst%3DF.%26aulast%3DFlor%26aufirst%3DP.%2BJ.%26atitle%3DSelective%2520blockade%2520of%2520metabotropic%2520glutamate%2520receptor%2520subtype%25205%2520is%2520neuroprotective%26jtitle%3DNeuropharmacology%26date%3D2000%26volume%3D39%26spage%3D2223%26epage%3D2230%26doi%3D10.1016%2FS0028-3908%2800%2900079-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Ossowska, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konieczny, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolfarth, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wieronska, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pilc, A.</span><span> </span><span class="NLM_article-title">Blockade of the metabotropic glutamate receptor subtype 5 (mGluR5) produces antiparkinsonian-like effects in rats</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">413</span><span class="NLM_x">–</span> <span class="NLM_lpage">420</span><span class="refDoi"> DOI: 10.1016/S0028-3908(01)00083-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=10.1016%2FS0028-3908%2801%2900083-1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2001&pages=413-420&author=K.+Ossowskaauthor=J.+Koniecznyauthor=S.+Wolfarthauthor=J.+Wieronskaauthor=A.+Pilc&title=Blockade+of+the+metabotropic+glutamate+receptor+subtype+5+%28mGluR5%29+produces+antiparkinsonian-like+effects+in+rats&doi=10.1016%2FS0028-3908%2801%2900083-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2FS0028-3908%2801%2900083-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0028-3908%252801%252900083-1%26sid%3Dliteratum%253Aachs%26aulast%3DOssowska%26aufirst%3DK.%26aulast%3DKonieczny%26aufirst%3DJ.%26aulast%3DWolfarth%26aufirst%3DS.%26aulast%3DWieronska%26aufirst%3DJ.%26aulast%3DPilc%26aufirst%3DA.%26atitle%3DBlockade%2520of%2520the%2520metabotropic%2520glutamate%2520receptor%2520subtype%25205%2520%2528mGluR5%2529%2520produces%2520antiparkinsonian-like%2520effects%2520in%2520rats%26jtitle%3DNeuropharmacology%26date%3D2001%26volume%3D41%26spage%3D413%26epage%3D420%26doi%3D10.1016%2FS0028-3908%2801%2900083-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Chiamulera, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Epping-Jordan, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zocchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcon, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cottiny, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tacconi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corsi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orzi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conquet, F.</span><span> </span><span class="NLM_article-title">Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice</span> <span class="citation_source-journal">Nat. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">873</span><span class="NLM_x">–</span> <span class="NLM_lpage">874</span><span class="refDoi"> DOI: 10.1038/nn0901-873</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=10.1038%2Fnn0901-873" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=11528416" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=1%3ACAS%3A528%3ADC%252BD3MXmtlaqurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2001&pages=873-874&author=C.+Chiamuleraauthor=M.+P.+Epping-Jordanauthor=A.+Zocchiauthor=C.+Marconauthor=C.+Cottinyauthor=S.+Tacconiauthor=M.+Corsiauthor=F.+Orziauthor=F.+Conquet&title=Reinforcing+and+locomotor+stimulant+effects+of+cocaine+are+absent+in+mGluR5+null+mutant+mice&doi=10.1038%2Fnn0901-873"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice</span></div><div class="casAuthors">Chiamulera, Christian; Epping-Jordan, Mark P.; Zocchi, Alessandro; Marcon, Clara; Cottiny, Cecilia; Tacconi, Stefano; Corsi, Mauro; Orzi, Francesco; Conquet, Francois</div><div class="citationInfo"><span class="NLM_cas:title">Nature Neuroscience</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">873-874</span>CODEN:
                <span class="NLM_cas:coden">NANEFN</span>;
        ISSN:<span class="NLM_cas:issn">1097-6256</span>.
    
            (<span class="NLM_cas:orgname">Nature America Inc.</span>)
        </div><div class="casAbstract">The study aims to show that mice lacking the mGluR5 gene do not self-administer (SA) cocaine.  It also aims to show that there was no increased locomotor activity in the mice following cocaine treatment, despite showing cocaine-induced increases in nucleus accumbens (NAcc) dopamine concns. similar to wild-type (WT) mice.  Baseline locomotor activity to cocaine did not differ between mutant and WT mice, which indicates that mGluR5 is essential for cocaine-induced hyperactivity.  When i.v. cocaine was substituted for food, WT mice acquired stable cocaine SA across a typical concn. range.  However, mutant mice did not self-administer cocaine at any concn., suggesting that the reinforcing properties of cocaine are absent in mice lacking mGluR5.  Although the exact mechanism of the mGluR5 contribution to cocaine dependence are not known, these results suggest that mGluR5 is essential in cocaine SA and locomotor effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcydOKjmWE77Vg90H21EOLACvtfcHk0ljPR8F8HxDrIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXmtlaqurc%253D&md5=707263d630dd1c17e6d200f885a48a60</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fnn0901-873&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnn0901-873%26sid%3Dliteratum%253Aachs%26aulast%3DChiamulera%26aufirst%3DC.%26aulast%3DEpping-Jordan%26aufirst%3DM.%2BP.%26aulast%3DZocchi%26aufirst%3DA.%26aulast%3DMarcon%26aufirst%3DC.%26aulast%3DCottiny%26aufirst%3DC.%26aulast%3DTacconi%26aufirst%3DS.%26aulast%3DCorsi%26aufirst%3DM.%26aulast%3DOrzi%26aufirst%3DF.%26aulast%3DConquet%26aufirst%3DF.%26atitle%3DReinforcing%2520and%2520locomotor%2520stimulant%2520effects%2520of%2520cocaine%2520are%2520absent%2520in%2520mGluR5%2520null%2520mutant%2520mice%26jtitle%3DNat.%2520Neurosci.%26date%3D2001%26volume%3D4%26spage%3D873%26epage%3D874%26doi%3D10.1038%2Fnn0901-873" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">O’Neil, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fell, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Svensson, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witkin, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, S. N.</span><span> </span><span class="NLM_article-title">Recent developments in metabotropic glutamate receptors as novel drug targets</span> <span class="citation_source-journal">Drugs Future</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">307</span><span class="NLM_x">–</span> <span class="NLM_lpage">324</span><span class="refDoi"> DOI: 10.1358/dof.2010.035.04.1487693</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=10.1358%2Fdof.2010.035.04.1487693" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2010&pages=307-324&author=M.+J.+O%E2%80%99Neilauthor=M.+J.+Fellauthor=K.+A.+Svenssonauthor=J.+M.+Witkinauthor=S.+N.+Mitchell&title=Recent+developments+in+metabotropic+glutamate+receptors+as+novel+drug+targets&doi=10.1358%2Fdof.2010.035.04.1487693"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1358%2Fdof.2010.035.04.1487693&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdof.2010.035.04.1487693%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Neil%26aufirst%3DM.%2BJ.%26aulast%3DFell%26aufirst%3DM.%2BJ.%26aulast%3DSvensson%26aufirst%3DK.%2BA.%26aulast%3DWitkin%26aufirst%3DJ.%2BM.%26aulast%3DMitchell%26aufirst%3DS.%2BN.%26atitle%3DRecent%2520developments%2520in%2520metabotropic%2520glutamate%2520receptors%2520as%2520novel%2520drug%2520targets%26jtitle%3DDrugs%2520Future%26date%3D2010%26volume%3D35%26spage%3D307%26epage%3D324%26doi%3D10.1358%2Fdof.2010.035.04.1487693" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Nicoletti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bockaert, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collingridge, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conn, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferraguti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoepp, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wroblewski, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pin, J. P.</span><span> </span><span class="NLM_article-title">Metabotropic glutamate receptors: From the workbench to the bedside</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">1017</span><span class="NLM_x">–</span> <span class="NLM_lpage">1041</span><span class="refDoi"> DOI: 10.1016/j.neuropharm.2010.10.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=10.1016%2Fj.neuropharm.2010.10.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=21036182" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkvVKisbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2011&pages=1017-1041&author=F.+Nicolettiauthor=J.+Bockaertauthor=G.+L.+Collingridgeauthor=P.+J.+Connauthor=F.+Ferragutiauthor=D.+D.+Schoeppauthor=J.+T.+Wroblewskiauthor=J.+P.+Pin&title=Metabotropic+glutamate+receptors%3A+From+the+workbench+to+the+bedside&doi=10.1016%2Fj.neuropharm.2010.10.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Metabotropic glutamate receptors: From the workbench to the bedside</span></div><div class="casAuthors">Nicoletti, F.; Bockaert, J.; Collingridge, G. L.; Conn, P. J.; Ferraguti, F.; Schoepp, D. D.; Wroblewski, J. T.; Pin, J. P.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">7-8</span>),
    <span class="NLM_cas:pages">1017-1041</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Metabotropic glutamate (mGlu) receptors were discovered in the mid 1980s and originally described as glutamate receptors coupled to polyphosphoinositide hydrolysis.  Almost 6500 articles have been published since then, and subtype-selective mGlu receptor ligands are now under clin. development for the treatment of a variety of disorders such as Fragile-X syndrome, schizophrenia, Parkinson's disease and L-DOPA-induced dyskinesias, generalized anxiety disorder, chronic pain, and gastroesophageal reflux disorder.  Prof. Erminio Costa was linked to the early times of the mGlu receptor history, when a few research groups challenged the general belief that glutamate could only activate ionotropic receptors and all metabolic responses to glutamate were secondary to calcium entry.  This review moves from those nostalgic times to the most recent advances in the physiol. and pharmacol. of mGlu receptors, and highlights the role of individual mGlu receptor subtypes in the pathophysiol. of human disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYXazI2Fc24bVg90H21EOLACvtfcHk0ljPR8F8HxDrIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkvVKisbo%253D&md5=9262bcfab0471270ff1b39ee022f0a8f</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2010.10.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2010.10.022%26sid%3Dliteratum%253Aachs%26aulast%3DNicoletti%26aufirst%3DF.%26aulast%3DBockaert%26aufirst%3DJ.%26aulast%3DCollingridge%26aufirst%3DG.%2BL.%26aulast%3DConn%26aufirst%3DP.%2BJ.%26aulast%3DFerraguti%26aufirst%3DF.%26aulast%3DSchoepp%26aufirst%3DD.%2BD.%26aulast%3DWroblewski%26aufirst%3DJ.%2BT.%26aulast%3DPin%26aufirst%3DJ.%2BP.%26atitle%3DMetabotropic%2520glutamate%2520receptors%253A%2520From%2520the%2520workbench%2520to%2520the%2520bedside%26jtitle%3DNeuropharmacology%26date%3D2011%26volume%3D60%26spage%3D1017%26epage%3D1041%26doi%3D10.1016%2Fj.neuropharm.2010.10.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Rocher, J.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonnet, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolea, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lutjens, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Poul, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Epping-Jordan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bessis, A.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludwig, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mutel, V.</span><span> </span><span class="NLM_article-title">mGluR5 negative allosteric modulators overview: a medicinal chemistry approach towards a series of novel therapeutic agents</span> <span class="citation_source-journal">Curr. Top. Med. Chem. (Sharjah, United Arab Emirates)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">680</span><span class="NLM_x">–</span> <span class="NLM_lpage">695</span><span class="refDoi"> DOI: 10.2174/1568026611109060680</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=10.2174%2F1568026611109060680" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=21261592" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkslSmsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=680-695&author=J.-P.+Rocherauthor=B.+Bonnetauthor=C.+Boleaauthor=R.+Lutjensauthor=E.+Le+Poulauthor=S.+Poliauthor=M.+Epping-Jordanauthor=A.-S.+Bessisauthor=B.+Ludwigauthor=V.+Mutel&title=mGluR5+negative+allosteric+modulators+overview%3A+a+medicinal+chemistry+approach+towards+a+series+of+novel+therapeutic+agents&doi=10.2174%2F1568026611109060680"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">mGluR5 negative allosteric modulators overview: a medicinal chemistry approach towards a series of novel therapeutic agents</span></div><div class="casAuthors">Rocher, Jean-Philippe; Bonnet, Beatrice; Bolea, Christelle; Lutjens, Robert; Le Poul, Emmanuel; Poli, Sonia; Epping-Jordan, Mark; Bessis, Anne-Sophie; Ludwig, Bernard; Mutel, Vincent</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">680-695</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Allosteric modulators of metabotropic glutamate receptors (mGluRs) subtypes 1-8 have been shown to offer a valid way to develop small mol. non aminoacid-like therapeutics that can be administered orally and that readily cross the blood-brain barrier.  Allosteric modulators of glutamatergic receptors and in particular mGluR5 have emerged as a novel and highly desirable class of compds. for the treatment of central nervous system (CNS) disorders and peripheral disorders.  This article provides medicinal chem. highlights around the chem. classes of potent and highly selective mGluR5 neg. allosteric modulators (NAMs) and their therapeutic potential.  In addn., it describes the medicinal chem. approach from the discovery to the clin. candidate selection of a new series of heteroaryl-butynylpyridines targeting mGluR5.  The multiparametric optimization of the initial starting point which ended in the selection of potential clin. candidates combining the best pharmacophoric features is presented.  The pharmacol. properties are reported and support the interest of these agents for new therapeutic approaches.  Furthermore, a summary of the diverse mGluR5 Positron Emission Tomog. (PET) radioligands is reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeXrv5HnHG77Vg90H21EOLACvtfcHk0lgFLQoP626Qag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkslSmsrw%253D&md5=aab29725fa93c1895f32f7dbe93a16f1</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.2174%2F1568026611109060680&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026611109060680%26sid%3Dliteratum%253Aachs%26aulast%3DRocher%26aufirst%3DJ.-P.%26aulast%3DBonnet%26aufirst%3DB.%26aulast%3DBolea%26aufirst%3DC.%26aulast%3DLutjens%26aufirst%3DR.%26aulast%3DLe%2BPoul%26aufirst%3DE.%26aulast%3DPoli%26aufirst%3DS.%26aulast%3DEpping-Jordan%26aufirst%3DM.%26aulast%3DBessis%26aufirst%3DA.-S.%26aulast%3DLudwig%26aufirst%3DB.%26aulast%3DMutel%26aufirst%3DV.%26atitle%3DmGluR5%2520negative%2520allosteric%2520modulators%2520overview%253A%2520a%2520medicinal%2520chemistry%2520approach%2520towards%2520a%2520series%2520of%2520novel%2520therapeutic%2520agents%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%2520%2528Sharjah%252C%2520United%2520Arab%2520Emirates%2529%26date%3D2011%26volume%3D11%26spage%3D680%26epage%3D695%26doi%3D10.2174%2F1568026611109060680" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Fuxe, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borroto-Escuela, D. O.</span><span> </span><span class="NLM_article-title">Basimglurant for treatment of major depressive disorder: a novel negative allosteric modulator of metabotropic glutamate receptor 5</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">1247</span><span class="NLM_x">–</span> <span class="NLM_lpage">1260</span><span class="refDoi"> DOI: 10.1517/13543784.2015.1074175</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=10.1517%2F13543784.2015.1074175" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2015&pages=1247-1260&author=K.+Fuxeauthor=D.+O.+Borroto-Escuela&title=Basimglurant+for+treatment+of+major+depressive+disorder%3A+a+novel+negative+allosteric+modulator+of+metabotropic+glutamate+receptor+5&doi=10.1517%2F13543784.2015.1074175"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1517%2F13543784.2015.1074175&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2015.1074175%26sid%3Dliteratum%253Aachs%26aulast%3DFuxe%26aufirst%3DK.%26aulast%3DBorroto-Escuela%26aufirst%3DD.%2BO.%26atitle%3DBasimglurant%2520for%2520treatment%2520of%2520major%2520depressive%2520disorder%253A%2520a%2520novel%2520negative%2520allosteric%2520modulator%2520of%2520metabotropic%2520glutamate%2520receptor%25205%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2015%26volume%3D24%26spage%3D1247%26epage%3D1260%26doi%3D10.1517%2F13543784.2015.1074175" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Quiroz, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamburri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deptula, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banken, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beyer, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabbia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parkar, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fontoura, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santarelli, L.</span><span> </span><span class="NLM_article-title">Efficacy and Safety of Basimglurant as Adjunctive Therapy for Major Depression: A Randomized Clinical Trial</span> <span class="citation_source-journal">JAMA Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">675</span><span class="NLM_x">–</span> <span class="NLM_lpage">684</span><span class="refDoi"> DOI: 10.1001/jamapsychiatry.2016.0838</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=10.1001%2Fjamapsychiatry.2016.0838" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2016&pages=675-684&author=J.+A.+Quirozauthor=P.+Tamburriauthor=D.+Deptulaauthor=L.+Bankenauthor=U.+Beyerauthor=M.+Rabbiaauthor=N.+Parkarauthor=P.+Fontouraauthor=L.+Santarelli&title=Efficacy+and+Safety+of+Basimglurant+as+Adjunctive+Therapy+for+Major+Depression%3A+A+Randomized+Clinical+Trial&doi=10.1001%2Fjamapsychiatry.2016.0838"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1001%2Fjamapsychiatry.2016.0838&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjamapsychiatry.2016.0838%26sid%3Dliteratum%253Aachs%26aulast%3DQuiroz%26aufirst%3DJ.%2BA.%26aulast%3DTamburri%26aufirst%3DP.%26aulast%3DDeptula%26aufirst%3DD.%26aulast%3DBanken%26aufirst%3DL.%26aulast%3DBeyer%26aufirst%3DU.%26aulast%3DRabbia%26aufirst%3DM.%26aulast%3DParkar%26aufirst%3DN.%26aulast%3DFontoura%26aufirst%3DP.%26aulast%3DSantarelli%26aufirst%3DL.%26atitle%3DEfficacy%2520and%2520Safety%2520of%2520Basimglurant%2520as%2520Adjunctive%2520Therapy%2520for%2520Major%2520Depression%253A%2520A%2520Randomized%2520Clinical%2520Trial%26jtitle%3DJAMA%2520Psychiatry%26date%3D2016%26volume%3D73%26spage%3D675%26epage%3D684%26doi%3D10.1001%2Fjamapsychiatry.2016.0838" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Micheli, F.</span><span> </span><span class="NLM_article-title">Methylphenyl ethynyl pyridine (MPEP)(Novartis)</span> <span class="citation_source-journal">Curr. Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">355</span><span class="NLM_x">–</span> <span class="NLM_lpage">359</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2000&pages=355-359&author=F.+Micheli&title=Methylphenyl+ethynyl+pyridine+%28MPEP%29%28Novartis%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMicheli%26aufirst%3DF.%26atitle%3DMethylphenyl%2520ethynyl%2520pyridine%2520%2528MPEP%2529%2528Novartis%2529%26jtitle%3DCurr.%2520Opin.%2520Invest.%2520Drugs%26date%3D2000%26volume%3D1%26spage%3D355%26epage%3D359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Kalgutkar, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardner, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obach, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaffer, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Callegari, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henne, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mutlib, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalvie, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Donnell, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harriman, S. P.</span><span> </span><span class="NLM_article-title">A comprehensive listing of bioactivation pathways of organic functional groups</span> <span class="citation_source-journal">Curr. Drug Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">161</span><span class="NLM_x">–</span> <span class="NLM_lpage">225</span><span class="refDoi"> DOI: 10.2174/1389200054021799</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=10.2174%2F1389200054021799" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=15975040" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=1%3ACAS%3A528%3ADC%252BD2MXkvF2is7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2005&pages=161-225&author=A.+S.+Kalgutkarauthor=I.+Gardnerauthor=R.+S.+Obachauthor=C.+L.+Shafferauthor=E.+Callegariauthor=K.+R.+Henneauthor=A.+E.+Mutlibauthor=D.+K.+Dalvieauthor=J.+S.+Leeauthor=Y.+Nakaiauthor=J.+P.+O%E2%80%99Donnellauthor=J.+Boerauthor=S.+P.+Harriman&title=A+comprehensive+listing+of+bioactivation+pathways+of+organic+functional+groups&doi=10.2174%2F1389200054021799"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">A comprehensive listing of bioactivation pathways of organic functional groups</span></div><div class="casAuthors">Kalgutkar, Amit S.; Gardner, Iain; Obach, R. Scott; Shaffer, Christopher L.; Callegari, Ernesto; Henne, Kirk R.; Mutlib, Abdul E.; Dalvie, Deepak K.; Lee, Jae S.; Nakai, Yasuhiro; O'Donnell, John P.; Boer, Jason; Harriman, Shawn P.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">161-225</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The occurrence of idiosyncratic adverse drug reactions during late clin. trials or after a drug has been released can lead to a severe restriction in its use and even in its withdrawal.  Metabolic activation of relatively inert functional groups to reactive electrophilic intermediates is considered to be an obligatory event in the etiol. of many drug-induced adverse reactions.  Therefore, a thorough examn. of the biochem. reactivity of functional groups/structural motifs in all new drug candidates is essential from a safety standpoint.  A major theme attempted in this review is the comprehensive cataloging of all of the known bioactivation pathways of functional groups or structural motifs commonly utilized in drug design efforts.  Potential strategies in the detection of reactive intermediates in biochem. systems are also discussed.  The intention of this review is not to "black list" functional groups or to immediately discard compds. based on their potential to form reactive metabolites, but rather to serve as a resource describing the structural diversity of these functionalities as well as exptl. approaches that could be taken to evaluate whether a "structural alert" in a new drug candidate undergoes bioactivation to reactive metabolites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOVj7cmxfwXrVg90H21EOLACvtfcHk0lgFLQoP626Qag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXkvF2is7k%253D&md5=b16dfc2de97c40a11218ecc3043bed66</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.2174%2F1389200054021799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389200054021799%26sid%3Dliteratum%253Aachs%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DGardner%26aufirst%3DI.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DShaffer%26aufirst%3DC.%2BL.%26aulast%3DCallegari%26aufirst%3DE.%26aulast%3DHenne%26aufirst%3DK.%2BR.%26aulast%3DMutlib%26aufirst%3DA.%2BE.%26aulast%3DDalvie%26aufirst%3DD.%2BK.%26aulast%3DLee%26aufirst%3DJ.%2BS.%26aulast%3DNakai%26aufirst%3DY.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DJ.%2BP.%26aulast%3DBoer%26aufirst%3DJ.%26aulast%3DHarriman%26aufirst%3DS.%2BP.%26atitle%3DA%2520comprehensive%2520listing%2520of%2520bioactivation%2520pathways%2520of%2520organic%2520functional%2520groups%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2005%26volume%3D6%26spage%3D161%26epage%3D225%26doi%3D10.2174%2F1389200054021799" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Stepan, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baillie, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalgutkar, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aleo, M. D.</span><span> </span><span class="NLM_article-title">Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: A perspective based on the critical examination of trends in the top 200 drugs marketed in the United States</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">1345</span><span class="NLM_x">–</span> <span class="NLM_lpage">1410</span><span class="refDoi"> DOI: 10.1021/tx200168d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx200168d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=1%3ACAS%3A528%3ADC%252BC3MXos1Whtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2011&pages=1345-1410&author=A.+F.+Stepanauthor=D.+P.+Walkerauthor=J.+Baumanauthor=D.+A.+Priceauthor=T.+A.+Baillieauthor=A.+S.+Kalgutkarauthor=M.+D.+Aleo&title=Structural+alert%2Freactive+metabolite+concept+as+applied+in+medicinal+chemistry+to+mitigate+the+risk+of+idiosyncratic+drug+toxicity%3A+A+perspective+based+on+the+critical+examination+of+trends+in+the+top+200+drugs+marketed+in+the+United+States&doi=10.1021%2Ftx200168d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Alert/Reactive Metabolite Concept as Applied in Medicinal Chemistry to Mitigate the Risk of Idiosyncratic Drug Toxicity: A Perspective Based on the Critical Examination of Trends in the Top 200 Drugs Marketed in the United States</span></div><div class="casAuthors">Stepan, Antonia F.; Walker, Daniel P.; Bauman, Jonathan; Price, David A.; Baillie, Thomas A.; Kalgutkar, Amit S.; Aleo, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1345-1410</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Because of a preconceived notion that eliminating reactive metabolite (RM) formation with new drug candidates could mitigate the risk of idiosyncratic drug toxicity, the potential for RM formation is routinely examd. as part of lead optimization efforts in drug discovery.  Likewise, avoidance of "structural alerts" is almost a norm in drug design.  However, there is a growing concern that the perceived safety hazards assocd. with structural alerts and/or RM screening tools as standalone predictors of toxicity risks may be over exaggerated.  In addn., the multifactorial nature of idiosyncratic toxicity is now well recognized based upon observations that mechanisms other than RM formation (e.g., mitochondrial toxicity and inhibition of bile salt export pump (BSEP)) also can account for certain target organ toxicities.  Hence, fundamental questions arise such as: When is a mol. that contains a structural alert (RM pos. or neg.) a cause for concern.  Could the mol. in its parent form exert toxicity.  Can a low dose drug candidate truly mitigate metab.-dependent and -independent idiosyncratic toxicity risks.  In an effort to address these questions, we have retrospectively examd. 68 drugs (recalled or assocd. with a black box warning due to idiosyncratic toxicity) and the top 200 drugs (prescription and sales) in the United States in 2009 for trends in physiochem. characteristics, daily doses, presence of structural alerts, evidence for RM formation as well as toxicity mechanism(s) potentially mediated by parent drugs.  Collectively, our anal. revealed that a significant proportion (∼78-86%) of drugs assocd. with toxicity contained structural alerts and evidence indicating that RM formation as a causative factor for toxicity has been presented in 62-69% of these mols.  In several cases, mitochondrial toxicity and BSEP inhibition mediated by parent drugs were also noted as potential causative factors.  Most drugs were administered at daily doses exceeding several hundred milligrams.  There was no obvious link between idiosyncratic toxicity and physicochem. properties such as mol. wt., lipophilicity, etc.  Approx. half of the top 200 drugs for 2009 (prescription and sales) also contained one or more alerts in their chem. architecture, and many were found to be RM-pos.  Several instances of BSEP and mitochondrial liabilities were also noted with agents in the top 200 category.  However, with relatively few exceptions, the vast majority of these drugs are rarely assocd. with idiosyncratic toxicity, despite years of patient use.  The major differentiating factor appeared to be the daily dose; most of the drugs in the top 200 list are administered at low daily doses.  In addn., competing detoxication pathways and/or alternate nonmetabolic clearance routes provided suitable justifications for the safety records of RM-pos. drugs in the top 200 category.  Thus, while RM elimination may be a useful and pragmatic starting point in mitigating idiosyncratic toxicity risks, our anal. suggests a need for a more integrated screening paradigm for chem. hazard identification in drug discovery.  Thus, in addn. to a detailed assessment of RM formation potential (in relationship to the overall elimination mechanisms of the compd.(s)) for lead compds., effects on cellular health (e.g., cytotoxicity assays), BSEP inhibition, and mitochondrial toxicity are the recommended suite of assays to characterize compd. liabilities.  However, the prospective use of such data in compd. selection will require further validation of the cellular assays using marketed agents.  Until we gain a better understanding of the pathophysiol. mechanisms assocd. with idiosyncratic toxicities, improving pharmacokinetics and intrinsic potency as means of decreasing the dose size and the assocd. "body burden" of the parent drug and its metabolites will remain an overarching goal in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3IhczIcvVDLVg90H21EOLACvtfcHk0lgq4e54HTUFkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXos1Whtbo%253D&md5=632b73f755738e49eb233bc8dca1fbcc</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Ftx200168d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx200168d%26sid%3Dliteratum%253Aachs%26aulast%3DStepan%26aufirst%3DA.%2BF.%26aulast%3DWalker%26aufirst%3DD.%2BP.%26aulast%3DBauman%26aufirst%3DJ.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DAleo%26aufirst%3DM.%2BD.%26atitle%3DStructural%2520alert%252Freactive%2520metabolite%2520concept%2520as%2520applied%2520in%2520medicinal%2520chemistry%2520to%2520mitigate%2520the%2520risk%2520of%2520idiosyncratic%2520drug%2520toxicity%253A%2520A%2520perspective%2520based%2520on%2520the%2520critical%2520examination%2520of%2520trends%2520in%2520the%2520top%2520200%2520drugs%2520marketed%2520in%2520the%2520United%2520States%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2011%26volume%3D24%26spage%3D1345%26epage%3D1410%26doi%3D10.1021%2Ftx200168d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Emmitte, K. A.</span><span> </span><span class="NLM_article-title">mGlu5 negative allosteric modulators: a patent review (2013 - 2016)</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">691</span><span class="NLM_x">–</span> <span class="NLM_lpage">706</span><span class="refDoi"> DOI: 10.1080/13543776.2017.1280466</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=10.1080%2F13543776.2017.1280466" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=28067079" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlemsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=691-706&author=K.+A.+Emmitte&title=mGlu5+negative+allosteric+modulators%3A+a+patent+review+%282013+-+2016%29&doi=10.1080%2F13543776.2017.1280466"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">mGlu5 negative allosteric modulators: a patent review (2013 - 2016)</span></div><div class="casAuthors">Emmitte, Kyle A.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">691-706</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Introduction: The pursuit of small mol. mGlu5 NAMs as treatments for a variety of psychiatric and neurodegenerative disorders has developed into a mature field.  In addn. to extensive preclin. studies, multiple compds. have advanced into clin. trials with the most advanced studies occurring in patients with FXS, PD-LID, and MDD.  Areas Covered: This review begins with an update of the clin. activity with mGlu5 NAMs, and then moves into a summary of patent applications filed since 2013.  The summaries are organized into three sep. sections: (1) inventions centered on improvements to existing clin. compds.; (2) new small mols. that maintain the prototypical disubstituted alkyne chemotype found in many mGlu5 NAM compds.; and (3) new small mols. that are not from a disubstituted alkyne chemotype.  Expert Opinion: It is a crit. moment for mGlu5 NAM research as recent reports from clin. trials have included some significant disappointments that have blunted prior optimism.  Still, research in this area remains active, and recent years have added several more attractive small mols. to this field.  There is now an arsenal of diverse chemotypes available to continue to probe this target in the hopes that a drug may yet emerge.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWQ94UvPC2ALVg90H21EOLACvtfcHk0lgq4e54HTUFkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlemsb0%253D&md5=f2c86384dc509c8677e4c94ec2bfabb9</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1080%2F13543776.2017.1280466&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2017.1280466%26sid%3Dliteratum%253Aachs%26aulast%3DEmmitte%26aufirst%3DK.%2BA.%26atitle%3DmGlu5%2520negative%2520allosteric%2520modulators%253A%2520a%2520patent%2520review%2520%25282013%2520-%25202016%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2017%26volume%3D27%26spage%3D691%26epage%3D706%26doi%3D10.1080%2F13543776.2017.1280466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Raboisson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breitholtz-Emanuelsson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahlloef, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heaton, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isaac, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jarvie, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kers, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minidis, A. B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nordmark, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheehan, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slassi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stroem, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terelius, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wensbo, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLeod, D. A.</span><span> </span><span class="NLM_article-title">Discovery and characterization of AZD9272 and AZD6538-Two novel mGluR5 negative allosteric modulators selected for clinical development</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">6974</span><span class="NLM_x">–</span> <span class="NLM_lpage">6979</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2012.08.100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=10.1016%2Fj.bmcl.2012.08.100" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=6974-6979&author=P.+Raboissonauthor=A.+Breitholtz-Emanuelssonauthor=H.+Dahlloefauthor=L.+Edwardsauthor=W.+L.+Heatonauthor=M.+Isaacauthor=K.+Jarvieauthor=A.+Kersauthor=A.+B.+E.+Minidisauthor=A.+Nordmarkauthor=S.+M.+Sheehanauthor=A.+Slassiauthor=P.+Stroemauthor=Y.+Tereliusauthor=D.+Wensboauthor=J.+M.+Wilsonauthor=T.+Xinauthor=D.+A.+McLeod&title=Discovery+and+characterization+of+AZD9272+and+AZD6538-Two+novel+mGluR5+negative+allosteric+modulators+selected+for+clinical+development&doi=10.1016%2Fj.bmcl.2012.08.100"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.08.100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.08.100%26sid%3Dliteratum%253Aachs%26aulast%3DRaboisson%26aufirst%3DP.%26aulast%3DBreitholtz-Emanuelsson%26aufirst%3DA.%26aulast%3DDahlloef%26aufirst%3DH.%26aulast%3DEdwards%26aufirst%3DL.%26aulast%3DHeaton%26aufirst%3DW.%2BL.%26aulast%3DIsaac%26aufirst%3DM.%26aulast%3DJarvie%26aufirst%3DK.%26aulast%3DKers%26aufirst%3DA.%26aulast%3DMinidis%26aufirst%3DA.%2BB.%2BE.%26aulast%3DNordmark%26aufirst%3DA.%26aulast%3DSheehan%26aufirst%3DS.%2BM.%26aulast%3DSlassi%26aufirst%3DA.%26aulast%3DStroem%26aufirst%3DP.%26aulast%3DTerelius%26aufirst%3DY.%26aulast%3DWensbo%26aufirst%3DD.%26aulast%3DWilson%26aufirst%3DJ.%2BM.%26aulast%3DXin%26aufirst%3DT.%26aulast%3DMcLeod%26aufirst%3DD.%2BA.%26atitle%3DDiscovery%2520and%2520characterization%2520of%2520AZD9272%2520and%2520AZD6538-Two%2520novel%2520mGluR5%2520negative%2520allosteric%2520modulators%2520selected%2520for%2520clinical%2520development%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D6974%26epage%3D6979%26doi%3D10.1016%2Fj.bmcl.2012.08.100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Mueller, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dawson, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meiler, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chauder, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bates, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felts, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamb, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menon, U. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jadhav, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kane, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gregory, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niswender, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conn, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsen, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winder, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emmitte, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindsley, C. W.</span><span> </span><span class="NLM_article-title">Discovery of 2-(2-benzoxazoyl amino)-4-aryl-5-cyanopyrimidine as negative allosteric modulators (NAMs) of metabotropic glutamate receptor 5 (mGlu5): From an artificial neural network virtual screen to an in vivo tool compound</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">406</span><span class="NLM_x">–</span> <span class="NLM_lpage">414</span><span class="refDoi"> DOI: 10.1002/cmdc.201100510</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=10.1002%2Fcmdc.201100510" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=406-414&author=R.+Muellerauthor=E.+S.+Dawsonauthor=J.+Meilerauthor=A.+L.+Rodriguezauthor=B.+A.+Chauderauthor=B.+S.+Batesauthor=A.+S.+Feltsauthor=J.+P.+Lambauthor=U.+N.+Menonauthor=S.+B.+Jadhavauthor=A.+S.+Kaneauthor=C.+K.+Jonesauthor=K.+J.+Gregoryauthor=C.+M.+Niswenderauthor=P.+J.+Connauthor=C.+M.+Olsenauthor=D.+G.+Winderauthor=K.+A.+Emmitteauthor=C.+W.+Lindsley&title=Discovery+of+2-%282-benzoxazoyl+amino%29-4-aryl-5-cyanopyrimidine+as+negative+allosteric+modulators+%28NAMs%29+of+metabotropic+glutamate+receptor+5+%28mGlu5%29%3A+From+an+artificial+neural+network+virtual+screen+to+an+in+vivo+tool+compound&doi=10.1002%2Fcmdc.201100510"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201100510&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201100510%26sid%3Dliteratum%253Aachs%26aulast%3DMueller%26aufirst%3DR.%26aulast%3DDawson%26aufirst%3DE.%2BS.%26aulast%3DMeiler%26aufirst%3DJ.%26aulast%3DRodriguez%26aufirst%3DA.%2BL.%26aulast%3DChauder%26aufirst%3DB.%2BA.%26aulast%3DBates%26aufirst%3DB.%2BS.%26aulast%3DFelts%26aufirst%3DA.%2BS.%26aulast%3DLamb%26aufirst%3DJ.%2BP.%26aulast%3DMenon%26aufirst%3DU.%2BN.%26aulast%3DJadhav%26aufirst%3DS.%2BB.%26aulast%3DKane%26aufirst%3DA.%2BS.%26aulast%3DJones%26aufirst%3DC.%2BK.%26aulast%3DGregory%26aufirst%3DK.%2BJ.%26aulast%3DNiswender%26aufirst%3DC.%2BM.%26aulast%3DConn%26aufirst%3DP.%2BJ.%26aulast%3DOlsen%26aufirst%3DC.%2BM.%26aulast%3DWinder%26aufirst%3DD.%2BG.%26aulast%3DEmmitte%26aufirst%3DK.%2BA.%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26atitle%3DDiscovery%2520of%25202-%25282-benzoxazoyl%2520amino%2529-4-aryl-5-cyanopyrimidine%2520as%2520negative%2520allosteric%2520modulators%2520%2528NAMs%2529%2520of%2520metabotropic%2520glutamate%2520receptor%25205%2520%2528mGlu5%2529%253A%2520From%2520an%2520artificial%2520neural%2520network%2520virtual%2520screen%2520to%2520an%2520in%2520vivo%2520tool%2520compound%26jtitle%3DChemMedChem%26date%3D2012%26volume%3D7%26spage%3D406%26epage%3D414%26doi%3D10.1002%2Fcmdc.201100510" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><div class="note"><p class="first last">The full PF number of PF470 is PF-06297470.</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=The+full+PF+number+of+PF470+is+PF-06297470."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balan, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barreiro, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boscoe, B. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chenard, L. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cianfrogna, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Claffey, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coffman, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drozda, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunetz, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fonseca, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galatsis, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grimwood, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lazzaro, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mancuso, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reese, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogers, B. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakurada, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skaddan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stepan, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trapa, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuttle, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verhoest, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaleska, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zasadny, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaffer, C. L.</span><span> </span><span class="NLM_article-title">Discovery and preclinical characterization of 1-methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-ylmethoxy)-1H-pyrazolo-[3,4-b]-pyrazine (PF470): A highly potent, selective, and efficacious metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">861</span><span class="NLM_x">–</span> <span class="NLM_lpage">877</span><span class="refDoi"> DOI: 10.1021/jm401622k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401622k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=861-877&author=L.+Zhangauthor=G.+Balanauthor=G.+Barreiroauthor=B.+P.+Boscoeauthor=L.+K.+Chenardauthor=J.+Cianfrognaauthor=M.+M.+Claffeyauthor=L.+Chenauthor=K.+J.+Coffmanauthor=S.+E.+Drozdaauthor=J.+R.+Dunetzauthor=K.+R.+Fonsecaauthor=P.+Galatsisauthor=S.+Grimwoodauthor=J.+T.+Lazzaroauthor=J.+Y.+Mancusoauthor=E.+L.+Millerauthor=M.+R.+Reeseauthor=B.+N.+Rogersauthor=I.+Sakuradaauthor=M.+Skaddanauthor=D.+L.+Smithauthor=A.+F.+Stepanauthor=P.+Trapaauthor=J.+B.+Tuttleauthor=P.+R.+Verhoestauthor=D.+P.+Walkerauthor=A.+S.+Wrightauthor=M.+M.+Zaleskaauthor=K.+Zasadnyauthor=C.+L.+Shaffer&title=Discovery+and+preclinical+characterization+of+1-methyl-3-%284-methylpyridin-3-yl%29-6-%28pyridin-2-ylmethoxy%29-1H-pyrazolo-%5B3%2C4-b%5D-pyrazine+%28PF470%29%3A+A+highly+potent%2C+selective%2C+and+efficacious+metabotropic+glutamate+receptor+5+%28mGluR5%29+negative+allosteric+modulator&doi=10.1021%2Fjm401622k"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm401622k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401622k%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DBalan%26aufirst%3DG.%26aulast%3DBarreiro%26aufirst%3DG.%26aulast%3DBoscoe%26aufirst%3DB.%2BP.%26aulast%3DChenard%26aufirst%3DL.%2BK.%26aulast%3DCianfrogna%26aufirst%3DJ.%26aulast%3DClaffey%26aufirst%3DM.%2BM.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DCoffman%26aufirst%3DK.%2BJ.%26aulast%3DDrozda%26aufirst%3DS.%2BE.%26aulast%3DDunetz%26aufirst%3DJ.%2BR.%26aulast%3DFonseca%26aufirst%3DK.%2BR.%26aulast%3DGalatsis%26aufirst%3DP.%26aulast%3DGrimwood%26aufirst%3DS.%26aulast%3DLazzaro%26aufirst%3DJ.%2BT.%26aulast%3DMancuso%26aufirst%3DJ.%2BY.%26aulast%3DMiller%26aufirst%3DE.%2BL.%26aulast%3DReese%26aufirst%3DM.%2BR.%26aulast%3DRogers%26aufirst%3DB.%2BN.%26aulast%3DSakurada%26aufirst%3DI.%26aulast%3DSkaddan%26aufirst%3DM.%26aulast%3DSmith%26aufirst%3DD.%2BL.%26aulast%3DStepan%26aufirst%3DA.%2BF.%26aulast%3DTrapa%26aufirst%3DP.%26aulast%3DTuttle%26aufirst%3DJ.%2BB.%26aulast%3DVerhoest%26aufirst%3DP.%2BR.%26aulast%3DWalker%26aufirst%3DD.%2BP.%26aulast%3DWright%26aufirst%3DA.%2BS.%26aulast%3DZaleska%26aufirst%3DM.%2BM.%26aulast%3DZasadny%26aufirst%3DK.%26aulast%3DShaffer%26aufirst%3DC.%2BL.%26atitle%3DDiscovery%2520and%2520preclinical%2520characterization%2520of%25201-methyl-3-%25284-methylpyridin-3-yl%2529-6-%2528pyridin-2-ylmethoxy%2529-1H-pyrazolo-%255B3%252C4-b%255D-pyrazine%2520%2528PF470%2529%253A%2520A%2520highly%2520potent%252C%2520selective%252C%2520and%2520efficacious%2520metabotropic%2520glutamate%2520receptor%25205%2520%2528mGluR5%2529%2520negative%2520allosteric%2520modulator%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D861%26epage%3D877%26doi%3D10.1021%2Fjm401622k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Palanisamy, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcek, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cappon, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whritenour, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaffer, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brady, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houle, C.</span><span> </span><span class="NLM_article-title">Drug-induced skin lesions in cynomolgus macaques treated with metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulators</span> <span class="citation_source-journal">Toxicol. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">995</span><span class="NLM_x">–</span> <span class="NLM_lpage">1003</span><span class="refDoi"> DOI: 10.1177/0192623315588114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=10.1177%2F0192623315588114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=26059827" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=1%3ACAS%3A528%3ADC%252BC28Xlt1Wqsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2015&pages=995-1003&author=G.+S.+Palanisamyauthor=J.+M.+Marcekauthor=G.+D.+Capponauthor=J.+Whritenourauthor=C.+L.+Shafferauthor=J.+T.+Bradyauthor=C.+Houle&title=Drug-induced+skin+lesions+in+cynomolgus+macaques+treated+with+metabotropic+glutamate+receptor+5+%28mGluR5%29+negative+allosteric+modulators&doi=10.1177%2F0192623315588114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-induced skin lesions in cynomolgus macaques treated with metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulators</span></div><div class="casAuthors">Palanisamy, Gopinath S.; Marcek, John M.; Cappon, Gregg D.; Whritenour, Jessica; Shaffer, Christopher L.; Brady, Joseph T.; Houle, Christopher</div><div class="citationInfo"><span class="NLM_cas:title">Toxicologic Pathology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">995-1003</span>CODEN:
                <span class="NLM_cas:coden">TOPADD</span>;
        ISSN:<span class="NLM_cas:issn">0192-6233</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Three orally administered metabotropic glutamate receptor 5 (mGluR5) neg. allosteric modulators caused skin lesions consistent with delayed type-IV hypersensitivity in cynomolgus macaques in 2- and 12-wk toxicity studies.  Several monkeys developed macroscopic skin lesions in multiple locations after 8 to 9 days of dosing; the most prominent effects involved the genital region of males and generalized erythema occurred in both sexes.  Microscopic lesions occurred in both clin. affected and unaffected areas and were characterized by lymphocytic interface inflammation, subepidermal bullae, and individual keratinocyte vacuolation/necrosis.  In the 12-wk study, clin. effects in 2 animals resolved with continued dosing, whereas in others the inflammatory process progressed with 1 female exhibiting systemic lymphocytic inflammation in multiple tissues.  The inflammatory infiltrate consisted of CD3 and CD4 pos. T lymphocytes with minimal CD68 pos. macrophages and only rare CD8 pos. T lymphocytes.  A subset of animals given a dosing holiday was subsequently rechallenged with similar lesions developing but with a more rapid clin. onset.  These skin lesions were consistent with type-IV delayed hypersensitivity with some features comparable to bullous drug eruptions in humans.  A relationship between these findings and the intended mode of action for these compds. could not be ruled out, given the occurrence across different chemotypes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpS0b8GvuCkpLVg90H21EOLACvtfcHk0lh8ItBNYx8Spg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xlt1Wqsbo%253D&md5=99ad96bc755c182aca73a1d14dc1d614</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1177%2F0192623315588114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0192623315588114%26sid%3Dliteratum%253Aachs%26aulast%3DPalanisamy%26aufirst%3DG.%2BS.%26aulast%3DMarcek%26aufirst%3DJ.%2BM.%26aulast%3DCappon%26aufirst%3DG.%2BD.%26aulast%3DWhritenour%26aufirst%3DJ.%26aulast%3DShaffer%26aufirst%3DC.%2BL.%26aulast%3DBrady%26aufirst%3DJ.%2BT.%26aulast%3DHoule%26aufirst%3DC.%26atitle%3DDrug-induced%2520skin%2520lesions%2520in%2520cynomolgus%2520macaques%2520treated%2520with%2520metabotropic%2520glutamate%2520receptor%25205%2520%2528mGluR5%2529%2520negative%2520allosteric%2520modulators%26jtitle%3DToxicol.%2520Pathol.%26date%3D2015%26volume%3D43%26spage%3D995%26epage%3D1003%26doi%3D10.1177%2F0192623315588114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Kremer, K. A. M.; Krishnan, L.; Venkatesan, A. M.; Jennings, M.; Zeldis, J.; Abe, T.; Mansour, T.; Strong, H.</span>Processes for Preparing Bicyclic Oxazine Carboxaldehyde and β-Lactamase Inhibitors. WO2009/006243A2, Jan 8,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=K.+A.+M.+Kremer&author=L.+Krishnan&author=A.+M.+Venkatesan&author=M.+Jennings&author=J.+Zeldis&author=T.+Abe&author=T.+Mansour&author=H.+Strong&title=Processes+for+Preparing+Bicyclic+Oxazine+Carboxaldehyde+and+%CE%B2-Lactamase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKremer%26aufirst%3DK.%2BA.%2BM.%26jtitle%3DProcesses%2520for%2520Preparing%2520Bicyclic%2520Oxazine%2520Carboxaldehyde%2520and%2520%25CE%25B2-Lactamase%2520Inhibitors%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Abass, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayas, A. S.</span><span> </span><span class="NLM_article-title">Substituted pyridopyrimidinones, 1: Convenient PTC alkylation and halogenation of 2-hydroxy-4H-pyrido[1,2-a]pyrimidin-4-one</span> <span class="citation_source-journal">Heteroat. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">19</span><span class="NLM_x">–</span> <span class="NLM_lpage">27</span><span class="refDoi"> DOI: 10.1002/hc.20245</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=10.1002%2Fhc.20245" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpsVyntw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2007&pages=19-27&author=M.+Abassauthor=A.+S.+Mayas&title=Substituted+pyridopyrimidinones%2C+1%3A+Convenient+PTC+alkylation+and+halogenation+of+2-hydroxy-4H-pyrido%5B1%2C2-a%5Dpyrimidin-4-one&doi=10.1002%2Fhc.20245"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Substituted pyridopyrimidinones, 1: Convenient PTC alkylation and halogenation of 2-hydroxy-4H-pyrido[1,2-a]pyrimidin-4-one</span></div><div class="casAuthors">Abass, Mohamed; Mayas, Aisha S.</div><div class="citationInfo"><span class="NLM_cas:title">Heteroatom Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">19-27</span>CODEN:
                <span class="NLM_cas:coden">HETCE8</span>;
        ISSN:<span class="NLM_cas:issn">1042-7163</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Alkylation of 2-hydroxy-4H-pyrido[1,2-a]pyrimidin-4-one (I) was investigated under solid-liq. phase transfer catalysis conditions (PTC) using tetrabutylammonium bromide and potassium carbonate.  The reaction with alkyl halides gave various 2-alkoxy products in fair yields.  Reaction of I with epichlorohydrin and chloroacetonitrile, under the same PTC conditions, afforded novel 1,3-disubstituted glycerol and oxazolopyridopyrimidone betaine derivs., resp.  Some 3-halo-, 3,3-dihalo, and 2,3-dihalopyrido[1,2-a]pyrimidines were also prepd. using different halogenating agents at different reaction conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBh9_2obzgT7Vg90H21EOLACvtfcHk0liJQq7J_xFLDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpsVyntw%253D%253D&md5=a7c7b0c7b8f6f04ed41fcb35cb94a3f0</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1002%2Fhc.20245&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhc.20245%26sid%3Dliteratum%253Aachs%26aulast%3DAbass%26aufirst%3DM.%26aulast%3DMayas%26aufirst%3DA.%2BS.%26atitle%3DSubstituted%2520pyridopyrimidinones%252C%25201%253A%2520Convenient%2520PTC%2520alkylation%2520and%2520halogenation%2520of%25202-hydroxy-4H-pyrido%255B1%252C2-a%255Dpyrimidin-4-one%26jtitle%3DHeteroat.%2520Chem.%26date%3D2007%26volume%3D18%26spage%3D19%26epage%3D27%26doi%3D10.1002%2Fhc.20245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Callegari, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malhotra, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bungay, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webster, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fenner, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kempshall, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaPerle, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michel, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kay, G. G.</span><span> </span><span class="NLM_article-title">A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder</span> <span class="citation_source-journal">br J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">235</span><span class="NLM_x">–</span> <span class="NLM_lpage">246</span><span class="refDoi"> DOI: 10.1111/j.1365-2125.2011.03961.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=10.1111%2Fj.1365-2125.2011.03961.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=21392072" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtV2qtrrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2011&pages=235-246&author=E.+Callegariauthor=B.+Malhotraauthor=P.+J.+Bungayauthor=R.+Websterauthor=K.+S.+Fennerauthor=S.+Kempshallauthor=J.+L.+LaPerleauthor=M.+C.+Michelauthor=G.+G.+Kay&title=A+comprehensive+non-clinical+evaluation+of+the+CNS+penetration+potential+of+antimuscarinic+agents+for+the+treatment+of+overactive+bladder&doi=10.1111%2Fj.1365-2125.2011.03961.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder</span></div><div class="casAuthors">Callegari, Ernesto; Malhotra, Bimal; Bungay, Peter J.; Webster, Rob; Fenner, Katherine S.; Kempshall, Sarah; LaPerle, Jennifer L.; Michel, Martin C.; Kay, Gary G.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">235-246</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">AIMS: To assess and compare the mechanisms of central nervous system (CNS) penetration of antimuscarinic overactive bladder (OAB) agents.  METHODS: Phys. properties were computed or compiled from the literature.  Rats were administered 5-hydroxymethyl tolterodine (HMT), darifenacin, oxybutynin, solifenacin, tolterodine or trospium s.c.  At 1 h postdose, plasma, brain and cerebrospinal fluid (CSF) concns. were detd. using LC-MS/MS assays.  Brain and plasma protein binding were detd. in vitro.  Permeability in the presence and absence of the efflux transporter P-glycoprotein (P-gp) was assessed in RRCK and MDCK-MDR1 transwell assays.  RESULTS: Oxybutynin displayed extensive CNS penetration, with brain: plasma ratios (B:P), unbound brain:unbound plasma ratios (Kp,free) and CSF:free plasma ratios each >1.  Tolterodine (B:P = 2.95, Kp,free = 0.23 and CSF:free plasma = 0.16) and solifenacin (B:P = 3.04, Kp,free = 0.28 and CSF:free plasma = 1.41) showed significant CNS penetration but with some restriction from CNS as indicated by Kp,free values significantly <1.5-HMT, darifenacin and trospium displayed much lower B:P (0.03-0.16), Kp,free (0.01-0.04) and CSF:free plasma (0.004-0.06), consistent with poor CNS penetration.  Permeability in RRCK cells was low for trospium (0.63 × 10-6 cm s-1), moderate for 5-HMT (11.7 × 10-6 cm s-1) and high for darifenacin, solifenacin, tolterodine and oxybutynin (21.5-38.2 × 10-6 cm s-1).  In MDCK-MDR1 cells 5-HMT, darifenacin and trospium, were P-gp substrates, whereas oxybutynin, solifenacin and tolterodine were not P-gp substrates.  CONCLUSIONS: Brain penetration was low for antimuscarinics that are P-gp substrates (5-HMT, darifenacin and trospium), and significant for those that are not P-gp substrates (oxybutynin, solifenacin and tolterodine).  CNS adverse events reported in randomized controlled clin. trials show general alignment with the preclin. data described in this study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB9FelRyq-h7Vg90H21EOLACvtfcHk0liJQq7J_xFLDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtV2qtrrM&md5=dbd56eb7943853a1f58f9d56d92316bb</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2125.2011.03961.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2125.2011.03961.x%26sid%3Dliteratum%253Aachs%26aulast%3DCallegari%26aufirst%3DE.%26aulast%3DMalhotra%26aufirst%3DB.%26aulast%3DBungay%26aufirst%3DP.%2BJ.%26aulast%3DWebster%26aufirst%3DR.%26aulast%3DFenner%26aufirst%3DK.%2BS.%26aulast%3DKempshall%26aufirst%3DS.%26aulast%3DLaPerle%26aufirst%3DJ.%2BL.%26aulast%3DMichel%26aufirst%3DM.%2BC.%26aulast%3DKay%26aufirst%3DG.%2BG.%26atitle%3DA%2520comprehensive%2520non-clinical%2520evaluation%2520of%2520the%2520CNS%2520penetration%2520potential%2520of%2520antimuscarinic%2520agents%2520for%2520the%2520treatment%2520of%2520overactive%2520bladder%26jtitle%3Dbr%2520J.%2520Clin.%2520Pharmacol.%26date%3D2011%26volume%3D72%26spage%3D235%26epage%3D246%26doi%3D10.1111%2Fj.1365-2125.2011.03961.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Feng, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mills, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davidson, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mireles, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janiszewski, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Troutman, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Morais, S. M.</span><span> </span><span class="NLM_article-title">In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">268</span><span class="NLM_x">–</span> <span class="NLM_lpage">275</span><span class="refDoi"> DOI: 10.1124/dmd.107.017434</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=10.1124%2Fdmd.107.017434" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=17962372" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1yktbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2008&pages=268-275&author=B.+Fengauthor=J.+B.+Millsauthor=R.+E.+Davidsonauthor=R.+J.+Mirelesauthor=J.+S.+Janiszewskiauthor=M.+D.+Troutmanauthor=S.+M.+de+Morais&title=In+vitro+P-glycoprotein+assays+to+predict+the+in+vivo+interactions+of+P-glycoprotein+with+drugs+in+the+central+nervous+system&doi=10.1124%2Fdmd.107.017434"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system</span></div><div class="casAuthors">Feng, Bo; Mills, Jessica B.; Davidson, Ralph E.; Mireles, Rouchelle J.; Janiszewski, John S.; Troutman, Matthew D.; de Morais, Sonia M.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">268-275</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Thirty-one structurally diverse marketed central nervous system (CNS)-active drugs, one active metabolite, and seven non-CNS-active compds. were tested in three P-glycoprotein (P-gp) in vitro assays: transwell assays using MDCK, human MDR1-MDCK, and mouse Mdr1a-MDCK cells, ATPase, and calcein AM inhibition.  Addnl., the permeability for these compds. was measured in two in vitro models: parallel artificial membrane permeation assay and apical-to-basolateral apparent permeability in MDCK.  The exposure of the same set of compds. in brain and plasma was measured in P-gp knockout (KO) and wild-type (WT) mice after s.c. administration.  One drug and its metabolite, risperidone and 9-hydroxyrisperidone, of the 32 CNS compds., and 6 of the 7 non-CNS drugs were detd. to have pos. efflux using ratio of ratios in MDR1-MDCK vs. MDCK transwell assays.  Data from transwell studies correlated well with the brain-to-plasma area under the curve ratios between P-gp KO and WT mice for the 32 CNS compds.  In addn., 3300 Pfizer compds. were tested in MDR1-MDCK and Mdr1a-MDCK transwell assays, with a good correlation (R2 = 0.92) between the efflux ratios in human MDR1-MDCK and mouse Mdr1a-MDCK cells.  Permeability data showed that the majority of the 32 CNS compds. have moderate to high passive permeability.  This work has demonstrated that in vitro transporter assays help in understanding the role of P-gp-mediated efflux activity in detg. the disposition of CNS drugs in vivo, and the transwell assay is a valuable in vitro assay to evaluate human P-gp interaction with compds. for assessing brain penetration of new chem. entities to treat CNS disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsQyRSOySyGLVg90H21EOLACvtfcHk0liJQq7J_xFLDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1yktbc%253D&md5=bbf8b6969bd6d6b3d741b6ef9e7853f3</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1124%2Fdmd.107.017434&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.107.017434%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DB.%26aulast%3DMills%26aufirst%3DJ.%2BB.%26aulast%3DDavidson%26aufirst%3DR.%2BE.%26aulast%3DMireles%26aufirst%3DR.%2BJ.%26aulast%3DJaniszewski%26aufirst%3DJ.%2BS.%26aulast%3DTroutman%26aufirst%3DM.%2BD.%26aulast%3Dde%2BMorais%26aufirst%3DS.%2BM.%26atitle%3DIn%2520vitro%2520P-glycoprotein%2520assays%2520to%2520predict%2520the%2520in%2520vivo%2520interactions%2520of%2520P-glycoprotein%2520with%2520drugs%2520in%2520the%2520central%2520nervous%2520system%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2008%26volume%3D36%26spage%3D268%26epage%3D275%26doi%3D10.1124%2Fdmd.107.017434" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Leeson, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springthorpe, B.</span><span> </span><span class="NLM_article-title">The influence of drug-like concepts on decision-making in medicinal chemistry</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">881</span><span class="NLM_x">–</span> <span class="NLM_lpage">890</span><span class="refDoi"> DOI: 10.1038/nrd2445</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=10.1038%2Fnrd2445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=17971784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=881-890&author=P.+D.+Leesonauthor=B.+Springthorpe&title=The+influence+of+drug-like+concepts+on+decision-making+in+medicinal+chemistry&doi=10.1038%2Fnrd2445"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">The influence of drug-like concepts on decision-making in medicinal chemistry</span></div><div class="casAuthors">Leeson, Paul D.; Springthorpe, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">881-890</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Despite the wide acceptance of drug-like principles such as the 'rule of five', this anal. of mols. currently being synthesized in leading pharmaceutical companies reveals that their phys. properties differ significantly from those of recently discovered oral drugs.  The marked increase in lipophilicity in particular could increase the likelihood of attrition in drug development.  The application of guidelines linked to the concept of drug-likeness, such as the 'rule of five', has gained wide acceptance as an approach to reduce attrition in drug discovery and development.  However, despite this acceptance, anal. of recent trends reveals that the phys. properties of mols. that are currently being synthesized in leading drug discovery companies differ significantly from those of recently discovered oral drugs and compds. in clin. development.  The consequences of the marked increase in lipophilicity - the most important drug-like phys. property - include a greater likelihood of lack of selectivity and attrition in drug development.  Tackling the threat of compd.-related toxicol. attrition needs to move to the mainstream of medicinal chem. decision-making.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTUeonLD6iebVg90H21EOLACvtfcHk0lhflumEybpOKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL&md5=5665a9e2dc266a1ee096e20625757ef7</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1038%2Fnrd2445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2445%26sid%3Dliteratum%253Aachs%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DSpringthorpe%26aufirst%3DB.%26atitle%3DThe%2520influence%2520of%2520drug-like%2520concepts%2520on%2520decision-making%2520in%2520medicinal%2520chemistry%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D881%26epage%3D890%26doi%3D10.1038%2Fnrd2445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Ryckmans, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horne, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Correia, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owen, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tutt, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, T.</span><span> </span><span class="NLM_article-title">Rapid assessment of a novel series of selective CB2 agonists using parallel synthesis protocols: A Lipophilic Efficiency (LipE) analysis</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">4406</span><span class="NLM_x">–</span> <span class="NLM_lpage">4409</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2009.05.062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=10.1016%2Fj.bmcl.2009.05.062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=19500981" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosVGlsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=4406-4409&author=T.+Ryckmansauthor=M.+P.+Edwardsauthor=V.+A.+Horneauthor=A.+M.+Correiaauthor=D.+R.+Owenauthor=L.+R.+Thompsonauthor=I.+Tranauthor=M.+F.+Tuttauthor=T.+Young&title=Rapid+assessment+of+a+novel+series+of+selective+CB2+agonists+using+parallel+synthesis+protocols%3A+A+Lipophilic+Efficiency+%28LipE%29+analysis&doi=10.1016%2Fj.bmcl.2009.05.062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Rapid assessment of a novel series of selective CB2 agonists using parallel synthesis protocols: A Lipophilic Efficiency (LipE) analysis</span></div><div class="casAuthors">Ryckmans, Thomas; Edwards, Martin P.; Horne, Val A.; Correia, Ana Monica; Owen, Dafydd R.; Thompson, Lisa R.; Tran, Isabelle; Tutt, Michelle F.; Young, Tim</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4406-4409</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of libraries were designed using the 1-(cyclopropylmethyl)-2-alkyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-5-ium templates 2a-b, and Sulfonamide derivs. 11a-n proved to be potent agonists of the CB2 receptor.  Anal. of the Lipophilic Efficiency (LipE) of potent compds. provided new insight for the design of potent, metabolically stable CB2 agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1cihq9YHuO7Vg90H21EOLACvtfcHk0lhflumEybpOKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosVGlsrg%253D&md5=b62d97e5f52a594cfdd510f32d2e566f</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.05.062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.05.062%26sid%3Dliteratum%253Aachs%26aulast%3DRyckmans%26aufirst%3DT.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26aulast%3DHorne%26aufirst%3DV.%2BA.%26aulast%3DCorreia%26aufirst%3DA.%2BM.%26aulast%3DOwen%26aufirst%3DD.%2BR.%26aulast%3DThompson%26aufirst%3DL.%2BR.%26aulast%3DTran%26aufirst%3DI.%26aulast%3DTutt%26aufirst%3DM.%2BF.%26aulast%3DYoung%26aufirst%3DT.%26atitle%3DRapid%2520assessment%2520of%2520a%2520novel%2520series%2520of%2520selective%2520CB2%2520agonists%2520using%2520parallel%2520synthesis%2520protocols%253A%2520A%2520Lipophilic%2520Efficiency%2520%2528LipE%2529%2520analysis%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D4406%26epage%3D4409%26doi%3D10.1016%2Fj.bmcl.2009.05.062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Stepan, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kauffman, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keefer, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verhoest, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, M.</span><span> </span><span class="NLM_article-title">Evaluating the differences in cycloalkyl ether metabolism using the design parameter ″Lipophilic Metabolism Efficiency″ (LipMetE) and a matched molecular pairs analysis</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">6985</span><span class="NLM_x">–</span> <span class="NLM_lpage">6990</span><span class="refDoi"> DOI: 10.1021/jm4008642</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4008642" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=6985-6990&author=A.+F.+Stepanauthor=G.+W.+Kauffmanauthor=C.+E.+Keeferauthor=P.+R.+Verhoestauthor=M.+Edwards&title=Evaluating+the+differences+in+cycloalkyl+ether+metabolism+using+the+design+parameter+%E2%80%B3Lipophilic+Metabolism+Efficiency%E2%80%B3+%28LipMetE%29+and+a+matched+molecular+pairs+analysis&doi=10.1021%2Fjm4008642"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fjm4008642&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4008642%26sid%3Dliteratum%253Aachs%26aulast%3DStepan%26aufirst%3DA.%2BF.%26aulast%3DKauffman%26aufirst%3DG.%2BW.%26aulast%3DKeefer%26aufirst%3DC.%2BE.%26aulast%3DVerhoest%26aufirst%3DP.%2BR.%26aulast%3DEdwards%26aufirst%3DM.%26atitle%3DEvaluating%2520the%2520differences%2520in%2520cycloalkyl%2520ether%2520metabolism%2520using%2520the%2520design%2520parameter%2520%25E2%2580%25B3Lipophilic%2520Metabolism%2520Efficiency%25E2%2580%25B3%2520%2528LipMetE%2529%2520and%2520a%2520matched%2520molecular%2520pairs%2520analysis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D6985%26epage%3D6990%26doi%3D10.1021%2Fjm4008642" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Gehlhaar, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verkhivker, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rejto, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherman, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fogel, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fogel, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freer, S. T.</span><span> </span><span class="NLM_article-title">Molecular recognition of the inhibitor AG-1343 by HIV-1 protease: Conformationally flexible docking by evolutionary programming</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">317</span><span class="NLM_x">–</span> <span class="NLM_lpage">324</span><span class="refDoi"> DOI: 10.1016/1074-5521(95)90050-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=10.1016%2F1074-5521%2895%2990050-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=9383433" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=1%3ACAS%3A528%3ADyaK2MXmvVClsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1995&pages=317-324&author=D.+K.+Gehlhaarauthor=G.+M.+Verkhivkerauthor=P.+A.+Rejtoauthor=C.+J.+Shermanauthor=D.+B.+Fogelauthor=L.+J.+Fogelauthor=S.+T.+Freer&title=Molecular+recognition+of+the+inhibitor+AG-1343+by+HIV-1+protease%3A+Conformationally+flexible+docking+by+evolutionary+programming&doi=10.1016%2F1074-5521%2895%2990050-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular recognition of the inhibitor AG-1343 by HIV-1 protease: Conformationally flexible docking by evolutionary programming</span></div><div class="casAuthors">Gehlhaar, Daniel K.; Verkhivker, Gennady M.; Rejto, Paul A.; Sherman, Christopher J.; Fogel, David B.; Fogel, Lawrence J.; Freer, Stephan T.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">317-24</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Current Biology</span>)
        </div><div class="casAbstract">An important prerequisite for computational structure-based drug design is prediction of the structures of ligand-protein complexes that have not yet been exptl. detd. by x-ray crystallog. or NMR.  For this task, docking of rigid ligands is inadequate because it assumes knowledge of the conformation of the bound ligand.  Docking of flexible ligands would be desirable, but requires one to search an enormous conformational space.  We set out to develop a strategy for flexible docking by combining a simple model of ligand-protein interactions for mol. recognition with an evolutionary programming search technique.  We have developed an intermol. energy function that incorporates steric and hydrogen-bonding terms.  The parameters in this function were obtained by docking in three different protein systems.  The effectiveness of this method was demonstrated by conformationally flexible docking of the inhibitor AG-1343, a potential new drug against AIDS, into HIV-1 protease.  For this mol., which has nine rotatable bonds, the crystal structure was reproduced within 1.5 Å rootmean-square deviation 34 times in 100 simulations, each requiring eight minutes on a Silicon Graphics R4400 workstation.  The energy function correctly evaluates the crystal structure as the global energy min.  We believe that a soln. of the docking problem may be achieved by matching a simple model of mol. recognition with an efficient search procedure.  The necessary ingredients of a mol. recognition model include only steric and hydrogen-bond interaction terms.  Although these terms are not necessarily sufficient to predict binding affinity, they describe ligand-protein interactions faithfully enough to enable a docking program to predict the structure of the bound ligand.  This docking strategy thus provides an important tool for the interdisciplinary field of rational drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAErS8tcVx2bVg90H21EOLACvtfcHk0lhkvvqLMQtbWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXmvVClsbg%253D&md5=527cfc114545ea76b64b48d0aee21856</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2F1074-5521%2895%2990050-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F1074-5521%252895%252990050-0%26sid%3Dliteratum%253Aachs%26aulast%3DGehlhaar%26aufirst%3DD.%2BK.%26aulast%3DVerkhivker%26aufirst%3DG.%2BM.%26aulast%3DRejto%26aufirst%3DP.%2BA.%26aulast%3DSherman%26aufirst%3DC.%2BJ.%26aulast%3DFogel%26aufirst%3DD.%2BB.%26aulast%3DFogel%26aufirst%3DL.%2BJ.%26aulast%3DFreer%26aufirst%3DS.%2BT.%26atitle%3DMolecular%2520recognition%2520of%2520the%2520inhibitor%2520AG-1343%2520by%2520HIV-1%2520protease%253A%2520Conformationally%2520flexible%2520docking%2520by%2520evolutionary%2520programming%26jtitle%3DChem.%2520Biol.%26date%3D1995%26volume%3D2%26spage%3D317%26epage%3D324%26doi%3D10.1016%2F1074-5521%2895%2990050-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Lovering, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bikker, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humblet, C.</span><span> </span><span class="NLM_article-title">Escape from flatland: Increasing saturation as an approach to improving clinical success</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">6752</span><span class="NLM_x">–</span> <span class="NLM_lpage">6756</span><span class="refDoi"> DOI: 10.1021/jm901241e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901241e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=6752-6756&author=F.+Loveringauthor=J.+Bikkerauthor=C.+Humblet&title=Escape+from+flatland%3A+Increasing+saturation+as+an+approach+to+improving+clinical+success&doi=10.1021%2Fjm901241e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success</span></div><div class="casAuthors">Lovering, Frank; Bikker, Jack; Humblet, Christine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6752-6756</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The medicinal chem. community has become increasingly aware of the value of tracking calcd. phys. properties such as mol. wt., topol. polar surface area, rotatable bonds, and hydrogen bond donors and acceptors.  The authors hypothesized that the shift to high-throughput synthetic practices over the past decade may be another factor that may predispose mols. to fail by steering discovery efforts toward achiral, arom. compds.  The authors have proposed two simple and interpretable measures of the complexity of mols. prepd. as potential drug candidates.  The first is carbon bond satn. as defined by fraction Sp3 (Fsp3) where Fsp3 = (no. of Sp3 hybridized carbons/total carbon count).  The second is simply whether a chiral carbon exists in the mol.  The authors demonstrate that both complexity (as measured by Fsp3) and the presence of chiral centers correlate with success as compds. transition from discovery, through clin. testing, to drugs.  To explain these observations, the authors further demonstrate that satn. correlates with soly., an exptl. phys. property important to success in the drug discovery setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC1f3Ed7nUBbVg90H21EOLACvtfcHk0li8yo31DXMi_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN&md5=4ca92c30c17c53d77ad376719bad951e</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm901241e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901241e%26sid%3Dliteratum%253Aachs%26aulast%3DLovering%26aufirst%3DF.%26aulast%3DBikker%26aufirst%3DJ.%26aulast%3DHumblet%26aufirst%3DC.%26atitle%3DEscape%2520from%2520flatland%253A%2520Increasing%2520saturation%2520as%2520an%2520approach%2520to%2520improving%2520clinical%2520success%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D6752%26epage%3D6756%26doi%3D10.1021%2Fjm901241e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Sherman, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beard, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farid, R.</span><span> </span><span class="NLM_article-title">Use of an induced fit receptor structure in virtual screening</span> <span class="citation_source-journal">Chem. Biol. Drug Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">83</span><span class="NLM_x">–</span> <span class="NLM_lpage">84</span><span class="refDoi"> DOI: 10.1111/j.1747-0285.2005.00327.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=10.1111%2Fj.1747-0285.2005.00327.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=16492153" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=1%3ACAS%3A528%3ADC%252BD28XhsVSjtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2006&pages=83-84&author=W.+Shermanauthor=H.+S.+Beardauthor=R.+Farid&title=Use+of+an+induced+fit+receptor+structure+in+virtual+screening&doi=10.1111%2Fj.1747-0285.2005.00327.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Use of an induced fit receptor structure in virtual screening</span></div><div class="casAuthors">Sherman, Woody; Beard, Hege S.; Farid, Ramy</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">83-84</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">A review.  The automated induced fit docking protocol was used to generate the DFG-out conformation from a p38 MAP kinase activation loop starting from a DFG-in structure (1a9u) and the ligand from 1kv1 (BMU).  In a virtual screening study of 25K decoy ligands and 46 known actives, using an ensemble consisting of the induced fit docking structure (DFG-out) and the 1a9u crystal structure (DFG-in), 14 actives were identified in the top 1% of the database, including BMU and BIRB 796.  3 Actives were identified when 1a9u was used alone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7PRgtFzy8u7Vg90H21EOLACvtfcHk0li8yo31DXMi_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhsVSjtL0%253D&md5=efe9900aacaaea6af805c1cbdb350c73</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1111%2Fj.1747-0285.2005.00327.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1747-0285.2005.00327.x%26sid%3Dliteratum%253Aachs%26aulast%3DSherman%26aufirst%3DW.%26aulast%3DBeard%26aufirst%3DH.%2BS.%26aulast%3DFarid%26aufirst%3DR.%26atitle%3DUse%2520of%2520an%2520induced%2520fit%2520receptor%2520structure%2520in%2520virtual%2520screening%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2006%26volume%3D67%26spage%3D83%26epage%3D84%26doi%3D10.1111%2Fj.1747-0285.2005.00327.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Dore, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okrasa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serrano-Vega, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennett, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooke, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Errey, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jazayeri, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tehan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weir, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiggin, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, F. H.</span><span> </span><span class="NLM_article-title">Structure of class C GPCR metabotropic glutamate receptor 5 transmembrane domain</span> <span class="citation_source-journal">Nature (London, U. K.)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">511</span><span class="NLM_x">, </span> <span class="NLM_fpage">557</span><span class="NLM_x">–</span> <span class="NLM_lpage">562</span><span class="refDoi"> DOI: 10.1038/nature13396</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=10.1038%2Fnature13396" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1ChurnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=511&publication_year=2014&pages=557-562&author=A.+S.+Doreauthor=K.+Okrasaauthor=J.+C.+Patelauthor=M.+Serrano-Vegaauthor=K.+Bennettauthor=R.+M.+Cookeauthor=J.+C.+Erreyauthor=A.+Jazayeriauthor=S.+Khanauthor=B.+Tehanauthor=M.+Weirauthor=G.+R.+Wigginauthor=F.+H.+Marshall&title=Structure+of+class+C+GPCR+metabotropic+glutamate+receptor+5+transmembrane+domain&doi=10.1038%2Fnature13396"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of class C GPCR metabotropic glutamate receptor 5 transmembrane domain</span></div><div class="casAuthors">Dore, Andrew S.; Okrasa, Krzysztof; Patel, Jayesh C.; Serrano-Vega, Maria; Bennett, Kirstie; Cooke, Robert M.; Errey, James C.; Jazayeri, Ali; Khan, Samir; Tehan, Ben; Weir, Malcolm; Wiggin, Giselle R.; Marshall, Fiona H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">511</span>
        (<span class="NLM_cas:issue">7511</span>),
    <span class="NLM_cas:pages">557-562</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Metabotropic glutamate receptors are class C G-protein-coupled receptors which respond to the neurotransmitter glutamate.  Structural studies have been restricted to the amino-terminal extracellular domain, providing little understanding of the membrane-spanning signal transduction domain.  Metabotropic glutamate receptor 5 (mGlu5 receptor) is of considerable interest as a drug target in the treatment of fragile X syndrome, autism, depression, anxiety, addiction and movement disorders.  Here we report the crystal structure of the transmembrane domain of the human receptor in complex with the neg. allosteric modulator, mavoglurant.  The structure provides detailed insight into the architecture of the transmembrane domain of class C receptors including the precise location of the allosteric binding site within the transmembrane domain and key micro-switches which regulate receptor signaling.  This structure also provides a model for all class C G-protein-coupled receptors and may aid in the design of new small-mol. drugs for the treatment of brain disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4LiHVA8klWLVg90H21EOLACvtfcHk0lhIIJ6qyAxFmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1ChurnK&md5=43a1f0b72a923044fa718729f97c075d</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1038%2Fnature13396&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature13396%26sid%3Dliteratum%253Aachs%26aulast%3DDore%26aufirst%3DA.%2BS.%26aulast%3DOkrasa%26aufirst%3DK.%26aulast%3DPatel%26aufirst%3DJ.%2BC.%26aulast%3DSerrano-Vega%26aufirst%3DM.%26aulast%3DBennett%26aufirst%3DK.%26aulast%3DCooke%26aufirst%3DR.%2BM.%26aulast%3DErrey%26aufirst%3DJ.%2BC.%26aulast%3DJazayeri%26aufirst%3DA.%26aulast%3DKhan%26aufirst%3DS.%26aulast%3DTehan%26aufirst%3DB.%26aulast%3DWeir%26aufirst%3DM.%26aulast%3DWiggin%26aufirst%3DG.%2BR.%26aulast%3DMarshall%26aufirst%3DF.%2BH.%26atitle%3DStructure%2520of%2520class%2520C%2520GPCR%2520metabotropic%2520glutamate%2520receptor%25205%2520transmembrane%2520domain%26jtitle%3DNature%2520%2528London%252C%2520U.%2520K.%2529%26date%3D2014%26volume%3D511%26spage%3D557%26epage%3D562%26doi%3D10.1038%2Fnature13396" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Rylander, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iderberg, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dekundy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baishen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Danysz, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bezard, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cenci, M. A.</span><span> </span><span class="NLM_article-title">A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys</span> <span class="citation_source-journal">Neurobiol. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">352</span><span class="NLM_x">–</span> <span class="NLM_lpage">361</span><span class="refDoi"> DOI: 10.1016/j.nbd.2010.05.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=10.1016%2Fj.nbd.2010.05.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=20452425" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpt12nu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2010&pages=352-361&author=D.+Rylanderauthor=H.+Iderbergauthor=Q.+Liauthor=A.+Dekundyauthor=J.+Zhangauthor=H.+Liauthor=R.+Baishenauthor=W.+Danyszauthor=E.+Bezardauthor=M.+A.+Cenci&title=A+mGluR5+antagonist+under+clinical+development+improves+L-DOPA-induced+dyskinesia+in+parkinsonian+rats+and+monkeys&doi=10.1016%2Fj.nbd.2010.05.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys</span></div><div class="casAuthors">Rylander, Daniella; Iderberg, Hanna; Li, Qin; Dekundy, Andrzej; Zhang, Jinlan; Li, Hao; Baishen, Ren; Danysz, Wojciech; Bezard, Erwan; Cenci, M. Angela</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Disease</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">352-361</span>CODEN:
                <span class="NLM_cas:coden">NUDIEM</span>;
        ISSN:<span class="NLM_cas:issn">0969-9961</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">L-DOPA remains the gold-std. treatment for Parkinson's disease but causes motor fluctuations and dyskinesia.  Metabotropic glutamate receptor type 5 (mGluR5) has been proposed as a target for antidyskinetic therapies.  Here, we evaluate the effects of fenobam, a noncompetitive mGluR5 antagonist already tested in humans, using rodent and nonhuman primate models of Parkinson's disease.  In both animal models, acute administration of fenobam attenuated the L-DOPA-induced abnormal involuntary movements (50-70% redn. at the doses of 30 mg/kg in rats and 10 mg/kg in monkeys).  The effect consisted in a redn. of peak-dose dyskinesia, whereas the end-dose phase was not affected.  Chronic administration of fenobam to previously drug-naive animals (de novo treatment) attenuated the development of peak-dose dyskinesia without compromising the anti-parkinsonian effect of L-DOPA.  In addn., fenobam prolonged the motor stimulant effect of L-DOPA.  We conclude that fenobam acts similarly in rat and primate models of L-DOPA-induced dyskinesia and represents a good candidate for antidyskinetic treatment in Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDjlZraTHwS7Vg90H21EOLACvtfcHk0lhIIJ6qyAxFmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpt12nu7w%253D&md5=19679fc03f2cba113ff8377f57893e71</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.nbd.2010.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nbd.2010.05.001%26sid%3Dliteratum%253Aachs%26aulast%3DRylander%26aufirst%3DD.%26aulast%3DIderberg%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DDekundy%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DBaishen%26aufirst%3DR.%26aulast%3DDanysz%26aufirst%3DW.%26aulast%3DBezard%26aufirst%3DE.%26aulast%3DCenci%26aufirst%3DM.%2BA.%26atitle%3DA%2520mGluR5%2520antagonist%2520under%2520clinical%2520development%2520improves%2520L-DOPA-induced%2520dyskinesia%2520in%2520parkinsonian%2520rats%2520and%2520monkeys%26jtitle%3DNeurobiol.%2520Dis.%26date%3D2010%26volume%3D39%26spage%3D352%26epage%3D361%26doi%3D10.1016%2Fj.nbd.2010.05.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Whritenour, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawabata, T. T.</span><span> </span><span class="NLM_article-title">Development and partial validation of a mouse model for predicting drug hypersensitivity reactions</span> <span class="citation_source-journal">J. Immunotoxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">141</span><span class="NLM_x">–</span> <span class="NLM_lpage">147</span><span class="refDoi"> DOI: 10.3109/1547691X.2013.812164</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=10.3109%2F1547691X.2013.812164" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=23879792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkvVyrs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2014&pages=141-147&author=J.+Whritenourauthor=S.+Coleauthor=X.+Zhuauthor=D.+Liauthor=T.+T.+Kawabata&title=Development+and+partial+validation+of+a+mouse+model+for+predicting+drug+hypersensitivity+reactions&doi=10.3109%2F1547691X.2013.812164"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Development and partial validation of a mouse model for predicting drug hypersensitivity reactions</span></div><div class="casAuthors">Whritenour, Jessica; Cole, Susan; Zhu, Xu; Li, Dingzhou; Kawabata, Thomas T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunotoxicology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">141-147</span>CODEN:
                <span class="NLM_cas:coden">JIOMAP</span>;
        ISSN:<span class="NLM_cas:issn">1547-691X</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Animal models that can be used to predict the allergenic potential of drug candidates have not been adequately optimized, validated, or characterized.  While initial validation data from an inter-lab. study of the mouse lymph node proliferation assay (LNPA) appeared promising, no addnl. investigations in this model have been reported.  The objectives of this study were to use pos. and neg. control drugs to further optimize and validate the LNPA utilizing a non-radioactive endpoint and det. the sensitivity, specificity, and predictivity of the model.  Drugs assocd. with hypersensitivity reactions in the literature were chosen to test in the model in addn. to drugs with few or no reports of hypersensitivity.  Mice received a s.c. injection of drug or vehicle into the scruff of the neck once daily for a period of 3 days.  On Day 6, draining lymph nodes were harvested, single cell suspensions prepd., and total cell nos. detd. for each animal by flow cytometry.  A stimulation index was calcd. by dividing the mean total cell no. for the drug-treated group by the mean total cell no. for the vehicle-treated animals.  Based on statistical anal. of the data, animals with a total cell no. ≥2.5× the mean of the vehicle group were classified as 'responders'.  Based on data generated to date with 12 pos. control and six neg. control drugs, the model had a sensitivity of 75%, a specificity of 74%, and a relatively good predictive value (measured by the Receiver Operating Characteristic AUC of 0.80).  The data here suggest that this model may be a useful tool for identifying drug candidates with the potential to produce allergic responses in the clinic.  Future studies will investigate the mechanism(s) for the lymph node responses in order to develop addnl. endpoints that may increase the sensitivity and specificity of the model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOLH2cKRcAyLVg90H21EOLACvtfcHk0liBJbp2d6CdoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkvVyrs7w%253D&md5=9f615491c1220b8f30095ed450822051</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.3109%2F1547691X.2013.812164&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F1547691X.2013.812164%26sid%3Dliteratum%253Aachs%26aulast%3DWhritenour%26aufirst%3DJ.%26aulast%3DCole%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DKawabata%26aufirst%3DT.%2BT.%26atitle%3DDevelopment%2520and%2520partial%2520validation%2520of%2520a%2520mouse%2520model%2520for%2520predicting%2520drug%2520hypersensitivity%2520reactions%26jtitle%3DJ.%2520Immunotoxicol.%26date%3D2014%26volume%3D11%26spage%3D141%26epage%3D147%26doi%3D10.3109%2F1547691X.2013.812164" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Soglia, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harriman, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barberia, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyd, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Contillo, L. G.</span><span> </span><span class="NLM_article-title">The development of a higher throughput reactive intermediate screening assay incorporating micro-bore liquid chromatography-micro-electrospray ionization-tandem mass spectrometry and glutathione ethyl ester as an in vitro conjugating agent</span> <span class="citation_source-journal">J. Pharm. Biomed. Anal.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">105</span><span class="NLM_x">–</span> <span class="NLM_lpage">116</span><span class="refDoi"> DOI: 10.1016/j.jpba.2004.04.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=10.1016%2Fj.jpba.2004.04.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=15351054" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=1%3ACAS%3A528%3ADC%252BD2cXntlems7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2004&pages=105-116&author=J.+R.+Sogliaauthor=S.+P.+Harrimanauthor=S.+Zhaoauthor=J.+Barberiaauthor=M.+J.+Coleauthor=J.+G.+Boydauthor=L.+G.+Contillo&title=The+development+of+a+higher+throughput+reactive+intermediate+screening+assay+incorporating+micro-bore+liquid+chromatography-micro-electrospray+ionization-tandem+mass+spectrometry+and+glutathione+ethyl+ester+as+an+in+vitro+conjugating+agent&doi=10.1016%2Fj.jpba.2004.04.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">The development of a higher throughput reactive intermediate screening assay incorporating micro-bore liquid chromatography-micro-electrospray ionization-tandem mass spectrometry and glutathione ethyl ester as an in vitro conjugating agent</span></div><div class="casAuthors">Soglia, John R.; Harriman, Shawn P.; Zhao, Sabrina; Barberia, John; Cole, Mark J.; Boyd, James G.; Contillo, Leonard G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical and Biomedical Analysis</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">105-116</span>CODEN:
                <span class="NLM_cas:coden">JPBADA</span>;
        ISSN:<span class="NLM_cas:issn">0731-7085</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">An in vitro reactive intermediate screening assay, incorporating the use of the close analog of glutathione, glutathione Et ester (GSH-EE) as a conjugating agent, was developed to identify compds. that form reactive intermediates in an in vitro metabolite generating system.  The biol. assay consisted of substrate [s] = 10 μM, human liver microsomes, an NADPH generating system, and glutathione Et ester.  Conjugates were extd. from the biol. matrix using a combination of protein pptn. and a semi-automated 96-well plate solid phase extn. (SPE) procedure.  A micro-bore liq. chromatog.-micro-electrospray ionization-tandem mass spectrometry (μLC-μESI-MS/MS) method detected glutathione Et ester conjugates using selected reaction monitoring (SRM) to simultaneously monitor for multiple MH+ to [MH - 129]+ transitions, where the 129 mass unit (Da) represents the neutral loss of the pyroglutamate moiety from GSH-EE.  The multiple MH+ to [MH - 129]+ transitions (SRM mass table) were generated for potential reactive intermediates of each compd.  Glutathione (GSH) and GSH-EE conjugate stds. were used to evaluate MS detection sensitivity.  Based on direct comparison of std. curve data, an approx. 10-fold increase in sensitivity was obsd. for conjugates contg. GSH-EE moiety vs. GSH.  In vitro expts. were conducted using literature substrates acetaminophen, rosiglitazone, clozapine, diclofenac and either GSH-EE or GSH as a reactive intermediate conjugating agent.  An increase in detection sensitivity was obsd. for each GSH-EE conjugate and in the case of acetaminophen-GSH-EE the peak area increase was approx. 80-fold.  Twelve drug compds., each having known biotransformation mechanisms, were used to further test the detection capabilities of the assay and establish a concordance to literature data.  When GSH was used in the assay, conjugates were detected for 4 out of the 12 test compds. (33%).  When GSH-EE was used in the assay, conjugates were detected for 10 out of the 12 test compds. (83%).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3NwMX6-E_3LVg90H21EOLACvtfcHk0liBJbp2d6CdoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXntlems7w%253D&md5=23e4c3df8558019ad3770d748a1f9815</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.jpba.2004.04.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jpba.2004.04.019%26sid%3Dliteratum%253Aachs%26aulast%3DSoglia%26aufirst%3DJ.%2BR.%26aulast%3DHarriman%26aufirst%3DS.%2BP.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DBarberia%26aufirst%3DJ.%26aulast%3DCole%26aufirst%3DM.%2BJ.%26aulast%3DBoyd%26aufirst%3DJ.%2BG.%26aulast%3DContillo%26aufirst%3DL.%2BG.%26atitle%3DThe%2520development%2520of%2520a%2520higher%2520throughput%2520reactive%2520intermediate%2520screening%2520assay%2520incorporating%2520micro-bore%2520liquid%2520chromatography-micro-electrospray%2520ionization-tandem%2520mass%2520spectrometry%2520and%2520glutathione%2520ethyl%2520ester%2520as%2520an%2520in%2520vitro%2520conjugating%2520agent%26jtitle%3DJ.%2520Pharm.%2520Biomed.%2520Anal.%26date%3D2004%26volume%3D36%26spage%3D105%26epage%3D116%26doi%3D10.1016%2Fj.jpba.2004.04.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Shaffer, C. L.</span><span> </span><span class="NLM_article-title">The discovery and preclinical characterization of the novel mGluR5 negative allosteric modulator PF470: Implications for mechanism-based toxicity</span> <span class="citation_source-journal">Curr. Neuropharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl 1</span><span class="NLM_x">) </span> <span class="NLM_fpage">55</span><span class="NLM_x">–</span> <span class="NLM_lpage">56</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2014&pages=55-56&issue=Suppl+1&author=C.+L.+Shaffer&title=The+discovery+and+preclinical+characterization+of+the+novel+mGluR5+negative+allosteric+modulator+PF470%3A+Implications+for+mechanism-based+toxicity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShaffer%26aufirst%3DC.%2BL.%26atitle%3DThe%2520discovery%2520and%2520preclinical%2520characterization%2520of%2520the%2520novel%2520mGluR5%2520negative%2520allosteric%2520modulator%2520PF470%253A%2520Implications%2520for%2520mechanism-based%2520toxicity%26jtitle%3DCurr.%2520Neuropharmacol.%26date%3D2014%26volume%3D12%26issue%3DSuppl%25201%26spage%3D55%26epage%3D56" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Shah, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stepan, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Mahony, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velichko, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Folias, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houle, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaffer, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcek, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whritenour, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stanton, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berg, E. L.</span><span> </span><span class="NLM_article-title">Mechanisms of skin toxicity associated with metabotropic glutamate receptor 5 negative allosteric modulators</span> <span class="citation_source-journal">Cell Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">858</span><span class="NLM_x">–</span> <span class="NLM_lpage">869</span><span class="refDoi"> DOI: 10.1016/j.chembiol.2017.06.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=10.1016%2Fj.chembiol.2017.06.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=28669525" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFSmsbjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2017&pages=858-869&author=F.+Shahauthor=A.+F.+Stepanauthor=A.+O%E2%80%99Mahonyauthor=S.+Velichkoauthor=A.+E.+Foliasauthor=C.+Houleauthor=C.+L.+Shafferauthor=J.+Marcekauthor=J.+Whritenourauthor=R.+Stantonauthor=E.+L.+Berg&title=Mechanisms+of+skin+toxicity+associated+with+metabotropic+glutamate+receptor+5+negative+allosteric+modulators&doi=10.1016%2Fj.chembiol.2017.06.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of Skin Toxicity Associated with Metabotropic Glutamate Receptor 5 Negative Allosteric Modulators</span></div><div class="casAuthors">Shah, Falgun; Stepan, Antonia F.; O'Mahony, Alison; Velichko, Sharlene; Folias, Alexandra E.; Houle, Christopher; Shaffer, Christopher L.; Marcek, John; Whritenour, Jessica; Stanton, Robert; Berg, Ellen L.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">858-869.e5</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Cutaneous reactions represent one of the most common adverse drug effects obsd. in clin. trials leading to substantial compd. attrition.  Three neg. allosteric modulators (NAMs) of metabotropic glutamate receptors (mGluRs), which represent an important target for neurol. diseases, developed by Pfizer, were recently failed in preclin. development due to delayed type IV skin hypersensitivity obsd. in non-human primates (NHPs).  Here we employed large-scale phenotypic profiling in standardized panels of human primary cell/co-culture systems to characterize the skin toxicity mechanism(s) of mGluR5 NAMs from two different series.  Investigation of a database of chems. tested in these systems and transcriptional profiling suggested that the mechanism of toxicity may involve modulation of nuclear receptor targets RAR/RXR, and/or VDR with AhR antagonism.  The studies reported here demonstrate how phenotypic profiling of preclin. drug candidates using human primary cells can provide insights into the mechanisms of toxicity and inform early drug discovery and development campaigns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvdz6FO63JvrVg90H21EOLACvtfcHk0lh0In64Oq_5RQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFSmsbjP&md5=b50f053ff58a295fa7476d95d325a9c4</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2017.06.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2017.06.003%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DF.%26aulast%3DStepan%26aufirst%3DA.%2BF.%26aulast%3DO%25E2%2580%2599Mahony%26aufirst%3DA.%26aulast%3DVelichko%26aufirst%3DS.%26aulast%3DFolias%26aufirst%3DA.%2BE.%26aulast%3DHoule%26aufirst%3DC.%26aulast%3DShaffer%26aufirst%3DC.%2BL.%26aulast%3DMarcek%26aufirst%3DJ.%26aulast%3DWhritenour%26aufirst%3DJ.%26aulast%3DStanton%26aufirst%3DR.%26aulast%3DBerg%26aufirst%3DE.%2BL.%26atitle%3DMechanisms%2520of%2520skin%2520toxicity%2520associated%2520with%2520metabotropic%2520glutamate%2520receptor%25205%2520negative%2520allosteric%2520modulators%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2017%26volume%3D24%26spage%3D858%26epage%3D869%26doi%3D10.1016%2Fj.chembiol.2017.06.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Hosea, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collard, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maurer, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, R. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kakar, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webster, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaumont, K.</span><span> </span><span class="NLM_article-title">Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches</span> <span class="citation_source-journal">J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">513</span><span class="NLM_x">–</span> <span class="NLM_lpage">533</span><span class="refDoi"> DOI: 10.1177/0091270009333209</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=10.1177%2F0091270009333209" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=19299532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlsFWmu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2009&pages=513-533&author=N.+A.+Hoseaauthor=W.+T.+Collardauthor=S.+Coleauthor=T.+S.+Maurerauthor=R.+X.+Fangauthor=H.+Jonesauthor=S.+M.+Kakarauthor=Y.+Nakaiauthor=B.+J.+Smithauthor=R.+Websterauthor=K.+Beaumont&title=Prediction+of+human+pharmacokinetics+from+preclinical+information%3A+comparative+accuracy+of+quantitative+prediction+approaches&doi=10.1177%2F0091270009333209"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches</span></div><div class="casAuthors">Hosea, Natilie A.; Collard, Wendy T.; Cole, Susan; Maurer, Tristan S.; Fang, Rick X.; Jones, Hannah; Kakar, Shefali M.; Nakai, Yasuhiro; Smith, Bill J.; Webster, Rob; Beaumont, Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">513-533</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">A review.  Quant. prediction of human pharmacokinetics is crit. in assessing the viability of drug candidates and in detg. first-in-human dosing.  Numerous prediction methodologies, incorporating both in vitro and preclin. in vivo data, have been developed in recent years, each with advantages and disadvantages.  However, the lack of a comprehensive data set, both preclin. and clin., has limited efforts to evaluate the optimal strategy (or strategies) that results in quant. predictions of human pharmacokinetics.  To address this issue, the authors conducted a retrospective anal. using 50 proprietary compds. for which in vitro, preclin. pharmacokinetic data and oral single-dose human pharmacokinetic data were available.  Five predictive strategies, involving either allometry or use of unbound intrinsic clearance from microsomes or hepatocytes, were then compared for their ability to predict human oral clearance, half-life through predictions of systemic clearance, vol. of distribution, and bioavailability.  Use of a single-species scaling approach with rat, dog, or monkey was as accurate as or more accurate than using multiple-species allometry.  For those compds. cleared almost exclusively by P 450-mediated pathways, scaling from human liver microsomes was as predictive as single-species scaling of clearance based on data from rat, dog, or monkey.  These data suggest that use of predictive methods involving either single-species in vivo data or in vitro human liver microsomes can quant. predict human in vivo pharmacokinetics and suggest the possibility of streamlining the predictive methodol. through use of a single species or use only of human in vitro microsomal prepns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrg67HcwS4O4LVg90H21EOLACvtfcHk0lh0In64Oq_5RQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlsFWmu74%253D&md5=a0941d53fe43392f8fb1562ee546705e</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1177%2F0091270009333209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0091270009333209%26sid%3Dliteratum%253Aachs%26aulast%3DHosea%26aufirst%3DN.%2BA.%26aulast%3DCollard%26aufirst%3DW.%2BT.%26aulast%3DCole%26aufirst%3DS.%26aulast%3DMaurer%26aufirst%3DT.%2BS.%26aulast%3DFang%26aufirst%3DR.%2BX.%26aulast%3DJones%26aufirst%3DH.%26aulast%3DKakar%26aufirst%3DS.%2BM.%26aulast%3DNakai%26aufirst%3DY.%26aulast%3DSmith%26aufirst%3DB.%2BJ.%26aulast%3DWebster%26aufirst%3DR.%26aulast%3DBeaumont%26aufirst%3DK.%26atitle%3DPrediction%2520of%2520human%2520pharmacokinetics%2520from%2520preclinical%2520information%253A%2520comparative%2520accuracy%2520of%2520quantitative%2520prediction%2520approaches%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2009%26volume%3D49%26spage%3D513%26epage%3D533%26doi%3D10.1177%2F0091270009333209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Ertl, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rohde, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selzer, P.</span><span> </span><span class="NLM_article-title">Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">3714</span><span class="NLM_x">–</span> <span class="NLM_lpage">3717</span><span class="refDoi"> DOI: 10.1021/jm000942e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm000942e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmsFeitb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=3714-3717&author=P.+Ertlauthor=B.+Rohdeauthor=P.+Selzer&title=Fast+calculation+of+molecular+polar+surface+area+as+a+sum+of+fragment-based+contributions+and+its+application+to+the+prediction+of+drug+transport+properties&doi=10.1021%2Fjm000942e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Fast Calculation of Molecular Polar Surface Area as a Sum of Fragment-Based Contributions and Its Application to the Prediction of Drug Transport Properties</span></div><div class="casAuthors">Ertl, Peter; Rohde, Bernhard; Selzer, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">3714-3717</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Mol. polar surface area (PSA), i.e., surface belonging to polar atoms, is a descriptor that was shown to correlate well with passive mol. transport through membranes and, therefore, allows prediction of transport properties of drugs.  The calcn. of PSA, however, is rather time-consuming because of the necessity to generate a reasonable 3D mol. geometry and the calcn. of the surface itself.  A new approach for the calcn. of the PSA is presented here, based on the summation of tabulated surface contributions of polar fragments.  The method, termed topol. PSA (TPSA), provides results which are practically identical with the 3D PSA (the correlation coeff. between 3D PSA and fragment-based TPSA for 34 810 mols. from the World Drug Index is 0.99), while the computation speed is 2-3 orders of magnitude faster.  The new methodol. may, therefore, be used for fast bioavailability screening of virtual libraries having millions of mols.  This article describes the new methodol. and shows the results of validation studies based on sets of published absorption data, including intestinal absorption, Caco-2 monolayer penetration, and blood-brain barrier penetration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhP6Qncx_h6LVg90H21EOLACvtfcHk0ljED65oYTV7HA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmsFeitb4%253D&md5=23ae4e7708bd8ddeb4a24ad160a29bd6</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Fjm000942e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm000942e%26sid%3Dliteratum%253Aachs%26aulast%3DErtl%26aufirst%3DP.%26aulast%3DRohde%26aufirst%3DB.%26aulast%3DSelzer%26aufirst%3DP.%26atitle%3DFast%2520calculation%2520of%2520molecular%2520polar%2520surface%2520area%2520as%2520a%2520sum%2520of%2520fragment-based%2520contributions%2520and%2520its%2520application%2520to%2520the%2520prediction%2520of%2520drug%2520transport%2520properties%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D3714%26epage%3D3717%26doi%3D10.1021%2Fjm000942e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4OO9" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4OO9','PDB','4OO9'); return false;">PDB: 4OO9</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i55"><a href="/doi/suppl/10.1021/acs.jmedchem.7b00604">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_48710"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.7b00604">10.1021/acs.jmedchem.7b00604</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Data on core modifications (supplementary to <a class="ref internalNav" href="#tbl2">Table 2</a>), characterization of the HTS hit <b>40</b>, characterization and synthesis of compounds <b>12</b> and <b>21e</b>, plasma metabolite profile of compound <b>8</b> from the rat and nonhuman primate toxicology studies, rat in vivo receptor occupancy of compound <b>11</b>, detailed off-target profile of compound <b>8</b>, and computational methods (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00604/suppl_file/jm7b00604_si_001.pdf">PDF</a>)</p></li><li><p class="inline">molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00604/suppl_file/jm7b00604_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00604/suppl_file/jm7b00604_si_001.pdf">jm7b00604_si_001.pdf (1.9 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00604/suppl_file/jm7b00604_si_002.csv">jm7b00604_si_002.csv (1.01 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.7b00604&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2017.60.issue-18%3Bwebsite%3Awebsite%3Aacspubs%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.7b00604%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.7b00604" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67994f4cc8461964","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
